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ABSTRACT  
With over 100 million cases of morbidity annually worldwide; control, elimination and 
eradication of malaria still remains a major challenge, particularly in sub-Saharan Africa. In 
some endemic countries, aggressive malaria control has reduced the malaria burden to a point 
where malaria elimination is becoming feasible. Nevertheless, sustained malaria control is 
crucial to prolong this downward trend for endemic countries.  A major factor that affects the 
effective treatment of malaria is the lack of awareness of the recommended treatment 
guidelines and standardised protocols to routinely decipher the quality of the available drugs 
in the regions. Nigeria bears more than a quarter of the global burden of malaria, with 97% of 
the population at risk of the disease. The high rate of counterfeit and substandard drugs in 
Nigeria is therefore a barrier to effective case management of malaria. Therefore, this project 
proposes to qualitatively and quantitatively analyse chemotherapeutic practices and outcomes 
at an individual and community level in two selected states (Lagos and Osun) in the South 
West Region of Nigeria, in a bid to define barriers to effective case management. 
 A quantitative approach, involving the use of questionnaires was used to explore the current 
pattern of malaria treatment and antimalarial drug use in Osun and Lagos State communities, 
pharmacies and hospitals. The study also investigated the different socio-economic factors 
affecting treatment behaviours in the communities. Commonly used antimalarial drugs, 
including Artemether combination drugs (ACTs) were also randomly sampled from the 
communities to check for substandard and counterfeits using in-vitro culture and FT-IR 
techniques.  
In Lagos and Osun urban regions of the study, ACTs contributed to primary treatment choice 
(60% and 59% respectively), although this was often a result of self-medication (50% and 
46% respectively).  The majority of the people in the rural regions (74% in Lagos and 57% in 
Osun) preferred non-ACTs, with a high level of self-medication. A strong significant 
association was found between employment, salary earned, hospital treatment and adherence 
to recognised malaria treatment recommendations (P < 0.001) in both urban regions. 
However, in the rural regions, only hospital treatment showed a significant association to 
recognised malaria treatment recommendations (P < 0.001). Also, there was also a strong 
association (P < 0.001) for self-medication and place where antimalarial was purchased in the 
Lagos rural region which was not observed in the Osun rural region. The gender of client also 
had a significant association (P < 0.001) with the type of store where treatment was received 
in Osun rural area but not in Lagos rural area.  Hospital data further shows that the rural 
xvi 
 
regions are the most challenging places to experience malaria infection. With already poor 
treatment practices in place, 81% of the suspected cases of malaria in Osun State rural area 
were confirmed positive. When compared to Lagos urban and Osun urban areas, where 65 % 
and 53% were confirmed to be positive, this shows the urgent need for improved intervention 
programmes to promote better treatment practices in the rural regions. However, low 
confirmation of malaria cases in the urban regions also illustrates the danger of self-
medication that occurs when patients visit pharmacy stores and drug vendors since often no 
form of diagnosis is offered at these establishments prior to treatment. 
While all of the ACT samples tested with Fourier Transformed–Infrared spectroscopy 
showed consistency with ACT reference drugs, some chloroquine (22%) and sulphadoxine-
pyrimethamine (20%), did not show consistency with reference samples; particularly if 
acquired from the rural regions. Moreover, some ACTs, primarily if acquired from the rural 
regions (65%), showed low efficacy against Plasmodium falciparum in vitro cultured 
parasites compared to reference samples.  
In addition to the ongoing intervention programmes creating awareness about effective 
malaria control and management of malaria, it is important to intensify efforts, especially in 
the rural regions, since this thesis work highlights that adherence to treatment practice is low 
and there is a high risk of treating malaria with either a counterfeit drug or a substandard 
antimalarial.  Creating a platform for effective case management of malaria infections will 
require collaboration across international and national boundaries, bringing together 
intervention programs and influencing health policy. 
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CHAPTER 1: INTRODUCTION  
1.1 Malaria: a historical perspective 
 Malaria’s history extends to antiquity (Balint, 2001; Krungkrai et al., 2010; Cox, 2002). 
Malaria or a disease similar to malaria has been around for more than 4,000 years. The name 
malaria was invented because the disease was thought to be associated with marshy areas 
giving rise to the misguided belief that it was caused by miasmas; the Italian ‘mal aria’, or 
‘bad air’ in  English. Despite decades of effort to effectively eradicate or at the very least 
manage and control malaria, it remains one of the most devastating diseases to scourge the 
earth. Harrison (1978) postulates that human primate ancestors showed some symptoms of 
malaria even before they were recognised as humans. The symptoms of malaria were 
described in ancient Chinese medical writings and later found in clay tablets from 
Mesopotamia (2000 BC) and Egyptian papyri from 1570 BC (Cox, 2010). However, more 
trusted data and historical records of malaria started from Hippocrates in ancient Greece (400 
BC), writings described the periodicity of malaria and the association between an enlarged 
spleen and people living in poor, marshy areas (Power, 2001). It was then widely identified in 
Greece by the 4th century BC, where it was responsible for the reduction of many of the city-
state populations (CDC, 2010), It is described in the writings of Assyrian, Indian, Arabic, and 
European physicians (Carter and Mendis 2003; Cox, 2002). In addition to ancient 
symptomatic descriptions, recent empirical evidence has shown the existence of Plasmodium 
falciparum malaria in Egyptian mummies from the Fayum depression in 800 BC 
(Lalremruata et al., 2013) and in amber preserved mosquitoes in the Dominican Republic 
from the mid-Tertiary period, 25-400 million years ago (Poinar, 2005). Extending through 
Darwinian descent, malaria has therefore had a huge impact on human exploration, 
colonisation and development of the world as we know it today (Harrison, 1978). More 
recently, malaria along with other diseases has had a huge impact on the world wars, where it 
is said that for every man lost in battle, another was lost to malaria. Frequently, the conditions 
of war encouraged the spread and resurgence of the disease (Cox, 2002; Harrison, 1978). The 
discovery of microorganisms by Antoni Van Leeuwenhoek in 1676 and Louis Pasteur and 
Roberk Koch in 1878-1879, incriminating microbes as the cause of infectious disease, 
triggered an intensified search for the actual cause of malaria (Cox, 2010). A French army 
surgeon named Charles Louis Alphose Laveran, in 1880, was the first person to observe the 
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presence of parasites in the blood of a soldier suffering from malaria (Cox, 2010); he later 
received a Nobel Prize in 1907. Laveran in his findings had concluded that there was only 
one Plasmodium species which he named Oscillaria malariae, however, William H. Welch 
in 1897 named the malignant tertian malaria Plasmodium falciparum. Italian investigators 
Giovanni Batista and Raimondo Filetti introduced the names Plasmodium vivax and 
Plasmodium malariae for two of the malaria parasite species, and in 1922 John William 
Watson Stephens named a fourth species Plasmodium ovale.  Sachs and Melaney (2002) 
defined malaria as “a protozoan infestation caused by the presence of the protozoa; 
Plasmodium in human or other vertebrate red blood cells, usually transmitted by the bite of 
infected female Anopheles mosquitoes that previously sucked the blood from a person with 
malaria”. Researchers suggest that malaria probably spread to the world from Africa in the 
fifteenth century during slave trade and European voyages of exploration (Cox, 2010; Power, 
2001; Olowe, 2015). Another hypothesis suggests that humans and apes both inherited P. 
falciparum infection from their ancestors and that the parasites co-evolved with their 
respective host for millions of years (Escalante&Ayala, 1994). However, this hypothesis has 
been refuted after the discovery of a large number of Plasmodium parasites from African 
apes; which clearly shows that P. falciparum infection is new for humans and infection must 
have occurred from a gorilla within the past 10,000 years (Sundararaman et al., 2016; Loy et 
al., 2017).  
Although the disease is usually transmitted by the bite of a blood sucking female Anopheles 
mosquito, transmission can also rarely occur through blood transfusion, trans-placental routes 
or by sharing contaminated needles. Environmental and geographical factors closely regulate 
the prevalence of malaria with low incidence reported in temperatures below 16°C or above 
30°C and altitudes higher than 2000m above sea level (Roberts & Matthews, 2016). There 
are four well-established species of the protozoa infecting humans; Plasmodium malariae, 
Plasmodium vivax, Plasmodium ovale and Plasmodium falciparum (the commonest and most 
deadly species).  However, a non-human primate malaria known as Plasmodium knowlesi can 
also infect humans (Su, 2010). Almost all deaths are caused by Plasmodium falciparum, as it 
is the only species that can induce the aggregation of infected erythrocytes to other 
erythrocytes and to the vascular endothelium. Plasmodium ovale was identified as a species 
and named in 1922 after an oval-shaped malaria parasite was discovered in an infected 
erythrocyte in the blood of a patient (Collins & Jeffery, 2005) but not much is usually said 
about it because it has a relatively low infection rate (Su, 2010). Malaria is entirely 
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preventable if diagnosed early and treated in accordance with WHO recommendations, 
however, over the years, there has been a major increase in resistance acquisition to 
commonly used antimalarial drugs. Affum et al., (2013) reports that a significant contributing 
factor to resistance acquisition is attributed to malpractices in prescription of the current 
antimalarial and the effects of a rapidly proliferating counterfeit drug industry in endemic 
areas.  
1.2 The global impact of malaria 
Malaria continues to be a dominant public health issue even in this millennium; globally, the 
disease is believed to be responsible for approximately a fifth of all causes of mortality due to 
infectious disease. This translates to over 100 million cases of morbidity, annually, 
worldwide and at least one death every 45 seconds, most of which (70%) are recorded in 
Sub-Saharan Africa (Jombo et al., 2011; WHO, 2017). An estimated number of 3.3 billion 
people, about half of the world’s population living in 109 countries, was mentioned by Hall et 
al.,(2009) to be at risk of contracting the deadly disease at a point in their lifetime. The WHO 
recorded 216 million cases of malaria worldwide (WHO, 2017), killing approximately 
445,000 people every year (WHO, 2018); mostly children under 5 years of age residing in 
Sub-tropical African countries. In a similar context, it had previously been reported by 
Trampuz et al., (2003) and Ishola et al., (2014) that Plasmodium falciparum is responsible for 
an estimated 300-500 million reported clinical episodes of malaria in Africa each year; with a 
significant proportion of people having poor access to public health facilities and thus 
resorting to self-medication and other unsafe methods of treatment. The extent of harm 
therefore caused by Plasmodium falciparum cannot be over-emphasised. However, the 
intense control measures implemented in collaboration with regional governments in endemic 
regions are beginning to bear fruit. The distribution of malaria vector species and their 
dominant global distribution can be seen in Figure 1.1 below. 
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Figure 1.1: A map showing the regional distribution of malaria vector species and their 
dominant global distributions (CDC, 2015). 
 A recent estimation by WHO (2016), shows an estimated 37% decrease in the incidence of 
malaria between 2000 and 2015; bearing in mind that sustenance of the gains made in recent 
control initiatives will prove a challenge if the pace of resistance acquisition is left 
unchecked. In a more recent estimation in the WHO Report (2018), it was reported that the 
global success in malaria control has paused, after an estimated 5 million more cases of 
malaria was recorded in 2016 than 2015, and deaths caused by malaria stood at around 
445,000. Also, Snow et al, (2005) found that about 515 million cases (range 300-660 million) 
of malaria were recorded in 2002; 50% higher than WHO’s assessment in the same year and 
200% higher for areas outside Africa. This may bring into question the accuracy of data and 
statistics reported by WHO from these countries. It should, however, be noted that African 
countries have very poor or sometimes non-existing methods of reporting cases of infectious 
diseases (including malaria), so differences in general statistics can be expected. 
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As already established, malaria is a complex disease that varies widely in epidemiology and 
clinical manifestations in different parts of the world (Chiyaka et al., 2009); there are number 
of factors that are responsible for this variability, including regional chemotherapeutic 
practices, the type of Plasmodium responsible for the disease, climatic and environmental 
conditions of the location and the behaviour and level of acquired immunity of exposed 
populations.  Most cases of malaria in 2015 are estimated to have occurred in the African 
region (88%), South-East Asia region (10%), and the Eastern Mediterranean region (2%). 
Similarly, it is estimated that in 2015 most deaths (90%) were in the African region, followed 
by the South-East Asia region (7%) and the Eastern Mediterranean region (2%) (WHO, 
2015). 85% of the malaria deaths in Africa occurred in young children under 5-years of age. 
The disease also poses a significant risk to immunocompromised individuals and naïve 
travelers to malaria-endemic regions (Andrews et al., 2014; Cohee & Laufer, 2017). 
Generally, the prevalence of malaria is associated with certain factors relating to suitable 
breeding habitats for the Anopheline vector including weather patterns, temperature, 
humidity (Kulkarni et al., 2010). Although freshwater habitats are preferred by the mosquito 
vector, several species of mosquitos have adapted to brackish water habitats (Ramasamy & 
Surendran, 2016; Skiff & Yee, 2014). The predominant global distribution of the disease 
maps to sub-Saharan Africa, South East Asia, and Latin America. Figure 1.2 describes the 
incidence and mortality rate of malaria globally, over 15 years. 
Figure 1.2: Global estimation of malaria case incidence and death rate (WHO, 2015).  
Showing a 37% decrease in incidence rate and 60% decrease in mortality rate between 2000 
and 2015. 
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1.3 Aetiology of malaria 
         Malaria is a life-threatening parasitic disease that is transmitted by the bites of female 
Anopheles mosquitoes already infected with Plasmodium species. Balaji et al., (2014) aptly 
describes malaria as an ancient, seasonal, periodic fever. The natural life cycle of malaria 
involves the Plasmodium parasite infecting two hosts; human and female Anopheles 
mosquitoes. Playfair (2004) describes the Plasmodium life cycle as complex and beyond 
imagination; adding that the successive morphologically unique stages in the mosquito gut, 
salivary glands, human blood, liver and repeating asexual cycles through the red cell makes it 
difficult to develop a vaccine against it. The Plasmodium life cycle (Figure 1.3) starts when 
an infected female Anopheles mosquito injects the parasites in the form of sporozoites into 
the bloodstream while feeding on a human. The sporozoites remain in the blood briefly (30 
minutes) until they invade the liver where the hepatic stage of the parasite’s life cycle is 
initiated by invading hepatocytes. Within the hepatocytes, they undergo a phase of asexual 
multiplication and differentiate into schizonts containing thousands of merozoites which 
rupture and target the red blood cells, initiating the cyclic asexual reproduction phase in red 
blood cells (it takes between 5-15 days before the release of merozoites into the 
bloodstream). The merozoites in the erythrocytes produce rings and trophozoites, which 
further divide to produce schizonts with more merozoites. It then takes about 48-72 hours for 
the red cells to rupture and release the merozoites which in turn attack other red blood cells 
and begin another asexual cycle. This process continues and at a point, some asexual 
merozoites develop into male and female gametocytes. Female Anopheles mosquitoes then 
pick these infective sexual forms of blood stage parasites (male and female gametocytes) 
during a blood meal. Within the mosquito, the gametocytes develop into male and female 
gametes, fertilization later occurs and a motile zygote (ookinete) is formed within the 
mosquito’s gut; the beginning of a process called sporogony. The ookinete transforms into an 
oocyst and burst to release sporozoites into the celeriac cavity of the mosquito. Sporozoites 
move to the mosquito’s salivary glands; and when the female Anopheles mosquito takes a 
blood meal from another human, the sporozoites are injected and the cycle re-establishes. 
Table 1.1 shows the different Plasmodium species in man, and disease features. 
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Figure 1.3: Malaria parasite life cycle showing the parasite development in the hepatic 
erythrocytic and mosquitoes stages (Biamonte et al., 2013). 
Table 1. 1: Malaria parasites of man (Playfair and Bancroft, 2004). 
Species  Liver stage Blood cycle and fever peaks Disease features 
P. falciparum 6-14 days 48hr (‘tertian’) Major complications; may be fatal 
(Cerebral malaria) 
P. vivax 12-17 days 48hr Seldom fatal 
P. malariae 13-40days 72hr (‘quartan’) Nephrotic syndrome 
P. ovale 9-18days 50hr Rarely severe/fatal 
1.4 Clinical signs and symptoms of malaria 
Malaria parasite infection may result in different forms of symptoms, from absent or very 
mild symptoms to severe disease and even death (Bartoloni & Zammarchi, 2012). Therefore, 
malaria has been categorised as severe (complicated) and uncomplicated. The good news is 
that malaria is curable if the disease is diagnosed early and appropriately and treated with a 
recommended antimalarial. As mentioned by Mackintosh et al., (2004), the majority of 
malaria cases present as generic febrile illnesses can be easily controlled by either 
antimalarial treatment or, eventually, by host responses. All the clinical symptoms associated 
with malaria are caused by the asexual erythrocytic or blood stage parasites (Autino et al., 
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2012; Mackintosh et al., 2004). When the parasite develops in the erythrocyte, a lot of known 
and unknown waste substances such as hemozoin pigment and other toxic factors accumulate 
in the infected red blood cell. These are dumped into the bloodstream when the infected cells 
lyse and release invasive merozoites. The hemozoin and other toxic factors such as glucose 
phosphate isomerase (GPI) stimulate macrophages and other cells to produce cytokines and 
other soluble factors which act to produce fever and rigors and probably influence other 
severe pathophysiology associated with malaria (Lamikanra et al., 2009). Macrophages and 
endothelial cells are then stimulated by these products to produce cytokines and inflammatory 
mediators such as tumour necrosis factor (TNF), interferon-γ, interleukin-1 (IL-1), IL-6, IL-8, 
macrophage colony-stimulating factor, and lymphotoxin, as well as superoxide and nitric 
oxide (NO) (Chakravorty et al., 2008; Mackintosh et al., 2004). The systemic manifestations 
of malaria such as headache, fever, rigors and other severe pathophysiology complications 
have been largely attributed to the various cytokines released in response to these parasites 
and red blood cell membrane products (Clark et al., 2006). In addition to these factors, the 
plasmodial DNA is also highly pro-inflammatory leading to the production of cytokines and 
fever (Mackintosh et al., 2004). 
1.4.1 Uncomplicated Malaria 
The period between the time of infection and when the parasite becomes detectable in the 
blood is called the prepatent period, while the period from the time of infection until the onset 
of malaria symptoms is termed the incubation period. The incubation period can be affected 
by a number of factors including parasite species, transmission type, degree of previous 
immune status of the host, the chemoprophylactic use of antimalarial drugs, and probably the 
density of parasite inocula. The shorter incubation periods (9-14 days) are observed most 
frequently with P. falciparum and P. vivax, and the longer ones (18-30 days) with P. 
malariae (Bartoloni & Zammarchi, 2012) with incubation period ranging from 9 to 30 days 
in all species. The most common symptoms that is observed in all the different malaria 
species are nonspecific and mimic a flu-like syndrome. Indeed, hallmark of malaria is fever. 
Up to two days before the onset of fever, prodromal symptoms such as headache, anorexia, 
nausea, vomiting, lassitude, dizziness, aching joints and muscles, backache in the lumbar and 
sacroiliac region and a sense of chillness may be experienced. Fever is usually irregular at 
first and the temperature rises with shivering and mild chills. Then after a few days, fever 
tends to become periodic. The classical malaria paroxysm presents three stages: a cold stage, 
followed by a hot stage with a terminal sweating stage. At the physical examination, 
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splenomegaly may be present during the acute attack but is more commonly observed after 
the second week. The liver may also be enlarged and palpable (Bartoloni & Zammarchi, 
2012). In case of P. falciparum infection, if uncomplicated malaria is not promptly treated, 
the disease can quickly progress to severe malaria (Bartoloni & Zammarchi, 2012).  
1.4.2 Complicated Malaria  
Severe malaria has been recognized as essentially two major disorders with relatively simple 
underlying pathogenesis for many years. Severe anaemia caused by destruction of red blood 
cells and cerebral malaria as a result of the destruction of small vessels of the brain by 
sequestered parasite (Mackintosh et al., 2004). In recent years, severe malaria has been re-
recognized as a complex multi-system disorder that presents with wide ranges of clinical 
features (Bartoloni & Zammarchi, 2012; Mackintosh et al., 2004). According to the most 
recent definition by WHO, in a patient with P. falciparum infection and no other clear 
symptoms, the presence of one or more of the clinical or laboratory features indicated in 
Table 1.2, categorizes the patient as suffering from severe malaria (Bartoloni & Zammarchi, 
2012; Farrar et al., (2014). This definition has been proposed to assist clinical and 
epidemiological descriptions as progression to these complications can be rapid and fatal. 
Accordingly, a malaria patient must be assessed and treated urgently and rapidly (Bartoloni & 
Zammarchi, 2012; Farrar et al., 2014; Mackintosh et al., 2004). 
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Table 1. 2: Clinical features of malaria and possible mechanisms for the disease 
(Bartoloni & Zammarchi, 2012). 
Syndromes  Clinical features Disease mechanisms 
Severe anaemia Shock; impaired 
consciousness;  
 
respiratory distress  
 
 
Reduced RBC production (reduced 
erythropoietin activity, pro-
inflammatory cytokines); increased 
RBC destruction (parasite-
mediated, eythrophagocytosis, 
antibody and complement-mediated 
lysis)  
 
Cerebral complications 
(Cerebral malaria)  
 
Impaired consciousness; 
convulsions; long-term 
neurological deficits  
 
Microvascular obstruction 
(parasites, platelets, rosettes, 
microparticles); pro-inflammatory 
cytokines; parasite toxins (e.g. GPI)  
 
Metabolic acidosis  
 
Respiratory distress, hypoxia, 
tachypnea; acidaemia; 
reduced central venous 
pressure  
 
Reduced tissue perfusion 
(hypovolaemia, reduced cardiac 
output, anaemia); parasite products; 
proinflammatory cytokines; 
pulmonary pathology (airway 
obstruction, reduced diffusion)  
 
Other  
 
Hypoglycaemia; 
disseminated intravascular 
coagulation  
 
Parasite products and/or toxins; pro-
inflammatory cytokines; cyto-
adherence  
 
Malaria in pregnancy  
 
Placental infection; low birth 
weight and foetal loss; 
maternal anaemia  
 
Premature delivery and foetal 
growth restriction; placental 
mononuclear cell infiltrates and 
inflammation; pro-inflammatory 
cytokines  
 
 
1.5 Malaria chemotherapy 
One of the most important and popular methods of controlling malaria is by chemotherapy. 
Most malaria control strategies today depend on the use of safe and effective drugs, as they 
have done for decades (Winstanley, 2006). Although, Mugatroyd (1952) described malaria 
chemotherapy as complicated, being that no antimalarial then was regarded as therapeutically 
effective against all stages of human malaria; studies have shown that there has been a great 
improvement to malaria chemotherapy all over the world (Na-Bangchang & Karbwang, 
2009; Nigussie et al., 2015). To date, malaria treatment/chemotherapy has relied majorly on 
chemically related drugs that belong to five classes of compounds: 
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 4-Aminoquinolines: for example, Chloroquine, Quinine, Mefloquine, Amodiaquine 
and Halofantrine, 
  8-Aminoquinolines: for example, Primaquine  
 Antifolate compounds: for example, Pyrimethamine, Proguanil, Dapsone, and 
Sulphadoxine.  
 Artemisisnin and derivatives: for example, Artemisinin, Artemether, and 
Dihydroartemisinin.  
  Hydroxynaphthoquinone: for example, Atovaquone (Schuck, 2013).  
Most of these drugs used to treat malaria target the erythrocytic stage of the parasite; 
however, some also target the hepatic stage as well (Santos &Torress, 2013).  Drugs from 
these three groups were/are used as monotherapy and can also be combined with each other 
depending on patterns of resistance already observed in particular regions. It is very 
important to understand that the success of malaria chemotherapy depends on the successful 
interaction of the three parties involved in transmission, i.e. the malaria parasite, the human 
host, and antimalarial drug. An effective malaria treatment using antimalarial drugs depends 
on the interaction between the human host and antimalarial drug, i.e., ‘pharmacokinetics’ and 
‘pharmacodynamics’ and also the interaction between the antimalarial drug and the parasite 
i.e., ‘drug resistance’ and ‘selective toxicity’. The main control of malaria in Nigeria is 
through chemotherapy, which leads to the importance of treating every case of malaria 
appropriately; including accurate diagnosis and effective treatment. For this reason, the use of 
counterfeit drugs also needs to be checked, having in mind that the use of these substandard 
drugs does not only affect the health of clients, it also increases the resistance of the malaria 
parasite (Bassat et al., 2016; Nayyar et al., 2012). 
1.5.1 4-Aminoquinolines 
The aminoquinoline drugs are among the most important antimalarial drugs. Most drugs from 
this group target the blood stage of the parasite’s life cycle (Nigussie et al., 2015) although 
some drugs also target the hepatic stage of the parasite’s life cycle. Quinolones are able to 
form a complex with haem in the parasite’s food vacuole, thereby preventing its 
polymerization into non-toxic haemazoin (Schlitzer, 2008). The haem which is then released 
builds up to poisonous levels so that it kills the parasite with its own toxic waste. The 
discovery of quinine is considered the most remarkable medical discovery of the 17th century 
(Achan, 2011) and the use of quinine to treat malaria was the first time a chemical compound 
was used to treat an infectious disease (David et al., 2005). Quinine is an extract from the 
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bark of cinchona tree native to South America and it has been used to treat malaria since the 
1600s. The cinchona tree is a rich source of medicinal alkaloids (Renslo, 2013). Quinine is 
used in malaria-endemic countries as a treatment for severe life-threatening malaria and also 
as a therapy to malaria parasites that have shown resistance to other available antimalarial 
drugs (Kone et al., 2012). Its use as a monotherapy has shown significant resistance (Renslo, 
2013). Other alkaloids apart from quinine include quinidine, cinchonidine and chichonine; all 
these alkaloids are effective against malaria. Between 1968 and 1986, the efficacies of these 
four alkaloids were tested and compared in 3600 patients, and results show that these four 
alkaloids had comparable efficacy rate of about 98% (Achan, 2011). For a very long time, 
quinine was the mainstay of treatment until other synthetic antimalarials became available. 
Chloroquine was discovered in 1934 by Hans Andersag and his group at Bayer AG (Thomé 
et al., 2013; Mushtaque and Shahjahan, 2015). However, chloroquine use did not start until 
the 1940s and because it showed great efficacies it was extensively used across all endemic 
countries (Abdi et al., 1995). From 1947 onwards chloroquine became the treatment of 
choice until recently (Saxena et al., 2003), in fact it was the only drug used for long periods 
of time in some areas in Africa (Mushtaque and Shahjahan, 2015) due to it being cheap and 
effective, with acceptable side effects (Thomé et al., 2013). After the second world war, 
chloroquine was the first-line of treatment against P. falciparum malaria and a lot of 
investment went into a mass drug administration in the Global Eradication Campaign 
launched by the WHO in 1955 (Severini et al., 2015). 
 There was a blow to the hope of effective treatment when resistance to chloroquine was 
observed. In the late 1980s, chloroquine resistant P. falciparum was noted on the Thai-
Cambodian border and in Colombia (Pickard et al., 2002; Wernsdofer et al., 1991). The 
widespread use of quinine in Thailand in the early 1950s is a suspected reason for the 
development of chloroquine resistance (Wernsdofer et al., 1994). In Africa, the first 
chloroquine resistance episode was documented in 1978 at the eastern part of the continent. 
However, the resistance spread to the central and southern part and by 1983 it was 
documented in West Africa (Wongsrichanalai et al., 2002). Chloroquine remains the 
treatment of choice for P. vivax, P. malariae, P. ovale and uncomplicated P. falciparum 
malaria in some geographical areas where this drug can still be trusted. High resistance of P. 
falciparum to chloroquine treatment was the main reason a whole lot of countries in Africa 
switch from chloroquine to SP as first-line treatment or even sometimes a combination of 
chloroquine and SP. However, most people in African countries still make use of chloroquine 
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as monotherapy against the WHO’s recommendations of ACTs. This is usually due to 
chloroquine being cheap and well tolerated (Na-Bangchang et al., 2009), and also a higher 
cost of quinine in combination with other drugs or ACTs (WHO, 2010). Achan et al., (2011) 
claim that by 2009, 38 African countries had made quinine-drugs, especially chloroquine, 
their first-line treatment for uncomplicated malaria, and 31 countries made quinine-drugs a 
second-line treatment for uncomplicated malaria. Further 32 countries made quinine-drugs a 
first-line treatment of malaria in the first trimester of pregnancy. 
1.5.2 Antifolates 
After the long use of chloroquine to treat malaria, the rampant resurgence of the disease was 
stalled by the discovery of another class of antimalarial drugs, the antifolates. This drug 
group was originally developed for the treatment of tumours; however, due to the success 
recorded antifolates were soon applied to other systems of rapidly dividing cells, such as 
bacteria and parasites. Proguanil was the first antifolate shown to be effective against 
Plasmodium, in 1945 during the Second World War (Nzila, 2006). Antifolate drugs are one 
of the first synthetic drugs used as antibiotics or antimicrobials, and antifolate combination 
such as sulphadoxine-pyrimethamine (SP) has been used to treat malaria (falciparum) for 
more than half a century (Venkatesan et al., 2013). Since the early 1960s where significant 
evidence of resistance to chloroquine was observed, rate of morbidity and mortality has also 
increased (Winstanley, 2001). Antifolate drugs are useful antimalarial because of their 
inhibition to folate metabolism of the parasite, both in the synthesis and use of folate 
cofactors (Yuthavong, 2013). Antifolate combination therapy uses a combination of 
dihydrofolate-reductase inhibitors (pyrimethamine, trimethoprim, proguanil) and sulfa drugs 
(dapsone, sulfalene sulphadoxine etc.). Popular antifolate combinations include sulfalene-
pyrimethamine (metakelfin) and sulphadoxine-pyrimethamine (SP or Fansidar). Proguanil 
and pyrimethamine have been used in monotherapy, but they had poor efficacy as 
antimalarial until the class I antifolates (dihydropteroate synthase inhibitors) and class II 
antifolates (dihydrofolate reductase inhibitors) were combined. Although SP is a combination 
of two drugs (sulphadoxine and pyrimethamine), it is not regarded as a combination therapy, 
as both drugs act on the folate pathway. However, the combination was found to have 
synergistic activity and was more effective than either drug used alone (Gregson and Plowe, 
2005). The most extensively used sulphadoxine-pyrimethamine combination is Fansidar (SP), 
at fixed-doses approved by the FDA in 1983 (Gesase et al., 2009). Fansidar was largely 
employed to target chloroquine-resistant parasite populations in the late 1980s and for some 
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years it effectively replaced chloroquine as a first line treatment for P. falciparum malaria 
(Miller and Su, 2011) 
In the 1970s, resistance to SP was first discovered in South Asia and South America which 
later spread to West Africa in the 1980s (Venkatesan et al., 2013; Farooq and Mahajan, 
2004). As a result of very low efficacy of SP as a treatment drug in many endemic countries, 
it was abandoned as first-line treatment (Bell and Winstanley, 2004) and the use of 
artemisinin combination therapies (ACTs) was adopted. However, compared to artemisinin, 
SP’s low cost and prolonged prophylactic effects are major factors that make its use as a 
preventive therapy on the rise in some endemic populations. A review carried out by Kulie 
(2007) provided evidence to show that intermittent preventive therapy of two SP doses 
reduced placental malaria. This evidence however led to the World Health Organization 
(WHO) recommendation of at least two doses of SP beginning in the second trimester of 
pregnancy (WHO, 2004). This has led to a recent increase (Fig 1.4) in the use of SP among 
pregnant women in Nigeria. 
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Figure 1.4: Diagram showing the % use of SP/Fansidar by pregnant women in Nigeria 
between 1960 and 2017. (Source: World Bank: Health Nutrition and Population Statistics, 
2018) 
1.5.3 Artemisinin and Artemisinin-Combination Therapy (ACTs) 
Artemisinin and its derivatives are the latest and most effective antimalarial drugs in current 
use. Artemisinin is derived from a Chinese sweet wormwood plant called Artemisia annua 
(Travassos and Laufer, 2009. Krungkrai et al., 2010). Artemisinin is thought to have been 
used as a therapeutic to treat high fevers as far back as 2000 years ago (Ploypradith, 2004). It 
enhances efficacy and has the potential of lowering the rate at which resistance emerges and 
spread (Mutabingwa, 2005); artemisinin drugs affect protein synthesis of the parasite. 
Fairhurst (2016) explained that artemisinins are pro-drugs that are ‘activated by haem iron-
mediated cleavage of their endoperoxide moiety within the parasite and this forms reactive 
oxygen that targets the nucleophilic groups in parasite proteins and lipids. The artemisinin 
derivatives are perceived to be the most promising antimalarial medicines because they offer 
the following pharmacological properties:  
 Rapid and sustained reduction of the parasite biomass (White et al., 1999)  
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 Rapid resolution of clinical symptoms (White et al., 1999) 
 Effective against chloroquine-resistant parasites (White et al., 1999) 
 Reduction of gametocyte carriage (White et al., 1999; Travassos and Laufer, 2009) 
 Broad stage specificity (Yeung et al., 2005; White et al., 1999) 
 7-day treatment in monotherapy (Travassos and Laufer, 2009; Yeung et al., 2005) 
 
Research has confirmed that artemisinin derivatives effectively and quickly clear 
Plasmodium parasites throughout the asexual blood stages and can also be combined with 
another antimalarial from a different group (Tilley et al., 2016; Wilson et al.,2013; Kulie et 
al., 1993). The reason why artemisinin needs to be combined with another drug is that the 
duration of therapy of artemisinin is between 5-7days. Therefore, parasites can sometimes 
evade the very short duration of action (Ittarat et al., 2003). However, when artemisinin is 
combined with another longer-acting drug it can effectively be administered over 3 days. The 
benefit of the combination is that the artemisinin derivatives quickly reduce the parasitaemia 
while the other long-acting drug clears the parasite (White et al., 1999).  However, a problem 
with this is that if there are new infections with mixed susceptible resistant parasites 
emerging after the Artemisinin residue has cleared the other drug might not be able to fight 
the infection effectively and this will lead to treatment failure (Hastings et al., 2000). This 
rationale is also established and effective in the treatment of cancer, tuberculosis, or infection 
with human immunodeficiency virus (Yeung et al., 2004). As defined by White (1999), the 
probability of a parasite developing resistance to a combination of two drugs is the product of 
the probability of the parasite developing resistance to the first drug and the second drug. 
This means that if the probability of a parasite developing resistance to drug A is 1 in 109 and 
drug B 1 in 109, the probability of developing resistance to drugs AB will be 1in 1018; 
therefore, representing a billion-fold reduction in probability. Moreover, adherence to seven-
day regimen is hard and extremely-low in endemic regions; so a three-day regimen makes 
adherence more possible because most people stop treatment when symptoms are cured and 
they feel better; which can also lead to recrudescence and drug resistance (Nosten et al., 
1994). According to WHO (cited in Balaji et al., 2014), combination drugs can be used as 
first-line treatment for children and people who have shown resistance towards chloroquine 
as an antimalarial drug. Since April 2001, WHO has recommended the use of artemisinin-
based combination therapies (ACTs) in countries where P. falciparum malaria has shown 
resistance to amodiaquine, chloroquine and sulphadoxine-pyrimethamine. However, the 
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WHO believes that the continuous consumption of artemisinin monotherapies in the private 
sector, if unabated, will promote resistance to artemisinin and compromise the effectiveness 
of ACTs.  
In a study by Rwagacondo et al., (2003) an artemisinin compound was partnered with SP and 
tested in an area with high SP resistance, treatment efficacy observed was very low compared 
to efficacy observed when artemisinin compound was combined with another drug of good 
efficacy and without resistance. This shows that even for ACT to be effective, artemisinin 
derivatives must be partnered with another effective drug so as to avoid treatment failure and 
further risk of drug resistance. However, this study did not mention about completion of 
dosage in people that participated in this test and also knowledge and perception of malaria 
treatment wasn’t recorded as these could have affected the result. Since resistance has been 
recorded with nearly all available antimalarials used as monotherapy, the use of artemisinin-
based combination therapy has been accepted in most malaria-endemic countries. SP is 
considered a single agent because the mode of action between sulphadoxine and 
pyrimethamine are similar (Talisuna, 2004). 
The use of ACT as first-line treatment of malaria is seen as a breakthrough in this regard. The 
WHO (2015) claims that in 2013, up to 392 million ACT treatment courses were procured by 
endemic countries – a rise from the 11 million that was recorded in 2005. However, there are 
a couple of concerns about the redeployment of ACTs, the most important one being cost 
(Boland et al, 2000). ACTs in Nigeria are very expensive (between $2.5 and $7.5 equivalent 
of ₦1125 to ₦3375), compared to SP and chloroquine that could be bought for as low as 10 
cents. So for these drugs to be generally accepted as the first-line treatment of malaria in 
Nigeria, there should be a decrease in the amount people pay for them, especially those in 
rural areas who cannot afford to buy them. As a result, people are easily deceived to buy 
substandard/fake ACTs of less quality for a cheaper price, leading to treatment failure, drug 
resistance and death. As Yeung (2003) states, another concern is that by deploying 
artemisinin derivatives and exposing everyone to it, there is a strong chance of the parasite 
developing resistance due to self-medication, wrong dosage etc.  In Nigeria, where the use of 
ACTs was officially adopted in 2005, there are still signs of improper use of antimalarial 
drugs such as inappropriate dosage, use of counterfeit or substandard drugs and the use of 
other ineffective drugs. The correct use of antimalarial drug is imperative not just to 
successfully treat malaria but also to avoid the spread of drug resistant malaria. 
Artemether/lumefantrine was the first fixed dose artemisinin-based combination therapy that 
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was recommended by the WHO to treat P. falciparum and it has shown a great level of 
efficacy across sub-Saharan Africa, Asia, and other areas with multi-drug resistance P. 
falciparum. Artemether works by blocking the conversion of haem to haemozoin in the food 
vacuole, as a result destroying existing haemozoin and releasing haem and a cluster of free 
radicals into the parasite. In Nigeria, the most commonly used ACTs are artemether-
lumefantrine, mefloquine-artesunate, and amodiaquine-artesunate. The Federal Ministry of 
Health (2007) explains that although the use of artemisinin-based combination therapy for the 
treatment of uncomplicated malaria has been introduced and advised in Nigeria for some 
years now, its utilization is still below expected levels. The reasons they identified for this 
includes; Low coverage of public sector health facilities where ACTs are free of charge or 
insufficient supply management and low awareness of ACT treatment by health workers and 
patients, Poor availability and high cost of ACT in the private sector. As found in China and 
Vietnam, (Meng et al., 2010; Witkowski et al., 2013) the progressive reduction of in vitro 
susceptibility to artemisinin of P. falciparum has confirmed the risk of resistance. 
 If P. falciparum develops resistance to the artemisinin derivatives currently used to treat 
malaria, there will be no alternative effective compounds to treat malaria over the next ten 
years. This is a major reason why quality antimalarial drugs must be used for every case of 
malaria, at a proper dosage and these must be presented after a proper diagnosis. Although 
policies that govern the use of antimalarial drugs are well established in countries that have 
adopted the use of ACTs as first line treatment for uncomplicated P. falciparum malaria, 
Ezenduka et al., (2014) explains that problems in implementation still persist, undermining 
the goals of malaria treatment policy. To successfully control malaria, treatment with 
efficacious antimalarial drugs is one of the most important factors to consider. Every country 
has a National Malaria Treatment Policy that approves the drugs for treatment of both 
uncomplicated and severe malaria and what to do if first line treatment fails. It must however 
be noted that artemisinin-resistant strains of Plasmodium falciparum have recently been 
discovered in Southeast Asia and it is a major risk to efforts to control malaria worldwide 
(Laurent et al., 2015). 
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1.5.4 Current chemotherapy recommendations  
Table 1. 3: Artemisinin and non-artemisinin containing drug combinations for malaria 
treatment. 
Artemisinin-based combinations  Safety  PK 
mismatch  
Evidence of resistance  
Artemether-lumefantrine  +/-  -  no/no  
Artesunate +mefloquine  +  -  no/yes  
Artesunate + SP  +/-  -  no/yes  
Artesunate + amodiaquine  +/-  -  no/yes  
Artesunate +pyronacridine  +/-  -  no/no  
Dihydroartemisinin + piperaquine  +/-  -  no/no  
artensuate+Chloroprogunil-dapsone  +/-  -  no/likely  
Non-Artemisinin combinations  
Sulfadoxine/Pyramethamine (SP)  +/-  +/-  yes/yes  
Chloroquine + SP  +/-  -  yes/yes  
Amodiaquine + SP  +/-  -  yes/yes  
Quinine + SP  +/-  -  some/yes  
Mefloquine +SP  +/-  -  some/some  
Quinine + tetracycline  -  +/+  some/no  
Quinine + Clindamycin  +  +  some/no  
Atovaquone-proguanil  +  +/-  no/no  
Chloroprogunil-dapsone  -  ++  Possible  
(Abbreviations are as follows -= poor, +/-= unclear, += acceptable, ++= desirable. Drugs with – in the title 
are approved whilst drugs with + are not (Matthews, 2015).  
Table 1.3 above describes various examples of artemisinin-based combinations of 
antimalarial drugs and non-Artemisinin combinations, including their safety for consumption 
and evidence of resistance. 
1.6 Drug resistance mechanisms  
Antimalarial drug resistance which is caused by the reduced susceptibility of parasites to 
commonly used antimalarial drugs is now generally believed to be a major threat to the 
ability to “roll back malaria” and other malaria eradication programs.  Drug resistance is one 
of the factors responsible for the spread of malaria to a new area and the re-occurrence of 
malaria in areas where it had once been eradicated. WHO Technical Report Series (1973) 
defined antimalarial drug resistance as “the ability of a parasite strain to survive and/or 
multiply despite the administration and use of a drug given in doses equal to or higher than 
those usually recommended but within a tolerance of the subject”. However, Bruce-Chwatt et 
al., (1986) subsequently modified this definition to add that “the drug must gain access to the 
parasite or the infected red blood cell for the duration of the time necessary for the normal 
action of the drug”. 
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Howard et al., (2003) rightly says that measuring the impact of drug resistance is vital to 
understanding the scope of the problem, which gives a greater insight into formulating 
policies to limit the emergence and spread of resistant organisms. Babalola et al., (2007) in a 
study reported that the incidence of P. falciparum resistance to chloroquine was observed all 
over the country (Nigeria). The same study also reported that combined antimalarial of 
pyrimethamine-sulphadoxine has shown a considerable amount of clinical failure when used 
to treat malaria; which invariably means that P. falciparum has developed resistance to this 
combination. The sample size of this study might not be big enough to generalise the result to 
the whole country, however, other studies done in different regions support this claim. There 
are direct and indirect effects of drug resistance to malaria effective case management. Apart 
from drug resistance resulting to treatment failure, it also increases the number of people that 
serve as host to P. falciparum or any other species hereby leading to a more dangerous form 
of malaria (e.g. cerebral malaria) and in such a way increasing morbidity and mortality. The 
global spread of P. falciparum drug resistance to antimalarial drugs such as 
sulphadoxine/pyrimethamine and chloroquine has been recognised as a serious public health 
problem in countries intensely affected by the disease (Mita et al., 2009; Weinsdorfer 1994; 
Talisuna et al., 2004). After a breakthrough in the development of antimalarials to fight 
malaria diseases since the 1940s, there has been a great blow to their effectiveness due to 
parasites ability to develop resistance to these drugs. Over the years, P. falciparum has grown 
resistant to different antimalarial drugs; for example, chloroquine used to be a very effective 
antimalarial drug until the late 1950s, when resistance was reported in South-America and 
Southeast-Asia which eventually spread throughout the world (Ishola et al., 2014). For a 
disease responsible for over 475,000 deaths worldwide every year with 70% recorded in sub-
Saharan Africa (Jombo et al., 2011), the development of resistant species has a huge 
significant influence on the control of malaria. 
After resistance to chloroquine was recorded, it was essential to produce alternative 
antimalarial drugs such as sulphadoxine-pyrimethamine (SP) to combat the disease. 
However, considering the WHO’s recommendation of combination therapy, SP is not 
considered to be one because even though it is a co-formulation of two drugs, the mechanism 
of action of both drugs are closely linked (Travassos and Laufer, 2009). Also, by the late 
1980s, resistance to mefloquine and SP was also widespread on the Thai-Cambodian and 
Thai-Myanmar border areas which later spread to Africa (Wongsrichanalai et al., 2004).  P. 
falciparum is the most common species of malaria parasite and it is responsible for the 
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majority of malaria deaths globally and in Nigeria. It is therefore expected, as P. falciparum 
has been around for many years that it is now highly resistant to most of the available 
antimalarial drugs. Oshikoya and Senbanjo (2010) explain that this problem has been 
aggravated by self-medication, use of counterfeit drugs and empiric treatment of malaria. 
However, amidst all claims of Chloroquine (CQ) and SP resistance, recent studies have 
shown that there may be an evidence of increased efficacy in these drugs as more people are 
beginning to use them with reports of an effective result. Adebayo & Krettli, (2011) explains 
that in Nigeria, a nationwide surveillance data on drug efficacy showed that chloroquine and 
sulphadoxine-pyrimethamine are no longer effective therapeutic options for the viable 
treatment of human malaria. Other antimalarial drugs such as mefloquine followed within a 
few years of introduction (Mockenhaupt, 1995). Wongsrichanalai et al., (2002) shows in a 
table (Table 1.4) that resistance to drugs commonly develops within 10-15 years after the 
introduction of a new antimalarial. 
Table 1. 4: Dates of introduction and first reports of antimalarial drug resistance 
(Wongsrichanalai et al., 2002). 
ANTIMALARIAL 
DRUG 
INTRODUCED FIRST REPORTED 
RESISTANCE 
DIFFERENCE 
(YEARS) 
Quinine 1632 1910 278 
Chloroquine 1945 1957 12 
Proguanil 1948 1949 1 
Sulphadoxine-
Pyrimethamine 
1967 1967 0 
Mefloquine 1977 1982 5 
Alovaquine 1996 1996 0 
The development of this resistance is usually caused by; 
 Drug pharmacokinetics (Hastings et al., 2002) 
 Drug over use (Simpson et al., 2000) 
 Cross-resistance between drugs (Iyer et al., 2001). 
Inadequate treatment through inappropriate prescription or administration, non-compliance or 
poor absorption (Simpson et al., 2000). 
The continuous spread of P. falciparum resistance to antimalarial drugs presents a serious 
threat to any form of malaria intervention or control programmes. As effective case 
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management (ECM) is the main strategy employed to control malaria, it is therefore 
imperative that every case of malaria is treated not only with the most effective drugs but also 
with the right dosage. Recently, it is believed that the main drive of malaria control in every 
malaria endemic country is early diagnosis and the effective treatment of every case found. 
One of the problems that affect this is that a large proportion of Nigerians (60-80%) treat 
malaria cases outside the official healthcare system and mostly at home using drugs at 
incorrect dosages. Hamel et al., (2001) defined home treatment of malaria as “any treatment 
for presumed malaria with antimalarial drugs that are not given during or after a visit to a 
health facility such as a health centre, a dispensary, a maternity centre, a private or public 
hospital”. The rapid spread of drug-resistant malaria parasites accompanied by adulterated 
drugs for case management in the market has made the treatment and control of malaria very 
challenging (Anyawu and Onyesome, 2007). 
1.6.1 Artemisinin-resistant Plasmodium falciparum malaria 
Artemisinins are the most rapidly acting of currently available antimalarial drugs. However, 
there is a fast and growing threat to its use as Southeast Asia (SEA) has been fertile ground 
for the emergence of drug-resistant P. falciparum malaria (Figure 1.6). Similar to a trend that 
has been recorded in chloroquine, sulfadoxine, pyrimethamine, quinine, and mefloquine, this 
region has now spawned parasites resistant to artemisinin, the world's most potent 
antimalarial drug (Woodrow and White, 2017). Partial resistance to ACT, defined as delayed 
parasite clearance in malaria patients treated with an ART derivative or an ACT, has been 
associated with mutations in the P. falciparum K13 gene (Straimer et al., 2017). As a result, 
areas where ACT is the first-line treatment of the disease are at risk of a failed drug due to the 
prevalence of artemisinin resistance. This worrisome development threatens to make malaria 
practically untreatable in South East Asia and threatens to compromise global endeavours to 
eliminate this disease. A recent series of clinical, in vitro, genomic and transcriptomic studies 
in South East Asia have defined in vivo and in vitro phenotypes of artemisinin resistance, 
identified its causal genetic determinant, explored its molecular mechanism, and assessed its 
clinical impact (Fairhurst et al., 2016). Specifically, these studies have established that 
artemisinin resistance manifests as slow parasite clearance in patients and increased survival 
of early-ring-stage parasites in vitro; it is caused by single nucleotide polymorphisms in the 
parasite K13 gene, which is associated with an upregulated "unfolded protein response" 
pathway that may antagonize the pro-oxidant activity of artemisinins, and selects for partner 
drug resistance that rapidly leads to ACT failures. In South East Asia, clinical studies are 
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urgently needed to monitor ACT efficacy where K13 mutations are prevalent, test whether 
new combinations of currently available drugs cure ACT failures, and advance new 
antimalarial compounds through preclinical pipelines and into clinical trials. Intensifying 
these efforts should help to forestall the spread of artemisinin and partner drug resistance 
from South East Asia to sub-Saharan Africa, where the world's malaria transmission, 
morbidity, and mortality rates are highest. Prolonged courses of artemisinin-based 
combination therapies are currently efficacious in areas where standard 3-day treatments are 
failing. 
 
Figure 1.5: The distribution of artemisinin resistance throughout the world. Dark Green 
regions are places where all parasites are not resistant to artemisinin, Red regions (primarily 
in South-East Asia) are places where a very high percentage carry a mutation (so-called K13 
polymorphism), which is associated with artemisinin resistance. 
1.6.2 Chloroquine-resistant Plasmodium falciparum malaria 
As the malaria parasite digests haemoglobin, large amounts of toxic by-product are formed. 
The parasite polymerizes this by-product in its food vacuole, producing non-toxic haemozoin 
(malaria pigment). It is believed that resistance of P. falciparum to chloroquine is related to 
an increased capacity for the parasite to expel chloroquine at a rate that does not allow 
chloroquine to reach levels required for inhibition of haem polymerization (Foley & Tilley, 
1997). This chloroquine efflux occurs at a rate 40 to 50 times faster among resistant parasites 
than sensitive ones (WHO, 2001). This situation is remarkable considering the major toxicity 
that occurs through the formation of the haem-chloroquine complex that inhibits haem 
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degradation by reduced glutathione (GSH). It is possible that higher levels of GSH in some 
parasites may help protect them from the toxic effects of chloroquine and thus contribute to 
resistance. In fact, both in P. falciparum and in the rodent malaria parasite Plasmodium 
berghei, it has been demonstrated that CQ-resistant lines contained higher levels of GSH than 
their sensitive counterparts (Meierjohann et al., 2002) and that this was related to increased 
expression of glutathione-S-transferase (Cravo et al., 2006) as well as γ-glutamylcysteine 
synthetase (Perez-Rosado et al., 2002). 
Further evidence supporting this mechanism is provided by the fact that chloroquine 
resistance can be reversed by drugs which interfere with this efflux system (WHO, 2001). It 
is unclear whether parasite resistance to other quinolone antimalarials (amodiaquine, 
mefloquine, halofantrine, and quinine) occurs via similar mechanisms. 
1.6.3 Antifolate-resistant Plasmodium falciparum malaria 
In combination, antifolate drugs act as synergistic inhibitors of folate biosynthesis, which in 
malaria parasites, is an obligatory requirement for the production of nucleotides and hence 
DNA synthesis. Antifolate combination drugs, such as sulfadoxine and pyrimethamine, act 
through sequential and synergistic blockade of 2 key enzymes involved with folate synthesis. 
Pyrimethamine and related compounds inhibit the step mediated by dihydrofolate reductase 
(DHFR) while sulfones and sulfonamides inhibit the step mediated by dihydropteroate 
synthase (DHPS) (WHO, 2001). Specific gene mutations encoding for resistance to both 
DHPS and DHFR have been identified. Specific combinations of these mutations have been 
associated with varying degrees of resistance to antifolate combination drugs (WHO, 2001). 
There are 4 single nucleotide mutations causing amino acid replacements associated with 
pyrimethamine resistance in the wild; a change from serine to asparagine at amino acid 
position 108 (S108N), from asparagine to isoleucine at position 51 (N51I), from cysteine to 
arginine at position 59 (C59R), and from isoleucine to leucine at position 164 (I164L). It is 
thought that these mutations arise sequentially, starting with S108N, as this mutation confers 
a 10-fold increase in the Ki value for pyrimethamine (the dissociation constant of the 
enzyme-inhibitor complex) while maintaining similar kinetic parameters to the wild type 
enzyme (Sirawaraporn et al., 1997). This is the only single mutation seen in the field 
(Sirawaraporn et al., 1997). Each sequential mutation adds further increases in Ki values, 
with the quadruple mutant exhibiting the highest value. DHPS mutations were found in five 
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positions 436, 437, 540, 581 and 623 (Brooks et al., 1994) and all gene mutations currently 
identified, cause diminished affinity of the binding of the drugs to their enzyme targets. 
1.6.4 Atovaquone-resistant Plasmodium falciparum malaria 
Atovaquone acts through inhibition of electron transport at the cytochrome bc1 complex 
(Ittarat et al., 1994). Although resistance to atovaquone develops very rapidly when used 
alone, when combined with a second drug, such as proguanil (the combination used in 
MalaroneTM) or tetracycline, resistance develops more slowly (Looareesuwan et al., 1996). 
Resistance is conferred by single-point mutations in the cytochrome-b gene. 
The cytochrome bc1 complex catalyzes the transfer of electrons from ubiquinol to cytochrome 
c, which is coupled to the translocation of protons across the inner mitochondrial membrane, 
thereby maintaining the membrane potential of mitochondria used to produce ATP by ATP 
synthase (Barton et al., 2010). The antimalarial drug atovaquone can inhibit the parasitic 
cytochrome bc1 complex by causing a collapse in the mitochondrial membrane potential, 
which is lethal for the parasite (Barton et al., 2010). Several mutations within the cytochrome 
b gene can lead to atovaquone resistance, with most mutations altering the ubiquinol binding 
site of the protein (Gil et al., 2003). This site is highly conserved across phyla. Studies with 
yeast and transgenic parasites support the theory that atovaquone binds to the ubiquinol 
binding site, thereby disrupting the electron transfer chain (Peters et al., 2002). It has been 
hypothesized that in the absence of atovaquone drug pressure the mutations in the ubiquinol 
binding sites might confer a fitness cost to the parasite (Barton et al., 2010). Indeed, a double 
mutation in this conserved protein (M133I and G280D) results in 5–9% fitness cost according 
to cell culture investigations (Peters et al., 2002). 
1.7 Disease control strategies  
The present approach to controlling malaria vectors is quite different from the approach that 
was in place in the early-mid 20th century. In the early years, more concentration was placed 
on just the breeding sites of mosquitoes. Efforts were made to drain swamplands and stagnant 
water of their content and potholes were covered or layered, with oil to disrupt egg laying and 
larval development.  
1.7.1 Vector control 
The first breakthrough of mosquito controls came in 1939 when 
dichlorodiphenyltrichloroethane (DDT) was discovered. This later became the major control 
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of mosquito for many years (Oliva et al., 2014). The use of DDT was later banned in some 
countries because of its toxicity; it was also claimed to be harmful to the food chain and fresh 
water. However, Curtis et al., (2000) explain that the extent of the harm that DDT in indoor 
spray for mosquitoes create is not clear and a link between DDT and morbidity has not been 
properly demonstrated. The ban of DDT led to it being replaced by pyretheroids which 
mosquitoes later developed resistance to (Van Dyk et al., 2010). 
Nets have been in use since very early times as a protection against different insects including 
the mosquito. In recent times, different types of nets have been developed; nets that are made 
of cotton, nylon, polyester, polyethylene and synthetic with cotton mixtures (Department 
Ministry of Health, 2002). Insecticide-treated nets which are the recommended type of nets 
for protection against mosquitoes either kill or irritate mosquitoes in addition to being a 
physical barrier (Roozendal, 1997), which is the main advantage an insecticide-treated net 
has over an ordinary untreated net. Curtis et al., 2000, describes an insecticide-treated net that 
they serve as human baited traps when somebody is sleeping inside by attracting and killing 
mosquitoes and other biting insects. As the name implies, insecticide-treated nets need to be 
treated regularly with chemicals for maximal benefit. The commonest chemicals used are 
second and third generation synthetic pyrethroids (Roozendaal, 1997; Clarke, 2001). Large-
scale trials of insecticide-treated nets conducted over two years period in different 
epidemiological settings across Africa show a reduction of between 15-33% in all cases of 
child mortality (Diallo et al., 2004). If ITNs are properly used, it can cut malaria transmission 
by at least 50% (UNICEF 2004). ITNs also provide significant protection for pregnant 
women against maternal anaemia and low birth weight, which are major contributors for 
neonatal morbidity (UNICEF, 2004). ITNs are seen to be expensive and some people even 
find their use to be too complex, however, it was argued that ITNS are cost-effective 
(Wiseman et al., 2003. Onwujekwe et al., 2003). 
It should be added, that even though IRS (Indoor residual sprays) and ITNs show 
effectiveness in controlling malaria, this on its own cannot eradicate the disease and more 
should also be done with effective management of every malaria case. In the early weeks of 
January 2018, the price of Baygon (one of the most trusted and used IRS in Nigeria) had gone 
up ₦2000 ($5.56) for a 500ml Can. Also, the price of Coartem, one of the most trusted ACTs 
was ₦1200 ($3.34). This is very worrying and against the belief ‘prevention is better than 
cure’; at least not in the case of IRSs financially. UNICEF’s statistics in 2007 showed that 
over 70% of Nigerians live on less than $1 a day, and 92% live on less than $2. It is even 
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more devastating when you compare the naira-dollar exchange rate now in 2018. Due to the 
harsh economy in Nigeria, the country is heading to a place where if nothing is done soon, it 
would not be sensible to advocate prevention over treatment in this area; this is because if 
people cannot afford to treat using recommended ACTs then how can they afford to use IRSs. 
1.7.2 Vaccine development 
Vaccine development (as seen in Figure 1.5), has historically contributed to the reduction in 
the spread and burden of infectious diseases. However, despite extensive efforts, there is 
currently no licenced vaccine available for the effective management of malaria. Following 
repeated exposure to infection, people living in malaria-endemic areas develop acquired 
immunity to limit the inflammatory response to the parasite (Artavanis-Tsakonas et al., 
2003), but this immunity seems to be specific for the parasite strain that resides in a specific 
area. Acquired immunity is therefore lost once the individual moves to an area with a 
different strain (Wang et al., 2009). An urgent need to develop an effective malaria vaccine 
cannot be over-emphasised; however, the production of a malaria vaccine has since proved 
difficult because of the hurdle in pinpointing the immune responses that protect against 
malaria (Holder, 2009). The WHO Expert Committee on Biological Standardization (ECBS) 
in 2012 provided a guideline to support quality, safety, and efficacy of new malaria vaccines; 
these vaccines are to target pre-erythrocytic and blood stages of Plasmodium falciparum 
cycle (WHO, 2015). In 2013, the Malaria Vaccine Technology Roadmap was revised by the 
WHO and was updated to focus more on research, vaccine development, important 
capacities, policy and commercialization (WHO, 2013). The malaria vaccine roadmap’s 
major goal was to produce a vaccine by 2015 with a protective efficacy of more than 50% 
against malaria disease and the vaccine must last longer than a year (WHO, 2013). The 
second goal is to produce a vaccine with 80% efficacy by the year 2025 (Claudia, 2014). 
There are three main types of malaria vaccines that could be developed. The pre-erythrocytic 
vaccines are the one that would target the liver-stage sporozoite and this would in turn 
decrease or eliminate blood stage infection.  
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Figure 1.6: Vaccine development cycle; an illustration of a vaccine product life-cycle from 
research and development through to post-licensure, and the key information requirement 
during the cycle (Ho et al., 2015) 
1.7.2.1 Pre-erythrocytic vaccines 
A pre-erythrocytic vaccine targets the sporozoites and hepatic stages of the parasite aiming 
either to prevent the sporozoites from getting into the liver cells or destroying infected liver 
cells and hence preventing the emergence of merozoites into the bloodstream (Duffy et al., 
2012). The most significant challenge for a pre-erythrocytic vaccine is the time frame. 
Sporozoites reach the liver in less than two hours after being injected by the mosquito (Mac-
Daniel et al., 2014). As a result, the immune system has a limited amount of time to eliminate 
the parasite. Although most of the potential pre-erythrocytic vaccines are still in Phase I or 
Phase II trials, one vaccine (RTS, S) has entered the Phase III trial and is showing promise 
(SCTP, 2015). RTS, S, RTS, S/SBAS2, developed by SmithKline Beecham Biologicals with 
the Walter Reed Army Institute of Research in 1987, conferred partial protection against 
malaria in phase II clinical trials (Minsoko et al., 2014). Targeting the pre-erythrocytic phases 
of P. falciparum, RTS, S is a fusion protein consisting of a malaria antigen (circumsporozoite 
protein) with hepatitis B surface antigen, and includes a new potent adjuvant (AS01) 
(Minsoko et al., 2014; Stoute et al., 1997; Takashima et al., 2016). RTS, S/ AS01 was the 
subject of a large multicentre Phase III trial involving more than 15,000 children over 11 sites 
in sub-Saharan Africa with the aim of licensure and deployment in 2015 (Barry & Arnott, 
2014). These trials have had some successes. The earliest results, released in October 2011, 
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showed that in children aged 5-17 months, vaccination with RTS, S reduced the risk of the 
clinical malaria episode and severe malaria by 56% and 47%, respectively (Barry & Arnott, 
2014). However, the results released in November 2012 indicated that the vaccine was less 
effective in infants aged 6-12 weeks at first vaccination. In that category, vaccination with 
RTS, S decreased both clinical malaria and severe malaria by 30%. Final results from the 
trial, that involved young children up to three years of age, showed a reduction in clinical 
malaria cases by 26% for the youngest children and 36% for children up to 17 months of age 
at first vaccination (Barry & Arnott, 2014; Tinto et al., 2015). Considering that the number of 
malaria cases averted was substantial, this represents an encouraging progress towards 
licensing of a first-generation malaria vaccine (Barry & Arnott, 2014). In July 2015, the 
European Medicines Agency recommended that the vaccine should be licensed for use in 
young children in Africa; WHO is considering the recommendation. Concurrently, a WHO 
advisory group has recommended pilot 17 implementations of the vaccine in 3-5 sub-Saharan 
African countries (Takashima et al., 2016). 
1.7.2.2 Erythrocytic vaccines or blood-stage vaccines 
The blood stage vaccines identify antigens on infected blood cells and fight against infected 
cells while the antibody-producing vaccines target the sexual stages of the parasite (Moorthy 
et al., 2007). The aim of the erythrocytic vaccines is to stop the rapid invasion and asexual 
reproduction of the parasite in RBCs. Recall that the blood stage parasites are responsible for the 
clinical symptoms of malaria (Richards & Beeson, 2009). Due to the significant number of 
merozoites produced, erythrocytic vaccines are designed to target merozoite antigens and hence 
prevent RBCs invasion; thus, reducing the parasite density. In addition to preventing the clinical 
symptoms, this will also reduce the density of gametocytes contributing to the reduction in 
malaria transmission (Barry & Arnott, 2014). Other approaches target a surface protein on 
infected red blood cells known as P. falciparum erythrocyte membrane protein (PfEMP1). 
PfEMP1 mediates adhesion to host cells, a mechanism that is associated with severe malaria 
(Hviid, 2010); however, there are no blood-stage vaccines that have had the comparable success 
of the RTS, S vaccine and most are still undergoing Phase I or II trials (Takashima et al., 2016). 
At the moment there are currently no licensed malaria vaccines although the RTS/S/AS01 
(MosquirixTM, GSK) is the most advanced candidate in clinical studies (Ho et al., 2015). 
RTS/S/AS01 is an example of a vaccine that targets the pre-erythrocytic sporozoites of P. 
falciparum. Moreno and Joyner (2015) however claim that the immunity of the vaccine 
diminishes over time, therefore another dose should be taken after 18 months. RTS/S/AS01 is 
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a very encouraging starting point for the development of vaccines. Nigeria is one of the Sub-
Saharan African countries where RTS/S/AS01 vaccine phase III or IV studies are ongoing or 
planned (Ho et al., 2015). However, Dunachie et al (2015) claim that RTS/S/AS01 vaccine 
has completed stage III clinical trials and has an efficacy of only 46% in children and 27% in 
infants. The efficacy rate recorded seems too low at the moment, but it can be improvised and 
probably there is still hope for a vaccine with 80% efficacy by 2025. 
1.7.2.3 Transmission-blocking vaccine (TBV) 
The transmission blocking vaccines aim to target antigens expressed during parasite stages in 
the mosquito host (Barry & Arnott, 2014). Although these altruistic vaccines would not 
directly protect an individual, they would prevent the onward transmission (Birkett et al., 
2013). During a blood meal, the mosquito takes up vaccine-induced antibodies along with 
Plasmodium gametes, enabling interference with parasites development and preventing 
transmission of the parasite to the next individuals (Jones et al., 2015; Shimp et al., 2013). 
The Pfs25 protein expressed on the surface of zygotes and ookinetes during the sexual stages 
of Plasmodium is a promising target for TBV development (Jones et al., 2015). Phase I 
human trial results using a recombinant Pfs25H/Montanide ISA51 formulation indicated that 
human Pfs25 specific antibodies block parasite infectivity to mosquitoes; however, the extent 
of blocking was likely to be insufficient for an effective TBV (Jones et al., 2015; Shimp et 
al., 2013). To overcome the poor immunogenicity, processes to produce and characterize 
recombinant Pfs25H conjugated to a detoxified 18 form of Pseudomonas aeruginosa exo-
protein A (EPA) have been developed. This new Pfs25-EPA conjugated nano-particle 
vaccine significantly enhanced the Pfs25 specific antibody responses in mice when adsorbed 
on Alhydrogel® (Shimp et al., 2013). However, the safety and immunogenicity of the Pfs25-
EPA vaccine in humans are currently under evaluation (Shimp et al., 2013). Ultimately, 
many scientists think that the next logical step is to combine multiple approaches to develop a 
malaria vaccine, but these individual stage vaccines must show efficacy on their own. 
Moreover, the major challenge is there are no known correlates for immunity, meaning there 
is no method other than costly clinical trials in humans to demonstrate a vaccine’s efficacy; 
thus, although great progress has been made, malaria vaccine development will continue to 
be a costly and multidimensional effort. 
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1.8 Roll back malaria 
There have been some global responses to the outrageous effects of malaria in Nigeria; this 
includes the establishment of the Roll Back Malaria partnership by the WHO and the Global 
Fund to fight AIDS, Tuberculosis and Malaria (GFATM) (Jimoh et al, 2008). Roll Back 
Malaria (RBM) was an initiative intended to half the suffering caused by malaria disease by 
2010; in the medium-term to reduce the number of malaria deaths to near zero by 2015; 
through substantial coverage of new tools and in the long term, to maintain near-zero deaths 
worldwide. However, it has obviously not achieved its goal as at 2015, forcing the WHO to 
set a further target of 90% reduction by 2030; Binka (2002) believes one of the reasons for 
this is that the RBM is being grossly underfunded. The World Health Organization, The 
United Nations Children’s Fund, the United Nations’ Development Programme and World 
Bank in 1998 joined forces to fight malaria in malaria-endemic countries. The creation of 
Roll Back Malaria Campaign and the greater focus on malaria in both local and international 
levels have increased demand for evidence on the economic impact of malaria. Chima et al 
(2003) explained that such information is needed to justify investment in research and 
control, and also to target control efforts both efficiently and equitably. So as to achieve the 
target of reducing malaria morbidity and mortality, Roll Back Malaria (RBM) has recognised 
access to prompt diagnosis and treatment of malaria incidence by the year 2015, as an outline 
in Millennium Development Goal (WHO, 2003). Chilaka (2005) explains that the main 
objective of the RBM initiative is to tackle the political efforts and help develop necessary 
economic and social conditions for the right tools to be used by all communities and 
countries that are affected by malaria.   
In addition, the goals of the RBM movement include meeting the malaria-related United 
Nations Millennium Development Goals (MDGs), Abuja Declaration; and the RBM 
Partnership Global Strategic Plan. RBM Partnership Global Strategic Plan is expected to 
coordinate all efforts at malaria control; it will promote the development and better utilization 
of all tools for malaria control – old, new and future - as and where appropriate, and it will 
help strengthen the health sector. The RBM thrust, however, conforms with the on-going 
health sector reform (HSR) initiative in Nigeria where first-phase implementation covered 
2004-2007 and sought to ensure the health of citizens in the country are guaranteed (FMoH, 
2005).  
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1.9 Malaria in Nigeria: a historical perspective 
Also known as the giant of Africa, Nigeria is by far the most populous country in Africa 
(over 182 million people) with a calculated growth rate of 3.2% annually. Nigeria is divided 
into six geopolitical zones, namely the North West, North East, North Central, South West, 
South East, and South South regions. It is also made up of 36 states and 774 LGAs (Local 
Government Areas). Malaria is endemic in Nigeria and creates a major public health issue 
despite the preventable/curable nature of the disease. Since malaria is associated with tropical 
and sub-tropical areas, the disease probably originated from Africa and was transferred to 
other parts of the world through human migration; especially during the slave trade era. There 
is no established information about the first occurrence of malaria in Nigeria; however, it is 
believed that during British colonization, colonialists created Government Reserved Areas 
(GRA) so as to build their homes far away from Nigerian citizens, because they believed 
flying long distances from breeding sites was a limiting factor for mosquitoes. Nigeria’s quest 
for effective control of malaria began well before the WHO global malaria eradication period 
between 1955 and 1968. It started by creating parastatals that monitored the spread of 
malaria, including the Ministry of Health that dealt with mosquitoes and malaria issues. Also, 
the National Malaria Control Committee (NMCC) was set up in 1975 with the sole aim of 
reducing malaria burden by 25%. The NMCC only recorded a small amount of success and it 
wasn’t till after 9 years (1988) that a major health reform was carried out. Within this new 
policy, malaria was planned to be eradicated using primary health care. However, in spite of 
these new policies, the malaria situation steadily worsened and is currently estimated at 65% 
of all ailments reported in Nigerian hospitals (Akanbi, et al., 2009). Currently, Nigeria bears 
up to 25% of the total cases of malaria recorded in Africa. An estimated number of 350,000 
lives are expected to be lost every year in Nigeria as a result of malaria infection; most of 
which are pregnant women and children under 5 years (WHO, 2018). Efforts to reduce the 
spread of malaria in Nigeria was boosted in 2003 when over 182 million LLINs were 
distributed over a couple of years. The Nigeria Institute of Medical Research (NIMR), in 
2018 raised an alarm over the continuous increase in the incidence of mosquitoes resistance 
to LLIN in 18 States out of a total of 36 States. These States includes; Lagos, Niger, Ogun, 
Nassarawa, Jigawa, Katina, Kebbi, Sokoto, Zamfara, Benue, Kwara, Anambra, Enugu, 
Rivers, Ondo, Oyo, Osun, (two of these States are represented in this study).  
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Malaria over burdens an already weak health system in Nigeria with more than 110 million 
recorded diagnosis of malaria recorded every year; 60% of all outpatient visits and 30% of all 
hospital admission cases (UNICEF, 2010). Considering the WHO (2005) estimation of 1 
million deaths globally, the rate of death recorded in Nigeria alone is staggering and needs 
urgent attention (Olowe et al., 2015, Afolabi et al., 2007, Jimoh et al., 2007). The huge social 
and economic burden on Nigeria and its citizens causes an estimated amount of ₦132billion 
(£278 million; $363 million) loss yearly in payments of prevention, treatment, and also work-
hours missed. A summary of a lot of studies from Nigeria has established that the most 
prevalent species of malaria parasite in Nigeria is P. falciparum; which is responsible for 
over 95% of all malaria infections. P. ovale, P. malariae and P. vivax are other parasites that 
can be found in Nigeria, even though they play a very minor or inconsequential role.    
With regard to the economic impact of malaria, it can either affect a population directly or 
indirectly. The effect of malaria is not solely limited to human health, mortality and 
morbidity; it also has a detrimental effect on the economy, productivity, national growth and 
development of the areas that are seriously affected by the disease. A high percentage of 
government funds that could have been used to improve lives are spent on dealing with 
morbidity and mortality from the prevalence of malaria. Malaria is a major influence on 
socialisation and the economic wellbeing of people who reside in affected areas. It affects the 
productivity of a society and nation as a whole; draining human resources, resulting in major 
interference to educational activities and causing persistent economic depletion (WHO, 
2008). Frequently, the effect of the disease on the social aspects of life is often ignored (Jones 
and Williams, 2004; Ovadje and Nriagu, 2011; Hong, 2013). Malaria is commonly associated 
with poverty and it is also associated with tropical and subtropical regions because of the 
climatic conditions. Tropical areas such as Nigeria have the optimal environmental 
combination of adequate temperature, humidity, and rainfall facilitating for the aggressive 
reproduction and survival of Anopheles mosquitoes. Malaria burden is not evenly distributed. 
The pattern of malaria transmission is such that the disease is centred in the tropics, but with 
a reach into subtropical regions in five continents (Sachs & Melaney, 2002). 
 Nigeria has one of the largest populations at risk of malaria in Africa and in the world 
(Adetola et al., 2014) and as a consequence, the direct effect of cost related to malaria 
treatment and control is enormous, given the resource-poor circumstances in the country 
(Sachs and Melaney, 2002). The research further showed a direct significant correlation 
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between the rate of economic growth and the burden of malaria, even after adjusting for 
confounding factors (Sachs and Melaney, 2002).                                                                                                             
1.10 The Nigerian health system and delivery structure 
The health care system or health system is designed to deliver healthcare services (as seen in 
Table 1.5). It is a combination of people, institutions and resources that deliver healthcare 
services to meet the needs of a target population. The effectiveness of any country’s health 
care delivery largely depends on the system under which it operates. The National health 
system is decentralized into a three-tier structure and constitutionally charges each tier with a 
specific level of responsibility in the health sector including stewardship, service provision 
and financing. There are three levels of government in Nigeria; Federal, State, and Local 
Government Area (LGAs). The federal level which is the highest level and also known as the 
Federal Ministry of Health (FMOH) is more concerned with the technical support for the 
whole system and also making policies. It also provides health services through the tertiary 
and apex referral institutions such as hospitals and National laboratories. The State 
governments are concerned with secondary health care system. It is also known as the State 
Ministries of Health (SMOH). They are also responsible for the support and regulation of 
primary health care services. The Local government tier (known as districts in other 
countries) is responsible for the primary healthcare where health services are organized 
through the ward. They are in charge of local dispensaries, routine immunization, 
environment sanitation/protection etc. There are about 774 LGAs in total and they are 
expected to target more people and provide easy access to health care by community 
members. It is, however, the weakest arm of health care system and effective access and 
treatment is non-existent which in turn forces most community members to seek health 
services from private providers (usually much more expensive) or at the State of Federal 
level.  Even though the local government in Nigeria can be compared to Councils or Districts 
in more developed countries, these districts usually have a population of about 145,000 to 
200,000 people compared to the LGAs with a population that can be more than 3 million 
people. To consider that the majority of these people depend on primary healthcare, 
especially people from rural areas, it is very disappointing how little effort and finance is 
invested to make sure people have access to good health from these centres. Apart from this, 
most times, confusion of roles and responsibilities occur among the three tiers of government, 
leading to weakness in coordinating and performance. Nigeria has a total of 34,173 health 
facilities: 30,098 primary, 3992 secondary, and 83 tertiary health care units (Agboghoroma et 
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al., 2013). The private sector constitutes 33% of all health facilities in Nigeria (Agboghoroma 
et al., 2013). Private health facilities include private not-for-profit, private for-profit, 
pharmacies, proprietary patent medicine vendors (PPMVs), and mobile clinics.    
 
Table 1. 5: Organization pyramid of the Nigeria Health Services 
Federal Governement Tertiary Services Federal Ministry of Health
State Government Secondary Health Services State Ministry of Health
Local Government Primary Health Services Council
Private Sector
Private Services Private Health Providers
 
 
 
 
36 
 
 
 
1.10.1 Nigeria 
 Nigeria has the second-largest economy in Africa. It is classified as an emerging market 
owing to rich reserves of natural resources and well-developed financial and communications 
sectors. The transportation sector and stock exchange of the country add to the finances. 
                                                      
Figure 1.7: Map of Nigeria showing Lagos State and Osun State regions where the study 
was conducted between 2015 and 2017.  
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 Nigeria (as seen in Figure 1.6 above) is a country comprising of thirty-six states and one 
Federal Capital Territory. The states are further divided into 774 Local Government Areas 
(LGAs). Malaria remains one of the most serious health problems worldwide (Narain, 2008) 
and it is a major public health problem in Nigeria (Federal Ministry of Health, 2005). The 
geographical location of Nigeria makes the climate suitable for malaria transmission 
throughout the country (see Figure 1.7). It is estimated that up to 97% of the country’s 
population of 186 million people are at risk of getting the disease. The remaining 3% of the 
population live in the mountains in southern Jos (Plateau State) and at these altitudes of 1,200 
to 1,400m they are at relatively low risk of malaria.   
             
Figure 1.8: Showing the clinical burden of P. falciparum and prevalence by region in 
Nigeria (Gething et al., 2011). 
Malaria accounts for about 60% of all outpatient attendance and 30% of all hospital 
admissions in Nigeria (Ladi-Akinyemi et al., 2018). Malaria increases the morbidity and 
mortality rates as well as health problems of developing countries, including Nigeria 
(Carrington, 2001). For instance in Nigeria, the National Malaria Control Programme 
(NMCP, 2007) reported that a child is sick due to malaria between 2 and 4 times a year and it 
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was estimated that malaria was responsible for nearly 110 million clinical cases and an 
estimated 300,000 deaths per year, including up to 11% of all maternal mortality. Monetary 
loss due to malaria in Nigeria is estimated to be about ₦132 billion (£2 million; $2.7 million) 
very year in terms of treatment cost, prevention and loss of man-hours ((Ladi-Akinyemi et 
al., 2018). In order to reduce malaria epidemics, the Nigerian government and international 
bodies have developed a series of control measures, dating back to over 60 years (Shiff, 
2002) thus, it is a desirable time point to investigate the extent of malaria burden and the 
effectiveness of various malaria control measures in Nigeria. The findings of the study are 
expected to generate awareness, which could lead to improvement in the level of government 
participation in the effective prevention and control of malaria in Nigeria. About half of 
Nigerian adults have at least one episode of malaria each year and 7 out of every 10 patients 
seen in Nigerian hospitals are ill of malaria (FMOH, 2005). Furthermore, malaria is one of 
the principal reasons for poor school attendance in many settings and is thought to account 
for 13 to 15 percent of medical reasons for absenteeism from school (Holding & Kitsao, 
2004). In addition, pregnant women are in the high-risk groups. The Roll Back Malaria 
program (RBM, 2005) reported that malaria was responsible for one death out of every ten 
women who died around childbirth, and three out of every ten deaths in children under 5 
years of age. 
Lagos is a huge city that attracts different professionals from Nigeria and abroad. Its 
internally generated revenue was estimated to be over ₦503.7bn (£1 billion; $1.3 billion) in 
2007 and it received a Federal government (FG) allocation of ₦178bn (£380 million; $490 
million). In contrast, Osun state, with more farmers and civil servants, manages to generate 
internal revenues of approximately ₦700million and it receives a FG allocation of ₦66bn 
(£142 million; $182 million). The wealth index of each State in Nigeria is shown more 
clearly in Figure 1.8 below. 
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Figure 1.9: Map showing Nigerian States by GDP in 2010. This information provided on 
this map illustrates the huge difference in wealth of people leaving in Osun State as compared 
to those living in Lagos State. (Source: http://services.gov.ng/states). 
1.10.2 Osun State 
Osun state was created in 1991 (Figure 1.9); carved out of Oyo State, it shares borders with 
Kwara State to the North, Ondo State to the east, Oyo state to the west and Ogun state to the 
south. The people of Osun State are mostly traders, farmers and civil servants by profession. 
Osun has a population of about 3,423,535 inhabitants, which is a representation of 2.5% of 
Nigeria’s total population. It covers an area of about 9,251 km2. There are no extensive 
records to predict the trend and pattern of malaria in Osun State, but over the years numerous 
research studies have been carried out on malaria; including epidemiology, prevalence, 
awareness, control, treatment, morbidity and mortality. A study conducted by Bamidele et al., 
(2012) on the community participation in malaria control in the Olorunda Local Government 
Area (Osun state) explains that the awareness of people about malaria infection is high and 
also, result shows more than 50% rate of community participation in malaria  control among 
participants. However, the same study reports a very low usage of insecticide treated nets 
(ITNs). 
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Figure 1.10: Maps of Osun State, South-West Nigeria; showing the urban (Osogbo (A)) 
and rural (Iwo (B)) regions where the current study was carried out (Source: VON, 2018). 
 
A similar result was observed by Isola et al., (2015) in a study to define perceptions and 
practice of malaria prevention within Osun State students. Students were shown to have a 
reasonable knowledge about malaria control and prevention; an impressive 86.5% of the total 
number interviewed reported malaria to be a mosquito-borne infectious disease. In a further 
study by Adegun et al., (2011) 75% of farmers interviewed reported that mosquitoes are the 
cause of malaria. Also, a study among tertiary students in Osun State by Adetola et al., 
(2014) to define perception and treatment practices among tertiary institution students in Oyo 
state and Osun state, showed that a high proportion of responders (67.5%) would take 
prescription advice from medical personnel before treating malaria; 60.8% however did not 
go for malaria diagnostic tests before taking an antimalarial drug. It should be noted that 
before you can provide an acceptable prescription from a doctor or medical personnel you 
must have been diagnosed at a medical centre and the presence of the malaria parasite must 
have been confirmed. Therefore, in this case, it is either medical personnel in the region that 
are not following the protocol or just 6.7% of the respondents were actually tested in the 
hospital and acquired a  prescription while others received medical advice outside the 
hospital recommendations. 
Malaria prevention and control strategy is still a challenge in Osun State. Malaria is 
responsible for the high rate of maternal and childhood mortality. Only 1.9% of households 
have at least one insecticide treated net. As described by SMOH (Osun State Ministry of 
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Health), the incidence rate of malaria in Osun state is constantly on the rise among vulnerable 
groups. The prevalence of malaria in children under 5 was 158,937 in 2006 and then 230,579 
in 2007. Among pregnant women, malaria incidence was recorded to be 619 in 2006 and then 
9731 in 2007; a massive increase from the previous year. More recent data on the general 
prevalence of malaria in this region is however not available. With regard to treatment, only 
10% of children under 5 were appropriately treated with ACTs in 2007. As recorded by 
SMOH, barriers to intervention by RBM programme in the State include low level of 
awareness on malaria, substandard ACTs or high cost of ACTs, low technical capacity of 
health workers, and unavailability of diagnostic equipment (RDT). The most recent 
intervention was supported by WHO in 2017, where over two million insecticide treated nets 
were distributed for malaria control (WHO, 2017). 
1.10.3 Lagos State  
Lagos state is located in the South-Western geopolitical zone. Although it is the state with the 
smallest land area in Nigeria, it is the most populous and arguably the most economically 
important state in the country (map in Figure 1.10). Lagos State contains Lagos city which is 
the most populous city in Africa with a population of over 21 million people many Nigerians 
relocate to the city from other regions and there is also many international visitors. Lagos is 
divided into the island and the mainland regions. The mainland harbours most of the 
inhabitants of Lagos and most industries are located there. Malaria is endemic in Lagos State 
and one of the most important reasons for this is people’s behaviour and the availability of 
stagnant water for breeding Anopheles mosquitoes.  
 
Figure 1.11: Maps of Lagos State, South-West Nigeria; showing the urban (Lagos Island 
(Lekki)) and rural (Lagos mainland (Ikorodu)) regions where the study was carried out. 
(Source: VON, 2018) 
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As seen in Figure 1.11, “The road to 2020; Mobilising the Private Sector in Nigeria’s Fight 
against Malaria” showed an increasing trend of malaria cases in Lagos state between 2004 
and 2014.  
 
Figure 1.12:  Trend of reported cases of Malaria in Lagos from 2004-2014. The number 
of malaria cases increased by 58% from 260,578 in 2005 to 622,562 in 2011. There was a 
reduction to 488,780 in 2012 and it increased to 547,150 in 2014. (Osunkiyesi, 2015) 
The Lagos State Commissioner for Health, Dr Jide Idris, at the 5th “Doctors Discuss 
Malaria’’ Programme, in Lagos, said the state recorded 1,199,002 cases in 2016. This shows 
that just like most States in the country, malaria incidence has been on the increase even 
though there have been numerous intervention programs to curb this. However, a study by 
Agomo & Oyibo (2013) showed a low malaria prevalence in a community in Lagos State and 
the reason was attributed to the scaling up of malaria intervention programs, and mainly 
because the study was carried out in an urban region. One of the strategies of intervention to 
control malaria in Lagos included free treatment of all malaria cases in all age groups; 
however, the state failed to meet set targets to end the trend of morbidity and mortality 
because of the sudden spread of chloroquine resistant strains of Plasmodium.  
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1.11 Malaria control and treatment 
In an attempt to eradicate malaria, the United Nations declared the years 2000-2010 as the 
malaria decade with the constitution of the Roll Back Malaria (RBM) Initiative. Since then, 
continuous efforts have been made not only by other international organisations but also in 
collaboration with malaria-endemic nations, with the sole aim of bringing the disease under 
control (Folande et al., 2005). In light of this, the World Health Organisation (WHO) in its 
effort to eradicate/control malaria infection in malaria endemic countries advocates three 
different strategies; 
 Effective Case Management (ECM) – the use of antimalarial drugs to get rid of 
malaria parasites from already infected individuals. 
 Integrated Vector Control (IVC) – the various methods of killing mosquitoes, such as 
mosquito coils and indoor residual sprays. 
 Personal Protection (PP) –the measures that prevent contact between mosquitoes and 
humans, such as insecticide-treated nets (ITNs). 
These three strategies are believed to be the driving force of all parastatals and organizations 
to create malaria-free nations. However, for the purpose of this study, more emphasis will be 
placed on malaria Effective Case Management and how it affects malaria control as a whole. 
One of the challenges of effective malaria control in Nigeria is research-based data on cases 
of treatment failure to drug-resistant P. falciparum, however, as explained by Aribodor et al., 
(2016), there is a difference between drug resistance and treatment failure. Inadequate clinical 
response or failure to clear malaria parasites after the use of a drug does not necessarily mean 
treatment failure and could be as a result of non-patency (inability of the drug to pass 
through). In an effort to reduce treatment failure, the WHO developed a protocol for 
assessment and monitoring drug efficacy. Patients are expected to be followed up for 14-
28days, depending on the drugs used and the intensity of transmission (WHO, 2002). 
However, these requirements are not in place in the Nigerian Health System (NHS) unless the 
patient is on hospital admission before they can be closely monitored.  
In Nigeria, it costs about $0.50 (₦200) to treat malaria using self-medication and about $7 
(₦3000) to seek treatment from an authorized health care provider. This is because, with self-
medication, some processes such has hospital registration (which costs money) can be 
skipped. The difference in price explains why there is a huge incidence of inappropriate 
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treatment methods in the country which in turn affects the effective control of the disease. 
Another way through which poverty affects malaria transmission is that poor individuals 
cannot live in houses that can protect them from mosquito bites, and they cannot afford the 
other preventive measures such as ITNs and IRS. On a larger scale, poor communities cannot 
invest in available preventive measures, governmental controls or development programs 
(Teklehaimanot and Mejia 2008). In most developed and undeveloped countries the rate of 
poverty directly affects malaria control; this could be the inability to afford common 
preventive measures such as mosquito coils, IRS etc. Housing conditions in these countries 
are also major factors that encourage the spread of malaria. Teklehaimanot and Mejia (2008), 
explain that the relationship between poverty and malaria has long been recognised but its 
paths are multiple and complex. Studies show a cycle between malaria and poverty meaning 
both leads to each other at some point in less developed countries. 
The complexity of the life-cycle of malaria parasite is a major challenge to malaria control 
efforts. The process of sexual reproduction in mosquitoes and asexual reproduction in 
humans makes it difficult to develop a vaccine which can target the parasite. This makes 
effective malaria treatment the best option available to effectively control and eradicate the 
disease. 
1.12 Treatment behaviour and perception 
Common symptoms of malaria include; fever, headache, back pain, chest pain, nausea, body 
weakness, vomiting, (Che et al., 2015). In severe cases, complicated malaria can lead to coma 
and sometimes death of person infected (Bell & Winstanley, 2004; Eugene-Ezebilo & 
Ezebilo, 2014). Malaria can easily be cured if diagnosed early and treated properly as 
recommended by the WHO. However, in recent years, there has been a major increase in the 
resistance of parasite to the commonly (recommended) used antimalarial (Affum et al, 2013). 
One of the challenges of effective case management of malaria is the fact that the symptoms 
are easily presumed by patients and most times wrong. In epidemic areas like Nigeria, 
feelings of a headache and nausea can easily be attributed to the presence of the disease and 
hence, treatment is sorted and most times without prior confirmation through recommended 
methods as advised by the Ministry of Health. Treatment of malaria without the confirmation 
of the parasite is a major barrier to effective case management and eventually leads to 
resistance of the parasite to drugs that would have been effective if used appropriately.  
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As rightly pointed out by Rumun and Terungwa (2015), the symptoms that are attributed to 
malaria vary and range from ‘feeling unwell’ to a rise in body temperature, especially in 
children. In most endemic areas malaria is over-diagnosed on the basis of symptoms alone 
because of its non-specificity of symptomatology. In this case, treatment is either delayed or 
an ineffective treatment is given and this can progress to severe malaria manifesting as coma, 
severe anaemia, renal failure, hypoglycaemia or acute pulmonary oedema.  
In Nigeria, Okeke & Okafor (2008), carried out a study to determine the perception and 
treatment seeking behaviour for malaria in rural Nigeria amongst 300 caregivers; the results 
showed that over 60% of respondents believe that malaria is just a common illness and 50% 
believe that heat from the sun caused malaria. Only 19.8% correctly said mosquito bites 
caused malaria. 
Treatment-seeking behaviour is determined by a number of factors; access to treatment 
source, attitude towards provider, perceived severity of illness, costs of services, educational 
status, and cultural belief (Okeke & Okeibunor, 2010). It is believed that rural and urban 
communities seek treatment differently. A study by Dida et al., (2015) on the treatment 
seeking behaviour and associated factors among malaria-suspected patients in Ethiopia 
showed that over 87% of respondents did not seek treatment within the recommended first 
24hours from the onset of illness. Also, 15.2% sought treatment from a non-medical centre 
before visiting the health institution. This data shows the extent of poor treatment seeking 
approaches by people living in rural areas in developing African countries. Treatment seeking 
behaviour is an underlying problem that affects the effective treatment of malaria. Similar 
results were also observed from a different study by Romay-Barja et al., (2015) while trying 
to understand the rural-urban differences in household treatment-seeking behaviour for 
suspected malaria in children. Results from this study showed that fever was the main 
symptom associated with malaria in both rural and urban areas, and most people first treated 
malaria at home before visiting private clinics and hospitals (for urban households) and 
hospital and health centre (for rural households). It should be put into consideration that most 
studies on treatment seeking might only show people’s approach to malaria treatment but 
they do not necessarily show the number of people who had malaria but treated it 
inappropriately or people who did not have the disease but got treated for it. Also, McCombie 
(2002) suggests that before examining evidence related to malaria treatment behaviour, it is 
necessary to consider the difficulties in defining malaria. This is because ‘every attempt to 
develop a clinical definition of malaria that has a predictive value higher than fever alone has 
been mostly unsuccessful.  
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A recent study by Singh et al., (2014) in the northern part of Nigeria showed that 12% of 
respondents had knowledge of the role mosquitoes play in malaria transmission and 10% 
know that it actually causes malaria. However, this same study showed that 90% of the 
respondents have a comprehensive knowledge about prevention. This proves that 
misconceptions about malaria transmission and its cause still exist and knowledge about 
prevention does not necessarily mean it affects the approach to treatment. 
1.13 Self-medication 
WHO (2000) agrees that self-medication is an important part of Public Health which plays a 
key role in healthcare systems. Evidence of self-medication can be traced back to the 1960s 
(Bhuyan, 2014). As quick treatment using an effective antimalarial drug is the most crucial 
technique in preventing mortality and morbidity from malaria, it is very important that when 
treatment is done it is in line with the recommendations of WHO and country’s health 
policies. However, in many malaria-endemic countries, health care structures are poor and 
most people find it difficult to access health care services (McCombie, 2002). Despite the 
growing research interest in self-medication, little information has been available about its 
major determinants especially in developing countries (Afolabi, 2008). 
There are various definitions of self-medication or self-care. Metta (2014) defined it as “a 
process in which individuals undertake disease prevention, detection, and treatment on their 
own without consultation to health care providers; it entails self-diagnosis and use of 
remedies previously prescribed for similar illness and/or the purchase of medications without 
personal advice”. McCombie (2002) defined self-treatment as “any treatment that does not 
involve consulting a health care provider or traditional healer”. However, for this thesis, self-
treatment is defined as any treatment that does not involve consulting health care providers 
prior to an attempt to buy antimalarial drugs to treat a suspected case of malaria. The reason 
for this is that some people actually visit health care providers such as in pharmacy stores to 
discuss their symptoms and buy any antimalarial drug the pharmacists prescribe. The WHO 
(2002) recommends that before any case of malaria is treated, there must have been a 
confirmation of the Plasmodium parasite in the client’s body. Research done in this area 
shows that people self-medicate because of three important factors; time, cost, and severity of 
symptoms (Vukovic, 1999). Self-medication can be because of the beliefs that patients spend 
too much time waiting to be diagnosed or treated for malaria at hospitals and clinics. They 
prefer a drug vendor or a pharmacy store where they can walk in and finish the whole malaria 
treatment process quickly. In addition to this, because people in malaria-endemic countries 
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treat malaria many times in short periods, they believe to have mastered the disease and are 
‘fit’ to prescribe the best treatment. They believe they know which one works better, how fast 
it works, and how your body reacts to it. Self-medication is so bad in Nigeria that people 
practise what is called ‘counting’; which literally means counting different kinds of 
antimalarial together to make it effective and fast too. Some people, because of the poor 
access and state of health facilities prefer to receive initial treatment for illnesses at home 
using antimalarial drugs purchased from local shops without prescription (Chipwaza et al., 
2014) than to go to the hospital; where the efficacy of drugs and its safety cannot be trusted, 
Mugisha et al., (2002) explains that self-treatment saves time and also reduces cost for 
treating sickness because people have the power to decide what to buy. It is generally 
believed that self-medication is prevalent among poor people, however, evidence shows that 
other socio-demographic factors such as age and educational level can also affect people’s 
attitude towards treatment. Luckvic et al., (2014) described more in details the numerous 
factors that influence self-medication to include; family attitudes, advertising of drug 
manufacturers, previous experiences with a disease or symptoms, and also, legislation 
regulating dispensing and sales of drugs. The risk associated with this is the lack of clinical 
evaluation by the care provider which could result in misdiagnosis and wrong choice of drugs 
(including the wrong dosage) (Hughes et al., 2001). It could also lead to treatment failure and 
other adverse drug reactions. 
Poor diagnostic ability in addition to limited knowledge of appropriate management of 
malaria results in the increase of self-medication and low rate of health care utilization 
(Afolabi, 2008). The availability of antimalarial drugs over the counter is also a factor that 
encourages self-medication. People can easily store these drugs at home to treat symptoms of 
malaria at any time they want. A hospital-based study in Tanzania showed that over 72% of 
respondents actually have already used home kept antimalarials for fever symptoms (Mnyika 
et al., 1995). 
It should be noted that self-medication is not without its advantages; it can help patients take 
care of minor ailments, reduce pressure on health care providers especially in developing 
countries where insufficient health care providers are prevalent. It can reduce the cost of 
treatment and pressure on medical services, but only when done appropriately and not in 
malaria suspicious cases. 
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1.14 Counterfeit drugs 
Counterfeit drugs are fast becoming a major public health issue, affecting not only 
developing countries but also developed countries with effective regulatory systems and 
market controls. The production of counterfeit drugs is a broad and under-reported problem 
that is affecting poorer countries (Akinyandenu, 2013). The WHO (2003) defined counterfeit 
medicine as “any medicine which is deliberately and fraudulently mislabelled with respect to 
its identity and/or source” and this may include medicines containing the wrong amount of 
active ingredients, wrong active ingredient, or no active ingredient. The detrimental effect of 
counterfeit drugs includes unexpected side effects, treatment failure or even death (Lawson et 
al., 2014). The WHO (2012) states that globally, more than 10% of drugs that are traded are 
counterfeits.  Counterfeiting in general is a huge problem in Nigeria; ranging from 
entertainment, currency, electronics, among others. None of these, however, can harm 
citizens as much as drug proliferating can. Counterfeit drugs are produced to look exactly like 
original drugs that it might only take a laboratory test to differentiate. As Taylor et al., (2001) 
rightly points out the quality of medicine produced in the majority of the less developed 
countries have incorrect active ingredients. For example, Newton (2014), described a case of 
a huge shipment from China of about 1.4million packets of antimalarial was seized in June 
2012. One of the groups seized was labelled to be produced by ‘Novartis Pharmaceutical 
Corporation’ one of the biggest antimalarial drug producers in Africa. It was labelled as a 
vital artemether-lumefantrine drug in the Country. It was however after the tablets were 
analysed using different analytical methods, that it was found that no artemether, 
lumefantrine, or any active pharmaceutical ingredients were in the tablets. 
Unlike counterfeit drugs, substandard drugs are most times genuine but for some reason or 
the other may not meet the drug quality requirement intended by the manufacturer. As Affum 
et al., (2013) explains it, substandard drugs most times either do not have up to the 
appropriate amounts of Active Pharmaceuticals Ingredients (API) or have more than the API 
required. However, it should be noted that the percentage of API in genuine or authentic 
drugs may be affected by extreme temperature or humidity (Taylor et al., 2001). There are 
numerous detrimental effects of the use of counterfeit or substandard drugs; from adverse 
side effects to treatment failure. One very important after effect of using a counterfeit drug 
for malaria case management is the development of drug-resistant parasites; the major 
contributor to the increasing rate of drug-resistant P. falciparum is the use of substandard 
anti-malarial drugs (Affum et al., 2013).  This is because these substandard drugs being used 
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do not have accurate API to clear the parasites from the infected body. Substandard 
medicines and medical products and counterfeit drugs cause avoidable, mortality, morbidity, 
drug resistance and loss of faith in health systems, which is one of the biggest problems of 
health seeking Nigerians. Over time, cases of treatment failure or death recorded in hospitals 
in Nigeria has made it hard to convince patients to trust and receive treatment for serious 
ailments (in this case, malaria) in hospitals. The WHO’s recommendation of ACTs as the 
first-line treatment of malaria is emphasised in Nigeria and this has made ACTs a major 
target for counterfeit production. WHO (2013) estimates that 60% of the counterfeit drugs 
purchased in developing countries does not have the Active Pharmaceutical Ingredients 
(API); 17% contained too much or too little while 16% contained the wrong ingredients 
A survey was carried out by Newton et al., (2006), on the proliferation of fake drugs between 
1999 and 2002, and results showed that 38% to 53% of the artesunate antimalarial drugs 
produced by Chinese and Indian companies were counterfeited. However, although there is 
not enough data to support this, some people actually buy these counterfeit drugs on purpose 
because of their price compared to the authentic drugs and also, because they think the 
substandard drugs are equally effective (Chiwendu, 2008). Akinyadenu (2013) says that 
counterfeit drugs are a cause of morbidity, mortality and loss of confidence in health and 
medicine structures especially in areas where they are endemic. The United Nation Office on 
Drugs and Crime implies that China and India are major exporters of counterfeit drugs 
Nigeria (UN, 2010). Therefore all ACTs that are imported into Nigeria from these countries 
should be properly monitored and evaluated from time to time. A report from Pfizer shows 
that the profit from counterfeiting even surpasses profits from heroin and cocaine (PGS, 
2007). The rate of fake drugs has continuously increased in the past decade that Osibo, 
(1998) suggested that there may be more fake drugs in circulation than genuine drugs; a 
statement later supported by WHO in 2013 (WHO, 2013). Nigeria is one of the countries at 
the centre of the massive counterfeit drug production/usage and this is largely due to 
inadequate infrastructure and the political will to properly introduce and enforce legislation. 
The Nigerian government in its effort to reduce substandard and counterfeit drugs in 1998 
introduced decree NO 21, which makes it illegal to sell or distribute banned and adulterated 
drugs (Akinyandenu, 2013). National Agency for Food and Drug Administration Control 
(NAFDAC), which was created in 1993 was introduced to help curb the distribution of fake 
drugs and was able to reduce drug failure rate by 16% in 2006 from the total number in 2002 
and circulation of counterfeit drugs fell by 80% between 2001 and 2006 (Akinyandenu, 
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2013). Poverty in developing countries, poor regulatory systems and the rising cost of 
original therapeutic agents are the main reasons behind the increase in the production of fake 
drugs because of the huge profit margin (Karunamoorthi, 2014). 
Little research has been done in Nigeria to determine the quality of antimalarial drugs 
including Taylor et al., (2001); “pharmacopoeial quality of drugs supplied by Nigerian 
pharmacies”. This study aimed to determine the API of different medicinal drugs being sold 
at pharmacy stores in two different urban areas using HPLC as a method of analysis. This 
study, however. did not necessarily check if these drugs were counterfeit or authenticate the 
source of the drugs. Using the British Pharmacopoeia limits, results showed that out of a total 
of 581 samples, 279 (48%) contained the amount of active ingredients outside the appropriate 
limit and for all the group of drugs checked, including antimalarial, antibacterial, and anti-
tuberculosis; more than 50% failed to meet the BP specifications. To improve on this 
research, the test of efficacy and authenticity of antimalarial drugs using FTIR and in-vitro 
cultures to determine two things; the prevalence of counterfeit drugs in the communities 
where this research is being done and also the efficacy of the antimalarial drugs in 
Plasmodium parasites across urban and rural areas of two different States will be done. 
Nigeria is one of the major selling sites for counterfeit product manufacturers (Figure 1.12).  
The porous control system of the Nigerian economy has enhanced the manufacturing and 
distribution of fake and substandard drugs in the country (Akinyadenu, 2013). Although there 
are various laws and policies that are in place to regulate and control the manufacture and 
distribution of drugs, Erhun et al., (2001) describes the situation as far from adequate. 
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Figure 1.13: Global repartition of medicine counterfeiting in the world – from level of 
production to selling (Dégardin et al., 2014). 
1.14.1 Quality assurance/control 
1.14.1.1 FT-IR 
FT-IR is a technique that is used to collect an infrared spectrum of absorption, emission, 
photoconductivity, or Raman scattering of a solid, liquid, or gas. FT-IR stands for Fourier 
Transform Infrared; it is the desired method of infrared spectroscopy. The process of infrared 
spectroscopy involves infrared radiation being passed through a sample; some of the radiation 
is absorbed by the sample being tested while some passes through it. It then provides a 
spectrum that represents the molecule’s absorption and transmission, providing a molecular 
fingerprint of the sample. Karzarian et al., (2013) defined FT-IR as a highly versatile, label-
free, and a non-destructive chemical imaging method that can be used to study a wide range 
of samples and systems. The information that FT-IR provides includes identifying unknown 
materials, determining the quality or consistency of a sample and it can also determine the 
amount of components in a mixture. Since every material is composed of unique 
combinations of atoms, no two compounds will therefore produce the exact same infrared 
spectrum. Generally, FT-IR spectrometers are widely used in petrochemical engineering, 
food analysis, organic synthesis, polymer science and pharmaceutical industry. In order to 
satisfy a safe and effective therapy, especially drug-related, it is imperative to identify and 
quantify the impurities present in raw materials, therefore, control of impurities is a key 
52 
 
component of the quality of pharmaceutical substances and their products and it also 
represents one of the biggest challenges for analysis in the industry. 
FT-IR spectroscopy is very often used in the pharmaceutical industry for the identification of 
drug products (Higgins et al., 2008) and like other optical spectroscopic techniques, FT-IR 
can also provide quantitative information and can be used to predict the concentration of 
pharmaceuticals in both solid and liquid states. 
1.14.1.2 NMR Spectroscopy 
Nuclear Magnetic Resonance spectroscopy is a powerful and theoretically complex analytical 
tool. NMR spectroscopy is an important technique that can be used to determine the physical 
and chemical properties of atoms and molecules. The NMR spectroscopy is an important 
technique for determining physical and chemical properties of atoms and molecules. It is the 
only spectroscopy method that provides complete information and interpretations of the 
entire spectrum such as information about the structure, reaction state, dynamics, and 
chemical environment of molecules. The technique relies on the fact that the atom’s 
intramolecular magnetic field changes its resonance frequency, giving access to the electronic 
structure of the molecule. The NMR spectroscopy is commonly used to analyse the properties 
of organic molecules, although it is applicable to any kind of sample that contains nuclei 
possessing spin. 
NMR spectroscopy plays a very important role in the continuous expansion of the 
pharmaceutical industry and most importantly since high-throughput screening the discovery 
process for new therapeutics (Powers, 2008). In the pharmaceutical line, there are three 
important stages that run every pharmaceutical company or industry; lead discovery, drug 
optimization, and clinical evaluation. NMR provides a valuable contribution to these three 
stages (Stockman et al., 2009). Fukushi (2006) believes NMR is the analytical tool used to 
determine the composition and chemical structure of both synthetic and natural product 
chemical leads. The mode of action of NMR is its use as a powerful, universal and fast-
screening technique to detect intermolecular interactions with unparalleled sensitivity and 
also its ability to provide information about structure-based design. NMR is well known for 
its ability to identify and quantify small molecules in a complex mixture (Lewis et al, 2007).  
Nyadong et al., (2009) and Holzgrabe et al., (2011) have also used NMR to identify 
counterfeit drugs from field samples. The three sub-discipline of NMR are solid-state NMR, 
NMR imaging (MRI) and solution- state NMR. 
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1.14.3 High Performance Liquid Chromatography (HPLC) 
HPLC is the premier analytical technique used in many pharmaceutical applications 
including potency/purity/performance assays, pharmacokinetics/bioanalytical testing, 
purification, high-throughput screening, In-Process control (IPC), monitoring and Quality 
Control (QC) testing. HPLC can provide information about the composition and quality of 
drug-related samples. HPLC play an important and critical role in the field of pharmaceutical 
industries and analysis since it is used to test the products and to detect the raw ingredient 
used to make them i.e., qualitative and quantitative analysis. Moreover, the importance of 
HPLC uses in these fields falls under the stringent regulations established by the U.S. Food 
and Drug Administration (FDA). This obligate all pharmaceutical companies to detect the 
quality of their products by using the HPLC before allowing them to sell it in the global 
market. It may also be used to further our understanding of the normal and disease process in 
the human body through biomedical and therapeutically research during investigation before 
the drugs registration.  
Other methods to determine the quality of a drug includes; the Near Infra-red Spectroscopy 
(NIR), which produces spectra that carry the information not only regarding chemical but 
also physical phenomena (Sauzier et al., 2016; Rodionova et al., 2018). 
1.15 Summary  
Effective malaria case management is pivotal to the complete removal of malaria disease in 
Nigeria and other countries. To rapidly promote this, the Federal Government has officially 
prohibited the use of inefficacious medicines such as chloroquine, SP and other 
monotherapies and has increased its effort to build the system to detect fake and substandard 
medicines while also monitoring pharmacovigilance in collaboration with NAFDAC. The 
only drug which has shown high efficacy against the malaria parasite is the Artemisinin-
based Combination Treatments (ACTs), and has been adopted by Nigeria for the treatment of 
uncomplicated cases. 
1.16 The aims and objectives 
The project proposes to qualitatively and quantitatively analyse chemotherapeutic practices 
and outcomes at an individual and community level in two selected States (Lagos and Osun) 
in the South West Region of Nigeria; in a bid to explore the relationship between socio-
economic backgrounds, self-medication practices, and treatment practices, as barriers for 
malaria case effective management. These two locations, with a close proximity, have similar 
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geographical properties but different wealth status. I am local to these areas as I have lived in 
both States; which is my main motivation to make a difference in these regions. This level of 
comparison (between a group of high socio-economic class and lower socio-economic class) 
provides an opportunity to identify and provide solutions to a group of people with the same 
malaria endemic rate but with different Socio-economic status (SES), exposure, and 
employment rate. Other project objectives to assist understanding these barriers are:   
 To compare malaria treatment data records from hospitals and regional pharmacies, in 
a bid to identify barriers to malaria effective case management as a result of a health 
provider’s non-adherence to recommendations and policy. 
 To qualitatively analyse randomly sampled antimalarial drugs from the region using 
FT-IR spectroscopy and in vitro culture methods to evaluate the spread of counterfeit 
drugs. 
 
Overall, the thesis work aims to contribute to strategies currently in use by 
international health organizations (such as WHO, UNICEF, etc.), governments and 
non-governmental organizations to improve malaria intervention programmes; the 
focus is upon Nigeria but findings could also be applicable to other malaria endemic 
countries.   
 
Research questions 
RQ1: Are the socio-demographics of residents in these regions (as defined by age, 
educational level, residence, and stated willingness to pay) associated with barriers to malaria 
effective case management and their malaria treatment-seeking behaviour (as defined by 
percentage of people who self-medicate or/and are treated with drugs outside the adopted 
recommendations)? 
RQ2: Is the type of medicine store (defined as pharmacy stores and PPMVs) where treatment 
is sought associated with adherence to recommended malaria treatment practices? 
RQ3: Are hospital care-givers adhering to the recommended treatment policies?  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Field sampling: Study 1 (Hospital) 
A retrospective evaluation of quality and types of malaria management was carried out in 25 
hospitals; including public and private owned Clinics in Osun State and 19 in Lagos State 
(Figure 2.1) as part of a larger study to investigate barriers to effective malaria case 
management in two Southwest States in Nigeria. It is commonly used in Social Sciences, for 
example information collected by the government for census etc. In this case, data already 
collected by doctors and nurses for hospital records are used as secondary data for this 
research.  
 
Figure 2.1: Sampling areas for current study: PHC = Primary Health Centre. CHC = 
Comprehensive Health Centre (General Hospitals, State Hospitals, Dental Centres and Staff 
Clinics). 
 
2.1.1 Hospital questionnaire 
Number of patients suspected to have malaria…………………………………………………. 
Suspected malaria patients in whom any test was carried out…………………………………. 
Suspected malaria patients assessed clinically only……………………………………………. 
Suspected malaria patients tested by microscopy……………………………………………… 
Suspected malaria patients tested by RDT……………………………………………………... 
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Cases appropriately tested using (RDT + Microscopy)………………………………………... 
Suspected malaria patients found to be negative……………………………………………….. 
Confirmed negative cases treated with antimalarial……………………………………………. 
Negative cases not given antimalarial………………………………………………………….. 
Cases found to be malaria positive……………………………………………………………... 
Positive cases appropriately treated with ACT………………………………………………… 
Positive cases treated with Quinine…………………………………………………………….. 
Positive cases treated with SP………………………………………………………………….. 
Positive cases not treated with antimalarial……………………………………………………. 
The questionnaire was designed after a selective literature review on malaria treatment 
practices in Nigerian hospitals with particular emphasis upon adherence to diagnosis and 
treatment guidelines (Bamiselu et al., 2016; Onwujekwe et al., 2009; Bello et al., 2013).  A 
purposive sampling method was adopted; hospitals with higher patient loads were targeted in 
a bid to cover as many patients as possible. 
 
2.2 Field sampling: Study 2 (Pharmacy and Patent and 
Proprietary Medicine Vendors (PPMVs) 
For data collected in regards to drugs purchased by clients, a prospective, descriptive, cross 
sectional survey was carried out in the two States at medicine retail outlets comprising of 
pharmacies and PMVs between the month of April and September 2015 and also repeated 
between September and November 2016 during the second year data collection phase. Cross-
sectional studies are simple in design and very useful at finding out the prevalence of a 
problem or attitude by taking a snap-shot or cross-section of the population.  This makes the 
method appropriate for this part of the research; the attitude or behaviour of a group of people 
towards malaria treatment can be analysed over a period of time. However, a disadvantage of 
cross-sectional study is that it is not longitudinal by design, where each participant is 
observed at multiple time points, thereby allowing trends in an outcome to be monitored over 
time (Sedwick, 2014). 
With the use of a questionnaire which is made up of 8 questions (refer to section 2.4.1), data 
such as the education level of the pharmacist, patient demographics, drug prescription 
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method, drugs requested and drugs purchased were obtained. Data were also collected to ask 
questions about pre-diagnosis, self-medication, and if pharmacist had influenced the clients’ 
decision on which drugs to buy. For the purpose of this research, self-medication was defined 
as drugs specifically requested by clients without a proof of prescription. However, it should 
be noted that people sometimes speak with relatives or friends that are qualified health 
providers and do not necessarily have a form of written prescription. 
The way Nigeria’s health system is set up makes it unrealistic or impossible to conduct a 
probability sampling for this study. To accurately capture the pattern of drug use and 
treatment in all Pharmacy Stores and PPMVs, a convenient sampling was used to purposely 
select a representative number of medicine retail outlets across urban and rural areas in the 
three States. This sampling was purposely designed to include pharmacy stores and PMVs 
with high rate of utilization or patient load, and retail stores with extremely low utilization 
levels were dropped. For example, outlets with very few clients and number of malarial cases 
attendance would not produce accurate data to effectively determine an association between 
variables, compared to data from other stores with high patient load, or test a hypothesis. So, 
pharmacy stores and PMVs with high utilization level (at least 20 antimalarial per week) 
were selected. The medicine retail outlets were strategically selected to cover all parts of the 
urban regions and also the rural regions of each State selected for this study, with 20 people 
targeted at 10 outlets in each region.  
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Figure 2.2: Area of Pharmacy and PPMV data collection site (Lagos rural) 
 
Figure 2.3: Area of Pharmacy and PPMV data collection site (Lagos urban) 
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Figure 2.4: Area of Pharmacy and PPMV data collection site (Osun urban) 
 
Figure 2.5: Area of Pharmacy and PPMV data collection site (Osun rural) 
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2.2.1 Pharmacy and PPMVs questionnaire  
1. Educational level of pharmacist/drug vendor:  Primary □ Secondary □ Tertiary □ none 
□ 
2. Which Antimalarial drug do you mostly prescribe to clients?  
 Amatem □ Coartem □ Leonart □ Combiart □ Choloquine □ Fansidar □  
Others (please provide with the name) …………………………….. 
3. Sex of client:    Male □   Female □ 
4. Has the client shown any proof of diagnosis?     Yes □    No □ 
5. Is the client self-medicating?   Yes □    No □ 
6. Which Antimalarial drug was purchased by client?  
 Amatem □ Coartem □ Leonart □ Combiart □ Choloquine □ Fansidar □  
Others (please provide with the name) …………………………….. 
7. Did the pharmacist influence the decision in which drug to buy?  
 Yes □    No □  
8. Price of Antimalarial drug purchased by client? ₦……….. 
 
This questionnaire was designed after a selective literature review on malaria treatment 
practices in medicine retail outlets. The previous studies (Beyeler et al., 2015; Ezenduka et 
al., 2014; Isiguzo et al., 2014; Liu et al., 2015; Mamodesan, 2015) have included questions 
such as education level of the drug seller, antimalarials sold (ACTs or non-ACTs) and price 
of drug. However, the current research also added questions on the influence of the drug 
seller on the type of antimalarial sold to the client since a preliminary interview showed that a 
lot of clients depended on the expertise or knowledge of the seller in prescribing an 
antimalarial. Also, a purposive sampling method was adopted; pharmacy stores and PPMVs 
with a high client visitation were targeted in a bid to cover as many patients as possible. 
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2.3 Field sampling: Study 3 (Community data) 
This descriptive cross-sectional study was done between April and September 2015 in the 
community survey and was repeated between September and November 2016 using cluster 
sampling methods. Volunteers were recruited from CELSUM (Centre for Life Support 
Mission) and were properly trained by prior lectures to distribute and assist those unable to 
complete the questionnaires. Information was collected on the demographic characteristics of 
the respondents in each selected household, and also participant’s malaria treatment method, 
willingness to pay for antimalarial and malaria dosage completion episodes were recorded. 
The economic status of responder was also recorded to be able to compare social economic 
status with willingness to pay for drug.  
In selecting the households for questionnaire administration, the state was first divided into 
two groups (urban centre and rural centre). From each centre, with a random sampling 
technique, participants were randomly picked to complete the questionnaire with everyone 
having an equal chance of being picked. The target of respondents was different for both 
States, with more participants recruited from Lagos compared to Osun State. This was done 
to accommodate possible errors in questionnaire filling or people not returning the completed 
questionnaires. Participants were interviewed using the questionnaire and their responses 
were recorded by them or the interviewer if need be. The Office for National Statistics (2010) 
explains that the main objectives of a questionnaire are to obtain accurate information from 
respondents, provide a logical structure to the interview so that it flows smoothly and 
facilitate data entry and processing through the use of coding. Cotetzee (2005) explains that 
not only is the use of questionnaires cheap, it also saves time as a lot of information can be 
collected within a short period of time. In contrast, Welman and Kruger (1999) argue that the 
possibility of response to a questionnaire is low and researchers have low control over the 
condition under which the questionnaire is being filled. Trained interviewers/enumerators 
were used in all centres to help in the gathering of data during the interview session with each 
participant. The interviewed participants within each centre were selected systematically such 
that after the first household, every 10 is selected until the target for the village is covered. A 
preliminary survey was done to find out the prices of the available antimalarials in the market 
and a mean of the sum was calculated to determine an ideal amount a client would be willing 
to pay for treatment. However, other questions such as gender, age, employment status and 
last case of malaria treated has been used in previous studies (Adetola et al., 2014; 
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Onwujekwe et al., 2013; Klein et al., 2012; Jimoh et al., 2007). Children under the age of 16 
were excluded from this study. 
2.3.1 Community questionnaire  
1. Sex:    Male □   Female □ 
2. Age group: 16-20 □   20-25 □ 26-30 □ 30 and above □ 
3. Marital status:  Single □ Married □ Divorced/Widowed □ 
4. Educational level:  Primary □ Secondary □ Tertiary □ none □ 
5. Socio-economic status: (Please tick which of the following you possess) 
    Car □ Television □ Generator □ Computer □ Owned apartment □ 
  Employed □   Unemployed □ 
 Salary earned per Month:  ₦0 - ₦10,000 □ ₦10,000 - ₦50,000 □ ₦50,000 and above □ 
6. How much are you willing to pay for treatment? 
Less than ₦500 □    More than ₦500 □ 
7. When was the last time you had malaria? 
Within the past 1 month □ within the past 6 months □ within the last 1 year□               can’t 
remember □. 
8. How often do you have malaria in a year? 
Less than 5 times in a year □   Between 5 and 10 times a year □ More than 10 times in a year 
□ 
9. Treatment sorted: Amatem □ Coartem □ Leonart □ Combiart □ 
Choloroquine □ Fansidar □ Herbal (please name)………………………. others (please 
name…………….. 
10. Were you diagnosed before treatment? (Microscopic and others) 
Yes □   No □ I don’t know □ 
11. Where did you get treatment from? 
Hospital □ Drug vendors □ Pharmacy store □ did not get treated □ others □ 
12. How often do you complete your antimalarial dosage? 
Always  □  Most times  □   I stop when I feel better  □ 
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2.4 Selection of drugs 
After field sampling and information about prescription and treatment method was gathered, 
the researcher went across pharmacy stores and PPMVs in the community where the field 
work was done to buy popular samples of antimalarial drugs mostly used by responders. This 
was done with the aim of checking for the level of substandard and counterfeit drugs usually 
used to treat malaria in these locations as a barrier to effective malaria case management. 
Sample drugs kept at room temperature just the way they are kept at Pharmacy Stores and 
were analysed within a short period of time. 
2.5 Data analysis 
The initial set of quantitative data obtained was analysed using Statistical Package for Social 
Science (SPSS). Quantitative variables were described using various statistical approaches as 
appropriate e.g. mean and median. Categorical variables are analysed using frequency and 
proportions. Pearson’s Chi-square test and Fisher’s LSD (Least Significance Difference) test 
was done to find an association between two variables using a p value of <0.05 as statistically 
significant. In case of borderline significance, a Fisher’s exact test or likelihood ratio was 
calculated. Data collection for this study was done over two years (2015-2016). The first year 
of data collection was done in Lagos (Lekki to represent urban region and Ikorodu to 
represent a rural region) and in Osun State (Osogbo to represent an urban region and Iwo to 
represent a rural region). The same process was repeated during the second batch of data 
collection; however, it also included Makoko village (rural) in Lagos. Socio-demographic 
data and data on treatment choice were collected in the communities with the use of a 
questionnaire, and this was related to data on treatment practices collected in hospitals, 
pharmacy stores and PPMVs that are co-located in the community where the research was 
being done. For every community where data collection was carried out in the first year, 100 
responders were targeted and 120 questionnaires were distributed each time. In the second 
batch of data collection, 60 participants were targeted and 100 questionnaires were 
distributed. 
2.6 Ethical considerations 
Ethical approval for this study was obtained separately in each State where the research was 
carried out. In addition to the ethical approval obtained from the University of Salford (CST 
15/32),  ethical approval was also obtained from the panel of the ethics board, Ministry of 
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Education, Osun State (OSHREC/PRS/569T/48) and the panel of the ethics board, at Lagos 
State University (LREC/10/15/418).  
2.7 Consent 
Informed Consent was also obtained from hospitals, medicine retail outlets and community 
individuals that participated in the study prior to obtaining any information. Confidentiality 
of data was assured and it was cleared that any participant could withdraw their data from this 
research if they decided not to participate in the research anymore. Copies of all the consent 
forms are available in the Appendix section. 
2.8 Willingness to pay (WTP)  
The literature (Asante & Okyere, 2003; Onwujekwe et al., 2007) describes three approaches 
to measure the economic burden of malaria: Production Function Approach (PF), Willingness 
To Pay Approach (WTP), Cost Of Illness Approach (COI).  The WTP was adopted for the 
purpose of this research; this is because there are different factors that can affect people’s 
willingness to pay for an antimalarial drug; the most important factor as stated by 
Onwujekwe et al., (2007) is income and social economic status. Considering the higher 
amount that a customer has to pay for an ACT compared to the amount you pay for other 
non-ACT drugs such as chloroquine (Quinine) and Fansidar (SP), it is therefore important to 
consider people’s willingness to pay for ACT as an important factor that can be a barrier to 
effective case management. The idea behind WTP approach is that it includes asking 
responders through the use of a questionnaire, how much they would be willing to pay to 
receive a health-related service or prevent an undesirable health outcome (Jimoh et al., 2007). 
In this study, a stated WTP was included to identify motivation behind treatment practices. 
2.9 Evaluating drug efficacy  
2.9.1 FT-IR spectral measurements 
For the acquisition of infrared spectra of standard drugs as well as field sample drugs in tablet 
form, a Thermo Nicolet 5700 FTIR spectrometer equipped with removable KBr optics and 
deuterated triglycine sulphate (DTGS) detector was used. The Thermo Nicolet 5700 FTIR 
spectrometer is controlled by OMNIC (Thermo Nicolet Analytical Instrument, Madison. WI), 
an IR spectra analysis software package. All spectra were recorded averaging 32 scans in the 
range of 4000-400 cm-1 at a resolution of 400 cm-1. Before taking the spectrum of each 
standard and sample drug, a fresh background was first recorded from a KBr pellet. This was 
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done so that data from the sample drug is not contaminated with other chemicals Also, the 
carbon dioxide and other chemicals in the air vibrate when hit with IR radiation and show up 
in the spectrum if a background spectrum has not been collected. The spectral patterns for the 
drugs were compared to reference standards obtained from assigned distributors. 
2.9.2 FT-IR Sample preparation procedure 
The only preparation required for the sample drugs for FTIR analysis is grinding. The tablet 
samples were weighed accordingly and ground to a fine powder in a mortar to reduce the 
particle size. The weight of each sample was calculated using the ratio of artemether and 
lumefantrine present in the drug (some ACTs may have a ratio of 20/120 or 40/480 
artemether and lumefantrine respectively). The pellets were scanned from 4000 to 400 cm-1 
on the Thermo Nicolet 5700-FT-IR spectrometer.                           
2.10 In vitro culture of Plasmodium falciparum  
All procedures were carried out in the pathogen laboratory (University of Salford) in a sterile 
hood (ESCO class II Biological safety cabinet), using aseptic techniques and pre-sterilised 
equipment. Virkon (Antec International, UK) was used to disinfect waste material before 
autoclaving and disposal. All routine culture methods were consistent with those employed 
by Read & Hyde (1993).  
2.10.1 Preparation of complete media  
RPMI 1640, 1x (+) L-Glutamine (+) and 25mM Hepes (Gibco, Life Technologies, UK) was 
used as the basis of the culture media. Four additives; 2.5 g bovine serum albumin fraction V 
(Sigma, UK), 2.5 ml 1 mg/ml hypoxanthine (Sigma, UK) in phosphate buffered saline (PBS) 
(Fisher Chemical, UK), 2.5 ml 40% glucose (dextrose anhydrous, Fisher Scientific, UK) in 
sterile water and 0.5 ml 50 mg/ml gentamycin (Sigma, UK) in PBS were transferred to a 50 
ml falcon tube along with approximately 20 ml RPMI 1640 from a newly opened bottle. The 
contents of the falcon tube were allowed to dissolve and were subsequently passed through a 
0.22 μm filter directly into the 500 ml bottle of RPMI 1640 medium using a 20 ml syringe. 
Following gentle mixing, the complete media was stored at 2-8°C. 
2.10.2 Washing Media  
A 500 ml bottle of pre-sterilised RPMI 1640, 1x (+) L-Glutamine (+) and 25mM Hepes 
(Gibco, Life Technologies, UK) without additives was used as washing media throughout the 
study and stored at 2-8oC for up to 2 weeks.  
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2.10.3 Preparation of human blood for culture of Plasmodium falciparum  
To remove leukocytes, O+ whole blood (obtained from the Manchester Blood Bank) was 
washed immediately before use. An equal volume of whole blood was added to two 50 ml 
falcon tubes and centrifuged for 5 mins and 3,400 rpm (1000 g). Following centrifugation, 
blood plasma and the pale layer (the buffy coat-containing white blood cells) that forms on 
top of the red blood cells was removed. Blood was then re-suspended in an equal volume of 
washing media for following centrifugation. The washing process was repeated 3x to ensure 
that all leukocytes were removed from the blood. For the latter of the three washes, complete 
media (not washing media) was used. Finally, full blood (100% haematocrit) was re-
suspended in an equal volume of complete media to give a final haematocrit of 50% and 
stored at 2-8oC until further use.  
2.10.4 In vitro Plasmodium falciparum culture  
To begin a new culture, 10 ml of complete media and 0.5ml of washed blood were added to a 
50ml culture flask and warmed to 37°C prior to the addition of the parasites. Approximately 
0.5ml of parasitized blood (retrieved from liquid nitrogen, refer to section 2.14.8) was then 
added to the warmed culture media to give a final haematocrit of 5%. Following inoculation, 
the parasite culture was gassed with a 5% CO2, 5% O2 and 90% N2 gas mixture (BOC 
Limited, UK) and placed in the incubator (Leec culture safe touch 190 CO2, Leec Limited, 
UK) at 37°C.  
2.10.5 Routine maintenance of a Plasmodium falciparum culture  
Parasites were routinely cultured at a final volume of either 10 ml or 30 ml in 25 cm3 or 75 
cm3 flasks respectively. For experimental set up, smaller flasks (12.5 cm3) with a final culture 
volume of 5 ml were used. For each of the varying flask volumes, the culture was maintained 
at approximately 5% final haematocrit (for every 10 ml of complete media 1 ml of 50% 
haematocrit blood was added). The media was changed at either 48 or 72 hour intervals. In 
brief, spent media was removed and discarded without dislodging the parasitized blood layer 
that formed at the bottom of the flask. Subsequent to the estimation of parasitaemia (see 
section 2.1.4), the continuous culture was diluted to 0.5-1% parasitaemia with washed blood 
(50% haematocrit). New complete media was added to give a final haematocrit of 5%. Both 
washed blood and complete media had been warmed (370C) prior to the dilution and re-
suspension procedure. The culture was then gassed (5% CO2, 5% O2 and 90% N2) and placed 
in the incubator under conditions described previously.  
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2.10.6 Estimation of parasitaemia  
One drop of concentrated parasitized blood (from the bottom of a culture flask) was 
transferred to the outer margin of a microscope slide. The blood was thinly smeared across 
the slide using a second slide and a single swift smooth action to obtain a monolayer of cells. 
The slide was then air dried at room temperature and fixed by rinsing in 100% methanol. 
After an additional air drying step, the slide was immersed in Giemsa stain at room 
temperature for ~20 minutes. The Giemsa staining solution was prepared by diluting Gurr’s 
Giemsa stain solution (BDH/VWR international limited, UK) 1:10 with Giemsa buffer. To 
prepare the buffer solution one tablet of pH 6.4 (BDH laboratory supplies, England) was 
added to 1 litre of freshly distilled water. Following staining, the slides were rinsed with a 
gentle stream of tap water, dabbed dry and viewed under oil immersion (x 100) using a Leica 
DM 500 compound microscope. Parasitaemia was estimated by counting the total number of 
red blood cells per field of view (approx 100-200) and noting those containing parasites. 
Multiple infections were counted as one (as only one parasite is expected to reach full 
development). For each slide, at least 3 fields of view were counted from which the average 
percentage of infected cells was calculated.  
2.10.7 Preservation in liquid nitrogen  
A predominantly ring stage culture at approximately 15-20% parasitaemia was selected for 
preservation in liquid nitrogen. In brief, the culture was centrifuged at 3,400 rpm (1000 g) for 
5 min, the supernatant removed and the culture reconstituted to a 50% haematocrit by adding 
an equal volume of warm (370C) complete media. Aliquots (0.5 ml) of the suspension were 
transferred into 2 ml cryotubes and 0.5 ml 20% dimethyl sulphoxide (sterile filtered DMSO, 
Sigma, UK) in Ringer’s solution (9 g NaCl, 0.42 g KCl and 0.25 g CaCl2/ Litre) was added. 
The tubes were immediately snap-frozen in liquid nitrogen for preservation and storage.  
2.10.8 Retrieval from liquid nitrogen  
Following an initial thawing period at 37°C the contents of the cryotube were transferred to a 
microcentrifuge tube and centrifuged at 14,000 rpm for ~1 min using the minispin 
(Eppendorf, UK) centrifuge. Once the supernatant had been discarded the parasitised blood 
was gently re-suspended in 1 ml of 10% (w/v) sorbitol (Fisher Scientific, UK) solution (in 
PBS) with continuous mixing. This was then centrifuged and the process repeated twice more 
with subsequent re-suspensions in 5 % (w/v) sorbitol (in PBS) and finally, complete media. 
Following the latter washing step in complete media, the culture was re-suspended in 
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complete media and inoculated into a culture flask containing 0.5 ml of newly washed blood 
(50 % haematocrit) and 10 ml of complete media.  
2.10.9 Sorbitol synchronisation  
During continuous culture P. falciparum parasites rapidly loose synchronisation. If 
synchronisation was required prior to experimental set-up, sorbitol synchronisation was used 
to obtain a predominantly ring stage parasite culture. Sorbitol (5% w/v) was prepared in 
distilled water and filtered through a 0.22 μm filter. The sorbitol solution was then added 
directly to pelleted parasite culture (9 ml to 1 ml of culture pellet) and incubated for 5 mins at 
room temperature. Following this, the culture was centrifuged at 3,400 rpm (1000 g) for 5 
mins and the supernatant was discarded. The parasite pellet was then subjected to three 
washing steps in complete media, before re-suspension in complete media at 50% 
haematocrit. The synchronised parasite culture was used to set up a new culture as described 
previously. 
2.10.10 Preparation of existing antimalarial primary stock solutions  
The four selected existing antimalarials used in the current study were obtained from Sigma 
Aldrich, UK. Primary stock solutions were prepared in accordance with manufacturer 
instructions. In brief, atovaquone (Mw = 366.84) was dissolved at 5 mg/ml (13.63 nM) in 
DMSO. For dihydroartemisinin (Mw = 284.35), 1.4 mg of the powder stock was dissolved in 
1 ml of DMSO to obtain a primary stock concentration of 5 mM. Proguanil was dissolved at 
1 mg/ml in acetonitrile:water (60/40). All primary stock solutions were passed through a 0.22 
μm porosity filter, aliquoted and stored at -20°C until further use. Chloroquine (Mw = 
515.86) was prepared freshly on the day of use. An initial stock solution was prepared at 5 
mM (10.32 mg/ 4 ml) and sterile filtered. For experimental set up, the primary stock solutions 
were further diluted with complete medium to give working solutions. Various amounts of 
the working solution were then transferred as required to achieve final test concentrations. 
2.10.11 Calculation of IC50 values  
For all dose response data sets, values were transferred from respective software programmes 
into Microsoft excel. The infected blood controls were set at 100% and percentage 
parasitaemia for drug treated samples was calculated relative to the infected control. For IC50 
and IC90 calculations, data was further processed using Gaphpad prism 5.0. Data was 
normalised so that the largest value in the data set corresponded to 100% and the smallest 
value corresponded 0%. Log-transformed drug concentrations were then plotted against the 
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dose response and the IC50 and IC90 values were determined using nonlinear regression 
(Graphpad prism 5.0). The log (inhibitor) vs. Normalised response-Variable slope option was 
selected for IC50 calculation whilst the log (agonist) vs. Response-find EC anything with the 
F values set at 10 was used for the IC90 calculations. 
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CHAPTER 3: ROLE OF SOCIO-ECONOMIC 
FACTORS IN THE TREATMENT OF MALARIA 
3.1 Introduction 
Despite the continuous effort in fighting malaria worldwide, the parasitic disease still kills 
close to 445,000 people annually (WHO, 2017). Children less than five years of age living in 
sub-Saharan Africa are mainly the affected groups. In sub-Saharan countries, different factors 
act as barriers for patients to receiving the appropriate treatment needed. For example, 
Yakasai et al., (2014) describes the relationship between poverty and treatment, reporting that 
up to 10% of monthly incomes could be spent on procuring a complete dose of ACT for a 
child in some countries of Sub-Saharan Africa (SSA). In some African cultures, gender is a 
huge determinant factor in decision making. Women are perceived to take care of the house 
and can be trusted to suggest what treatment to be used for what disease; even though in most 
cases the men pay for them (Lampietti et al., 1999). As rightly explained by the WHO 
(2007), a gender approach contributes to both understanding and fighting malaria because 
there are gender norms and values that influence  many aspects of family life which could 
affect disease patterns and access to treatment and care. Furthermore, though men may be 
more vulnerable than women to exposure, women are known to be more vulnerable to the 
consequences of malaria (Bates, et al., 2004). Therefore, gender and malaria issues are 
increasingly being incorporated into malaria control strategies in order to improve their 
coverage and effectiveness in different contexts. 
The level of education is also one of the significant determinant factors when it comes to 
people’s attitude to treatment. In the case of malaria and Nigeria, it is not known if the reason 
why educated people buy appropriate drugs is because of the knowledge they have on the 
disease itself or the fact that they can afford it because they have a financial advantage. As 
mentioned by Dike et al., (2006), most interventions for reducing the burden of malaria and 
other diseases depend on improved consumers’ knowledge about the disease and its control; 
however, exposure to malaria prevention and treatment might not mean high degree 
attainment. An in-depth understanding of how different socio-demographic factors, 
knowledge gaps, and attitudes relate to malaria treatment is very important when developing 
guidelines and recommendations for effective case management and prevention in many 
malaria endemic areas of the world including Nigeria. The purpose of this study was to 
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address this gap by conducting surveys of the knowledge, attitudes and practices of people, 
from variable socio-demographic backgrounds, residing in selected rural and urban malaria 
endemic areas in Nigeria. 
3.2 Objective 
This study aims to characterize the practice of presumptive treatment of malaria in Nigeria 
and determine where interventions for malaria treatment delivery should be targeted. 
3.2.1 Research question 1 and hypothesis: 
Does the socio-demographics of residents in these regions (as defined by age, educational 
level, residence, and stated willingness to pay) associate with barriers to effective malaria 
case management and their malaria treatment-seeking behaviour (as defined by percentage of 
people who self-medicate or/and are treated with drugs outside the adopted 
recommendations)? 
H0: there is no association between participants’ socio-demographics in these regions and 
their malaria treatment-seeking behaviour  
H1: there is an association between participants’ socio-demographics in these regions and 
their malaria treatment-seeking behaviour  
3.3 Results 
3.3.1 Lagos Urban Community 
A total of 178 people responded and returned questionnaires which were correctly filled 
(Table 3.1). 73 (41%) of the responders were female while 105 (59%) were male. People 
aged 30 and above treated malaria the most (32%) out of all the age groups recorded. 95 
responders had a formal education to a tertiary level (53%), 31 (17.4%) participants had 
primary education while 42 (23.6%) had secondary and only 9 (5%) lacked a formal 
education. With regard to the last case of malaria participants had experienced, 31 
respondents (17%) received malaria treatment from PPMVs while 53 people (30%) visited 
the hospital, 82 participants (46%) received treatment from pharmacy stores and 6 people 
(3%) claimed they did not treat the disease at all. 88 people (50%) admitted that they weren’t 
diagnosed before treatment while 63 (35%) were diagnosed; the rest were not sure. The use 
of ACTs was 107 (60%) while 71 (40%) of the participants treated malaria with non-ACTs. 
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89 participants (50%) said they are willing to pay more than ₦500 for treatment while only 
89 (50%) also said they are not willing to. 
3.3.2 Lagos Rural Community 
A total of 121 people responded and returned the questionnaires which were correctly filled 
(Table 3.1). 68 (56%) of the responders were female while 53 (44%) were male. Only 28 
(23.1%) responders had a formal education to a tertiary level; 31 (25.6%) participants had 
primary education, 31(25.6%) had secondary education and 31 (25.6%) lacked a formal 
education. With regard to the last case of malaria participants had experienced, 47 
respondents (39%) received malaria treatment from PPMVs while 32 people (26%) visited 
the hospital, 17 participants (14%) received treatment from pharmacy stores and 12 people 
(9.9%) claimed they did not treat the disease at all. Only 27 people (22%) could confirm that 
they were diagnosed before receiving treatment, 60 (50%) were not diagnosed and 34 people 
(28%) were not sure if they were diagnosed. The use of ACTs was poor, with 32(26%) only 
using the recommended drug while 89 (74%) responders claimed to have treated malaria with 
non-ACTs. 36 participants (30%) said they are willing to pay more than ₦500 for treatment 
while as many as 85 (70%) people said they are not willing to. 
3.3.3 Osun Urban Community 
A total of 142 people responded and returned the questionnaires which were correctly filled 
(Table 3.1). 63 (44%) of the responders were female while 79 (56%) were male. People aged 
30 and above treated malaria the most (35%) out of all the age groups recorded. 82 (23%) 
responders had a formal education to a tertiary level, 16 (11%) participants had primary 
education, 39 (28%) had secondary education and 5 (4%) lacked a formal education. With 
regard to the last case of malaria participants had experienced, 28 respondents (20%) received 
malaria treatment from PPMVs while 63 people (44%) visited the hospital and 41 
participants (30%) received treatment from pharmacy stores. All participants were treated for 
malaria although 10 people sought other methods of treatment. More people (54%) confirmed 
that they were diagnosed before treatment in this region, while the remaining participants 
were either not diagnosed or not sure. The use of ACTs was more than non-ACTs with 83 
(59%) using the recommended drug while 59 (41%) responders claimed to have treated 
malaria with non-ACTs. 68 participants (48%) said they are willing to pay more than ₦500 
for treatment while 74 (52%) people said they are not willing to. 
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3.3.4 Osun Rural Community 
A total of 90 people responded and returned the questionnaires which were correctly filled 
(Table 3.1). 50 (56%) of the responders were female while 40 (44%) were male. People 
between ages 26 and 30 treated malaria the most (32%) out of all the age groups recorded. 23 
(25%) responders had a formal education to a tertiary level, 31 (34%) participants had 
primary education, 12 (14%) had secondary education and 24 (27%) lacked a formal 
education.  With regard to the last case of malaria participants had experienced, 50 people 
(56%) in this region preferred visiting the hospital for treatment, 22 respondents (24%) 
received malaria treatment from PPMVs and 15 people (17%) visited pharmacy stores. 35 
people (39%) admitted that they weren’t diagnosed before treatment while 20 (22%) were 
diagnosed; the rest were not sure. The use of ACTs was recorded in 39 (43%) participants 
while 51(57%) of the participants treated malaria with non-ACTs. 11 participants (12%) said 
they are willing to pay more than ₦500 for treatment while as many as 79 (88%) said they are 
not willing to. 
Table 3.1: Socio-demographic characteristics of respondents (% given to the nearest 
figure) 
Variable Lagos 
urban 
Lagos rural Osun urban Osun rural 
 n % N % N % N % 
Total  178 100 121 100 142 100 90 100 
Age 16-20 22 12 21 17 21 15 12 13 
        21-25 54 30 41 34 39 28 27 30 
        26-30 45 25 30 25 33 23 29 32 
          30+ 57 32 29 24 49 35 22 24 
Sex M 105 59 53 44 79 56 40 44 
        F 73 41 68 56 63 44 50 56 
Education  none  9 5 31 26 5 3 24 27 
                 Primary 31 17 31 26 16 11 31 34 
             Secondary 42 24 31 26 39 28 12 13 
                 Tertiary 95 54 28 23 82 58 23 26 
Marital status  Single 115 65 64 53 72 51 32 36 
                        Married 63 35 55 46 70 49 58 64 
Employment   Yes 109 61 50 41 49 35 38 42 
                          No 69 39 71 59 93 65 52 58 
Salary <₦50,000 79 44 86 71 77 54 75 83 
              >₦50,000 99 56 35 29 65 46 15 16 
WTP >₦500   No 89 50 85 70 74 52 79 88 
                       Yes  89 50 36 30 68 48 11 12 
Self-medication No 63 35 27 22 76 53 20 22 
                              Yes 88 49 60 50 49 35 35 39 
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                         Not sure 27 15 34 28 17 12 35 39 
ACT use No 72 40 89 74 59 42 51 57 
               Yes 106 60 32 26 83 58 39 43 
Treated Hospital 53 30 32 26 63 44 50 56 
               Pharmacy 83 47 17 14 41 30 15 17 
               PPMV 31 17 47 39 28 20 22 24 
Dose completion Always 66 37 50 41 32 23 13 14 
                        Most times 37 21 24 20 30 21 40 44 
I stop when I feel better 72 40 47 39 80 56 37 41 
1 
To create a more representative size from each area, 400 participants were recruited in Lagos 
State with a total of 300 completing and returning the questionnaires (75% respondent 
success rate). Being the State with a lower population density, 300 people were targeted in 
Osun State with 234 people completing the questionnaires (78% respondent success rate). 
 
3.3.5 Relationship between education status and willingness to pay for ACT 
across the four regions 
The relationship between education status and willingness to pay for ACTs across all regions 
was explored. As depicted in the Figure 3.1 below, education status was defined as four 
categories; None (those without any formal education), Primary (those with only basic 
education), Secondary (those with post-basic education) and Tertiary (this includes 
universities, polytechnics, and colleges of education). 
Figure 3.1 below gives information about how the level of education among participants 
might influence their willingness to pay more than ₦500 (average price for an ACT) for 
malaria treatment. It can be seen that only people with tertiary education that live in the urban 
region of Lagos State are willing to spend more than ₦500 to pay for ACTs; those without 
any education, primary education and secondary education are not willing to spend as much 
on ACTs for malaria treatment. In other regions, more people across all education levels are 
willing to pay less than ₦500 except for the Osun urban region where there are equal 
numbers of people willing to pay more than ₦500 and less than ₦500. The difference 
between willingness to pay between the urban and the rural regions is very large and is of 
concern. Even though willingness to pay does not necessarily translate to action, it is seen to 
be a strong motivational force behind paying for treatment. As observed willingness to pay is 
                                                 
1 As of April 2015 when this data was collected the exchange rate of the local currency equates £1 = ₦500  
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worst in Osun rural region, although it can be argued that this region is the least economically 
viable region of the four study regions.  
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                  A (Lagos urban)                                                  B (Lagos rural)                             
   
                       C (Osun urban)                                               D (Osun rural) 
                                                                                                                                   
Figure 3.1: Graphs showing the relationship between the education status of 
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participants and their willingness to pay </> ₦500 (=£1 as at April 2015) for ACTs 
across all the regions of the study; A (Lagos urban), B (Lagos rural), C (Osun urban) and D 
(Osun rural).                                         
3.3.6 Relationship between education status and self-medication practices 
across the four regions 
Another comparison was made to explore the relationship between educational status and 
self-medication practices in these regions. As defined earlier, for this study, self-medication 
is defined as receiving or buying an antimalarial drug without a prior diagnosis or 
prescription. Patient groups were clustered according to definitive diagnostic status prior to 
treatment either by RDTs or through microscopic method. The 3 categories of responses 
include: ‘Yes’ (those who were diagnosed before treatment), ‘No’ (those who were not 
diagnosed before treatment) and ‘I don’t know’ (responder was unsure if they had been 
diagnosed). 
Figure 3.2 below illustrates how the level of education among participants might influence 
self-medication. In this case self-medication is simply defined as any participant that has not 
been tested to confirm presence of malaria parasites prior to treatment. In Lagos urban region, 
self-medication is seen to be higher across all groups except for those with tertiary education. 
Lagos State rural region shows a high level of self-medication across all groups regardless of 
their educational status. More people were diagnosed (53.5%) before treatment in Osun urban 
region; with a higher percentage among participants with tertiary education. 80% of 
participants in Osun rural region either self-medicated or did not remember being diagnosed 
before treatment. Similar to the relationship between education level and WTP (section 
3.4.5), there appears to be a correlation between participants with tertiary education living in 
the urban region and confirmation of diagnosis. 
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                       A  (Lagos urban)                                                  B (Lagos rural)                             
   
                       C (Osun urban)                                          D (Osun rural) 
                                                                                                                             
Figure 3.2: Graphs showing the relationship between education status (None, Primary, 
Secondary and Tertiary) and self-medication practices (including those who said ‘Yes’ to 
diagnosis, ‘No’ and ‘I don’t know’) across the four regions of the study; A (Lagos urban), B 
(Lagos rural), C (Osun urban) and D (Osun rural).                                        
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3.3.7 Relationship between education status and ACT use across the four 
regions. 
Education and awareness is known to influence treatment practices. In compliance to the 
WHO recommendations, the FMOH has recommended the use of ACT drugs as first line 
treatment of malaria in these regions, making it an important factor to consider as barrier for 
effective case management. The common ACT in Nigeria is a combination of artemether-
lumefantrine, and other options of treatment includes SP and chloroquine, both of which have 
been banned for malaria treatment except for special cases. Figure 3.3 below illustrates how 
the level of education among participants might influence the drug used for malaria 
treatment. Participants were also asked about the drug they use to treat malaria and it can be 
seen that most participants in Lagos urban region seek ACT drugs for treatment, also among 
the secondary school group, more people went for ACTs than any other group of antimalarial. 
However, this result is not the same in the rural region as more participants across all 
education levels preferred non-ACT compared to ACTs drugs for treatment. In Osun urban 
region, there was better use of ACTs between tertiary and secondary school groups (similar 
to Lagos urban). Also, tertiary group and primary school group in Osun rural area showed 
better use of ACTs compared to other education status. Excluding the Lagos rural region, this 
data shows a relationship between educational level and the use of ACTs since people with a 
tertiary level of education are more likely to use an ACT to treat malaria. 
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                           A (Lagos urban)                                            B (Lagos rural)                            
               
                           C (Osun urban)                                                 D (Osun rural) 
                                                                                                                             
Figure 3.3: Graphs showing education status and ACT use across the four regions. 
Participants responses in this case are categorised into ‘Yes’ (the use of ACT for treatment) 
and ‘No’ (using other antimalarial or no treatment at all); A (Lagos urban), B (Lagos rural), C 
(Osun urban) and D (Osun rural).                                        
3.3.8 Relationship between education status and place of treatment 
Treatment attitude and practices by care givers vary depending on what type of health 
provider has been visited. Hospital care givers are perceived to be better exposed to trainings 
and also, their practices are recorded and monitored. This is in contrast to practices at drug 
vendors, who are not necessarily trained to dispense drugs and are mostly in the business for 
profit. In this case, place where treatment was sought was categorised into ‘No treatment’ 
(those that were not treated), ‘Hospital’, ‘Drug vendors’, ‘Pharmacy stores’ and ‘Others’ 
(including traditional and spiritual). 
Figure 3.4 below illustrates how the level of education among participants might influence 
where they go for malaria treatment.  In Lagos urban region, most people visited a pharmacy 
for malaria treatment regardless of their education level except for those who had no 
education (could have been affected by the total number of participants). Drug vendors were 
more patronised amongst people living in the Lagos rural region (39%) followed by a 
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hospital visit (26%), which is recorded across all education level. In Osun urban and rural 
regions, hospital visits are more common. Waiting times at the hospital is a huge factor that 
can easily affect this result. Lagos Sate has the most populous city in Africa and one can 
expect a huge patient load at the hospitals. With a population of just over 3 million 
(compared to Lagos with about 24 million), the patient load in the hospitals of Osun State can 
be relatively more easily accessible with less queues and hassle. The only question is 
affordability and quality of treatment. This result does not show that education level affects 
where treatment is sought and instead, suggests that community trust in effective and easy 
treatment providers is most important. 
  
                         A (Lagos urban)                                           B (Lagos rural) 
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                             C  (Osun urban)                                          D (Osun rural) 
                                                                                                                           
Figure 3.4: Graphs showing the relationship between education status and place where 
treatment was received across the four regions; A (Lagos urban), B (Lagos rural), C (Osun 
urban) and D (Osun rural). Categorised into ‘No treatment’ (those that were not treated), 
‘Hospital’, ‘Drug vendors’, ‘Pharmacy stores’ and ‘Others’ (including traditional and 
spiritual).                                        
3.3.9 Relationship between employment status and WTP across the four 
regions. 
This section explores relationship between those in employment (including self-employment 
and part-time) and those that are unemployed and their willingness to pay at least ₦500 for 
malaria treatment. 
Figure 3.5 below illustrates how participant’s employment status might influence their 
willingness to pay more than ₦500 for malaria treatment. The graph shows more employed 
participants willing to pay more than ₦500 compared to people that are not employed.  Up to 
80% of the respondents that are willing to pay in the urban region have a tertiary level of 
education. This is however not so in the rural region, as it is observed that both groups have 
more respondents that are not willing to pay up to ₦500 for malaria treatment. In Osun urban, 
little difference can be observed between employed participants that are willing to pay up to, 
or over ₦500 for malaria treatment. This is quite understandable because Osun State is a 
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poorer state than Lagos State and being employed in Osun State isn’t necessarily the 
economic advantage associated with being employed in Lagos State. Participants in some sort 
of employment in the urban area of both States show more willingness to pay more than 
₦500 for malaria treatment as opposed to rural areas where both employed and unemployed 
participants are not willing to pay that much.  
 
 
         
 
               A (Lagos urban)                                                              B (Lagos rural)            
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                            C (Osun urban)                                            D (Osun rural) 
                                                                                                                                 
Figure 3.5: Graphs showing employment status (including self-employment and part-
time employment) and WTP at least ₦500 for treatment across the four regions; A 
(Lagos urban), B (Lagos rural), C (Osun urban) and D (Osun rural).                                        
3.3.10 Relationship between employment status and self-medication across 
the four regions. 
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                   A (Lagos urban)                                           B (Lagos rural)            
 
 
             
                     
                             C (Osun urban)                                    D (Osun rural) 
                                                                                                                           
Figure 3.6: Graphs showing employment status and self-medication across the four 
regions; A (Lagos urban), B (Lagos rural), C (Osun urban) and D (Osun rural). “Yes” = 
diagnosed, “No” = not diagnosed, “I don’t know” = unsure.          
This section illustrates how the level of participant’s employment status might influence self-
medication. As seen in Figure 3.6 above, in both urban regions, the number of employed 
people that were diagnosed before treatment was more than those that were not diagnosed. 
The difference in Lagos urban however is so little and a cause for concern.  It can be 
suggested that self-medication is common across all the groups but employed people in Osun 
urban region are more likely to seek diagnosis. The chart does not distinctively show better 
treatment approach in people that are employed in this case, as the level of self-medication is 
high between both unemployed and employed groups. In some cases, malaria patients, 
depending on the symptoms they have, may not be sure if they have been diagnosed or not. 
For example, if a patient is unconscious on arrival in the hospital, there is a possibility of 
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being diagnosed and they are not aware, as treatment practice in most hospitals does not 
really require doctors to make it clear what process will be/has been done to treat a patient. 
This means that a number of the patients who are not sure could have been diagnosed before 
treatment, however, the chart still shows that a lot of improvement is required to check self-
medication. 
                              
3.3.11 Relationship between employment status and place where treatment 
was received across the four regions. 
Figure 3.7 below illustrates how participant’s employment status might influence place where 
they were treated for malaria. As previously observed more participants visited the pharmacy 
stores in Lagos urban region, PPMVs in Lagos rural and hospitals in both Osun urban and 
Osun rural regions. Employment status did not change where participants are more likely to 
be treated. As hospitals and registered pharmacy stores are more likely to follow the WHO 
recommendation for malaria treatment, the group at greater risk of wrong treatment are those 
in the Lagos rural region where most participants, either employed or unemployed, visited 
PPMVs. 
 
  
                           A (Lagos urban)                                           B (Lagos rural)                        
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                                C (Osun urban)                                    D (Osun rural) 
                                                                                                                           
Figure 3.7: Graphs showing relationship between employment status and place where 
treatment was received across the four regions; A (Lagos urban), B (Lagos rural), C (Osun 
urban) and D (Osun rural).                              
3.3.12 Relationship between employment status and ACT use across the 
four regions. 
   
                                A (Lagos urban)                                           B (Lagos rural)                        
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                                   C (Osun urban)                                    D (Osun rural) 
                                                                                                                                  
Figure 3.8: Graphs showing employment status and ACT use across the four regions; A 
(Lagos urban), B (Lagos rural), C (Osun urban) and D (Osun rural).   
The Figure 3.8 above illustrates how a participant’s employment status might influence the 
use of ACTs as a treatment option for malaria. As price of drug is a very important factor to 
consider in this study, one can observe that more people in employment chose ACT drugs to 
treat malaria. Out of a total of 107 participants that used ACT in the Lagos urban region, 74 
(70%) were employed while 33 (30%) were unemployed. This is a significant difference that 
points to the effect employment status has on the use of ACTs in this region. In Lagos rural 
region, both groups opted more for non-ACT drugs with only 28% of the employed using 
ACTs. This probably reflects the difference in the standard of living in these regions even 
though they are within the same State.  Use of ACTs was more observed in the employed 
group in Osun urban as well; 77% (64) of the 83 people that used ACTs in this region were 
employed.  Similar to what is observed in the Lagos rural region, participants in the Osun 
rural region used more non-ACTs regardless of their employment status. 
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3.3.13 Relationship between monthly salary and ACT use across the four 
regions.        
Figure 3.9 above illustrates how participant’s monthly salary might influence their treatment 
practice with regard to antimalarial drug type used. It can be observed that people who earn 
up to, or more than ₦50,000 (£100), are more likely to use an ACT in the urban areas in both 
states. This was not the case in the rural regions, as it can be seen that even a larger 
percentage of those who earn more than ₦50,000 preferred non-ACTs for treatment. The 
difference in this practice between regions points to the fact that in some cases, employment 
or financial buoyancy, might not be enough to follow recommended procedure with regard to 
malaria treatment. In places were awareness of recommended treatment isn’t absent, other 
responsibilities would play a role in affecting the type of antimalarial used for treatment. 
 
 
  
                             A (Lagos urban)                                 B (Lagos rural)                               
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                           C (Osun urban)                                    D (Osun rural) 
                                                                                                                              
Figure 3.9: Graph showing monthly salary (</> 50,000) and ACT use across the four 
regions; A (Lagos urban), B (Lagos rural), C (Osun urban) and D (Osun rural).                                                            
3.3.14 Relationship between monthly salary and place where treatment was 
received across the four regions. 
 
                                   A (Lagos urban)                                 B (Lagos rural)                               
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                               C (Osun urban)                                    D (Osun rural) 
                                                                                                                                     
Figure 3.10: Graphs showing monthly salary and place where treatment was received 
across the four regions; A (Lagos urban), B (Lagos rural), C (Osun urban) and D (Osun 
rural). 
The Figure 3.10 above illustrates how participant’s monthly salary might influence the place 
where malaria treatment is received. Regardless of monthly income, 46% of participants in 
Lagos urban region visited pharmacy stores; followed by hospital among those earning over 
₦50,000 and drug vendors among those earning less than ₦50,000. In Lagos rural, there is 
almost an equal likelihood of visiting the hospital or drug vendors among those earning more 
than ₦50,000 whereas a higher percentage (41%) of those earning less than ₦50,000 visited 
patent medicine vendors.  Regardless of monthly income, more participants in Osun urban 
and rural regions visited hospitals more than any other place, followed by pharmacy stores 
among those earning more than ₦50,000 in Osun urban and pharmacy store/drug vendor 
among those earning less than ₦50,000. In Osun rural, most participants visited the hospital 
for treatment. Interestingly, people that earned less than ₦50,000 were almost twice  as likely 
to visit the hospital (59%) than a  PPMVs (23%)  or pharmacy stores (16%) whereas for those 
earning more than ₦50,000, there was little difference in hospital or PPMV visits. 
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3.3.15 Relationship between WTP and ACT use across the four regions. 
Figure 3.11 below illustrates how willingness to pay more than ₦500 might influence ACT 
use for malaria treatment. Does willingness to pay a particular price for treatment actually 
translate to practice? Out of a total of 178 participants in Lagos urban, 50% were willing to 
pay over ₦500 for malaria treatment and 50 said they were not willing to.  Out of the 
participants willing to pay, 70% actually used an ACT for treatment. Also, among those not 
willing, 50% used an ACT for treatment. A similar result was observed in other regions since 
not all those who claim to be willing to pay up to ₦500 actually treated malaria with ACTs 
and some who are not willing eventually paid over ₦500 for ACT treatment. This shows that 
WTP does not necessarily translate to practice. Different factors might affect a patient’s 
willingness to pay for antimalarials such as affordability at that point, other responsibilities, 
combination with other drugs which increases total price, and accessibility. Also, people that 
are not willing to pay could be advised of proper treatment method at the point of purchase 
and this might change their attitude towards treatment. 
 
 
 
                             A (Lagos urban)                                 B (Lagos rural)                               
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                           C (Osun urban)                                    D (Osun rural) 
                                                                                                                         
Figure 3.11: Graphs showing WTP and ACT use across the four regions; A (Lagos 
urban), B (Lagos rural), C (Osun urban) and D (Osun rural).                                        
3.3.16 Relationship between place where treatment was received and ACT 
use across the four regions. 
This section will help explore the type of treatment participants received from different health 
providers. Adherence to recommendations is very crucial to successfully removing barriers to 
effective malaria case management. This is further explored and discussed in Chapter 4. All 
providers are expected to adhere to the use of ACT for malaria treatment (except for special 
cases like 3rd trimester of pregnancy) but this is not always the case. 
Figure 3.12 below illustrates how the place where participants visited for treatment might 
influence the appropriate treatment of malaria. As observed in Lagos urban region, 47% of 
the total number of participant visited the pharmacy store, 30% visited the hospital and 17% 
visited a drug vendor and the remainder either used other methods or did not get treated. Out 
of the total visits to the hospital (53), 72% (38) were treated with the recommended ACT 
drug. 66% (55) of visits to the pharmacy store resulted in being treated with ACTs whereas 
only 38% (12) were treated with ACTs at a PPMV store. Non-ACT drugs were the preferred 
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in the rural region of Lagos State; in the hospital, treatment with ACTs is almost equal to 
treatment with non-ACTs but other outlets sold more non-ACTs and the use of ACTs is low. 
Similar to Lagos urban, a better treatment practice is seen in the hospital and pharmacy stores 
compared to other groups in Osun urban; however, the use of non-ACTs for treatment is high 
in the Osun rural region except in the hospital where more cases were treated with ACTs. 
This result shows that place of  treatment has an influence on  the type of drug purchased; as 
hospitals and pharmacy stores are recommended to treat malaria, one can see that a level of 
adherence to the FMOH and WHO recommendation is being followed in these venues, 
although not completely. It should also be noted that some hospital-diagnosed malaria cases 
are treated with chloroquine injections; this would have increased the data for non-ACTs at 
the hospital, though by an unknown amount. 
 
   
                             A (Lagos urban)                                 B (Lagos rural)                               
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                              C (Osun urban)                                    D (Osun rural) 
                                                                                                                              
Figure 3.12: Graphs showing place where treatment was received and ACT use across 
the four regions; A (Lagos urban), B (Lagos rural), C (Osun urban) and D (Osun rural).                                        
3.3.17 Relationship between antimalarial drug use and malaria case 
frequency across the four regions. 
    
                             A (Lagos urban)                                 B (Lagos rural)                               
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                              C (Osun urban)                                    D (Osun rural) 
                                                                                                                              
Figure 3.13: Graphs showing place where treatment was received and ACT use across 
the four regions; A (Lagos urban), B (Lagos rural), C (Osun urban) and D (Osun rural).      
Figure 3.13 above illustrates how the use of ACT for malaria treatment might affect the 
number of malaria cases that participants suffer in a year. As observed across all regions, 
malaria occurrences are fewer with ACT users. None of the ACT users have cases running 
over 10 times a year. Out of a total of 106 people that use ACTs in Lagos urban, 78% (83) 
have less than five cases of malaria in a year while 23% have between 5-10 occurrences. 50% 
of those who used non-ACTs had more than 5 cases of malaria in a year. In Lagos rural 
region where a total of 89 people (74%) treated malaria with non-ACTs, 50% of these people 
had malaria occurrence over 5 times in a year. Osun urban also showed that the majority of 
ACT users have less than 5 occurrences of malaria in a year while most non-ACT users have 
more than 5 cases a year. This result confirms the efficacy of ACTs as antimalarials; 
producing a long-lasting effect in the body of the infected. Non-ACTs are not as effective as 
ACTs, which means the malaria parasite can easily re-infect, or recrudescence is more 
rampant when ACTs are not used. 
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3.3.18 Relationship between history of malaria and ACT use across the 
four regions. 
An effective ACT has the ability to clear more parasitaemia from the blood of an infected 
person than other antimalarials. Due to the resistance that has been recorded in other 
antimalarials (for e.g. chloroquine and SP), malaria recrudescence is very common. This 
section aims to explore how often those who appropriately treat malaria with ACTs have 
malaria compared to those who use other antimalarial groups. 
Figure 3.14 below further illustrates what was observed on how ACT treatment might affect 
the number of malaria cases and history of malaria. In both Lagos and Osun urban regions, it 
can be seen that most people that treat malaria with ACTs either had a last occurrence of 
malaria as far back as 6 months, or they cannot remember. In this context, we expect that the 
reason why participants can’t remember the last occurrence is because it is not recent and 
could have occurred a very long time before this study was done. This means in Lagos urban, 
93% of the total participants that treated malaria with an ACT, have at least 6 months interval 
in infection. Also, in Osun urban, 94% of participants that treated malaria with ACTs, have at 
least a 6 month interval between malaria infections. 
 
 
             
                                 A (Lagos urban)                                      B (Lagos rural)                               
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                                 C (Osun urban)                                    D (Osun rural) 
                                                                                                                             
Figure 3.14: Graphs showing history of malaria and ACT use across the four regions; A 
(Lagos urban), B (Lagos rural), C (Osun urban) and D (Osun rural).                                        
3.3.19 Antimalarial dosage completion across the four regions.               
Dosage completion is an integral part of effective treatment of malaria and also prevents 
treatment failure and development of parasite resistance to the drug used. It is a common 
practice that health seekers usually stop taking their medication once symptoms have reduced 
or disappeared. This is a threat to the long term use of the artemether-lumefantrine 
combination and ACTs in general. Participants were asked if they completed their dosage the 
last time they had malaria and responses was categorised into ‘Always’, ‘Most times’ and ‘I 
stop when I feel better’. 
Figure 3.15 below illustrates the relationship between the use of ACTs and completion of 
dosage as required. In the Lagos urban region, out of a total of 175 participants, 106 (60%) 
treated malaria with ACTs out of which only 42% (44) completed the recommended dosage. 
A totally different outcome is noticeable in Lagos rural region, with only 9 participant (28%) 
ACT users claiming to complete their dosage. In this region, not only is the use of ACT as 
malaria treatment incredibly low, the ability to stick to the recommended dosage is even 
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worse. In Osun urban, even though there is a better use of ACTs, only 24 (29%) participants 
of a total of 83 ACT users claim to complete their dosage; with most people stopping when 
they don’t have the symptoms anymore. In the rural area of Osun state, 11 (28%) participants 
that use ACTs to treat malaria confirm that they completed the recommended dosage. 
Although it should be noted that some participants that did not treat with ACTs could have 
appropriately treated with chloroquine injections, but with emphasis on ACT drugs, this 
result shows a terrible compliance rate with respect to the recommended treatment method. If 
dosage completion isn’t taken seriously, the malaria parasite will soon develop resistance to 
the commonly used ACTs as has been recorded for all non-ACT drugs. 
 
 
 
                                 A (Lagos urban)                                      B (Lagos rural)                               
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                                C (Osun urban)                                    D (Osun rural) 
                                                                                                                                     
Figure 3.15: Graphs showing antimalarial drug type used for treatment and dosage 
completion across the four regions; A (Lagos urban), B (Lagos rural), C (Osun urban) and 
D (Osun rural).                                        
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3.3.20 Statistical analyses of the data 
 
Table 3. 2: Association of socio-economic variables with treatment practice in Lagos urban 
area. 
Variable  Appropriate diagnosis      ACT use 
 X2        df P-value X2 df P-value 
Total        
Age 16-20 44.321 6 <0.001 5.495 3 0.139 
        21-25       
        26-30       
          30+       
Sex M 3.148 2 0.207 1.162 1 0.281 
        F       
Education  none  35.870 6 <0.001 13.191 3 0.004 
                 Primary       
             Secondary       
                 Tertiary       
Marital status  Single 5.046 2 0.80 0.224 1 0.636 
                        
Married 
      
Employment   Yes 13.770 2 0.001 6.430 1 0.011 
                          No       
Salary <₦50,000 19.992 2 <0.001 7.730 1 0.005 
              >₦50,000       
WTP >₦500    11.636 2 0.003 5.971 1 0.015 
Treated Hospital 32.065 2 <0.001 4.623 1 0.032 
               Pharmacy 14.845 2 0.001 2.911 1 0.088 
               PPMV 0.453 2 0.797 6.769 1 0.451 
 
Table 3. 3: Association of socio-economic variables with treatment practice in Lagos rural 
area. 
Variable  Appropriate diagnosis ACT use 
 X2 df P-value X2 df P-value 
Total        
Age 16-20 9.564 6 0.144 3.562 3 0.313 
        21-25       
        26-30       
          30+       
Sex M 0.011 2 0.994 0.679 1 0.410 
        F       
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Education  none  11.147 6 0.084 5.456 3 0.141 
                 Primary       
             Secondary       
                 Tertiary       
Marital status  Single 3.699* 4 0.448 1.288 2 0.525 
                        Married       
Employment   Yes 2.333 2 0.311 0.106 1 0.745 
                          No       
Salary <₦50,000 4.705 2 0.095 0.628 1 0.428 
              >₦50,000       
WTP >₦500    3.306 2 0.191 1.292 1 0.256 
Treated Hospital 14.416 2 0.001 9.334 1 0.002 
               Pharmacy 3.380* 2 0.184 1.242 1 0.265 
               PPMV 2.103 2 0.349 0.33 1 0.856 
 
Table 3. 4: Association of socio-economic variables with treatment practice in Osun urban 
area. 
Variable  Appropriate diagnosis ACT use 
 X2 df P-value X2 df P-value 
Total        
Age 16-20 26.755* 6 <0.001 3.365 3 0.339 
        21-25       
        26-30       
          30+       
Sex M 9.648 2 0.008 0.004 1 0.952 
        F       
Education  none  21.827* 6 0.001 20.781* 3 <0.001 
                 Primary       
             Secondary       
                 Tertiary       
Marital status  Single 8.317 2 0.016 0.504 1 0.478 
                        Married       
Employment   Yes 10.862 2 0.004 11.926 1 0.001 
                          No       
Salary <₦50,000 7.725 2 0.021 7.490 1 0.006 
              >₦50,000       
WTP >₦500    8.975 2 0.11 3.207 1 0.073 
Treated Hospital 39.159 2 <0.001 6.050 1 0.014 
               Pharmacy 8.509 2 0.055 2.299 1 0.129 
               PPMV 25.340 2 0.008 7.424 1 0.006 
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Table 3. 5: Association of socio-economic variables with treatment practice in Osun rural 
area. 
Variable  Appropriate diagnosis ACT use 
 X2 df P-value X2 df P-value 
Total        
Age 16-20 3.496* 6 0.743 6.753 3 0.080 
        21-25       
        26-30       
          30+       
Sex M 7.930 2 0.019 0.326 1 0.568 
        F       
Education  none  2.811* 6 0.832 6.007 3 0.209 
                 Primary       
             Secondary       
                 Tertiary       
Marital status  Single 4.804 2 0.127 0.254 1 0.705 
                        Married       
Employment   Yes 3.653 2 0.238 1.129 1 0.482 
                          No       
Salary <₦50,000 1.749 2 0.482 2.036 1 0.213 
              >₦50,000       
WTP >₦500    0.177* 2 0.873 2.986 1 0.084 
Treated Hospital 15.552 2 <0.001 3.306 1 0.018 
               Pharmacy 6.634 2 0.034 0.081 1 0.775 
       
               PPMV 18.336 2 <0.001 10.458 1 0.001 
 
Chi squared result to determine an association between SES variables such as education level, 
stated WTP, and recommended treatment practice across the four regions are summarized in 
Table 3.2 to 3.5. In the Lagos urban region, there is an association between age and self-
medication but no association with the use of ACTs; a similar result was also recorded in Osun 
urban region. Both rural regions did not show an association between age and treatment practice. 
It can also be seen that the use of ACTs is not associated with any age group; meaning all age 
groups run the risk of improper treatment of malaria with a non-ACT as recommended. Also, in 
the entire four regions as seen in table 3.2 to 3.5 there is no association between gender and 
treatment practice, meaning both genders are at equal risk of poor malaria treatment practice. 
There is however a strong association between education level and diagnosis (P<0.001) in Lagos 
urban area, and an association with the use of an ACT in the same region. This is also found in 
the urban area of Osun State; however, there was no association between education level and 
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treatment practice in the rural areas (Ikorodu, Iwo). No association was also found between 
marital status and treatment across the four regions; however, employment status showed a 
positive association with self-medication and the use of ACTs in the urban regions only. Lagos 
urban region and Osun state urban region shows that there is an association between employment 
and salary earned by participants and mode of treatment; this can be largely due to the ability to 
afford effective treatment. WTP as much as ₦500 as stated by participants did not have an 
association with actual payment for ACTs except for Lagos urban region; this shows that other 
factors such as affordability, trust, and access can also affect the use of ACTs even if participants 
are willing to pay a particular amount for malaria treatment. An association between treatment 
received at the hospital and appropriate diagnosis is recorded across the four regions; with three 
of them having a strong association (P<0.001). A statistically significant association was also 
found between hospital visits and appropriate treatment with ACTs across the four regions. 
However, treatment in PPMV stores in Osun rural region showed a significant association with 
appropriate diagnosis before treatment and sale of ACTs. To further investigate the association 
found between education status and treatment patterns, an LSD test was done. 
LSD (Least Significant Difference) is the value at a particular level of statistical probability (e.g. 
P≤0.01- means with 99% accuracy) when exceeded by the difference between two varietal 
means for a particular characteristic, then the two varieties are said to be distinct for that 
characteristic at that or lesser levels of probability. When an analysis of variance (ANOVA) 
gives a significant result, this indicates that at least one group differs from the other groups. Yet, 
the omnibus test does not indicate which group differs. In order to analyze the pattern of 
difference between means, the ANOVA is often followed by specific comparisons, and the most 
commonly used involves comparing two means (the so called “pairwise comparisons”). Fisher's 
LSD method is used in ANOVA to create confidence intervals for all pairwise differences 
between factor level means while controlling the individual error rate to a significance level 
specified. Fisher's LSD method then uses the individual error rate and number of comparisons to 
calculate the simultaneous confidence level for all confidence intervals. This simultaneous 
confidence level is the probability that all confidence intervals contain the true difference.  
LSD analysis (Table in Appendix) shows in detail what educational group has an effect or an 
association with the use of ACTs. People that are educated to a tertiary level in Lagos urban are 
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very likely (p < 0.001) to use an ACT to treat malaria compared to other type of educational 
level. This might be expected because people in this group usually get the best jobs and are 
generally paid a higher salary. Though the use of ACTs is very encouraging, it is also worrying 
that there is no relationship found between any educational group and appropriate diagnosis with 
either RDT or microscopy which indicates that a lot of negative cases could have been treated 
with ACTs. Also, a similar result was found in Osun state urban region, however, people with 
secondary education also showed a significant association with ACT (p < 0.05) 
3.4 Discussion 
Having in mind that Nigeria has the largest number of cases of malaria in the world (Dawaki et 
al., 2016) continuous effort has been made over years to reduce this epidemic. Also, most of the 
interventions and targets attached to achieving a particular aim in regards to treatment and 
prevention have not been achieved (Amoran et al., 2013; Umaru et al., 2015); this is a threat to 
planned eradication of malaria. As much as malaria infection is a problem, over the years, 
effective treatment of infected people has proved a challenge in all areas of the country (Omo-
Aghoja et al., 2008; Jeu, 2013; Uzochukwu et al., 2010). As recommended by WHO and the 
FMOH, effective treatment can be achieved by following two major steps of appropriate 
diagnosis and treatment using recommended ACTs. However, incompliance with stated 
recommendations and guidelines to treatment for one reason or the other are major barriers and 
threat to eradication or effective management of malaria.  
With respect to the data presented in this chapter, the null hypothesis stated that there is no 
association between participants’ socio-demographics in these regions (as defined by age, 
educational level, residence, and stated willingness to pay) and their malaria treatment-seeking 
behaviour (as defined by percentage of people who self-medicate or/and are treated with drugs 
outside the adopted recommendations. According to Etika (2018), nearly 70% of Nigeria’s 
population of 180 million people are aged below 35. For this reason, this study has divided the 
age categories into four groups and purposely done to concentrate more on the youths as defined 
by Alhasan & Tyabo, (2013); which is between the age of 16 and 35. By doing this, the study is 
able to concentrate more on the age groups where most of these treatments are believed to be 
done. Also, because of the difference in population density between these two regions, more 
participants were approached in Lagos compared to Osun State. The result of this study showed 
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that not all the variables under consideration were significantly associated with treatment 
practices. In other words, the null hypothesis can be accepted for some variables and rejected for 
other variables in the different study regions. 
 For example, treatment practices including diagnosis and ACT use are significantly associated 
with some socio-economic factors such as education level, WTP, salary earned and treatment 
received in hospitals in the Lagos urban region. In the Lagos rural region, most of these 
significant associations were not found; only treatment received in the hospital showed an 
association with recommended treatment practice. When compared, urban region in Osun 
showed the similar result as Lagos urban and the rural region in Osun, like Lagos, showed an 
association between hospital treatment; however, in Osun, an association was also found 
between PPMVs and appropriate treatment practice. Low level of education and awareness in the 
Osun rural region could mean that clients totally depend on the expertise of the medicine seller. 
Although the treatment practice in Lagos PPMVs conforms with the results of Isiguzo et al., 
(2014), the Osun PPMV data is different; with most patients visiting the hospital as opposed to 
medicine retail outlets. Osun State hospitals provide free treatment for uncomplicated malaria, 
although this is practised in Lagos State, the process is more reliable in Osun State and the 
waiting time in Osun is generally shorter compared to Lagos with a much larger population. 
Earning less in a region where hospital treatment is free could be a leading reason why people in 
Osun State preferred hospital treatment compared to a busy State as Lagos, where patients want 
to rush in, get their drugs, and be on their way.  Overall, the results show a similar trend in 
treatment practice in the urban regions of both States and in the rural regions. People that reside 
in the urban regions of these two States, who earn up to ₦50,000, are very likely to treat with an 
ACT, and those who receive treatment in the hospitals are likely to be treated and diagnosed 
appropriately. This is a massive improvement for the hospital caregivers and shows that training 
that has been offered over the years is now beginning to yield results. Chapter 4 and 5 further 
investigates practices in the health sector and this is discussed in more detail. However, this 
result further lays emphasis for more specific intervention programs rather than general 
programs, so barriers can effectively be tackled at a more focused level.  
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3.4.1 Compliance with ACT use 
Overall, across both communities, ACTs were preferred as the treatment of first choice among 
participants in the urban region and a small number of participants in the rural region; which 
corroborates findings by Magham et al., (2011). This could be good news considering that the 
recommended first-line treatment method for malaria is the use of ACTs; however, a reason for 
concern is the low acceptance in the rural regions and the high rate of self-medication among 
clients that actually use ACTs. There is a high possibility that the majority of people using ACTs 
without a prior diagnosis do not actually have a malaria infection; this inappropriate use may 
contribute in the long term to Plasmodium drug resistance. With regard to the use of ACTs, as 
explained by Bablola et al., (2007) the high cost of ACTs is a primary reason for people using 
chloroquine and SP as a first line treatment for malaria despite the reduced efficacy or known 
reactions to these drugs. The preference of ACTs in the urban communities may be because of 
the awareness through TV adverts and intervention programs in the environment, or expectation 
of efficacy. The findings of this study show an improvement with the use of ACTs in both States 
which confirms the findings by Ezenduka et al., (2014) in the eastern part of Nigeria (it should 
however be noted that  most of the participants in this study also used ACTs to treat an 
unconfirmed case of Plasmodium). Malaria symptoms are often assumed in Nigeria if one has a 
headache and elevated body temperature. Awareness of ACT use is a major factor that can 
improve malaria treatment, aside from intervention programs- mouth to mouth advice, TV and 
radio adverts, and health provider advice has helped increased awareness of ACTs in the urban 
areas. However, this effort has not been replicated with regard to ensuring diagnosis before 
treatment. As discussed by Onwujekwe et al., (2005), treatments through medical outlets are 
mostly based on clinical symptoms which have led to 50% non-malaria cases being treated as a 
malaria infection. 
Findings from this study showed that self-medication is still a common practice among both 
communities where this study was carried out. Self-medication was observed among all age 
groups, sex, urban and rural regions and across all social economic status. This result confirms 
the findings of Babalola et al., (2007) and Chipwaza et al., (2014). However, there is an 
association between education level and appropriate diagnosis in the urban areas of both States. 
As mentioned by McCombie (2002), inappropriate prescription and use of antimalarials will 
increase the risk of developing parasite resistance.  This study shows that a lot of self-medication 
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happens in the PPMVs, confirming the findings of Metta et al., (2014), McCrombie (2002), 
Goodman et al., (2007). It also shows that the majority of the participants have either got their 
treatment from pharmacy stores or a PPMVs, which is consistent with previous studies (Afolabi, 
2008; Ranno et al., 1988). As most pharmacy stores in Nigeria are privately owned and are for 
profit, owners would rather yield to a customer request regardless of government 
recommendations and policies than to see the customer leave. The result, however, further 
strengthens the fact that the use of ACTs for malaria treatment is the way forward towards 
eradication of malaria in Nigeria since it has been recorded that a majority of Nigerians would 
have at least 4 -5 cases of malaria in one year. If the use of ACTs can be embraced by everyone 
and strong measures are in place to ensure its authenticity and safety, then barriers to effective 
case management can be removed.       
3.4.2 SES and adherence to recommendations 
Affordability is a major issue and barrier to the effective management of health care, especially 
treating malaria in endemic regions. Drug cost constitutes the bulk of expenses on malaria 
treatment (Salawu et al., 2016). As pointed out by Chuma et al., (2010), lack of money 
contributes to poor drug compliance and people who can’t afford the recommended treatment are 
often given other types of treatment because they are cheaper than the recommended 
antimalarial. Although essential, the price of a particular drug is not the only factor to be 
considered while discussing cost of treatment; in some areas, cost of treatment is largely affected 
by transportation, hospital or health care charges among other factors. The total mean price for 
the most available antimalarial at the time this study started was ₦500. Willingness to pay is the 
maximum or comfortable amount an individual is willing to pay or sacrifice to procure a service 
or avoid something undesirable.  Willingness to pay is an integral part of malaria intervention 
programs to improve treatment and eradication and it has been used in various studies including 
Uganda (Hansen et al., 2012), Nepal (Morey et al., 2003) and Nigeria (Onwujekwe et al., 2010). 
This study also used salary earned by respondents to determine if they are willing to pay up to 
₦500 for malaria treatment; the findings showed that even among people that earned over 
₦50,000 monthly, a small percentage are willing to pay. This result showed that in the rural 
regions, majority of those in employment and earning at least ₦50,000 still don’t treat malaria 
properly; showing that treatment practice in rural areas is generally not affected by amount 
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earned, but low awareness to recommended treatment pattern might be a barrier (Bamiselu et al., 
2016). This finding is in contrast to Chuma et al., (2010) which state that lack of cash was the 
reason why people are not seeking appropriate treatment. It should be noted however that this 
study was done in 2010 and a lot has changed in Nigeria since then; especially with the country’s 
economy going into recession recently. Also, the decision to subsidize ACTs has not improved 
people’s willingness to pay for them; as a matter of fact, within the two years of data collection 
in Nigeria, the price of Coartem (one of the most used and most effective antimalarial drugs in 
Nigeria) increased from ₦650 to ₦1850. Most ACTs are above ₦500, which means people are 
forced to pay for these drugs at that price and those that can’t afford it would simply go for an 
alternative such as chloroquine. In a study by Uzochukwu et al., (2010) the willingness to pay 
for RDTs by respondents was positive; 90.7% in rural areas and 89% in urban. However, the 
mean WTP in urban areas during this study was ₦372.30 and ₦296.28 in rural areas; both of 
which are less than ₦500 that was used in this study. 
There was a statistically significant association between those who stated a willingness to pay 
₦500 or more and actual payment; this is supported in a study by Aizuddin et al., (2012) where 
factors such as age, education, income, locality rural/urban are factors that can affect an 
individual’s WTP for healthcare. However, this study did not check for an association between 
willingness to pay and actual payment. For example, as mentioned by Jimoh et al., (2007) 
economic burden plays an important role in people’s actual adherence to practices they are 
willing to engage in. This study found that participants who are in employment and reside in 
urban areas are more likely to be willing to pay as much for treatment; however, although this 
can be observed in Figures 3.2-3.5, there is no statistically significant result to support this. 
Considering the resources available to people living in rural areas and the high rate of malaria 
cases, it is not surprising to see that most people are not willing to pay as much for treatment of 
one case of malaria. A significant association between salary earned and place where treatment 
was recorded was only found in Lagos urban region, with other regions showing no significant 
association. This result is similar to what was found by Onwujekwe et al., (2011), where there 
was no statistically significant difference across SES groups and place where treatment was 
received. Educational level and social economic status to an extent appear to have a positive 
impact on the treatment practices among both communities. This corroborates the findings of 
Jombo et al., (2010). A large number of respondents had a formal education with a small 
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percentage having just primary and no education at all. The south west region has a high level of 
western education compare to the northern region (Gobir et al., 2014).  
3.4.3 Treatment centres and adherence  
With regard to treatment completion, treatments obtained from drug stores and pharmacy stores 
cannot be monitored, due to the fact that most people receive treatment from drug stores, it 
explains why a lot of patients do not complete their dosage as observed in this study. This was 
also observed by Gobir et al., (2014). Most participants from rural areas receive treatments from 
hospitals and drug vendors, which may be due to the facts that these rural areas do not have a lot 
of legal pharmacy stores around them. Primary health care centres which are located in the rural 
areas would have been the cheapest option to receive treatment, but poor services, shortage of 
medicines and attitude towards patients by health care providers is one of the reasons people 
sought alternative treatment. There was no correlation observed between educational status of 
people living the rural areas and hospital treatment of malaria. This finding is in contrast to 
previous studies (Habeeb et al., 1993. Sayeed, 1998. Abosede, 1994). This study also found that 
in cases where pharmacists or PPMVs were in a place to influence the decision of a client, most 
have influenced them to buy an ACT. This confirms the finding of Okeke et al., (2009) that 
claims that drug vendors can also give correct verbal advice to patients, and strongly advises the 
inclusion of PPMVs in malaria control strategies. Monotherapy was used more in PPMVs 
compared to hospitals and pharmacy stores, which also confirms the finding of Ezenduka et al., 
(2014).  
A clear preference for drug outlets was recorded in this study. This is also supported by 
Landscape of Antimalarial Medicines in Nigeria (2016) and other studies (Isiquzo, et al., 2014; 
Goodman et al., 2007) where over 70% of malaria treatments were received at a medicine store. 
Reasons for these visits include; long waiting times at the hospital (Ogunnowo et al., 2015; 
Umar and Umar, 2011), affordability of drugs (Chuma et al., 2010) and the ability to influence 
treatment (Prach et al., 2015). However, medicine outlets have a history of improper treatment 
practices, including high rates of self-medication (Prach et al., 2015; Goodman et al., 2007), 
counterfeit drugs (Liu et al., 2016; Afolabi, 2008) and substandard drugs (Beyeler et al., 2015). 
PPMVs have been described to be the worst place to be treated in Nigeria; for example, 
Berendes et al., (2012) in a study to describe the effectiveness of PPMVs in malaria control 
111 
 
found that all drug vendors in the district failed to stock and sell first-line antimalarials, replacing 
them with drugs such as chloroquine, sulphadoxine-pyrimethamine and oral artesunate. This 
practice is common among PPMVs (Beyeler et al., 2015; Prach et al., 2015; Goodman et al., 
2007) and calls for an urgent need to regularly monitor and improve the quality and availability 
of medicines sold by these sellers. 
Also, the only venue for treatment that has a statistically significant association in the study area 
(P<0.001 in three of the four regions) with proper diagnosis and ACT use was the hospital. This 
compliance with recommendation was not recorded in any drug store, which confirms the 
worrying state of adherence to policy among medicine sellers. However, this improvement in 
adherence recorded in the hospitals, which was also found by Ezenduka et al., (2014), suggests 
that over the years, hospital treatment is continually improving  from what was described by 
Saka and Fakeye (2015) were poor adherence to guidelines for children in rural health facilities 
of Southwest Nigeria was found. Although there was no statistically significant association 
across SES groups and where individuals received treatment, there is a significant association 
between those that visited hospitals for treatment and being treated appropriately in line with the 
WHO recommendations. 
3.5 Conclusion 
Findings from this study indicate that there is a high level of self-reported malaria across all SES 
groups and geographic areas, with the better-off SES groups in general reporting more malaria 
than worse-off SES groups, and with more malaria reported in urban areas compared to the rural 
areas. Formal education impacts on the use of appropriate antimalarial drugs but it does not 
relate to adequate awareness of appropriate treatment practices, including diagnosis and 
completion of dosage as advised.  
The drug prescription pattern in the hospitals is improving while no meaningful improvement 
can be seen in the prescription pattern at medicine outlets. The prescription of CQ, SP including 
monotherapy artesunate in drug stores will undermine the attainment of the Millennium 
Development Goal. Although rural and urban individuals are quite aware of the 
recommendations for treatment, increasing drug prices is a major barrier to adherence. Success 
recorded over the years with effective malaria treatment, when ACTs were sold at a subsidised 
rate, is being threatened by the continuous price increase in ACTs, thereby making even people 
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in higher SES groups opt for cheap antimalarials against recommendations.  Drug vendors are 
major health providers in Nigeria and it has been advised that they should be made partners in 
the health care network because they are likely to continue as a major source of antimalarial 
drugs for most rural communities in the foreseeable future.  However, evidence has shown that 
adherence by drug vendors has not improved over a long time and it decreases the chance of 
eradication. Therefore, efforts should be made towards improving malaria eradication by 
educating caretakers and drug vendors while provision of more functional primary health care 
facilities with readily available drugs and improving the conditions of roads with a good 
transportation network may improve accessibility to appropriate health care in rural areas. 
Hospitals and primary health centres where recommendations are being followed should be at 
the forefront of malaria treatment until drug vendors can be trusted to treat every case 
appropriately. 
Overall, malaria public enlightenment efforts need to be intensified and effective malaria 
preventive and treatment methods should be affordable and support should be provided to make 
malaria diagnosis and treatments at hospitals free. 
Policy makers and programme managers should develop distribution channels for malaria 
prevention and treatment which can better protect everyone from malaria. This is in accordance 
with the notion of universal access to malaria control interventions, since targeting the poor and 
other supposedly vulnerable groups may not adequately cover the true picture of people who 
require malaria control services and expose them to increased burden of the disease and 
potentially catastrophic costs that could lead to impoverishment or further impoverishment. This 
means that to substantially decrease the burden of the disease, there should be mass deployment 
of malaria control intervention tools such as Artemisinin-based combination therapy (ACTs) and 
RDTs, without preference to any SES group or people residing in different geographic locations. 
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CHAPTER 4: TREATMENT PRACTICES IN 
HOSPITALS, PHARMACIES AND PROPRIETARY 
PATENT MEDICINE VENDORS (PPMVs) 
4.1 Introduction 
Drug stores are believed to be the most popular place for Nigerians to seek treatment. Isiquzo et 
al., (2014) and Goodman et al., (2007) claim that nearly 60% of all treatment for malaria 
happens at a drug store; either a pharmacy store or a PPMV (owner-operated drug retail outlets 
are known as patent and proprietary medicine vendors). The WHO and Federal Ministry of 
Health (FMOH) currently recommend confirmatory blood tests for all suspected malaria cases 
prior to treatment. Furthermore, treatment should only be with an ACT upon confirmation of 
parasitaemia (this includes not administering ACTs to patients or buyers with unconfirmed blood 
tests) (FMOH, 2004; WHO, 2010). Considering the proportion of patients that visit both 
pharmacy stores and PPMVs for malaria treatment compared to other places, this means that the 
efficacy of malaria treatment and the road to eradication largely depends on adherence to 
recommendations and policies at these outlets.  
Efforts have been made to help promote effective case management in pharmacy stores and 
PPMVs by providing Rapid Diagnostic Tests (RDTs) to improve point-of-care diagnosis; 
however, this is not seen to be practical as a lot of drug vendors either do not have RDTs 
available or they are not well trained to use them. Also, a reasonable proportion of consumers 
purchase medication for a relative or friend, who is probably too weak from the symptoms to 
visit the store. There is a huge difference in practice between pharmacy stores and PPMVs; the 
pharmacy stores are predominantly privately owned and staffed by formally trained pharmacists 
and are usually patronized by people of higher economic class. However, the PPMVs, which are 
commoner pharmacy stores, are either owned or staffed by untrained vendors.  Also, from a 
business perspective, the PPMVs are lower scale investments that offer little return and hence 
they are loosely regulated and often found in the more rural regions of the country (Beyeler et 
al., 2015). Due to the fact that PPMVs invest in cheaper drugs, the quality of health service that 
they provide is poor and less trusted compared to pharmacy stores. PPMVs are only licensed to 
sell over-the-counter medicines, but in a bid to allow and ensure equitable access of the larger 
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population to chemotherapy, antimalarials were included in the drugs they may sell. Goodman et 
al., (2007) however assessed that these stores do not stock ACTs and they have little or no 
awareness of the recommended treatment guidelines; which is why many health care providers 
continue to prescribe and sell less effective and unsafe drugs such as chloroquine. This is a 
significant problem considering that up to 60% of household members reported with fever 
received treatment from a PPMV (Oyeyemi et al., 2015; National Population Commission, 
2012).  Predictably therefore, 58% of malaria deaths occur amongst people that reside in the 
rural regions (Gwatkin and Guillot, 1999). 
In May 2005, Nigeria adopted a new malaria drug policy to combat issues regarding malaria 
diagnosis and treatment. While policies and recommendations are more likely to be adhered to in 
the hospitals and clinics, and may provide a better quality treatment due to the qualifications of 
health providers, other factors such as long waiting and travel times are common reasons as to 
why patients often seek other faster but non-conventional methods. An assessment of indirect 
cost of treatment of malaria by Obieche & Odili (2016) showed that more than 50% of the 254 
patients studied spent 2-4 hours at the hospital before they got to the pharmacy for their 
medications. Confirmatory malaria microscopy testing is one of the advantages of seeking 
malaria treatment at the hospital; however, as rightly suggested by Salawu et al., (2016), the cost 
of hospital services are unaffordable for many families and may account for the delays observed 
in accessing hospital services for medical treatment. Indeed, the average cost for treatment of 
uncomplicated malaria in private hospitals among adults, children and pregnant women was 
₦3,941 (Salawu et al., 2016). About ₦406 (10.3%) of the treatment cost was spent on 
consultation, ₦1064 (27.7%) was spent on laboratory investigations and ₦2,444 (62%) was 
spent on antimalarial drugs. These consultation and laboratory testing costs are more than a 
patient would pay for antimalarials sourced from a pharmacy store or a PPMV.  
This chapter therefore seeks to describe and compare profiles of patients and treatment practices 
in the PPMV, pharmacy store and hospital settings; including where patients are more likely to 
self-medicate and where patients are more likely to be correctly treated with the use of ACTs in 
line with the newly adopted treatment policy. Findings can be used to describe in detail, the 
barriers to the effective management of malaria cases by health providers at the diagnosis and 
treatment stages.  
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4.2 Objective 
This chapter aims to better characterize the practice of presumptive treatment of malaria in 
Nigerian drug stores and hospitals, in order to evaluate reasons for failure of effective case 
management practices and to determine where interventions for malaria treatment delivery 
should be targeted. 
4.2.1 Research question 2 and hypothesis: 
Does the type of drug store (defined as pharmacy stores and PPMVs) where treatment is 
delivered influence adherence to recommended malaria treatment practices? 
H0: there is no association between type of drug store and adherence to recommended malaria 
treatment-seeking practices. 
H1: there is an association between type of drug store and adherence to recommended malaria 
treatment-seeking practices. 
4.2.2 Research question 3 and hypothesis: 
Are hospital caregivers adhering to the recommended treatment policies?  
H0: there is no association between hospitals (including private and public) where treatment is 
received and adherence to recommended malaria treatment-seeking practices. 
H1: there is an association between hospitals (including private and public) where treatment is 
received and adherence to recommended malaria treatment-seeking practices. 
4.3 Results  
4.3.1 Evaluation of treatment practices in pharmacy stores and PPMVs 
A total of 10 pharmacy stores and 10 PPMV stores were evaluated in each state. This sampling 
was carefully chosen to cover the drug stores in both States and regions that have a high patient 
load. The medicine retail outlets were strategically selected to cover all parts of the urban regions 
and also the rural regions of each State selected for this study, with 20 people targeted at 10 
outlets in each region.  Even though 10 of each type of drug store was chosen in each State, 20 
responders were expected for each store in Lagos, while 15 responders were targeted for each 
store in Osun State. This was done to create a more representative sampling of responders, 
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considering that Lagos State has a higher population that Osun state. The respondent success rate 
in Lagos State was 75% and 80% in Osun State. With the use of a questionnaire (refer to section 
2.4.1) questions asked included the pharmacist’s influence on the drug purchased by the buyer. 
This question was included because in some cases, patients rely on the expertise of the drug 
seller and they ask them which drug is best. The pharmacist can now advise on the range of 
drugs that they think will be appropriate. However, the buyer’s decision can still be influenced 
by the price of the drug. Tables 4.1- 4.2 below shows the socio-graphic distribution results in 
both States, while Figures 4.3 – 4.4 shows sociographic distribution according to region. 
Table 4. 1: Treatment practices at pharmacy and PPMV stores in Lagos State 
Characteristics  Pharmacies PPMVs Total   
   Patients 
(N/%) 
Patients 
(N/%) 
Patients 
(N/%) 
X2 df P-value 
Respondents  165 (74) 57 (26) 222 (100)    
Sex Female 95 (57.7)      43 (75.4) 138 (62.2) 8.241* 1 0.004 
 Male 70 (42.3) 14 (24.6) 84 (37.8)    
Drug used ACT 147 (89.1) 20 (35.1) 167 (75.2) 47.720** 1 P<0.001 
 Non-
ACT 
18 (10.9) 37 (64.9) 55 (24.8)    
Self-medication  136 (82.4) 57 (100) 193 (86.9) 4.518*** 1 0.034 
Drug seller’s 
influence 
ACT 104 (70.7) 17 (85) 121 (72.5) 1.001**** 1 0.317 
 Non-
ACT 
5 (27.8) 31 (83.8) 36 (65.5)    
2  
Table 4.1 shows that out of a total of 222 patients that visited both pharmacies and PPMVs in 
this region, 57 (26%) visited PPMVs while 165 (74%) visited pharmacies. In total, there were 95 
(57.7%) female and 70 (42.3%) male clients that visited the pharmacy stores, while 43 (75.4%) 
female and 14 (24.6%) male clients visited the drug vendors. As such, though female clients 
sought malaria treatment more than males, a larger proportion of females received their treatment 
from drug vendors.  Of all the clients that visited pharmacy stores, 136 (82%) were self-
medicating compared to 193 (86.9%) of those that visited drug vendors. A significantly higher 
                                                 
2 * Association between gender and place where treatment was received. ** Association between type of 
antimalarial purchased and where treatment was received. *** Association between self-medication and place where 
treatment was received. **** Association between sellers influence and drug purchased. 
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percentage of the patrons of pharmacies (147/165, 89%) purchased an ACT with 18 (11%) 
opting for a non-ACT treatment. In contrast, 20 (35.1%) clients bought an ACT at a drug vendor 
while 37 (70%) clients bought a non-ACT drug. Even though all the drug sellers in this area 
admitted that they are aware of malaria treatment drug policy and they usually prescribe an ACT 
to a client seeking malaria treatment, this knowledge does not translate into practice as not only 
did a whole lot of drug sellers sell non-ACTs to clients, they sometimes influenced the use of 
non-ACTs. 71% of the ACTs sold in the pharmacy store were influenced by the pharmacist but 
so was the 29% of the non-ACTs used. Also, 85% of ACTs purchased at a drug store were 
influenced by the seller and 84% of non-ACTs. 
Table 4. 2: Treatment practices at pharmacy and PPMV stores in Osun State 
Characteristics  Pharmacies PPMVs Total   
   Patients 
(N/%) 
Patients 
(N/%) 
Patients 
(N/%) 
X2 df P-value 
Respondents  141 (40.5) 96 (59.5) 237 (100)    
Sex Female 36 (25.5)      54 (56.3) 90 (38) 0.187* 1 0.665 
 Male 105 (74.5) 42 (43.7) 147 (62)    
Drug used ACT 91 (64.5) 47 (49.0) 140 
(59.5) 
0.081** 1 0.776 
 Non-
ACT 
50 (35.5) 49 (51.0) 99 (40.5)    
Self-
medication 
 82 (58.2) 73 (76.0) 155 (65) 15.574*** 1 P<0.001 
Drug seller’s 
influence 
ACT 40 (28.4) 34 (35.4) 74 (52.9) 2.478**** 1 0.317 
 Non-
ACT 
14 (9.9) 29 (30.2) 43 (43.4)    
3 
Table 4.2 shows that in Osun State, during the period of data collection, recruited PPMVs 
attended to a total of 96 (59.5%) malaria treatment cases and licensed pharmacists attended to a 
total of 141 (40.5%) individual malaria treatments. In total, there were 36 (40%) female and 105 
(71.4%) male clients that visited the pharmacy stores, while 54 (60%) female and 42 (28.6%) 
male clients visited the drug vendors. This contrasts with the Lagos State data showing females 
                                                 
3 * Association between gender and place where treatment was received. ** Association between type of 
antimalarial purchased and where treatment was received. *** Association between self-medication and place where 
treatment was received. **** Association between sellers influence and drug purchased. 
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sought treatment more than males.  However, similar to Lagos State, men visited pharmacy 
stores more than PPMVs and a larger proportion of female clients received malaria treatment 
from drug vendors.  Of all the clients that visited pharmacy stores, 82 (58.2%) were self-
medicating compared to 73 (76%) of those that visited drug vendors. The number of ACTs used 
in pharmacy stores was 91 (64.5%) with 50 (35.5%) opting for a non-ACT. In contrast, 47 (49%) 
clients purchased an ACT at a drug vendor, while 49 (51%) clients bought a non-ACT drug. The 
sale of non-ACTs by these sellers, who had previously admitted and showed an awareness of the 
recommended policy with regard to treatment type shows that their awareness does not translate 
into practice. 40% of the ACTs sold in the pharmacy store were influenced by the pharmacist but 
so was the 14% of non-ACTs used. Also, 72.3% of ACTs purchased at a PPMV was influenced 
by the seller and 59.2% of non-ACTs. 
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Table 4. 3: Comparison of the treatment practices at pharmacy and PPMV stores in Lagos and Osun State urban areas 
4 
 
 
 
 
                                                 
4 * Association between gender and place where treatment was received. ** Association between type of antimalarial purchased and where treatment was 
received. *** Association between self-medication and place where treatment was received. **** Association between sellers influence and drug purchased. 
Characteristics                              Lagos urban                    Osun urban   
  Pharmacies 
(N/%) 
PPMVs 
(N/%) 
X2 df P-value Pharmacies 
(N/%) 
PPMVs 
(N/%) 
X2 df P-value 
Respondents  84 (78.5) 23 (21.5)    88 (68.2) 41 (31.8)    
Sex Female 44 (52.4)      12 (52.2) 3.548* 1 0.986 30 (34.1) 18 (43.9) 1.152 1 0.283 
 Male 40 (47.6) 11 (47.8)    58 (65.9) 23 (56.1)    
Drug used ACT 77 (91.7) 7 (30.4) 40.118** 1 P<0.001 65 (73.9) 15 (36.6) 16.500 1 P<0.001 
 Non-ACT 7 (8.3) 16 (69.6)    23 (26.1) 26 (63.4)    
Self-medication  75 (89.3) 21 (91.3) 0.080*** 1 0.778 44 (50) 24 (58.5) 0.818 1 0.366 
Drug seller’s 
influence 
ACT 54 (70.1) 3 (42.9) 1.926**** 1 0.165 36 (55.4) 6 (40) 2.445 1 0.118 
 Non-ACT 5 (71.4) 11 (68.8)    11 (47.8) 10 (38.5)    
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Table 4.4: Comparison of the treatment practices at pharmacy and PPMV stores in Lagos and Osun State rural areas 
Characteristics              Lagos rural                    Osun rural   
  Pharmacies 
(N/%) 
PPMVs 
(N/%) 
X2 df P-value Pharmacies 
(N/%) 
PPMVs 
(N/%) 
X2 df P-value 
Respondents  35 (30.4) 80 (69.6)    38 (34.9) 71 (65.1)    
Sex Female 25 (71.4) 57 (71.3) 3.442 1 0.984 24 (63.2) 18 (25.4) 13.571 1 P<0.001 
 Male 10 (28.6) 23 (28.7)    14 (36.8) 53 (74.6)    
Drug used ACT 9 (25.7) 27 (33.8) 16.101 1 P<0.001 16 (42.1) 22 (30.9) 7.445 1 0.006 
 Non-ACT 26 (74.3) 53 (66.2)    22 (57.9) 49 (69.1)    
Self-medication  18 (51.4) 77 (96.3) 34.047 1 P<0.001 32 (84.2) 56 (78.9) 0.453 1 0.505 
Drug seller’s 
influence 
ACT 9 (100) 14 (51.9) 3.552 1 0.505 8 (50) 13 (59.1) 0.252 1 0.144 
 Non-ACT 11 (42.3) 39 (73.6)    18 (81.8) 30 (61.2)    
5 
                                                 
5 * Association between gender and place where treatment was received. ** Association between type of antimalarial purchased and where treatment was 
received. *** Association between self-medication and place where treatment was received. **** Association between sellers influence and drug purchased. 
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Tables 4.3 and Table 4.4 provide information on the treatment practices in similar regions of 
both States. In the urban regions of Lagos and Osun State there is a strong significant association 
between the type of antimalarial used and type of medicine retailer visited (pharmacy or PPMVs) 
(Table 4.3). This result shows that people that visited pharmacy stores are more likely to buy a 
recommended ACT for malaria treatment compared to those that visited a PPMV store, where 
they are likely to use a non-ACT, against the WHO recommendations. A similar finding with 
regard to type of antimalarial used and store where it was purchased was also observed in the 
rural regions of Lagos and Osun States (Table 4.4).   There was also a strong association (p < 
0.001) for self-medication and place where antimalarial was purchased in the Lagos rural region 
which was not observed in the Osun rural region. Also, gender of client had a significant 
association (p < 0.001) with the type of store where treatment was received in Osun rural area 
but not in Lagos rural area.   
4.3.2 Evaluation of treatment practices in hospitals 
The type and number of hospitals used in both regions has been previously described in section 
2.3 of the thesis. The rate of malaria when compared between an urban region and a rural region 
is usually higher in the rural areas; however, the number of cases is usually higher in the urban 
regions due to the overall population density of the towns and cities. Urban regions in Nigeria, 
especially in both States where this research was done, have more learned people, better access 
to and options for treatment. In addition, higher socio-economic status enhances affordability of 
treatment and preventive measures compared to the rural regions in which people are generally 
less well educated and living in poor housing conditions. As confirmed in the table below (Table 
4.3), the total malaria incidence in the rural regions (=1057) is less than the number recorded in 
the urban regions (=1172).  
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Table 4.5: Hospital clinical records (Lagos State and Osun State) 
 
A clinical examination is standard in all of the hospitals and usually precede other forms of 
examination; this includes checking the body temperature with the use of a thermometer, asking 
questions about symptoms that the patient has noticed and sometimes also checking the patient’s 
blood pressure.  During the period of data collection, the number of patients suspected to have 
malaria was 1546 in Lagos urban hospitals, 941 in Lagos rural hospitals, 1359 in Osun urban 
hospitals and 456 in Osun rural hospitals. In the Osun urban area 98% of patients were tested 
with an appropriate malaria diagnostic test; in the other three areas, all patients were suitably 
tested. In Lagos urban area 1472 (95%) patients were tested clinically and with RDT only; none 
of these patients were tested with a combination of RDT and microscopy. 769 (50%) were 
negative and 140 (18%) were given an antimalarial.  449 (84%) of the positive cases in this 
region were treated with an ACT, 51 (10%) were administered quinine and 36 (7%) people were 
given SP. In Lagos rural, 932 (99%) were tested clinically and with RDT only, similar to Lagos 
urban, none of the patients in Lagos rural were tested with a combination of RDT and 
microscopy. Of the patients tested, 253 (27%) tested negative and none of these people were 
offered an ACT for treatment. 597 (87%) of those that tested positive were given an ACT, 57 
(8%) were give quinine while 34 (5%) were given SP. In Osun Urban, 1300 (98%) were tested 
clinically and with the use of RDT, 45 (3.4%) patients were tested with the combination of RDT 
and microscopy in this region. Of the patients tested during this period in Osun urban, 691 (52%) 
    LAGOS STATE     OSUN STATE
                                HOSPITAL DATA (MAY - SEPTEMBER 2015) URBAN RURAL URBAN RURAL
Number of patients suspected to have malaria 1546 941 1359 456
Suspected malaria patients in whom any test was carried out 1546 941 1327 456
Suspected malaria patients assessed clinically only 74 9 30 0
Suspected malaria patients tested by microscopy 0 0 45 20
Suspected malaria patients tested by RDT 1472 932 1300 440
Cases appropriately tested using (RDT + Microscopy) 0 0 45 20
Suspected malaria patients found to be negative 769 253 691 87
Confirmed negative cases treated with antimalarial 140 0 15 0
Negative cases not given antimalarial 629 253 1173 87
Cases found to be malaria positive 536 688 636 369
Positive cases appropriately treated with ACT 449 597 564 290
Positive cases treated with quinnine 51 57 30 45
Positive cases treated with SP 36 34 42 34
Positive cases not treated with antimalarial 0 0 0 0
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tested negative and of these negative cases, 1% were treated with an antimalarial. 564 (84%) of 
the positive cases in this region were treated with an ACT, 30 (5%) were given quinine and 34 
(5%) were given SP. In Osun rural region, 440 (97%) were tested clinically and with RDT while 
20 (4.4%) were tested using a combination of RDT and microscopy. Of the patients tested during 
this period, 87 (19%) were negative and none of these people were given an antimalarial. 290 
(79%) of the positive cases were treated with an ACT, 45 (12%) were treated with quinine and 
34 (9%) were treated with SP. in Osun rural. All of the four regions treated all positive malaria 
cases with an antimalarial. 
 
 
Figure 4.1: Graphical representation of diagnosis practices in selected hospitals in Lagos 
urban region. An encouraging adherence to recommendation can be seen in this region with 
95% patients tested clinically and with the use of RDTs. 
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Figure 4.2: Graphical representation of diagnosis practices in selected hospitals in Lagos 
rural region. An encouraging adherence to recommendation can be seen in this region with 99% 
patients tested clinically and with the use of RDTs 
 
 
Figure 4.3: Graphical representation of diagnosis practices in selected hospitals in Osun 
urban region. An encouraging adherence to recommendation can be seen in this region with 
97% patients tested clinically and with the use of RDTs 
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Figure 4.4: Graphical representation of diagnosis practices in selected hospitals in Osun 
rural region. An encouraging adherence to recommendation can be seen in this region with 96% 
patients tested clinically and with the use of RDTs. 
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Figure 4.5: Graphical representation of antimalarial drug used to treat malaria cases in 
selected hospitals across the four regions. Most cases were treated with ACTs even though 
a small percentage were treated with chloroquine and SP. 
As seen in Figure 4.5, Diagnosis practice in recruited hospitals in Lagos urban areas shows 
that majority of the hospitals diagnosed visiting patients by clinical examination and then 
using RDT to confirm parasite in the body of patients. The rate of ACT use across the four 
regions can be seen in Figure 4.9 where it shows that a lot of hospitals are accepting and 
showing their awareness towards the use of ACT for malaria treatment even though there are 
still cases of prescriptions that are not in accordance to the WHO and FMOH 
recommendations. 
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Figure 4.6: Graphical representation of the incidence of malaria compared to the 
suspected cases of malaria in selected hospitals across the four regions. 
Figure 4.10 shows the confirmed incidence of malaria to be 81% in Osun rural hospitals, 47% 
in Osun urban hospitals, 73% in Lagos rural hospitals, and 35% in Lagos urban hospitals. 
Figure 4.10 can also be interpreted to show the dangers of self-medication; especially in the 
urban areas.  
4.4 Discussion 
4.4.1 Treatment practices in pharmacy stores and PPMVs in Osun and 
Lagos State 
This study documents the case management of drug dispensers for treatment of malaria fever 
at community pharmacies and PPMVs in Lagos State and Osun State. This study has 
provided insight and expanded the current limited evidence around the effect drug dispensers 
(pharmacies and PPMVs) have on effective management of malaria. As most studies on the 
presumptive management of malaria have been done in one region or State of the country, 
this study compares the management of malaria at two different regions at the same time. As 
Lagos State and Osun State are both in the Southwest region, Lagos is a large commercial 
state with a lot of ‘high class’ residents compared to the more ‘quiet’ Osun State where socio-
economic status is generally low, being that most residents are either farmers, market women, 
low scale business owners and civil servants. As such, one would expect attitude and 
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practices related to malaria treatment to be different in these two regions. Many studies have 
confirmed that drug outlets are the main access for many health-care products and services, 
especially drug vendors (WHO, 2004; Ladner et al., 2017). Drug vendors are only allowed to 
sell ‘off-the-counter’ drugs; however, there is an exception for antimalarials. This was 
introduced to reduce the huge pressure on hospitals and other public health services. 
However, due to the fact that most of these stores are low scale businesses and mostly 
patronised by people of lower economic status, vendors invest and stock cheap drugs of 
lower quality (Beyeler et al., 2015). Also, studies further mentioned that most of these poor 
people that patronise the PPMVs also depend on them for advice and guidance with regard to 
diagnosis and treatment methods (Ajayi et al., 2002; Ross-Degnan et al., 1996).  
All of the providers in this study stated a preference for ACT as a treatment regime for 
uncomplicated malaria in contrast to what was reported by Goodman et al., (2007) and Ajayi 
et al., (2013). However, the reason for this could not be confirmed and it was unclear whether 
it was awareness of policy change or because of an experience-driven awareness of the 
efficacy of ACTs compared to other antimalarials. Also, in contrast to Goodman et al., 
(2007), and Mangham-Jefferies et al., (2014) there is no difference in pharmacy store owners 
and PPMVs with regard to the type of antimalarial the sellers preferred and prescribed; with 
all of them admitting to preferring ACTs for malaria treatment. This result is encouraging and 
has shown a positive in comparison to earlier studies where awareness of ACTs as first line 
treatment of malaria was very low among drug vendors. This shows that awareness 
programmes such as ‘Roll Back Malaria, which has been ongoing over the years in Nigeria, 
are beginning to yield positive results with regard to the awareness of recommended malaria 
drug regimes. This awareness of the drug sellers can undoubtedly positively influence clients 
and patients directly, or indirectly, if managed properly.  
Gender predominance for malaria treatment was different in the two locations where this 
study was done. The predominance of the female gender in Lagos State is consistent with 
many studies (Ezenduka et al., 2014; Meremikwu et al., 2011; Sears et al., 2013) showing 
that more females sought out malaria treatment. However, a contrasting result was found in 
Osun State where more males patronised a drug store for treatment; Lampietti et al., (1999) 
explains that in some cases or areas, a restricted mobility upon women may impede their 
attendance at health centres. Also, exposure patterns and gender norms could have been 
responsible for the difference in treatment pattern by gender in the two States. As explained 
by WHO (2007), exposure patterns and infection can be affected by gender norms if men are 
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more likely to be working in fields/farms at dusk, or if women are expected to fetch water 
from streams in the morning. Therefore, as rightly put by Ricci (2012) ‘A cautious 
understanding of the gender-related dynamics of treatment seeking behaviour, as well as of 
decision making, resource allocation and financial authority within households is key to 
ensuring effective malaria control programmes.’ Health interventions in malaria over the 
years (WHO, 2006), have mostly concentrated on awareness for women more than men, 
which has made a massive impact on health promotion among women; especially in cases of 
malaria in pregnancy. However, it is critical to start including men in these intervention 
programs because recent studies are beginning to reveal that there is no longer a significant 
difference with regard to seeking treatment for malaria between the two genders. Also, in 
most cases, whoever is buying drugs from a drug store might be buying it on behalf of a sick 
individual, which means everyone has to be part of these awareness programs and 
intervention programs to truly be able to effectively manage malaria across every household. 
Adherence to the policy of confirming malaria cases by RDT and microscopy before 
treatment is very poor in this study. Drug outlets are meant to either follow a prescription 
from a doctor showing that diagnosis has been arrived at clinically, or they are required to 
perform one in stores. However, up to 82% of patients that visited Lagos pharmacies are 
suspected to be self-medicating, and all of the patients that visited PPMVs in Lagos State did 
not have any proof of diagnosis and were still treated for malaria. A similar result was found 
in Osun State where 58.2% of patients at pharmacies and 76% at PPMVs self-medicated. 
These findings are similar to data published in other studies in Nigeria (Oyeyemi et al., 2015; 
Ezenduka et al., 2014; Meremikwu et al., 2007; Uzochukwu et al., 2010). The findings also 
corroborate a more recent study by Ladner et al., (2017), where the use of ACTs, or any 
antimalarial drug, was not dependent on the patient having a confirmed diagnosis of malaria 
or an antimalarial prescription. Table 4.1 and Table 4.2 also shows that there is evidence of 
an association between the type of drug store where treatment is received and self-medication 
in both States; a result supported by Chipwaza et al., (2014). The level of self-medication 
across these two regions shows the high probability of over-diagnosis and over-use of 
antimalarial drugs at these stores as opposed to the current treatment guidelines; the 
consequences of which include, high rates of morbidity and mortality (Mulenga and 
Kawimbe, 2015), an increase in parasite resistance (Quedraogo et al., 2008; Awad et al., 
2005) and a diminishing trust of malaria treatment. 
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This study also clearly demonstrates that the knowledge of policy may not translate into 
actual adherence to recommended guidelines for treatment of malaria by vendors in both 
states. The result showed that even though all of the drug sellers stated an ACT as the drug 
preferred, the sale of ACTs in Lagos pharmacies was 89%, 35% in PPMVs and 65% in Osun 
pharmacies and 49% in PPMVs. This result shows that awareness is not commensurate with 
practice. This can be linked to what was previously observed by Oyeyemi et al., (2015). The 
power of buyers to influence their own treatment due to affordability, or trust in a particular 
drug, was clearly evident. As these stores are for profit, sellers would rather succumb to the 
buyer’s choice of treatment than see them walk out to the next store where their choice would 
be granted. So, in this case, seller’s awareness can only lead to advice or suggestions and it is 
ultimately left to the patient to decide what course of treatment suits them best. This was also 
observed by Mangham-Jefferies et al., (2014), where there was evidence in Nigeria and 
Cameroon of provider’s choice dependence on their patient. In some cases, patients tell the 
seller how much they have and it’s left to the seller to find a drug that fits the client’s price 
range (which most times is not an ACT). This is evident in this study which observed that 
store owners who have already admitted awareness of ACTs as first-line antimalarials still 
influence a client’s use of other drugs such as chloroquine and SP. It should be noted 
however, that the use of ACTs has improved compared to what was earlier recorded in 
Nigeria (Okeke et al., 2006; Erhun et al., 2004; Ezedinachi et al., 1991); however, to totally 
eradicate malaria or effectively manage it, a total compliance to the recommended drug has to 
be used for every confirmed malaria incidence. Treatments in pharmacy stores can be more 
easily monitored and influenced than practices in PPMVs because most PPMVs fail to 
register under the Pharmacist Council of Nigeria; which is the regulatory body for both 
pharmacists and drug vendors. For this reason, information about health awareness and 
promotion can more easily be passed across pharmacy stores. Also, education level is 
required for specified laws governing the licensing of pharmacists but not necessarily in 
PPMVs. Consequently, anyone can start a PPMV business regardless of their background or 
training they have that is connected to having adequate knowledge of illness perception and 
management, which in turn contributes to dispensing of antimalarials (Beyeler et al., 2000).  
ACTs are approximately ten times more costly than previously used monotherapies so the use 
of RDTs prior to treatment may improve cost-effectiveness. Furthermore, in a study by 
Ezennia et al., (2017), the cost benefit of malaria diagnostic tests among pharmacists showed 
that RDT-based malaria treatment is cost-beneficial for pharmacy practitioners. Also, 
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Azikiwe et al., (2012) did a comparative study on the two methods of diagnosis; rapid 
diagnostic tests (RDTs) and microscopy. Result showed that RDTs based on the malaria 
antigen (whole blood) method is as specific as traditional microscopy and even appears more 
sensitive than microscopy.  The subsidised provision of RDTs, similar to ACTs subsidy, 
should be assessed to examine the impact on the uptake of RDTs in the health sector.  
4.4.2 Treatment practices in hospitals in Osun and Lagos State 
A major disadvantage of retrospective evaluation is the inability to randomize and 
standardize the experiment, which necessitates both careful interpretation and tentative 
application of results to the general population (Lazarski et al., 2001). Also, important 
questions or data could have been missed at the time the data was collected. However, 
retrospective studies have the ability to cover larger study populations, longer follow-up 
periods, and often are shielded from bias because data was often collected for reasons other 
than the study (Lazarski et al., 2001). Also, because of the time constraint on the current 
study, retrospective data that covered as far back as 12 months was determined to be the best 
approach. Hospitals in Osun State and Lagos State were conveniently sampled due to the 
availability of secondary data which is the foundation of the retrospective evaluation. 
Secondary data are data collected by someone other than the user or researcher.  
The WHO recommends that before any suspected case of malaria is treated, the presence of 
Plasmodium species must first be confirmed in the patient’s body (FMOH, 2011). It was 
further recommended that confirmation should be done with the use of both RDT (Rapid 
Diagnostic Test) and microscopy after clinical assessment has been carried out (Udoh et al., 
2013). It is encouraging that over 90% of people that visited the hospitals during the time of 
this study were tested both clinically and with the use of RDT. This is an improvement 
compared to a study by Ughasoro et al., (2013) and Udoh et al., (2013) describing up to 98% 
of children in the study being treated just on a presumptive basis as a result of a high notion 
held by doctors that most fever cases are malaria. Also, Uzochukwu et al., (2010) recorded 
31% of RDT use in a hospital in Nigeria; while Barat et al., (1999) claimed that clinicians 
rely on clinical symptoms instead of microscopic diagnosis. The high use of RDTs in this 
area for diagnosis could mean that distribution and acceptance has increased over the years. 
However, total compliance with the WHO recommendations, which includes the use of 
microscopy tests, must be strictly adhered to so as to achieve meaningful results with regard 
to effective case management and the eradication of malaria. The WHO has also advised that 
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malaria rapid diagnostic tests (RDTs) can help with providing a quick, effective and accurate 
diagnosis in cases where demonstration of parasitaemia has previously been unavailable or 
where microscopy-based diagnosis may be unreliable, as noted by Tagbo et al., (2007).  
To enable effective diagnosis of all malaria cases, the diagnostic method used must be 
accurate and available at the point of care. This could be the motivation behind the recent 
huge increase in the use of RDTs at the hospital with little importance placed on microscopic 
diagnosis. Another factor to be considered in this case is the recent effort by the government 
to provide cheap and accessible RDTs at the hospitals to ease diagnosis and to improve 
treatment methods (Bamiselu et al., 2016). One of the frequent reasons for over-treatment of 
malaria, as highlighted in the introduction, is the assumption of infection through symptoms 
only. As discussed by Cohen et al., (2015), after a long exposure to malaria, especially in 
endemic countries, ‘familiar’ symptoms are easily assumed to be malaria and treatment is 
provided when unnecessary. Indeed, data in this chapter shows a high level of suspected 
malaria cases being negative following testing; particularly in Lagos urban region. Similar to 
a study by Ughasoro et al., (2013), this common practice is responsible for the continuous 
wastage of drug, health complications, decrease in confidence for antimalarial drugs due to 
presence of symptoms after dosage completion and eventually P. falciparum resistance. This 
further places emphasis on the benefits of diagnostic and microscopy testing before 
treatment. The data in this chapter show that Osun State rural area is the most challenging 
place to have malaria, considering the fact that not only is treatment practice poor but the 
presence of counterfeit and substandard drugs in the market exacerbate the problems. With 
about 81% of the people who suspected that they had malaria being confirmed infected 
following hospital diagnosis in Osun State rural region, this does not only promote the use of 
accurate diagnostic methods, but also highlights the urgent need to promote recommended 
treatment practice in this region. A similar result was found in Lagos rural region. Housing 
conditions and structures, environmental factors and awareness are factors that increases 
exposure to the disease in rural areas, but if treatment practices can be done appropriately as 
recommended, this will reduce the barriers of effective malaria treatment. In both urban 
areas, there are less confirmed malaria cases, with 65% and 53% in Lagos and Ousn 
respectively. However, this does illustrate the danger of self-medication that occurs when 
patients visit pharmacy stores and drug vendors.  This study shows that more people in the 
rural areas of both States might malaria compared to the urban regions where less than half of 
suspected cases were confirmed. This is more worrying for people living in the rural regions 
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because of the already established poor treatment practices by people who reside in these 
regions (discussed in Chapter 3). Asides a high level of self-medication, poor access to 
effective treatment, preference of non-ACT antimalarials due to affordability, and the high 
level of counterfeit and substandard drugs that they are exposed to (this is better discussed in 
Chapter 5 and 6). Figure 4.11 shows 65% and 53% falsely suspected malaria cases in Lagos 
urban and Osun urban areas respectively, and with an average of 50% of individuals self-
medicating (as discussed in Chapter 3), it highlights the large number of ongoing cases of 
wrong treatment in  urban areas. This in turn, will lead to over use of ACTs and would 
encourage drug resistance 
Also, the data in this chapter showed that in some areas, cases found to be negative were still 
treated with an antimalarial as opposed to the policy and recommendations to not treat 
negative cases with antimalarial. This is similar to what was observed by Bottieau et al., 
(2012); indeed, this abuse of ACTs in negative cases will result in a negative clinical and 
economic impact (Skarbinski et al., 2009). As recorded in previous studies the treatment of 
unconfirmed malaria has a dangerous effect, ranging from drug resistance of the parasite to 
medical complications on the user’s part (Ocan et al., 2015; Okeke et al., 2005; Mehta et al., 
2007).  If this practice is not checked over time, there is  the risk of losing the only drug that 
is presently trusted to effectively treat malaria; just like chloroquine (Wellems and Plowe, 
2001; Grigg et al., 2016) and SP (World Health Organization 2001; Okell et al., 2016). 
Since ACT is the recommended first line treatment of malaria in Nigeria, data with regard to 
treatment choice was also collected from hospitals in the areas where research was done. The 
results showed that there is an encouraging rate of ACT prescription and treatment method in 
the hospitals; both in the urban regions and in the rural areas. About 83% of the antimalarials 
used in the hospitals on the island in Lagos were ACTs, 86% in Ikorodu, 88.7% in Osogbo 
and 78% in Iwo. This shows that there is a strong awareness about the recommended and 
effective method of treatment across these regions. 
However, even though only a few instances were noted, some cases of malaria are still 
treated with Chloroquine and SP. These two drugs have been banned in Nigeria as a first-line 
treatment therapy and only ACTs are to be used to treat malaria. Over 10% of the total 
patients in the period of this survey were treated outside the recommendation of WHO and 
the Ministry of Health and this would be a barrier to malaria effective case management and 
the eradication of malaria in Nigeria.  As much as this is an improvement from earlier studies, 
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were the use of chloroquine and SP was a lot higher (Olurishe et al., 2007; Mokuolu et al., 
2007), the reduction observed in this study is similar to that observed by Udoh et al (2013). 
However, it should be noted that chloroquine injections are still allowed and effective in 
Nigeria for urgent cases of malaria; also, as explained by doctors interviewed, some patients 
are administered chloroquine if there is no health improvement after being treated with ACT, 
or they react negatively to ACTs. 
Since RDTs have shown a high success rate, more efforts should be introduced to encourage 
its use across all hospitals and drug stores. There is still the argument of practices in public 
and private health sectors; for example, in a study by Bamiselu et al., (2016) RDT kits were 
more available in the public health facilities (82%) than private health facilities (19.2%).  
Also, considering that a higher patient load in public health facilities could make adherence 
to recommendations difficult, health providers in public health facilities tend to receive more 
training support from government agencies than their counterparts in private facilities and 
may be expected to adhere better to practice guidelines; however, Adesanya et al., (2012) 
argues that reverse is actually the case. 
In general, this study showed a better level of awareness and adherence to the national 
treatment guideline among health providers, as reported by Bamiselu et al., (2016).  This 
contrasts with Ogochukwu et al (2010) which revealed that Nigerian hospital prescribers had 
poor adherence to national antimalarial treatment guidelines and policy. Also, only 15.5% of 
health workers in Tanzania were aware of the government’s health policy (Minzi, & Haule, 
2008); this shows that over the years, there has been an improvement in the awareness and 
adherence of health workers to health guidelines. Even though more still needs to be done, 
the use of RDTs has increased in hospitals as well as the use of ACTs. However, the 
availability and use of the recommended ACT in the hospitals in both regions is 
commendable and shows the level of confidence the health facilities has in ACT and to some 
extent, the effect of initiatives such as affordable medicine facility for malaria (AMFm). This 
is a positive finding in the push to improve the case management of malaria in the state. It 
also indicates the progress made over the years when compared to results of a study on 
malaria control practice done in 2010, which showed that less than a fifth of the primary and 
secondary health facilities used the recommended. The malaria treatment regime is depicted 
in table 4.5 below. 
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Table 4.6: The WHO recommended malaria treatment procedure 
All patients who present to the 
outpatient department of the sentinel 
sites health centres
Malaria 
suspected
Malaria not 
suspected 
Diagnstic test 
done
1
Negative diagnostic test Positive diagnostic test
Antimalarial 
inappropriate
ly prescribed
Antimalarial 
appropriately not 
prescribed
Antimalarial 
appropriately 
prescribed
Antimalaria 
inappropriately not 
prescribed
2
Artemether-
lumefantrine not 
prescribed
Artemether-
lumefantrine 
prescribed
Diagnostic test not 
done
Presumptive 
treatment for 
malaria
1
 
4.5 Conclusion 
Twelve years after the change in antimalarial treatment policy in Nigeria, a substantial 
increase in the awareness of health providers has been recorded. However, awareness among 
drug sellers in PPMVs and pharmacy stores has not translated to practice. Adherence to 
prescription and recommended treatment practices was lower among drug sellers than it was 
in the hospitals. Even though an individual is more likely to be treated with a non-ACT at a 
PPMV store, the sale of non-ACTs is also considerably high in the pharmacy stores  and this 
is a cause for concern. This study has further shown that patients are at the driving point of 
treatment decisions at these stores. Even though more awareness is needed across all health 
providers, hospital providers are generally showing an increase in policy adherence. 
Deteriorating practices at the drug stores, in contrast to the improvements recorded in the 
hospitals, therefore suggest that malaria treatment seekers should be encouraged to visit 
hospitals.  For this to occur, increased effort should be made to provide a conducive 
environment for treatment; this includes reduced waiting periods and subsidised treatment.  
Since there is an increase in the awareness of drug dispensers about the recommended 
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antimalarials, these stores should be empowered and made to operate under strict laws to 
comply with the recommendations of treatment. Moreover, old/out-of-date antimalarials 
should be taken off the counter across all stores and replaced with subsidised ACTs.  
Although the role of provider-patient relationships in hindering or promoting access to 
medicines is well documented, interventions to improve the situation are inadequately 
considered in policy design, particularly in low income countries. Training and periodic re-
training of drug sellers to enable them to provide correct and full therapy for uncomplicated 
malaria, appreciate the importance of giving verbal advice to care-givers and recognize and 
refer promptly all severe malaria cases is recommended. The effectiveness of such training 
has been recorded in different settings (Kassam et al., 2015). 
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CHAPTER 5: INVESTIGATING THE QUALITY OF 
ANTIMALARIAL DRUGS USING FOURIER 
TRANSFORM INFRARED SPECTROSCOPY (FT-IR)  
5.1 Introduction  
The FT-IR process can be used to identify a compound or the composition of a sample and it 
is based on the fact that chemical bonds have specific frequencies of vibrations when infrared 
radiation is absorbed. The resulting spectrum is dependent upon the molecule possessing 
specific features that change its dipole movement during vibration; the greater the change 
then the more intense the absorption will be. For example, as homonuclear diatomic 
molecules have a dipole moment of zero, no matter how long the bond, such a molecule does 
not have a vibrational spectrum. Infrared spectroscopy is used more often for qualitative 
analysis than it is for quantitative. For a conclusive identification of a group of samples 
(antimalarial drugs in this case) features of spectra across all samples must match the 
spectrum observed for a reference standard.  
The infrared spectrum is rich in structural information; the spectral lines are produced by the 
absorption of incident radiation by the vibrational modes of functional groups in the 
molecule; these absorptions adhere to the Beer-Lambert law and hence intensify as a function 
of solute concentration which provides a means for determining the concentration of mixture 
components. The FT-IR spectrometer measures the infrared absorption and transmittance 
spectrum to check vibrational frequencies and provides details on chemical structure and 
bonding type. The presence of multiple bond dipoles within a typical organic molecule, the 
possibility for several vibrational modes being associated with each dipole, and the coupling 
of vibrational and rotational transitions gives rise to a pattern of absorptions and a 
corresponding characteristic infrared fingerprint for a compound 
There are different types of measurement methods which can be performed using infrared 
spectroscopy including the diffuse reflection method and the attenuated total reflection 
method.  To achieve the best result, a measurement method that fits with the sample form 
must be selected. From the sample viewpoint, it is possible to use more than one method to 
measure an infrared spectrum for a single sample. However, for the purpose of this research, 
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attenuated total reflection (ATR) was adopted. Attenuated total reflection (ATR) is a method 
that allows the direct measurement of powder samples and avoids the need to solubilise 
powder samples in potassium bromide (KBr) or liquid paraffin (Elmer, 2005).  The 
attenuated total reflection (ATR) method involves pressing the sample against a high-
refractive-index prism and measuring the infrared spectrum using infrared light that is totally 
internally reflected in the prism. In comparison with other methods of FT-IR spectroscopy, 
the ATR method is an excellent method for obtaining infrared information for the powder 
sample surface. However, care is required with the wavenumber dependency of the 
absorption peak intensity and with the peak deformation towards the first-order differential 
form due to the anomalous dispersion of the refractive index for inorganic and other high-
refractive-index samples (Elmer, 2005). It is important to have a reference spectrum (possibly 
spectrum of one of the drugs that has been previously analysed) so as to be able to compare 
spectra and find out the quality of the sample drugs. Antimalarial tablets for analysis in this 
chapter were kept according to manufacturer’s instructions in dry, sealable, rubber sachets at 
room temperature until analysed. To analyse, samples were carefully ground and kept away 
from light and humidity. Ground samples were placed on the FT-IR machine and 3 different 
spectra for 3 different days were recorded. Drugs were labelled to include name of tablet, 
artemether/lumefantrine ratio, date, place purchased and price of drug.  
5.1.1 FT-IR Spectra analysis. 
After the FT-IR machine had been used to analyse the antimalarials, spectra results were 
analysed with respect to group frequencies. There are three different groups: mid-infrared 
region, near-infrared region and far-infrared region. 
Mid-Infrared region (4000-400cm-1): is divided into four sub-regions and the nature of 
group frequency can be determined by the region that it is located. 
1) X-H stretching region (4000-2500cm-1) 
 O-H stretching produces a broad band in the region 3700-3600cm-1 
 N-H stretching are observed in the region 3400-3300cm-1 
 C-H stretching bands from aliphatic compounds will be observed in the region 3000-
2850 cm-1, and C-H stretching bands adjacent to a double will be observed in the 
range 3100-3000cm-1. 
 
2) Triple bond region (2500-2000cm-1) 
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 C≡C absorb in the range 2300 and 2050cm-1, and its stretching is normally weak 
 C≡N are observed between 2300 and 2200cm-1, and its stretching is of medium 
intensity 
3) Double-bond region (2000-1500cm-1) 
 C=O stretching usually occurs in the 1830-1650cm-1 region 
 C=c stretching occurs around 1650 cm-1 and its much weaker 
 C=N stretching occur in the same region but stronger. 
4) Finger print region (1500-650 cm-1).  
Near-infrared region (13000-4000 cm-1): The absorptions seen in this region are overtones 
or combinations of the fundamental stretching bands, which occur in the 3000-1700 cm-1 
region. They are commonly due to C-H, N-H, or O-H stretching. 
Far-infrared region (400-100 cm-1): This region provides information about molecules that 
contain heavy atoms, molecular skeleton vibrations, molecular torsions and crystal lattice 
vibrations. This region is not as useful as the mid-infrared region but it can provide some 
information about the vibration of the molecule. 
An example spectrum showing the absorbance spectra of erythromycin is seen in Figure 5.1 
below. 
 
Figure 5.1: An example of the FT-IR spectra of different concentrations of 
erythromycin showing an absorption peak between the region 1700 cm-1 and 1750 cm-1 
where the C=O stretching  occurs.  (Source: Ali et al., 2012). 
FT-IR data can also be viewed as a transmittance spectrum, as seen with artemether in Figure 
5.2.  
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Figure 5.2: An example of the FT-IR spectrum of artemether showing a transmittance 
peak between the region 3000-2850cm-1 where the C-H stretching bands usually occur 
(Source: Wang et al., 2015). 
Antimalarial drugs target malaria parasites to eradicate them and thereby stop their 
multiplication and also, the reoccurrence of the disease. Unless an effective drug is used, little 
or no reduction in the multiplication of parasite can be expected. This makes drug efficacy in 
malaria treatment an important factor and all drugs must meet standard expected by the 
Ministry of Health or the regulatory organisation of the country concerned. 
5.2 Objectives 
One of the recommendations of the WHO and the Federal Ministry of Health (FMOH) is to 
treat every case of malaria appropriately using artemether/lumefantrine combination therapy 
(ACT). This chapter will qualitatively investigate the threat of poor quality and counterfeit 
drugs that are sold in the market in the two study regions (Osun and Lagos) using FT-IR 
spectroscopy to provide a basis for spectral comparisons of the antimalarials being used with 
their reference standards. This would not only show the level of discrepancy existing within 
the drug groups but also within the regions where this study is being carried out. 
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5.3 Results 
All drug samples were analyzed within their recommended shelf life periods through FT-IR 
and the spectra below are the results of the sample drugs. The experiment was repeated thrice 
over three days to establish stable spectral signatures and then one spectrum was used to 
represent samples. Not all of the drugs sampled are ACTs, and non-ACT drugs showed 
absorption at different wavelengths.  
5.3.1 Artemether  
Figure 5.3: Artemether FT-IR Spectrum (pure reference sample from Novartis UK). 
Shows C-H stretching bands from aliphatic compounds observed in the region 3000-2850cm-
1
, and a fingerprint region, from about 1500cm
-1
 to 500 cm
-1
. 
 
Artemether, an artemisinin derivative, is a medication used to treat uncomplicated malaria 
caused by P. falciparum. For ACT regimes, it is used in combination with lumefantrine 
which has a longer mode of action in the human body. This combination therapy exerts its 
effects against the erythrocytic stages of Plasmodium species and may be used to treat 
infections caused by P. falciparum and unidentified Plasmodium species, including infections 
acquired in chloroquine-resistant areas. The spectral result of artemether from this study, as 
shown in Figure 5.3, shows C-H stretching bands from aliphatic compounds observed in the 
region 3000-2850cm-1 which is consistent with spectra from previous studies (Yu et al., 
2012). This broad band observed is the most important part of the artemether FT-IR 
spectrum, as the fingerprint region does not reflect on the efficacy of the drug itself. The 
fingerprint region, to the right-hand side of the spectrum (from about 1500 to 500 cm-1), 
usually contains a very complicated series of absorptions. This is because of the various 
bending vibrations within the molecule. It is much more difficult to pick out individual bonds 
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in this region than it is in the "cleaner" region at higher wavenumbers. The importance of the 
fingerprint region is that each different compound produces a different pattern of troughs in 
this part of the spectrum. 
5.3.2 Lumefantrine  
Figure 5.4: Lumefantrine FT-IR spectrum (pure reference sample from Novartis UK). 
Shows N-H stretching bands from aliphatic compounds observed in the region 3400-3300cm-
1
, and a fingerprint region, from about 1500cm
-1
 to 500 cm
-1
. 
Lumefantrine is a dichlorobenzylidine derivative that is also very effective for the treatment 
of various species of Plasmodium, including multi-drug resistant strains of P. falciparum. 
When combined with artemether (ACT), it serves as the first-line treatment for 
uncomplicated malaria in many malaria endemic countries. It has a primary action as a blood 
schizontocidal and a secondary action as an inhibitor of nucleic acid and protein synthesis 
within the malarial parasite, thus providing a longer duration of antimalarial action (Ezzet et 
al., 2000; Hamrapurka et al., 2010). This therefore makes lumefantrine an important drug in 
the struggle for eradication and effective case management of malaria. Figure 5.4 shows the 
FT-IR spectrum of lumefantrine with a broad N-H stretching that can be observed in the 
region 3400-3300cm-1. 
143 
 
5.3.3 Coartem reference sample  
Figure 5.5: Coartem reference sample FT-IR spectrum (pure reference sample from J 
Jeckor Pharmacy in Lagos urban region). Shows lumefantrine in the region 3400-3300cm-
1, artemether in the region 3000-2850cm
-1 
and a fingerprint region, from about 1500cm
-1
 to 
500 cm
-1
. 
Since artemether and lumefantrine are two different derivatives, one can decipher which drug 
contains both medications by observing the broad FT-IR spectra at the artemether region and 
the lumefantrine region. For example, one of the most popular globally used ACT 
combinations is Coartem. Coartemether (Riamet™ in Europe, Coartem in Africa and the 
United States) is a combination of artemether and lumefantrine (20/120mg or 80/480mg) 
used for the treatment of uncomplicated malaria in adults and children weighing > 4.5kg and 
it is becoming widely distributed in Africa. Coartem is generally well tolerated though there 
are some adverse effects, including gastrointestinal upset, headache, and dizziness. Figure 5.5 
illustrates the FT-IR spectrum of ACTs located in the mid-infrared region (4000-400 cm-1); 
the presence of O-H groups in the drugs is indicated by a broad band in the region 3600-3400 
cm-1 and C-H stretching bands from aliphatic compounds overlap with this band in the range 
3000-2850 cm-1.  The spectrum also indicates strong C=O stretching bands at 1650 and 1550 
cm-1 showing that the molecule contains carbonyl groups. The spectrum for each drug also 
indicates strong bands at 1400-1350 cm-1. The 1500-650cm-1 region represents a fingerprint 
region in which each band in the spectrum can be specified to a particular deformation of the 
molecule.  
Fingerprint region 
Artemether 
Lumefantrine 
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5.3.4 Lonart reference Sample  
Figure 5.6: Lonart reference sample FT-IR spectrum (pure reference sample from Bliss 
JVS Ltd in Lagos urban region). Shows lumefantrine in the region 3400-3300 cm-1, 
artemether in the region 3000-2850 cm
-1 
and a fingerprint region, from about 1500 to 500 cm
-
1. 
Lonart is one of the most commonly used antimalarial drugs in Nigeria and it also contains 
artemether and lumefantrine in the ratio 1:6 respectively (20/120mg or 80/480mg). The 
Lonart FT-IR spectrum (Figure 5.6) is as expected from an ACT drug; lumefantrine is 
represented by a broad N-H stretching band observed in the region 3400-3300cm-1and 
artemether C-H stretching bands are seen in the region 3000-2850cm-1. The fingerprint region 
can be affected by other substances in the drug (eg. colouring, sweetener etc.); however, the 
fingerprint for each type of drug should be the same and differ across different types of ACT 
(or other groups). 
5.3.5 Amatem reference sample 
Amatem is a common antimalarial drug used in Nigeria and it contains artemether and 
lumefantrine in the 1:6 amount (20/120mg or 80/480mg). The Amatem FT-IR spectrum 
(Figure 5.7) is consistent with results observed for other ACT drugs; lumefantrine is indicated 
by the broad N-H stretching observed in the region 3400-3300cm-1and artemether C-H 
stretching bands are seen in the region 3000-2850cm-1. As expected, the fingerprint region of 
Amatem shows a spectrum that is different from Lonart and Coartem. 
Artemether 
Lumefantrine 
Fingerprint region  
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Figure 5.7: Amatem reference sample FT-IR spectrum. Shows lumefantrine in the region 
3400-3300 cm-1, artemether in the region 3000-2850 cm
-1 
and a fingerprint region, from about 
1500cm
-1
 to 500 cm
-1
. 
5.3.6 ACT drug spectra (Pharmacy and PPMVs) 
Table 5.1: Antimalarial brands that are commonly used in the study area.  
ANTIMALARIAL ACT 
Yes/No 
CONTENT EXPIRY DATE 
Combisunate Yes Artemether/Lumefantrine Jul-18 
Chloroquine No Chloroquine phosphate Jun-18 
Fansidar No Sulfadoxine/Pyrimethamine Oct-19 
Lonart Yes Artemether/Lumefantrine Jun -18 
Lumartem Yes Artemether/Lumefantrine Feb-17 
Coartem Yes Artemether/Lumefantrine Jun-19 
Artesunate No Artesunate Sep-17 
 
Table 5.1 shows a list of the mostly used antimalarial drugs that were purchased from the 
research area. These drugs include ACTs and non-ACTS and they were sampled across 
pharmacy stores and PPMVs in both Osun and Lagos States. 
All ACTs that were purchased from pharmacy stores and drug vendors had spectra consistent 
with the reference drugs that were acquired from the drug manufacturers/ licensed 
distributors. The presence of lumefantrine was confirmed bythe broad N-H stretching bands 
in the region 3400-3300cm-1artemether was shown by the C-H stretching bands in the region 
Lumefantrine 
Artemether 
Fingerprint region  
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3000-2850 cm-1(Figure 5.7 - Figure 5.14,).  The fingerprint regions also have the same 
troughs for the same drugs but differences are apparent between the types of ACT (Figures 
5.7 – Figure 5.14).  For example, Lonart drugs which were purchased from Osun state urban 
and rural regions and Lagos state urban and rural regions were compared and the spectra 
result was consistent across all regions (Figures 5.8 and 5.9). It should be noted that the 
fingerprint region of both urban and rurally sourced drugs is also the same.  
 
Figure 5.8: Lonart FT-IR spectra from Osun rural and urban regions (rural, rural, and 
urban). The presence of lumefantrine in the region 3400-3300 cm-1, artemether in the region 
3000-2850 cm
-1 
and a fingerprint region, from about 1500 to 500 cm
-1 
can be observed. 
Figure 5.9: Lonart FT-IR spectra from Lagos rural and urban regions (rural, rural, rural, 
urban, urban, and urban). The presence of lumefantrine in the region 3400-3300 cm-1, 
artemether in the region 3000-2850 cm
-1 
and a fingerprint region, from about 1500 to 500 cm
-
1 
can be observed. 
Osun urban 
Osun rural 
 
Osun rural 
Lagos urban 
 
Lagos urban 
 
Lagos urban 
Lagos rural 
Lagos rural 
Lagos rural 
Lumefantrine 
Artemether 
Fingerprint region  
Lumefantrine 
Artemether 
Fingerprint region  
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Coartem drugs in Osun State were also cross referenced and the result showed consistent 
troughs across the State, including the fingerprint region (Figure 5.10). The presence of 
lumefantrine and artemether can be confirmed by broad N-H stretching in the region 3400-
3300cm-1 and C-H stretching bands from in the region 3000-2850cm-1 respectively.
   
Figure 5.10: Coartem FT-IR spectra from Osun urban and rural regions (urban, urban, 
and rural). The presence of lumefantrine in the region 3400-3300 cm-1, artemether in the 
region 3000-2850 cm
-1 
and a fingerprint region, from about 1500 to 500 cm
-1 
can be observed. 
Figure 5.11 Combisunate FT-IR spectra from Osun and Lagos urban and rural regions.  
The presence of lumefantrine in the region 3400-3300 cm-1, artemether in the region 3000-
2850 cm
-1 
and a fingerprint region, from about 1500 to 500 cm
-1 
can be observed. 
Combisunate drugs in Lagos State urban and rural areas, when cross referenced, showed 
consistent troughs across the State, including the fingerprint region (Figure 5.11).  
Osun rural 
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All ACTs drug samples, when compared by urban and rural region of both states showed the 
same consistency as expected. Some of these drugs are represented in Figure 5.12 – Figure 
5.15.  
Figure 5.12: FT-IR spectra from ACT samples purchased from stores in Osun urban 
region. The presence of lumefantrine in the region 3400-3300 cm-1, artemether in the region 
3000-2850 cm
-1 
and a fingerprint region, from about 1500 to 500 cm
-1 
can be observed. 
(Lonart, Amatem, Coartem, Combiart, Combisunate, Combisunate). 
 
Figure 5.13: FT-IR spectra from ACT samples purchased from stores in Osun rural 
region. The presence of lumefantrine in the region 3400-3300 cm-1, artemether in the region 
3000-2850 cm
-1 
and a fingerprint region, from about 1500 to 500 cm
-1 
can be observed 
(Amatem, Coartem, Lonart, Combisunate, Lonart). 
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Figure 5.14: FT-IR spectrum from ACT samples purchased from stores in Lagos urban 
region. The presence of lumefantrine in the region 3400-3300 cm-1, artemether in the region 
3000-2850 cm
-1 
and a fingerprint region, from about 1500 to 500 cm
-1 
can be observed 
(Lonart, Combiart, Combiart, Combisunate, Combisunate, Lonart). 
Figure 5.15: FT-IR spectrum from ACT samples purchased from stores in Lagos rural 
region. The presence of lumefantrine in the region 3400-3300 cm-1, artemether in the region 
3000-2850 cm
-1 
and a fingerprint region, from about 1500 to 500 cm
-1 
can be observed 
(Lumartem, Amatem, Lonart, Lonart, Lonart, Lonart, Lumartem). 
5.3.7 Artesunate drug spectra  
As described by the WHO, artesunate is a water-soluble hemi-succinate derivative of 
Artemisinin.  Although artesunate is a derivative of artemisinin, it is not an artemether-
lumefantrine combination. Artesunate has been reported to clear fever in patients with severe 
P. falciparum malaria 16-25 hours after parenteral administration and hence it is a very 
effective drug against malaria. The following results show the spectra recorded from 
artesunate that were purchased from the study area. 
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Figure 5.16: Artesunate reference sample (Pure reference sample from Phat Pharm 
Pharmaceuticals in Lagos urban region) FT-IR spectrum. Shows absorbance in the region 
3500-3000 cm-1 and in the region 3000-2850 cm
-1 
and a fingerprint region, from about 1500 
to 500 cm
-1
. 
 
Figure 5.17: FT-IR spectrum of artesunate (Lagos urban). Shows absorbance in the 
region 3500-3000 cm-1and in the region 3000-2850 cm
-1 
and a fingerprint region, from about 
1500 to 500 cm
-1. 
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Figure 5.18: FT-IR spectrum of artesunate (Osun urban). Shows absorbance in the region 
3500-3000 cm-1and in the region 3000-2850 cm
-1 
and a fingerprint region, from about 1500 to 
500 cm
-1
. 
3.3.8 Chloroquine spectra (Albert healthcare Ltd) 
Chloroquine (7-chloro-4-(4-diethylamino-l-methylbutylamino) quinoline) is a very common 
chemotherapeutic agent for the prevention and clinical treatment of malaria in Nigeria. Years 
after its development, the efficiency, safety, stability, low cost and ease of manufacture of 
chloroquine have all contributed to making it the most widely used synthetic antimalarial 
drug (Slater, 1993). Therefore, because of its easy accessibility and cheapness, it is vital to 
include chloroquine spectra in this study to examine if similar results will be observed across 
different regions. The spectra below show all chloroquine samples that were tested in both 
Lagos and Osun State. 
Figure 5.19: FT-IR Spectrum of a chloroquine reference sample (pure reference sample 
from Albert healthcare Ltd).   
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Figure 5.20: Chloroquine FT-IR spectra across the four regions (Lagos rural, Lagos rural, 
Lagos rural, Lagos urban, Lagos urban, Lagos rural, Osun Urban, Osun rural, Osun urban) 
As shown (Figure 5.20), not all chloroquine samples produced the expected spectrum across 
both States; particularly one of the samples from Lagos rural region. These discrepancies in 
the spectra of chloroquine highlight the level of counterfeit or substandard drugs in the field; 
especially among non-ACTs. The samples purchased from Osun state shows that only two 
spectra were as expected. Chloroquine spectra of drugs from Lagos showed that five samples 
had the same spectra, including the fingerprint region, whilst one showed a totally different 
spectrum. The inconsistency in chloroquine spectra (Figure 5.20), shows that the content of 
some of these drugs have been mislabelled; whether intentionally or not, and they are 
therefore fake drugs.  
5.3.9 Fansidar spectra (Swiss Pharma Ltd) 
Fansidar is an antimalarial from the SP group and it is commonly a treatment choice for 
malaria in Nigeria because of its cheap price compared to ACTs. It is also the recommended 
treatment drug for pregnant women in their 3rd trimester. The spectrum of a Fansidar tablet 
that was purchased from an authorised distributor (Figure 5.21) was compared with randomly 
collected samples from the field of study. Although not as much as ACT samples tested, one 
of the few Fansidar samples tested was found to be inconsistent with the reference sample 
and the other samples (Figure 5.22). 
Lagos rural 
Lagos rural 
Lagos rural 
Lagos rural 
Lagos urban 
Lagos urban 
Osun urban 
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 Figure 5.21: FT-IR Spectrum of the Fansidar reference sample (pure reference sample 
from Swiss Pharma Ltd).   
 
Figure 5.22: Fansidar FT-IR Spectra across the four regions. Shows that one of the five 
Fansidar spectra from Lagos and Osun is not consistent with the reference spectrum and with 
spectra from other samples 
Table 5.2 is a summary of the FT-IR analysis that was done on different antimalarial drugs 
that are preferred by participants from the four different regions of the study. It should 
however be noted that there is a limit to what can be concluded from this result. The quick 
drug sampling that was done included the purchase of about 60 drugs across the four regions 
of the research to show the possibility of the presence of counterfeit drugs in this region and 
to create a link with the already flawed treatment practices in these regions.  
 
Osun urban 
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Table 5.2: Summary of the antimalarial drug quality across the study area as assessed 
by FT-IR analysis. 
 
LOCATION 
                SP CHLOROQUINE ARTESUNATE 
(Monotherapy) 
                ACT (AL) 
Total Failed Total Failed Total Failed Total  Failed 
Lagos urban 2               0                       3                      0 2               0 6                  0 
Lagos rural 2               0 3                      1 0               0 7                  0 
Osun urban 1               1 2                      0  1               0 6                 0 
Osun rural 0               0 1                      1 0               0 5                  0 
Grand total 5                1 9                      2 3               0 24                 0 
 
5.4 Discussion 
The continuous increase in malaria prevalence and the threat of P. falciparum resistance to 
monotherapies lead to the WHO 2006 guidelines that specifically recommend combination 
therapy of ACTs for effective treatment of malaria cases caused by P. falciparum (Mosha et 
al., 2014; Makanga & Koudsood, 2009). Since artemether acts quickly by reducing the 
biomass of the parasite by approximately 10,000 times per sexual life cycle (Premji, 2009) 
another antimalarial that lasts longer to eliminate residual parasites after artemether is also 
needed. This combination is needed to avoid recrudescence and the parasite developing 
resistance to either of the drug in combination. However, a major setback to the effective 
control of malaria through appropriate treatment is the issue of counterfeit and substandard 
drugs. Counterfeit or substandard pharmaceutical formulations are a serious public health 
concern to communities, individuals, and to the government. WHO defines counterfeit drugs 
as “a drug that has been deliberately and fraudulently mislabelled with respect to identity 
and/or source”. National and international authorities have different ways of defining terms 
relating to medicine quality. The WHO has used the term ‘substandard, spurious, falsely 
labelled, falsified and counterfeit’ (SSFFC) to encompass the range of poor-quality medicines 
(WHO, 2016). However, recent years have brought a new dimension and attention to the 
difference between the terms ‘falsified’ and ‘substandard’ medicines. As defined by (Newton 
et al., 2011; Nayyar et al., 2012) ‘falsified’ medicine is deliberately and fraudulently 
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mislabelled with regard to its identity or source. Therefore, falsification can apply to both 
branded and generic products and refer to medicines in which the active pharmaceutical 
ingredients (API) could theoretically be correct, wrong, insufficient, or absent, or be a result 
of fake packaging. This is the definition adopted for this study and will be used 
interchangeably with fake drugs and counterfeit drugs. A ‘substandard’ medicine on the other 
hand, is a genuine drug product that does not meet quality specifications because of 
manufacturing error or that degrades over time within the recommended shelf-life (Bassat et 
al., 2016; Attaran et al., 2012). 
Keledis et al (2007) describes a continuous increase in the number of counterfeit and 
substandard drugs reported in the last decade, most of which were found in developing 
countries. In Nigeria, few studies have been published to describe fake drugs in the context of 
API although some studies (Pincock, 2003; Ahmad, 2004) have shown that diseases with 
greater risk of death, such as AIDS, and malaria, are targets for counterfeit producers. As 
seen from different studies on drug efficacy, different techniques can be used to determine 
fake and substandard drugs; from physical to laboratory analyses. In addition to physical 
differentiation (packaging, tablet colour, text on pack etc.) the quality of antimalarial drugs 
can be tested in the laboratory using FT-IR (Sundaramoorthi et al., 2017; Kiruthika et al., 
2015), NMR (Holzgrabe 2017; Siddiqui et al., 2017) and HPLC (Nikolin et al., 2004; 
Siddiqui et al., 2017) among others. For this study however, FT-IR was used to qualitatively 
determine the presence of artemether/lumefantrine in ACTs and consistency in drug content 
across all groups and regions. This study is the first study to use FT-IR as a qualitative 
method to test drug quality from Nigeria, however, a more detailed study that examines up to 
200 drug samples in each region will provide a richer result through which a definite 
conclusion can be reached.  
The reference drugs that were purchased from trustworthy manufacturers or distributors 
showed consistent spectra with a pure AL combination (Figure 5.4 - Figure 5.6). The spectra 
result of all AL drugs that were acquired from urban and rural regions showed the presence of 
artemether and lumefantrine peaks at their expected IR regions. However, it should be noted 
that even though FT-IR confirms that these drugs have artemether and lumefantrine, there is 
the question of API to consider since the presence of the right substance does not guarantee 
the right quantity of this substance.  
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The spectra of chloroquine drug samples that were purchased from all drug outlets in Osun 
state and Lagos state showed that one sample lacked drug. The spectra of chloroquine 
acquired from medical outlets in Osun state showed that three samples from the urban area as 
well as two samples from the rural area do not have a spectra that is consistent with the 
reference sample. In Lagos state, the FT-IR spectra showed that one chloroquine sample from 
the rural area was inconsistent with the others and with the reference sample. Following the 
recommendations of WHO and the adoption of ACTs as the first-line treatment for malaria in 
Nigeria since January 2015, chloroquine tablets are not meant to be used for malaria 
treatment. Not only has P. falciparum resistance to chloroquine been recorded in many 
studies (Onwujekwe 2009; Sidhu et al., 2002; Mekonenn et al., 2014), it is also a target for 
counterfeit producers because it is cheap and easy to buy. With Fansidar (SP group), out of 
the 5 of the samples that were tested, four of the drugs were consistent with the reference 
sample and the sample from Osun urban region showed a different IR absorption peak in the 
region 2800-3000 cm-1 showing C-H stretching bands from aliphatic compounds which isn’t 
found in other samples.  
The drugs that did not pass the FT-IR test in this context either did not have the expected 
active ingredients or they had other active ingredients that are not expected. The results of 
this study are similar to that reported by Onwujekwe et al., (2009) in the Southeast region of 
Nigeria using HPLC chromatography.  In this study (Onwujekwe et al., 2009) a large number 
of SP drugs (40.7%) and chloroquine (53.6%) failed the quality test (did not meet the 
tolerance limit for quality test) and all ACTs passed the quality test. One major concern with 
the noticeable increase in fake SP formulations is the danger it poses to pregnant women in 
Nigeria since the national policy on malaria control prescribes the use of intermittent 
preventive treatment with SP for chemoprophylaxis against malaria in pregnant women 
(Ugwu et al., 2013). 
In contrast to Onwujekwe et al., (2009), this study does not provide enough information to 
conclude that there are more counterfeit drugs in the urban regions compared to rural regions 
or in Lagos State compared to Osun State. However, the pattern of fake drugs that was found 
in this study has equity implications for appropriate treatment of malaria in Nigeria. As 
rightly decided by health authorities to make ACTs the trustworthy mode of malaria 
treatment, the high cost of these drugs means the poor people of lower socio-economic status 
groups are left to treat malaria with cheap and easily accessible drugs like chloroquine and SP 
formations. Despite the fact that ACTs are sold at a subsidised rate in malaria endemic 
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countries, the price between most ACTs and commonly used SP formations and chloroquine 
is still very high and this is why chloroquine is regarded as a poor people’s drug. Similar to 
what was recorded by Kelesidis & Falagas (2015), the most common substandard/counterfeit 
antimicrobials include beta-lactams (among antibiotics) and chloroquine; this study therefore 
strengthens opinion that cheap and commonly used drugs by poor people are major targets of 
the counterfeit drug producers and it disagrees with researchers that believe inexpensive 
drugs like chloroquine are not targets. For example, Whitty et al., (2008) said completely 
fake drugs are rare where drugs are cheap. The fact that there are more poor people in Nigeria 
makes cheap counterfeit antimalarials a business target for counterfeit producers. 
Although Newton et al., (2006) found in Cambodia that out of 133 drug vendors 71% had 
counterfeit artesunate, Onwujekwe et al., (2009) also found an increasing rate in counterfeit 
artemether monotherapy such as artesunate sold in drug outlets; for example, 25% of 
artemisinin monotherapy tested did not meet the tolerance limit for quality test.  However, 
this was not found to be the case in this study, as all the artesunate samples tested passed 
even though not enough artesunate were tested to firmly draw a conclusion. In support, a 
study by Ofori-Kwakye et al., (2008) was carried out to evaluate the quality of artesunate 
tablets sold in retail and wholesale pharmacies in Kumasi, Ghana. Artesunate tablets were 
purchased from pharmacies in Kumasi to check for mechanical properties of the tablets such 
as uniformity of weight, breaking strength and the rate of disintegration in aqueous medium; 
before colorimetric methods were used to determine the presence of artesunate. Results of 
this study showed that none of the artesunate tablets sampled was found to be counterfeit. 
ACTs in this study showed a 100% pass rate, this result compares well with those from other 
studies such as Onwujekwe et al., (2009), where all ACTs met the USP tolerance limits for 
quality test. However, Newton et al., (2014) found no artemether, lumefantrine or any other 
pharmaceutical ingredients in the drugs labelled “artemether-lumefantrine” tablets that were 
seized in Luanda, Angola. Compared to other types of antimalarial, fake ACTs are not yet 
prevalent in the drug market; for this reason, urgent intervention should be developed and 
implemented so as to quickly curb counterfeit producers from infiltrating the ACT market,  
To improve on the quality treatment available to malaria patients, drug quality must definitely 
be improved; therefore, it is imperative to increase educational intervention for health 
providers, and patients to be able to identify between quality drugs and fake drugs. This is 
important because studies have shown that even healthcare providers, including doctors, 
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sometimes do not follow the procedures and guidelines of patient treatment. For example, a 
study by Ugwu et al., (2013) showed that 54.5% of general practitioners prescribed other 
antimalarials for acute treatment of malaria in the first trimester instead of quinine as 
recommended by the World Health Organization and the national malaria control programme 
of the Federal Ministry of Health (FMOH) (2012). This shows that with the effective 
treatment of malaria, even the GPs may not be abreast with a new concept of treatment of 
acute malaria in the first trimester where quinine is the drug of choice and is also currently 
the only anti-malaria drug that is effective and safe for use in the first trimester of pregnancy. 
More emphasis and more campaigns need to be established to advise people to steer clear of 
chloroquine as a treatment for malaria. The fact that some of the chloroquine samples in this 
study did not have the same spectrum as the reference sample is very worrying considering 
the prevalence of malaria in this region. A lot of patients can be exposed to this and could 
develop a worse complication, or even die as a result. 
If the use of ACTs for malaria treatment is being promoted among citizens then the fight 
against counterfeiting should also be taken more seriously. If more people believe in the use 
of ACTs but cannot afford them because of their huge price, they can then be easily lured into 
buying fake ACTs at a cheaper price. This will in turn increase the amount of ACTs in the 
market and this will eventually be hard to control. 
5.4.1 ACT potential target for modern counterfeiters 
As one of the most potent antimalarials that has been well-tolerated, ACT is a major target 
for drug counterfeiters. It takes nearly six months to grow the plant Qinghao, which produces 
artemisinin and from which the combination ACT comes. The huge prevalence of malaria 
leads to a massive demand for artemisinin which is in short supply (Newton et al., 2006). The 
major reason why ACTs are usually targeted in developing countries is mainly because of its 
market price. ACT is relatively expensive; the cost of a course for an adult and a young child 
is US$ 1.20-3.50 (Karunamoorthi, 2014) (it had increased to about $5 by the time this study 
was being concluded). In a country where the poverty level is extremely high, there is a call 
for cheaper trusted drugs to treat a disease which some people have more than 10 times in a 
year. In Third World countries, citizens usually face high exposure to different diseases 
because of lack of amenities and when combined with corruption, insufficient drug regulation 
and weak law enforcement, it becomes a very frustrating situation were people can give or 
receive treatment without any form of monitoring. This creates a huge opportunity and it’s a 
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major driving force to establish a counterfeit anti-malarial industry to produce and distribute 
fake antimalarials. This is usually the case in Nigeria, in addition to insufficient amenities and 
ability to detect and identify the quality of antimalarials, poor consumer and health worker 
knowledge about these drugs and lack of punitive action  against counterfeiters make these 
drugs attractive targets for counterfeiters. In Nigeria, much investment, or money, is not 
needed to start a counterfeiting business and fake drugs can be produced in the backyard of 
houses, or in a small room.  
In the case of ACTs where drug prices of medicines are high and the difference in price with 
other identical products exists there is a huge possibility for the consumer to seek medicines 
outside the normal supply system. Some rural areas in Nigeria lack transport and there is no 
easy connection to the urban areas. This reduces their access to original drugs that can be 
purchased from trustworthy pharmacy stores and therefore patients resort to local stores who 
might only be licensed to sell off the counter drugs. Poverty, and the lack of an official 
supply chain, are major factors in creating markets for counterfeit products (Bamitale, 2013)  
5.4.2 Consequences of counterfeit medicine 
Effective and appropriate drug use is the key to treatment in public health. In this case, fake 
antimalarials, which usually contain no, or less active ingredients, either lead to patients 
being at substantial risk of developing severe malaria or dying from complications. A 
prediction by Seiter (2009) to quantify the cost of ineffective antimalarials from prior 
estimates states that in a country of about 20 million people, there may be four million 
treatments and nearly 800,000 cases treated with poor quality antimalarials, causing up to 
4,000 childhood deaths. Fake antimalarials will lead to recrudescence of disease and can also 
lead to resistant parasites. Evidently, the recent emergence of artemisinin resistance or 
tolerance of a P. falciparum strain in the Thailand-Cambodia border makes protection of an 
effective drug supply imperative.  This means the drug does not help the patient get better 
and can also be harmful to the patient. For example, the treatment of uncomplicated malaria 
with this type of drug can lead to severe malaria and this may result in death. Another type of 
counterfeit drug is the drugs that have no active ingredient but contain harmful ingredients. 
For example, a tragedy occurred on a larger scale in Panama when a Chinese chemical 
manufacturer sold diethylene glycol, the active ingredient in antifreeze, as pharmaceutical-
grade glycerin to a European company Buckley and Gostin (2013). Because this is often used 
as the solvent in cough syrup, it led to kidney failure in the people who ingested it. A total of 
about 60,000 bottles were sold to people and as a result, more than 219 people lost their lives 
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to kidney failure brought on by diethylene glycol poisoning (Núñez, 2011); some news 
reported more than 500 deaths. Another case of a counterfeit drug is that of a 
GlaxoSmithKline's over-the-counter weight-loss medication “Orlistat” which was distributed 
in the United States. The counterfeit contained the controlled substance sibutramine instead 
of Orlistat (Blackstone et al., 2014). 
Substandard and counterfeit antimalarials are directly or indirectly associated with higher 
morbidity, mortality and stunted socio-economic growth due to additional healthcare costs 
because of treatment failure and they impose a severe burden of disability adjusted life years 
(DALYs) at the national level. Even when patients are treated with genuine drugs, no 
response is seen due to resistance caused by the previous intake of fake drugs (Akunyili, 
2004). 
In Nigeria, counterfeit antimalarials cannot be easily identified from genuine drugs which has 
led to a steady diminishing of the confidence of the public healthcare providers and systems 
at large. The problem of counterfeit drugs has embarrassed the Nigerian healthcare providers 
and denied the confidence of the public on the nation’s healthcare delivery system.  The 
following are notable recorded occurrences in Nigeria that shed more light on how 
devastating the consequences of counterfeit drugs can be. Starting in 1989, some poorly 
manufactured chloroquine syrup killed a number of children in U.N.T.H, Enugu; of which 
there are no statistics, partly because many of the deaths were not even reported (Akunyili, 
2004).  Later in 1990, the “Paracetamol syrup” disaster occurred when 109 children died in 
Ibadan and Jos, after taking paracetamol/cough syrup produced with the toxic ethylene glycol 
solvent instead of propylene glycol (Itodo and Oyinye, 2017). During a meningitis epidemic 
in Niger in 1995, more than 50,000 people were inoculated with fake vaccines resulting in 
2,500 deaths.  Also, Odion (2017) recorded that in 2002, 3 patients reacted adversely to 
infusions manufactured by a Nigerian company. Some of the adverse reactions exhibited by 
the patients were severe rigor, vomiting, sweating, restlessness, seizure, impaired level of 
consciousness, etc. The reactions stopped immediately after the administration of the 
infusions were discontinued. Investigations by NAFDAC on the offensive infusions collected 
from the hospital revealed that three batches were heavily contaminated. 
In 2003, counterfeit adrenaline was reported to have contributed to the death of three children 
during open-heart surgery in Nigeria. Further investigations by NAFDAC revealed that the 
suxamethonium used in the surgical procedure was a counterfeit product. Later in 2004, some 
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hospitals reported cases of adverse reactions from the use of contaminated infusions produced 
by four Nigerian companies. Consequently Bamitale (2013) sampled infusions and water for 
injection from all over the country and results confirmed that some batches of infusions 
produced by the companies were heavily contaminated with microorganisms. The extent of 
counterfeit problems in Nigeria is better described by the fact that counterfeit products 
(drugs, food, cosmetics, medical devices, chemicals, and water including all drinks but 
mostly pharmaceuticals) prized at over N8b ($60 million) were seized and destroyed in 
Nigeria by the National Agency for Food and Drug Administration and Control (NAFDAC) 
between April 2001 and December 2004.  
5.4.3 Drug law-enforcing agency in Nigeria (NAFDAC) 
The problems of fake drug proliferation in Nigeria have affected the credibility of the 
healthcare system and can exert very harmful effects on the consumer resulting in illness, 
disability and even death; anyone can be a victim. Some of the incidents have resulted in 
death even among children because most times the consumers do not know the quality of 
what they are buying or taking. This makes it imperative that there is a need to intensify 
effort in fake drug eradication. The National Agency for Food and Drug Administration and 
Control (NAFDAC) is Nigeria’s equivalent of the US Food and Drug Administration (FDA). 
The main purpose for creating this agency is to protect public health in Nigeria by 
maintaining the safety of food, cosmetics, vaccines, drugs, veterinary products, herbal 
preparation and so on. National Agency for Food and Drug Administration and Control 
(NAFDAC) is the government agency in Nigeria that is fully empowered to regulate and 
control the importation, exportation, manufacture, advertisement, distribution, sale and use of 
drugs in order to ensure that safe and quality drugs are available to the public. As NAFDAC 
tasks herself dutifully in fighting fake drugs, more challenge come from unscrupulous drug 
dealers who sometimes have the backings of lawmakers and politicians making the stipulated 
drug laws and standard unattainable  
Legislative measures taken on counterfeit medicines, including revised approaches to ensure 
that standards for quality, safety and efficacy are implemented and distribution chains 
effectively controlled. In many countries regulatory oversight of pharmaceuticals is 
ineffective, especially of distribution channels. Coordinated action at the local level is 
essential between health authorities, police, customs, and judiciary institutions to ensure 
proper regulation, control, investigation and prosecution. IMPACT will help countries with 
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weak regulatory systems to strengthen them by improving collaboration and drawing from 
the experience, capacity and resources of all IMAPCT stakeholders. 
5.5 Conclusion 
Weak policies and translating existing policies into practice have proved very challenging in 
all departments in developing countries including Nigeria. Even though there isn’t a 
widespread occurrence of fake ACTs at the moment compared to chloroquine and Fansidar, 
these drugs were once the first-line drug choice for malaria treatment and after a period of 
time were hugely invaded by counterfeit producers. This means ACTs are even at greater risk 
considering the more advanced technology in the world now and the higher number of 
counterfeit producers compared to the 1980’s. Prior to the introduction of ACT, it was 
already known that many, and the majority in some settings; especially rural, struggled to 
afford the market price of antimalarials. This was the motivation behind counterfeiting the 
available drugs; transitioning into the use of ACT for existing first-line antimalarials, even if 
completely effective, was therefore likely to have little impact, although limited impact is far 
better in this case to no impact at all. The impact of ACTs cannot be felt if their distribution is 
not channelled to reach both rich and the poor; if this is achieved, it could lead to lasting 
health gains. New approaches or interventions need to be developed; it cannot safely be 
assumed that some of the strategies, which worked when malaria was by far the most 
common cause of potentially fatal febrile illness, will necessarily, remain appropriate.  
One of the major strategies through which counterfeit products are stopped in developed 
countries and which developing countries struggle with is the government’s lack of ability to 
stop fake medicines from entering the private market through customs and policing. The 
recommended actions for improving the quality of drugs for effective malaria treatment 
should include refresher and fresh training and capacity building for all policy makers, 
providers and consumers but with special and priority emphasis on PPMVs who are usually 
the first point of contact for patients in the rural areas, or urban areas that want cheap genuine 
drugs; so as to enhance the quality of drug acquisition. As such, information about the quality 
of drugs used in the co-packaging or co-prescriptions as ACT is very useful for improving 
malaria case management. In addition to this, the government needs to invest in forensic 
chemical analysis and simple field tests which will enhance drug quality monitoring. 
Improved access to inexpensive genuine medicines, strong support of drug regulatory 
authorities, vigorous law enforcement, and international cooperation with determined 
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political leadership will also improve access to genuine drugs. The National Agency for 
Food, Drug Administration and Control (NAFDAC) will be able to tackle the high incidence 
of counterfeit drugs if they are decentralised and are able to perform at the Local Government 
Areas (LGA) level as opposed to working from the Federal level. In this case, NAFDAC can 
collaborate with the State Ministry of Health (SMOH) in each State for easy and more 
effective monitoring. This will help improve on the fight of NAFDAC against counterfeit 
drugs that has been recorded in the urban areas over the years but haven’t had any impact in 
rural areas against substandard and counterfeit drugs.  
An effective approach would have been to take all malaria drugs off the counter and make 
sure only registered pharmacy stores have access to buy and can sell to patients. However, 
even though this can help monitor channels of drug distributions, it will put a lot of pressure 
on case management because of the huge number of people that seek treatment daily.  
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CHAPTER 6: INVESTIGATING THE QUALITY OF 
ACT ANTIMALARIAL DRUGS USING IN-VITRO 
CULTURE.  
6.1 Introduction. 
The continuous spread of substandard antimalarials in malaria endemic regions, including 
Nigeria, is one of the major barriers to public health and is a threat to the usefulness of 
antimalarial drugs.  
Bearing in mind that malaria drug resistance has been recorded across most antimalarial 
groups, two important factors that can also lead to resistance to the new ACTs include the 
continuous use of counterfeit/falsified drugs for treatment and also the use of substandard 
drugs for treatment. It should however be noted that counterfeit drugs are not the same as 
substandard drugs. As defined by WHO, substandard drugs are “genuine medicines produced 
by manufacturers authorized by the NMRA (National Medicine Regulatory Authority) which 
do not meet quality specifications set for them by national standards” (WH0, 2008). To 
further add, substandard drugs can also be as a result of the way the drugs have been handled 
after they have been manufactured correctly. 
To minimise the emergence of drug resistance to new antimalarial drugs, the WHO in 2001 
recommended the use of ACTs as a first line treatment of malaria; a policy that in 2005 was 
adopted by the Nigerian government (Ojurongbe et al., 2013). Combination therapy is seen to 
be an effective approach to reducing the probability of resistance of parasites to the used 
antimalarial; particularly if the mode of action of the two drugs in the combination is 
different. As explained by Gupta et al., (2002), the idea is to combine a fast acting and short 
half-life drug with a slowly eliminated drug that maintains a minimum inhibitory 
concentration level for at least 7 days. However, developing countries usually lack advanced, 
or even basic techniques to effectively test and ascertain the standard and quality of 
antimalarials in the market,  thereby leading to a high exposure of citizens to counterfeit and 
substandard drugs. This factor led Newton et al., (2006) to describe Africa as the next likely 
destination for counterfeit and substandard drug producers; an accurate description, as we can 
see now in 2018 (Siva, 2010; Burns, 2006; Sambira, 2013). 
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Different studies have reported cases of substandard antimalarial drugs in African countries, 
such as Cameroon (Basco et al., 2014), Tanzania (Minzi et al., 2003) and Ghana (El Duah 
and Ofori-Kwaye, 2012). In addition, a trend of studies in Nigeria has consistently found the 
existence of substandard drugs in the market. In 2008, the WHO collected drug samples from 
six Sub-Saharan countries for evaluation. 63.9% of the 28.5% (n=1437) of drugs that failed 
were from Nigeria (WHO, 2011). Analysis of drug samples by Onwujekwe et al., (2009) in 
Anambra State, South-eastern Nigeria, found the 37% of antimalarial drugs tested did not 
have the required amount of active ingredients; most samples that failed were primarily 
quinine and SP. The authors concluded “our study highlights the need for increased 
pharmacovigilance and greater regulatory control on local ACT production, importation, 
drug storage, and provision” (Onwujekwe et al., 2009). .  In 2012, NAFDAC reported 19.6% 
of samples around the country were not up to standard, and more recently, Kaur et al., (2015) 
found 9.3% of substandard drugs in Enugu State. 
Over the years, focus has been placed on falsified drugs with little attention given to 
substandard medicines (Johnston and Holt, 2014). Like counterfeit drugs, substandard 
medicines also reach patients and affect effective treatment because of poor manufacturing 
and quality control practices even though the production of the drug is genuine. Also, storage 
patterns in hospitals and medicine stores have the tendency to reduce the potency of the 
drugs. The inability to afford or access “high price” ACTs has been a contributing factor to 
the booming counterfeit and substandard drug market in Nigeria. This makes the rural and 
poor areas a major target for producers. The distribution and production of substandard drugs 
in Nigeria is a vast and underreported problem. Asides from the morbidity and mortality it 
causes, it is also a factor behind the loss of confidence in drug treatment practices. 
6.2 Objectives. 
As one of the recommendations of the WHO and also the federal Ministry of Health (FMOH) 
is to treat every case of malaria appropriately using artemether/lumefantrine combination 
therapy (ACT). This chapter will investigate the threat of substandard ACTs that are sold in 
the market in the two study regions (Osun and Lagos) by using in-vitro culture methods to 
compare the percentage of P. falciparum cleared by each drug. This approach should 
highlight the level of discrepancy within each drug product and also within the regions where 
this study is being carried out. 
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6.3 Methods 
Refer to Chapter 2 for detailed methodology.  Note, all tested drugs were solubilised in 
chloroform prior to in vitro assays being carried out. 
Table 6. 1: List of drugs tested, including weights and concentrations (all drugs were tested 
using FT-IR spectroscopy and they all showed the presence of Artemether/Lumefantrine). 
Region Drug name 
(Code) 
Drug weight Artemether/lumefantrine 
ratio 
Expiry date 
Lagos rural A 230 mg (0.23g) 20/120 mg July-2018 
 B 730 mg (0.73g) 80/480 mg June-2018 
 C 250 mg (0.25g) 20/120 mg June-2018 
 D 680 mg (0.68g) 80/480 mg February-2017 
 E 680 mg (0.68g) 80/480 mg May 2017 
 F 230 mg (0.23g) 20/120 mg July-2018 
 1F 250 mg (0.25g) 20/120 mg May 2017 
 1D 230 mg (0.23g) 20/120 mg Sept 2017 
Lagos urban G 950 mg (0.95g) 80/480 mg July-2018 
 H 250 mg (0.25g) 20/120 mg Sept 2017 
 I 250 mg (0.25g) 20/120 mg June-2018 
 J 680 mg (0.68g) 80/480 mg June-2019 
 K 680 mg (0.68g) 80/480 mg July-2018 
Osun rural L 230 mg (0.23g) 20/120 mg September 2017 
 M 960 mg (0.96g) 80/480 mg June-2018 
 N 730 mg (0.73g) 80/480 mg Sept 2017 
 O 680 mg (0.68g) 80/480 mg July-2018 
 1K 250 mg (0.25g) 20/120 mg May 2017 
Osun urban P 230 mg (0.23g 20/120 mg June-2018 
 Q 680 mg (0.68g) 80/480 mg May 2017 
 R 730 mg (0.73g) 80/480 mg July-2018 
 S 250 mg (0.25g) 20/120 mg May 2017 
 T 730 mg (0.73g) 80/480 mg June-2018 
 
6.4 Results. 
In vitro drug assays were carried out in triplicate at 5 nM, 10 nM and 20 nM concentrations.  
Figure 6.1 shows a reduction in parasitaemia at 20 nM concentration for all the sampled 
drugs. Indeed, at 20 nM drug A appears to be the most efficacious, with almost 60% 
parasitaemia reduction in comparison to a 30-40% reduction for the other drugs.  Moreover, it 
can be seen that drug A also shows a parasitaemia reduction of almost 40% at 10 nM 
concentration; this efficacy is not recorded in the other drugs. Indeed, drugs B and D showed 
no reduction at 10 nM concentration while drugs C, E and F showed about 15% reduction in 
parasitaemia. This data confirms that even though all of the drugs tested contain the 
recommended Artemether/Lumefantrine, the concentration at which they are effective may 
vary. 
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Figure 6.1: The effects of 6 (A-F) ACTs on parasiteamia %. A range of ACTs 
concentrations were incubated with 1% ring stage cultures of P. falciparum multi-drug 
resistant K1 strain 72 hours under the conditions described previously. Tests were done in 
triplicate and were analysed using SYBR Green-based methodology. 
For this reason, 20 nM drug concentrations was chosen for subsequent assays as shown 
below. 
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Figure 6.2: Analysis of sampled ACTs (20 nM concentration) in Lagos urban region 
against P. falciparum multidrug resistant K1 strain.  Each drug was assayed in triplicate 
and standard error of the mean is shown. 
As shown (Figure 6.2), all drugs sampled from the Lagos urban region resulted in an 
approximate 80 % reduction in parasitaemia.  This shows that all the sampled drugs from this 
area, regardless of brand (H and I are the same brand and J and K are the same brand), are of 
the expected standard.  
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Figure 6.3: Analysis of sampled ACTs (20 nM concentration) in Osun urban region 
against P. falciparum multidrug resistant K1 strain.  Each drug was assayed in triplicate 
and standard error of the mean is shown. 
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As shown (Figure 6.3), all drugs sampled from the Osun urban region showed about 80% 
reduction in parasitaemia.  This confirms that the drugs, regardless of brand (drugs R and T 
are the same brand), are all of the expected standard. 
In contrast to the above, the drugs tested at 20 nM concentration from the Osun rural region 
(Figure 6.4) were more inconsistent in their efficacy to reduce levels of parasitaemia.  Indeed, 
drug 1K appeared to reduce parasitaemia to approximately 70% of control levels compared to 
the approximate 80% observed for other drugs tested; this includes drug M, which is the same 
brand as 1K. 
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Figure 6.4: Analysis of sampled ACTs (20 nM concentration) in Osun rural region 
against P. falciparum multidrug resistant K1 strain. Each drug was assayed in triplicate 
and standard error of the mean is shown. 
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Figure 6.5: Analysis of sampled ACTs (20 nM concentration) in Lagos rural region 
against P. falciparum multidrug resistant K1 strain. Each drug was assayed in triplicate 
and standard error of the mean is shown. 
The in vitro drug assays that contrasted most with the other tests were those carried out with 
the samples from Lagos rural region (Figure 6.5).  The most efficacious drug from this area 
(drug C) produced an approximate 70% reduction in parasitaemia, others showed an 
approximate 50% reduction in parasitaemia and drug B was least effective; parasitaemia was 
reduced by approximately 25%.  Moreover, drug B is the same brand as drugs N, R and T 
(Osun rural and urban regions; Figures 6.4 and 6.3) and drug C is the same brand as drugs H, 
S and M (Osun rural and urban, Lagos urban; Figures 6.4, 6.3 and 6.2).  This demonstrates 
that the Lagos rural region is particularly susceptible to substandard ACTs in the marketplace 
relative to the other study areas.     
6.5 Discussion 
There is very little research done to describe the quality of antimalarial drugs and reports are 
not available for the majority of malaria endemic countries (Tabernero et al., 2014; Kaur et 
al., 2015). Use of the term substandard is less controversial and there is consensus among 
most organizations that substandard drugs are those that fail to meet established quality 
specifications. When a regulator approves a drug, they approve a quality standard, outlined in 
the accepted pharmacopeia or in the manufacturer’s approved dossier. As the WHO explains, 
substandard products are the drugs that “do not meet the quality specifications set for them in 
national standards” (WHO, 2009). 
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Even though most studies have concentrated on counterfeit drugs in Nigeria (Salisu et al., 
2017; Adeyemi et al., 2017; Joda et al., 2017), very few have checked for a combination of 
counterfeit and substandard drugs. In a study by Kaur et al., (2015) to assess the quality of 
ACTs purchased from pharmacies, PPMVs and other public health facilities in Enugu 
metropolis, Nigeria,  9.2% of the drugs purchased were of poor quality, with 1.2% falsified, 
1.3% degraded and 6.8% substandard in one or more of the APIs. A limitation of this study  
is the relatively low number of drugs tested across each region; however, the proportion of 
substandard drugs that was found is in broad agreement with that observed by Bate (2012) 
where antimalarial samples from pharmacy stores in Lagos were assayed by Raman 
spectrometry between 2007-2012 and 23% of ACTs were substandard. More recently an 
evaluation of the quality of anti-hypertensive drugs in Lagos State by using HPLC showed 
that of 102 drug, samples, up to 76% did not meet quality standard Ndichu (2018). 
Interestingly, it was further reported that most of the drugs that did not meet the drug purity 
standards were from low social economic status areas Ndichu (2018). This is also the case in 
the current study since findings clearly show more substandard drugs in the rural area of 
Lagos compared to the other urban areas. It can be suggested that the prevalence of 
substandard drugs is determined by the type of disease, or ailment, and also, the awareness of 
a target group. For example, a disease with high prevalence among people of low economic 
status, residing in rural areas, might attract more counterfeit and substandard drugs. 
Awareness and the ability to afford and decipher between authentic and substandard drugs is 
also a factor that helps the sale of substandard drugs in these areas. Although one would 
expect the urban areas to be a primary target of substandard drugs because of the profits that 
could be accumulated if these drugs are exposed to large urban markets, control and 
monitoring measures that are present in the urban areas will to a large extent limit the sales of 
counterfeit and substandard drugs. For example, most pharmacy stores in the urban areas 
obtain their drugs from an accredited distributing company and this is not always the case in 
rural areas. Another factor that can be responsible for substandard drugs is the storage 
methods. Certain drugs should be stored in at a particular temperature and exposure to heat 
and sunlight must be avoided otherwise the efficacy of such drugs will be compromised. 
Results from this study highlight the importance for the need to carry out a larger scale study 
to provide a more thorough representation of the rate of substandard drugs in each 
community and to provide suitable intervention approaches that meet the needs of each 
community. Data in this chapter also corroborates the study of Kaur et al., (2015) which 
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suggests that the prevalence of poor quality drugs in sub-Saharan Africa could be 
overestimated. However, where it is prevalent, the consequences of substandard drugs can be 
seen on an individual (patient) level, or in a more general (community level). 
6.5.1 Consequences of substandard antimalarials 
Consequences of substandard ACTs and counterfeit drugs are usually similar, and in the long 
run can affect patients directly or indirectly, affect communities and also, reduce trust in the 
drugs in question. Substandard/counterfeit antimalarials may have serious consequences for 
both patients and global health, such as increased antimalarial resistance, treatment failure, 
and side effects (Nwokike et al., 2018; Newton et al., 2017).  
6.5.1.1 Consequences for patients 
Substandard drugs pose a very serious public health concern for patients as they can directly 
result in death (Johnson and Holt, 2014) even though falsified drugs receive more attention 
with respect to causing unnecessary deaths. As described by Keldeis and Falagas (2015), 
using an excessive dose of the active ingredient in low-quality antimicrobials may be toxic to 
humans, especially in children, or with antimicrobials with a narrow therapeutic range, such 
as quinine.  Developed countries have measures in place to put in check the quality of drugs 
that citizens are exposed to (see Appendix). A drug with insufficient API may also lead to la 
ack of clinical response if not death; an example of this has been recorded by Newton et al., 
(2006) and Keoluangkhot et al., (2008) in antimalarial treatment failing because the drugs 
contained less than the stated dose of API.  There is an extensicve literature to show that in 
some cases, substandard drugs have caused devasting morbidity in humans (IMPACT, 2010; 
Newton et al., 2011; Harris et al., 2009). 
6.5.1.2 Consequences for the community 
Very importantly, substandard antimicrobial medicines, in this case antimalarials, may 
promote parasite drug resistance (Thu et al., 2017; Blasco et al., 2017). Keldeis and Falagas 
(2015) describe that emergence of antimicrobial resistance as a result of low-quality 
antimicrobials has been reported with antimicrobials that are often used in combination 
therapy; as antimalarials are often used. On a more general level, low-quality antimalarials 
may significantly decrease confidence in the efficacy of some antimalarials. It has been 
recorded in some cases were poor-quality drugs have led to physicians losing confidence in 
specific antibiotics and thus opting for other antibiotics as the drugs of choice for infections. 
When therapeutic failure or adverse events occur, patients may also experience a loss of 
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confidence in health systems, health professionals as well as registered pharmaceutical 
products and brands (Gautam et al., 2009). This can be easily linked with antimalarials, 
leading to the prescription of more ‘trusted’ expensive antimalarials that patients in 
developing countries are not able to afford. Also, when these people cannot afford the 
treatment, they either find other ways to treat or they stay untreated; posing a risk of infection 
to other people in the community that are not infected.  
Cases of substandard antiviral drugs being responsible for the emergence of drug resistant 
viruses including HIV have been documented (Wertheimer & Norris, 2009; Jordan et al., 
2008) and substandard anthelmintics have been implicated in the development of drug-
resistant human helminths (Geerts & Gryseels, 2001), thus further aggravating the economic 
burden of treating infectious diseases. 
6.6 Conclusion 
Like counterfeit antimalarial drugs, substandard drugs also create an expanding problem 
throughout developing countries with possible devastating consequences for global public 
health if not checked with ultimate urgency. To begin with, appropriate design studies need to 
be implemented to fully understand the magnitude of the problem as mere speculations would 
not suffice. In addition, initiatives have been developed to counteract counterfeiting and these 
should be encouraged; including collaboration between patients, health workers, local, 
national, and international organizations, and industry. It is also imperative to invest in 
technologies that can effectively assist in detecting substandard drugs as the lack of this 
resource in developing countries limits the implementation of many measures to combat the 
production of substandard drugs. As expected, the rate of malaria incidence in Nigeria over 
the years and the huge amount attached to its treatment has led to the increase of substandard 
drugs in the country. Where economic and regulatory environments are less structured, 
supply chain security strategies that fixate on ‘counterfeits’ often fail in limiting the 
prevalence of poor quality medicines. 
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CHAPTER 7: GENERAL DISCUSSION.  
7.1 Overview 
Malaria is a long-standing global health issue and many efforts have been made to eliminate 
and control the disease. Around the world, 113 countries have eliminated malaria and 34 
middle-income and some low-income countries are in the malaria elimination phase (Zelman 
et al., 2014). However, most low-income countries in malaria-endemic regions of the world 
are still undergoing malaria control programs (Zelman et al., 2014). Malaria 
disproportionately affects low-income countries, such as those of Sub-Saharan Africa, where 
47 of 54 countries are malaria endemic and most are currently in malaria control programmes 
(Omumbo, et al., 2013). The malaria story in Nigeria is one that is complex and unique, 
usually because of a complex national health system and a population with huge religious and 
cultural differences. Although there is a very active private and public health sector that is 
generally available to the people, because of a very poor public health system and poor 
adherence to regulations, treatment practices continue to deteriorate over years in the 
presence of numerous intervention programs. A dwindling economy also plays an important 
role in health care allocation which is usually skewed towards urban areas, leaving half of 
Nigeria’s population, who live in rural areas, with limited access to health care facilities and 
pharmacists (SFH, 2012). In most cases, the ability to afford appropriate treatment is not 
guaranteed as willingness to pay for appropriate drugs can be affected by the ability to also 
afford other important everyday expenses in each household.  
Thirteen years after a change in antimalarial treatment policy, the high awareness among 
PPMVs was yet to translate to a commensurate increase in the sale of the newly adopted 
drugs (ACTs). Chloroquine, Fansidar, and other artemisinin monotherapy drugs still flood the 
medicine stores with urgent consequences for malaria control. Profit is the main motivation 
behind the sale of drugs for these sellers; so to an extent, awareness of treatment policies does 
not matter as much in treatment patterns. Having recorded that similar factors such as 
knowledge of treatment policies that affect medicine stores also affect the clients; exorbitant 
prices of the ACTs means that most clients wouldn’t demand them and this leads to sellers 
not stocking these drugs. Also, the continued availability of older ineffective antimalarial 
drugs in the market has created options for malaria treatment and this needs to be addressed 
in order to optimize the effect of ACTs in fighting the disease. 
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Nigeria’s domestic pharmaceutical production is a growing industry, and it represents about 
30% of the country’s pharmaceutical needs (SFH, 2012); however, the other 70% is primarily 
imported from China and India via drug traders who have a reputation  for smuggling drugs 
through Niger and Benin, or repackaging expired drugs from neighbouring countries 
(Oluwatuyi and Ileri, 2014). Hospitals are also vital in the treatment of malaria, especially 
where there is short waiting time and the location is easily accessible (Salawu et al., 2016). 
The purpose of the quantitative, descriptive, non-experimental part of this research was to 
investigate the association between residents of two Southwestern states (Lagos and Osun) 
and factors that can act as barriers to effective malaria case management such as (a) socio-
demographics of residents and (b) stated willingness to pay for the ACT and actual payment. 
The quality of antimalarial drugs normally available for residents at the medicine stores 
(including pharmacies and drug vendors) in these areas were further investigated using FT-IR 
and in vitro culture to check for counterfeit and substandard drugs respectively.   
7.2 Research question 1 
Does the socio-demographics of residents in these regions, as defined by age, educational 
level, residence, and stated willingness to pay, have an association with barriers to malaria 
case effective management and their malaria treatment-seeking behaviour (as defined by 
percentage of people who self-medicate or/and are treated with drugs outside the adopted 
recommendations)? 
Self-medication is still a very common practice in Nigeria and it is a major barrier to malaria 
case effective management. This study found a statistically significant association (p < 0.01) 
between education level, employment status, salary earned monthly and appropriate diagnosis 
before treatment in urban areas.  However, this significant association was not recorded in the 
studied rural areas and hence all residents of the rural areas have an equal probability of self-
medicating. The results of this study align with a study conducted by Onwujekwe et al., 
(2009) that found that home-based care and self-prescribing were common practices amongst 
adults and child caretakers, with patients often starting self-treatment with drugs from the 
commercial sector and then turning to the formal health providers, if needed. Also, in a study 
by Jombo et al., (2011), low educational levels, low family incomes, and lack of jobs were 
important contributory factors towards the people’s resolve to self-medication for malaria. 
This study has shown that not only is self-medication more prevalent in the rural areas of 
Nigeria; in confirmation with what was recorded by Arikpo et al., (2009), Abasiubong et al., 
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(2012), Bonti, (2017), and Ayanwale et al., (2017), education level and employment status 
does not play a role in influencing treatment practice.  Numerous intervention programmes in 
the urban areas are positively influencing residents with regard to malaria diagnosis. A 
similar result was also found with regard to antimalarial used for treatment since there was a 
statistically significant association (p < 0.01) between education level, employment status, 
salary earned monthly and appropriate malaria treatment with an ACT only in urban areas; as 
also noted in other studies (Chatio et al., 2015); Efunshile et al., 2013). The lower salary 
range of people who reside in the rural areas compared to those that live in the urban areas 
means that affordability of recommended drugs in the rural areas is a challenge. The cost of 
ACTs is up to 20 times that of other conventional antimalarial drugs such as chloroquine and 
sulphadoxine-pyrimethamine used for the treatment of uncomplicated malaria. As a 
consequence, people in rural areas are unable to afford the high cost of ACT, bearing in mind 
that being in employment in rural areas is not as economically advantageous as in urban 
areas. However, when association was calculated using salary earned, there was still no 
significant association.  
7.3 Research Question 2  
Is the type of medicine store where treatment is sought (pharmacy store and PPMV) 
associated with adherence to recommended malaria treatment practices? 
This part of the research was done to illustrate the practical realities in the treatment of 
uncomplicated malaria in public and private health facilities in Nigeria, which bears a major 
impact on implementation of malaria treatment guidelines. This study has shown that drug 
sellers still maintain a treatment pattern that is outside the WHO recommendations. 
Pharmacists are expected to run a legal and trusted business; however, this is not always the 
case. PPMVs usually do not have the necessary qualifications but have been allowed to 
administer antimalarials for better coverage of treatment. A lot of these sellers are introduced 
to the business from a variety of backgrounds unconnected with having adequate knowledge 
of illness perception and management, making effective malaria control impracticable 
(Treleaven et al., 2015; Beyeler et al., 2015). Also, some pharmacists leave their stores to be 
manned by an inexperienced apprentice, potentially exposing visiting patients to wrong 
prescriptions. These factors are likely to contribute to inappropriate dispensing of antimalarial 
drugs, especially where some of the clients do not have a prescription and are naïve of what 
malaria first-line treatment is. Supported by Isiguzo et al., (2004), pharmacy stores are more 
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likely to stock and sell ACTs than PPMVs, which would have been encouraging if more 
people didn’t visit PPMVs for treatment. Also, self-medication was high in both medicine 
stores across the four regions which was also found by others (Ayanwale et al., 2017; 
Babatunde et al., 2016). This undermines therapeutic efficacy and may promote the 
emergence and further spread of drug-resistance. In reality, access to ACTs is still very poor 
and most cases of malaria are still treated with chloroquine by the PPMVs. Furthermore, 
chloroquine drugs and other monotherapy were administered commonly, a finding consistent 
with earlier studies in Nigeria (Onwujekwe et al., 2009). This large number of chloroquine 
and SP treatments indicates that clients have a bigger influence in dictating the drugs they 
want and sellers are primarily motivated by their need to make profit and not by any wish to 
provide a public health good. It was encouraging to observe in this study that the preference 
for ACTs by the sellers was increased from that recorded by Mangham-Jefferies et al., (2014) 
were 69% of providers had a preference for ACT; though alternatives included quinine and 
artemisinin-monotherapy, which according to the WHO recommendations, should be 
reserved for cases of severe malaria, and sulphadoxine-pyrimethamine, which was the former 
first-line treatment.  However, awareness and preference of ACTs did not prevent some 
sellers from selling unrecommended drugs. Training can have an effect that goes beyond 
informing providers about treatment policy and can influence their preferences over different 
treatments; as having access to guidelines is not a good predictor that providers will supply 
the recommended treatment.  The results of this study however suggest that more punitive 
and strict measures are required to ensure that medicine sellers adhere to the 
recommendations of the WHO and FMoH.  
7.4 Research Question 3  
Are hospital caregivers adhering to the recommended treatment policies?  
 The results of this study show an encouraging pattern of adherence to the Test, Treat, and 
Track strategy (3Ts) as recommended by the WHO. The 3Ts  strategy was initiated to 
effectively manage all suspected cases of malaria; starting with proper diagnosis with the use 
of RDTs or microscopy, treatment with recommended ACT if the result is positive and then 
full documentation.  In this study, a high rate (mean = 97.25% across the four regions) of 
compliance to this recommendation was observed; an improvement from what was recorded 
by Meremikwu et al (2007), which reported a laboratory test rate of 45%. The use of 
laboratory techniques for diagnosis has proven to be effective (Mukry et al., 2017; WHO, 
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2006; Odugbemi et al., 2018), however over the years its use has been generally poor; 
whether due to limited availability, or lack of trust.  This has been a major barrier to the 
effective management of suspected malaria cases. For example, Ezenduka et al., (2014) 
describes the use of laboratory diagnosis for malaria treatment in the two facilities where a 
study was done to be limited to 49%, with health providers depending on presumptive 
diagnosis, contrary to the test and treat recommendations of current guidelines. This result 
can be linked with the high rate of over-diagnosis (Ezenduka et al., 2014) and wrong 
prescription methods (Uzochukwu et al., 2010; Chitakata et al., 1998) in the hospitals in 
Nigeria. It also reflects the level of confidence and popularity to which prescribers attach to 
presumptive malaria treatment. Findings by Onwujekwe et al., (2009) and Uzochukwu et al., 
(2010), confirm this, in which over 80% and 51.1% respectively, of healthcare providers are 
confident in clinical diagnosis of malaria, including those at the hospitals. This therefore 
shows that there is an improvement since these studies have been done. However, it should 
be noted that these studies were conducted in the south-eastern part of the country, so other 
factors such as level of awareness could have affected the difference. Aside from time 
wastage; morbidity and drug resistance are very common consequences that have been 
attributed to wrong diagnosis. This accentuates the urgent need for intensified efforts at 
promoting the use of RDTs to detect malaria parasites before treatment is offered. In addition, 
the findings of this study showed a clear preference for ACT as the drug of choice for 
uncomplicated malaria at these facilities, which is an indication of compliance with policy 
recommendation. However, some negative cases were still treated with an antimalarial, 
contrary to the recommendations of the WHO. Reasons why some negative cases were 
treated for malaria are believed to include the unreliability of laboratory results due to poor 
laboratory reagents and also RDT insensitivity.  
Finally, a larger percentage of participants in the rural regions that suspected that they had 
malaria were actually confirmed to have malaria. This observation is undoubtedly a wake-up 
call for policy makers and the government (both nationally and locally), to intensify their 
effort in these regions on the eradication of malaria. The link provided in this study is that 
those who live in the rural areas are more prone to malaria infection and unfortunately, they 
mostly self-medicate, seek cheap treatment from unlicensed providers and are more likely 
exposed to counterfeit or substandard drugs.   
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7.5 Substandard/fake antimalarial drugs 
In a country where nearly half the population is illiterate, poverty is still rampant and 
consumer awareness is low, the spread of fake and substandard drugs is a cause for alarm. 
The presence of counterfeit drugs shown in this study corroborates earlier reports (Bassat et 
al., 2016); albeit, this research has only found some SPs and chloroquine tablets to be 
counterfeit. Although this study did not find an ACT to be counterfeit, similar to Izevbekhai 
et al., (2017) it should be noted that the number of drugs assessed is smaller than those tested 
in other studies. However, of concern was the finding that some ACTs acquired from the 
rural regions showed less efficacy when compared to other ACTs (either same or different 
brands).  This also confirms the report of Kelesidis, & Falagas, (2015) that cheap drugs are 
major targets for counterfeit makers because, in a poor region, there is a bigger market for 
fake and cheap drugs. The situation is worsened by the fact that the government and many 
pharmaceutical companies are reluctant to publicize the problem to health staff and the 
public, apparently motivated by the belief that the publicity will harm the sales of brand-
name products in a fiercely competitive business. They argue that publicly attacking these 
fake drugs could prevent patients taking their genuine medicines (Cookburn 2005). This is 
unacceptable, as the continuous use of these drugs has potentially killed a number of citizens, 
or at the very least worsened, or caused, their illness. It is, however, imperative that the 
physicians, government, regulatory authorities, and pharmaceutical companies prioritize a 
habit of alerting key audiences, stakeholders and the general public about counterfeit 
medicines in communities and across countries. This would send a signal across borders that 
the health and good living of patients takes priority over the reputation of pharmaceutical 
companies. In support of this, Cockburn et al., (2007) urges a change to mandatory reporting 
to governmental authorities, which should also have a legal duty to investigate, issue 
appropriate public warnings, and share information across borders. This is not a role for the 
pharmaceutical industry due to a serious conflict of interest. 
7.5.1 Actions to reduce fake drugs 
Considering that some fake drugs were found from the small sample size of drugs tested, the 
need for a more intensive fight against drug proliferation cannot be over-emphasised. Also, 
there is an urgent need for data of sufficient sample size with random sampling design to 
reliably estimate the prevalence of poor-quality medicines in these regions and across the 
country as a whole. In a study by Oladepo et al., (2007) asking for suggestions from PPMVs 
on how to stop the counterfeit market, a substantial proportion of PPMVs (64%) said that 
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stronger government regulation was needed to minimise the availability of fake drugs, while 
nearly a quarter called for PPMV self-regulation through the associations. It is vital to invest 
in the strengthening of medicine regulatory authorities, especially NAFDAC. The mandate of 
the NAFDAC, which includes safeguarding the health of the public, increase supply of 
quality medicines into the Nigerian health system and fight against counterfeit and sub-
standard medicines in the drug supply chain has been boosted by the collaboration with the 
United States Pharmacopeia (USP), with the assistance of the United States Agency for 
International Development (USAID), in an agreement to work on a road map that will act as 
a guide towards ensuring the quality monitoring of medicines in Nigeria. Also, determination 
from political office holders and a clear coordinated role between the police, customs 
officials and NAFDAC is crucial. The benefit of this has been recorded by the successful 
investigation into counterfeit medicine in other countries (Newton et al., 2008; Cockburn et 
al., 2007). Unfortunately, being a poor developing country, there is limited access to the wide 
range of sophisticated quality-assurance markers and machines have been developed in other 
developed countries. As rightly mentioned by Newton et al., (2010), support for Medicine 
Regulated Authorities (MRAs) and the development of regional laboratories to allow the 
regulation of the drug supply will be crucial to allow interventions. The good news is that not 
as much effort in combating counterfeit drugs is needed to curb substandard drugs. Actions 
required in this case may be more direct because malicious/criminal intent is not involved; 
however, these interventions will involve costly improvements in manufacturing companies 
and periodical inspections. 
7.5.2 Possible intervention actions 
Possible intervention actions to improve the present situation will have to address a number 
of inter-related factors. Very importantly, interventions need to address the lack of knowledge 
about appropriate diagnosis and treatment, which will require continuous training of medicine 
sellers (PPMVs and pharmacy store owners) and educating the public. As this research has 
shown an improved adherence to treatment policy in the hospitals in the two study regions, it 
highlights that continuous training and the ability to hold treatment providers responsible 
when they go against recommendations should be adopted. This will involve the design of 
strategies for communicating with a variety of audiences including government regulators, 
boards of pharmacists and PPMVs, doctors, and community members. These strategies will 
have to take into account the fact that a substantial proportion of PPMVs obtain information 
from drug suppliers, rather than government. They also need to take into account the many 
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inter-state differences in the characteristics of PPMVs and the market within which they 
operate. Better still, pharmacy stores and hospitals should be better equipped and managed to 
have the capacity for treating malaria on a larger scale. This will mean that PPMVs can 
continue to sell only ‘over the counter medicine’ which was the initial plan when they were 
created. As Oladepo (2017) has advised, measures like this may require innovative 
approaches to explain reasons for radical changes in what has been proposed as appropriate 
treatments for malaria. If this can be successfully achieved, then there would be less worry 
over the spread of counterfeit and substandard drugs that are usually supplied by PPMVs.   
With regard to fake and substandard drugs, a lot of work will be required to promote effective 
partnerships between government regulators and these associations. A study has shown that 
strong support by PPMVs, government policy-makers and members of the community for an 
increased role of communities in monitoring drug quality (Beyeler et al., 2015). To 
successfully achieve this, community members should be trained and have enough 
information on how to identify fake drug packages and what to look out for. This will also 
involve training people to undertake these tasks, which could include looking for NAFDAC 
registration and expiry dates. Technology wise, it is high time the country invested in new 
simple technologies for testing drugs or scanning product identification, or for utilising 
information and communications technology to be able to provide real-time support to 
PPMVs and regulators could also be considered. Something like this was introduced recently 
that enables a reference number on a drug to be sent to a number and this provides 
information about the drug, including the expiry date. Unfortunately, although this in an 
improvement, the drug information is received following a delay (up to 24 hours) and this is 
not good enough considering the urgency required for treating malaria infections. Within this 
time frame, a patient could have used a fake antimalarial, or an expired antimalarial. The 
impact of subsidy of ACTs cannot be over-emphasised and people have argued that instead of 
subsidy at local level, it should be done globally (Laxminarayan et al., 2006; Arrow et al., 
2005). The issue with this is, even with endemic regions, economic status plays a vital role in 
the treatment pattern. ACT subsidy needs to be a function of a particular group of people to 
understand how much most people would be able to afford. For example, the price at which 
ACT subsidy would make a significant difference in treatment pattern in Lagos urban would 
not necessary make an impact in Osun rural.  
182 
 
7.6 Conclusions, recommendations and future directions 
Studies of this nature are intended to provide insight for further investigation and intervention 
and are often therefore limited in what they are able to conclude. The study involved cross-
sectional and retrospective assessments and hence follow-up studies will be needed to capture 
changes over time to better identify factors that are causally related to improve knowledge or 
treatment of malaria. The inferences in this study were derived from interviews and 
observations of communities, drug outlets and hospitals. Notwithstanding these limitations, 
these studies allowed identification of more focused questions for research and intervention, 
which remains challenging in a weakly regulated environment. Also, later studies should 
recruit a larger number of participants than this study has, to create a larger sample set to be 
analysed; results would then be more conclusive. In addition, a more representative drug 
sample set should be tested for in vitro efficacy to allow conclusions on what is happening 
across regions and therefore allow more widespread recommendations to be provided. 
It has been established that ACT is the best and most effective antimalarial on the market. It 
is also the recommended first line therapy for uncomplicated malaria in several countries, 
especially sub-African countries. Although limited, the preliminary findings of this study on 
the field is that the ACT regulations have been good over the years. This is good news 
considering ACTs have been the first line treatment drugs for malaria; however, a 
depreciating economy means the price of ACTs are unbearable in the region; forcing citizens 
to go for cheaper drugs.  This therefore moves the spotlight to other non-ACTs and thus 
creates malpractices; for example, they become a target for counterfeiting. The benefits of 
subsidised ACTs, which was noticed in the past, are beginning to wear out because of the 
recent huge increase in ACT price; forcing even working people to struggle with its use. 
Malaria control programs should put into consideration the findings of this study while 
developing targeted interventions to improve treatment pattern. To begin with, the 
government needs to implement programmes that will make ACTs more affordable to the 
people as well as creating awareness and educating citizens of the recommended drugs and 
the dangers of using other antimalarials that are not ACTs. As already advised by Oyeyemi et 
al., (2015), the Pharmacists Council of Nigeria (PCN) should without further delay revise the 
approved list of antimalarial drugs that PPMVs are allowed to sell and the government should 
initiate effort to withdraw non-ACT antimalarials from the market. Also, to maintain long-
term efficacy there is a need to train healthcare providers on appropriate dosing and 
dispensing of ACTs. The poor adherence that was recorded in this study, especially in the 
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retail sector, calls for more efforts to improve adherence to ACTs both in the urban and rural 
areas. Barriers to adherence should be addressed because nonadherence could be a platform 
for the development of antimalarial resistance. At community level people should be 
educated on the adverse effects and implications of poor adherence to ACT. Healthcare 
providers, policy makers, and other stakeholders involved in malaria control programs should 
take note of these findings when designing targeted interventions to improve ACT adherence. 
Educational programmes to increase awareness and understanding of ACT dosing regimen 
are interventions urgently needed to improve adherence to ACTs. Patients, or caregivers, 
should be provided with an adequate explanation at the time of prescribing and/or dispensing 
ACTs. Prescribers, dispensers, and vendors should, therefore, give a clear and 
comprehensible explanation on how to use ACTs. User-friendly packaging (e.g., blister 
packs) should be used to encourage completion of the treatment course and correct dosing. 
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8 APPENDIX 
    Appendix I:  Consent and Questionnaires       
    
            Community perspective on malaria treatment. 
The main aim of this research is to qualitatively and quantitatively analyse malaria 
chemotherapeutic practices and outcomes at an individual and community level in three 
selected states (Lagos, and Osun) in the Southwest region of Nigeria in a bid to define 
barriers to effective malaria case management. 
SECTION 2: CONSENT FORM 
I confirm that I have read/been explained to and understood the information presented above about the 
purpose and nature of this study.  
I have also had the opportunity to clarify any doubts with ___________________________.  
I understand that my participation will involve answering some questions related to my knowledge and 
opinions about malaria treatment.  
I understand that my participation is voluntary and that I can withdraw my consent at any time without 
prejudice to my rights.  
I understand that the interviews will be noted down in the questionnaire for the purpose of analysis.  
I understand that my confidentiality will be protected.  
I hereby consent to participate voluntarily in this study. 
 
--------------------------------------                 --------------------------------------      ------------------- 
    Name of Participant                                Signature of Participant                 Date 
 
--------------------------------------------            ---------------------------------         -------------------- 
           Name of witness                                        Signature of witness                        Date 
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                                                                                                                         State………………. 
                                                                                                                         GPS location…………… 
                                                                                                                          Rural/Urban………… 
                                                                                                                          Code…………………. 
1. Sex:    Male □   Female □ 
2. Age group: 16-20 □   20-25 □ 26-30 □ 30 and above □ 
3. Marital status:  Single □ Married □ Divorced/Widowed □ 
4. Educational level:  Primary □ Secondary □ Tertiary □ none □ 
5. Socio-economic status: (Please tick which of the following you possess) 
    Car □ Television □ Generator □ Computer □ Owned apartment □ 
  Employed □   Unemployed □ 
 Salary earned per Month:  ₦0 - ₦10,000 □ ₦10,000 - ₦50,000 □ ₦50,000 and above □ 
6. How much are you willing to pay for treatment? 
Less than ₦500 □    More than ₦500 □ 
7. When was the last time you had malaria? 
Within the past 1 month □ within the past 6 months □ within the last 1 year□               can’t remember 
□. 
8. How often do you have malaria in a year? 
Less than 5 times in a year □   Between 5 and 10 times a year □ More than 10 times in a year □ 
9. Treatment sorted: Amatem □ Coartem □ Leonart □ combiart □ 
choloquine □ Fansidar □ Herbal (please name)………………………. others (please 
name…………….. 
10. Were you diagnosed before treatment? (Microscopic and others) 
Yes □   No □ I don’t know □ 
11. Where did you get treatment from? 
Hospital □ Drug vendors □ Pharmacy store □ did not get treated □ others □ 
12. How often do you complete your antimalarial dosage? 
Always  □  Most times  □   I stop when I feel better  □ 
                
186 
 
                  Pharmacy store questionnaire 
The main aim of this research is to qualitatively and quantitatively analyse malaria 
chemotherapeutic practices and outcomes at an individual and community level in three 
selected states (Oyo, Lagos, and Osun) in the Southwest region of Nigeria in a bid to define 
barriers to effective malaria case management. 
SECTION 2: CONSENT FORM 
I confirm that I have read/been explained to and understood the information presented above about the 
purpose and nature of this study.  
I have also had the opportunity to clarify any doubts with ___________________________.  
I understand that my participation will involve answering some questions related to my knowledge and 
opinions about malaria treatment.  
I understand that my participation is entirely voluntary and that I can withdraw my consent at any time 
without prejudice to my rights.  
I understand that the interviews will be noted down in the questionnaire for the purpose of analysis.  
I understand that my confidentiality will be protected.  
I hereby consent to participate voluntarily in this study. 
 
--------------------------------------                 --------------------------------------      ------------------- 
    Name of Participant                                Signature of Participant                 Date 
 
--------------------------------------------            ---------------------------------         -------------------- 
           Name of witness                                        Signature of witness                        Date 
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                                                                                                                         State………………. 
                                                                                                                         GPS location…………… 
                                                                                                                          Rural/Urban………… 
                                                                                                                          Code…………………. 
1. Educational level of pharmacist/drug vendor:  Primary □ Secondary □ Tertiary □ none 
□ 
2. Which Antimalarial drug do you mostly prescribe to clients?  
 Amatem □ Coartem □ Leonart □ combiart □ choloquine □ Fansidar □  
Others (please provide with the name) …………………………….. 
………………………………………………………………………… 
3. Sex of client:    Male □   Female □ 
4. Has the client shown any proof of diagnosis?     Yes □    No □ 
5. Is the client self-medicating?   Yes □    No □ 
6. Which Antimalarial drug was purchased by client?  
 Amatem □ Coartem □ Leonart □ combiart □ choloquine □ Fansidar □  
Others (please provide with the name) …………………………….. 
7. Did the pharmacist influence the decision in which drug to buy?  
 Yes □    No □ 
8. Price of Antimalarial drug purchased by client? ₦……….. 
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                   Hospital questionnaire 
The main aim of this research is to qualitatively and quantitatively analyse malaria 
chemotherapeutic practices and outcomes at an individual and community level in three 
selected states (Oyo, Lagos, and Osun) in the Southwest region of Nigeria in a bid to define 
barriers to effective malaria case management. 
SECTION 2: CONSENT FORM 
I confirm that I have read/been explained to and understood the information presented above about the 
purpose and nature of this study.  
I have also had the opportunity to clarify any doubts with ___________________________.  
I understand that my participation will involve answering some questions related to my knowledge and 
opinions about malaria treatment.  
I understand that my participation is entirely voluntary and that I can withdraw my consent at any time 
without prejudice to my rights.  
I understand that the interviews will be noted down in the questionnaire for the purpose of analysis.  
I understand that my confidentiality will be protected.  
I hereby consent to participate voluntarily in this study. 
 
--------------------------------------                 --------------------------------------      ------------------- 
    Name of Participant                                Signature of Participant                 Date 
 
--------------------------------------------            ---------------------------------         -------------------- 
           Name of witness                                        Signature of witness                        Date 
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                                                                                                                         State………………. 
                                                                                                                         GPS location…………… 
                                                                                                                          Rural/Urban………… 
                                                                                                                          Code…………………. 
 
Number of patients suspected to have malaria…………………………………………………. 
Suspected malaria patients in whom any test was carried out…………………………………. 
Suspected malaria patients assessed clinically only……………………………………………. 
Suspected malaria patients tested by microscopy……………………………………………… 
Suspected malaria patients tested by RDT……………………………………………………... 
Cases appropriately tested using (RDT + Microscopy)………………………………………... 
Suspected malaria patients found to be negative……………………………………………….. 
Confirmed negative cases treated with antimalarial……………………………………………. 
Negative cases not given antimalarial………………………………………………………….. 
Cases found to be malaria positive……………………………………………………………... 
Positive cases appropriately treated with ACT………………………………………………… 
Positive cases treated with quinine……………………………………………………………... 
Positive cases treated with SP………………………………………………………………….. 
Positive cases not treated with antimalarial……………………………………………………. 
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Appendix II: Ethical Approvals 
Academic Audit and Governance Committee 
College of Science and Technology Research Ethics Panel 
(CST)  
To Oluwafemi Olanrewaju AKINSOLA (and Dr Niroshini Nirmalan / Dr Debapriya 
Mondal) 
cc: Professor Judith Smith, Head of School of ELS 
MEMORANDUM 
From Nathalie Audren Howarth, College Research Support Officer 
Date 27/07/2015 
Subject: Approval of your Project by CST 
Project Title: Qualitative and Quantitative Evaluation of Antimalarial Chemotherapeutic 
Practices and Outcomes in the Southwest Region of Nigeria. 
REP Reference: CST 15/32 
Following your responses to the Panel's queries, based on the information you provided, I can 
confirm that they have no objections on ethical grounds to your project.  
If there are any changes to the project and/or its methodology, please inform the Panel as soon as 
possible.  
Regards, 
Nathalie Audren Howarth 
College Research Support Officer 
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Appendix III: Tables showing hospital data, community data, and drug 
store data 
 
 
 
 
 
 
 
 
    LAGOS STATE     OSUN STATE
                                HOSPITAL DATA (MAY - SEPTEMBER) URBAN RURAL URBAN RURAL
Number of patients suspected to have malaria 1546 941 1359 456
suspected malaria patients in whom any test was carried out 1546 941 1327 456
suspected malaria patients assessed clinically only 74 9 30 0
suspected malaria patients tested by microscopy 0 0 45 20
suspected malaria patients tested by RDT 1472 932 1300 440
cases appropriately tested using (RDT + Microscopy) 0 0 45 20
suspected malaria patients found to be negative 769 253 691 87
confirmed negative cases treated with antimalarial 140 0 15 0
negative cases not given antimalarial 629 253 1173 87
cases found to be malaria positive 536 688 636 369
positive cases appropriately treated with ACT 449 597 564 290
positive cases treated with quinnine 51 57 30 45
positive cases treated with SP 36 34 42 34
positive cases not treated with antimalarial 0 0 0 0
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Community result Lagos Urban 
 
 
ParticipantSex M/F Age groupM.status Education Employement statusSalary properties ownedWTP (₦) History cases/yearTreatment Diagnosed? Place where treated completion of dosage?
1 F 1 S S U 2 ₦500 2 2 Fansidar No Drug vendors I stop when I feel better
2 M 2 S S U 2 ₦500 0 1 Fansidar No Drug vendors Most times
3 F 3 S T E 3 ˃₦500 3 1 Amatem No Drug vendors Always
4 M 4 M S E 2 ₦500 2 1 Herbal (Agbo iba) No Others Most times
5 F 3 S T E 3 ˃₦500 0 1 Coartem No Pharmacy store Always
6 M 4 M T E 3 ˃₦500 1 1 Amatem No Pharmacy store Always
7 F 3 S S E 2 ₦500 0 1 Chloroquine No Drug vendors Most times
8 M 4 M T E 3 ˃₦500 0 1 Lonart Yes Hospital Always
9 M 4 M T E 3 ˃₦500 0 1 Lonart Yes Pharmacy store Always
10 M 4 M T 3 ˃₦500 0 1 Lonart Yes Hospital Always
11 F 4 M T E 3 ˃₦500 2 1 Coartem Yes Hospital Always
12 M 3 S T E 3 ˃₦500 0 1 Coartem Yes Hospital Always
13 M 4 M T E 3 ˃₦500 0 1 Lonart Yes Hospital Always
14 F 4 M T E 3 ˃₦500 0 1 Coartem No Pharmacy store Always
15 F 3 S T E 3 ˃₦500 0 1 Amatem Yes Hospital Always
16 M 4 M T E 3 ˃₦500 0 1 Lonart Yes Hospital Always
17 M 4 M T E 3 ˃₦500 0 1 Coartem No Pharmacy store Always
18 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
19 F 3 S T E 3 ˃₦500 1 1 Chloroquine Yes Hospital Always
20 M 2 S S U 2 ₦500 0 1 Fansidar No Drug vendors Most times
21 M 3 S T E 3 ˃₦500 0 1 Fansidar No Pharmacy store Most times
22 M 4 S T E 3 ˃₦500 0 1 Amatem Yes Hospital Always
23 M 4 M T E 3 ˃₦500 2 1 Herbal (Agbo iba) No Others I stop when I feel better
24 M 3 S T E 3 ₦500 2 1 Lonart No Pharmacy store Most times
25 F 2 M N U 1 ˂₦500 1 2 Chloroquine No Drug vendors I stop when I feel better
26 F 4 S T E 3 ˂₦500 0 1 I don’t know No treatment
27 F 4 S T E 3 ˃₦500 1 1 Chloroquine Yes Hospital I stop when I feel better
28 M 4 M T E 3 ˃₦500 2 1 Coartem Yes Hospital Always
29 M 2 S P U 1 ˂₦500 1 2 Fansidar No Pharmacy store I stop when I feel better
30 M 2 S T U 1 ₦500 2 1 Fansidar No Drug vendors I stop when I feel better
31 F 4 M T E 3 ₦500 0 1 Amatem Yes Hospital I stop when I feel better
32 M 4 S T E 3 ˃₦500 2 1 Coartem Yes Pharmacy store Always
33 F 4 M T E 3 ˃₦500 0 1 Fansidar No Hospital Always
34 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
35 F 4 M T E 3 ˂₦500 0 1 Amatem No Pharmacy store Always
36 F 4 M T E 3 ˃₦500 2 1 Chloroquine Yes Hospital Always
37 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
38 M 3 S T E 3 ˃₦500 0 1 Fansidar Yes Pharmacy store Always
39 F 3 M T E 3 ˃₦500 0 1 Coartem Yes Hospital Always
40 F 3 S T S 3 ˃₦500 0 1 Coartem Yes Hospital Always
41 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
42 M 4 M S E 3 ₦500 2 1 Amatem I don’t know Hospital I stop when I feel better
43 M 4 M T E 3 ˃₦500 0 1 Lonart Yes Hospital Always
44 M 2 M S U 1 ˂₦500 1 2 Fansidar No Drug vendors Most times
45 F 4 M T E 3 ˃₦500 0 1 Chloroquine Yes Hospital Always
46 M 4 M T E 3 ˃₦500 2 1 Lonart No Pharmacy store Always
47 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
48 M 4 M T E 3 ˃₦500 3 1 Lonart No Pharmacy store Always
49 M 3 S T E 3 ˃₦500 2 1 Lonart No Pharmacy store Most times
50 F 3 S T E 3 ˂₦500 2 1 Lonart Yes Hospital Always
51 M 3 S T S 3 ˂₦500 2 1 Coartem No Pharmacy store Always
52 F 3 S T E 3 ˂₦500 2 2 Lonart Yes Pharmacy store Most times
53 F 2 S T E 2 ₦500 2 1 Amatem No Hospital I stop when I feel better
54 M 1 S T U 1 ˂₦500 2 1 Artesunate I don’t know Pharmacy store Most times
55 F 3 S T E 3 ˃₦500 2 2 Lonart Yes Pharmacy store Always
56 M 3 S T E 3 ˃₦500 0 1 Amatem Yes Pharmacy store Always
57 M 4 S T E 3 ˃₦500 0 1 Chloroquine No Pharmacy store Most times
58 M 3 S T E 3 ˃₦500 1 1 Lonart Yes Hospital Always
59 M 3 S T E 3 ˃₦500 2 1 Amatem Yes Drug vendors Most times
60 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
61 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
62 M 3 M T E 3 ˃₦500 2 1 Fansidar No Pharmacy store Always
63 M 3 S T S 3 ˃₦500 0 3 Amatem No Drug vendors Most times
64 M 4 M T E 3 ˃₦500 0 1 Lonart Yes Hospital Always
65 M 4 M T E 3 ˃₦500 0 1 Fansidar Yes Hospital Most times
66 F 4 M T E 3 ˃₦500 0 1 Fansidar No Hospital Always
67 M 1 S N S 1 ˂₦500 1 2 Chloroquine No Pharmacy store I stop when I feel better
68 F 4 S T E 3 ˃₦500 0 1 Fansidar No Pharmacy store I stop when I feel better
69 M 3 S T E 3 ˃₦500 0 1 Lonart Yes Hospital Always
70 M 3 S T E 3 ˃₦500 0 1 Lonart No Pharmacy store I stop when I feel better
71 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
72 M 2 S S S 2 ₦500 0 3 Amatem No No treatment
73 F 3 S T E 3 ˃₦500 0 1 Fansidar No Pharmacy store Always
74 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
75 M 4 M T E 3 ˃₦500 0 2 Lonart Yes Pharmacy store Most times
76 M 3 S T E 3 ˃₦500 0 2 Lonart Yes Pharmacy store Most times
77 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
78 M 3 M T E 3 ˃₦500 2 2 Amatem Yes Hospital Most times
79 M 4 M T E 3 ˃₦500 0 2 Coartem No Pharmacy store I stop when I feel better
80 M 3 S S E 2 ₦500 2 3 Herbal (Agbo iba) No Others I stop when I feel better
81 M 2 S N U 1 ˂₦500 1 2 Chloroquine No Drug vendors I stop when I feel better
82 M 4 M T E 3 ₦500 0 1 Coartem Yes Hospital Always
83 M 3 S T E 3 ˃₦500 0 1 Coartem Yes Pharmacy store Most times
84 M 4 M T E 3 ˃₦500 2 1 Fansidar No Pharmacy store Always
85 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
86 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
87 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
88 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
89 F 3 M T U 1 ˂₦500 0 1 Fansidar No Others I stop when I feel better
90 F 4 M T U 2 ˃₦500 2 2 Fansidar Yes Hospital Most times
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91 F 4 M S E 2 ˂₦500 2 1 Chloroquine No Pharmacy store Always
92 F 3 S T E 1 ˂₦500 1 1 Coartem Yes Hospital Most times
93 F 2 S S E 1 ˂₦500 2 1 Amatem I don’t know Hospital I stop when I feel better
94 M 2 S T E 1 ˂₦500 0 1 Chloroquine No Drug vendors I stop when I feel better
95 M 2 S T E 1 ˂₦500 1 2 Lonart No Pharmacy store Always
96 M 4 M T E 2 ˂₦500 1 1 Herbal No Pharmacy store Always
97 F 4 M T E 2 ˃₦500 0 1 Chloroquine Yes Hospital Always
98 M 3 S T E 3 ˃₦500 1 1 Coartem No Drug vendors Always
99 F 3 M T E 2 ˂₦500 1 1 Chloroquine Yes Drug vendors Always
100 F 4 S T U 1 ˂₦500 1 2 Chloroquine No No treatment
101 M 2 S T U 1 ˂₦500 0 3 Lonart I don’t know Pharmacy store I stop when I feel better
102 M 1 S S U 1 ˂₦500 0 3 Chloroquine Yes Hospital I stop when I feel better
103 F 1 S S U 1 ˃₦500 0 1 Herbal I don’t know Hospital Always
104 M 1 S S U 1 ˂₦500 0 1 Coartem I don’t know Others I stop when I feel better
105 F 2 S S U 1 ˂₦500 1 1 Amatem Yes Hospital I stop when I feel better
106 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
107 F 3 S S U 1 ˂₦500 0 1 Fansidar I don’t know Pharmacy store I stop when I feel better
108 F 2 S S U 1 ˃₦500 2 1 Herbal Yes Drug vendors Always
109 F 3 S N U 2 ˃₦500 1 2 Lonart Yes Pharmacy store Most times
110 F 4 S T E 1 ˂₦500 0 1 Chloroquine Yes Hospital I stop when I feel better
111 M 1 S S U 1 ˂₦500 2 1 Coartem Yes Drug vendors I stop when I feel better
112 M 1 S S U 1 ˂₦500 0 1 Chloroquine Yes Hospital Always
113 F 2 M N U 1 ˂₦500 1 2 Chloroquine No Drug vendors I stop when I feel better
114 M 4 S T U 1 ˂₦500 2 1 Herbal I don’t know Drug vendors I stop when I feel better
115 M 2 S T E 1 ˂₦500 0 1 Lonart I don’t know Hospital I stop when I feel better
116 F 3 M T E 2 ˃₦500 1 1 combiart I don’t know Drug vendors I stop when I feel better
117 F 2 S P U 1 ˂₦500 1 2 Fansidar No Pharmacy store I stop when I feel better
118 F 1 S S E 2 ˂₦500 1 1 Chloroquine Yes Drug vendors Most times
119 F 4 S T E 2 ˃₦500 1 2 Herbal No Pharmacy store Always
120 F 1 S S E 2 ˃₦500 1 2 Lonart I don’t know Hospital I stop when I feel better
121 M 3 M T E 2 ˂₦500 1 2 Chloroquine Yes Drug vendors Most times
122 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
123 M 4 M S S 2 ˃₦500 0 1 combiart I don’t know Hospital I stop when I feel better
124 F 3 M T E 2 ˃₦500 2 2 Chloroquine I don’t know Hospital I stop when I feel better
125 F 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
126 F 2 S T U 2 ˃₦500 0 1 Herbal I don’t know Hospital I stop when I feel better
127 M 2 S T E 2 ˃₦500 1 2 Fansidar Yes Drug vendors Most times
128 F 2 S T E 1 ˂₦500 0 1 Chloroquine No Drug vendors Most times
129 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
130 M 2 S T U 1 ˂₦500 0 1 Chloroquine Yes Pharmacy store Always
131 M 3 M T E 2 ˃₦500 2 2 Coartem Yes Drug vendors I stop when I feel better
132 M 2 M S U 1 ˂₦500 1 2 Fansidar No Drug vendors Most times
133 F 3 S T E 1 ˂₦500 0 1 Fansidar No Drug vendors I stop when I feel better
134 M 4 M T E 2 ˃₦500 1 1 Chloroquine Yes Hospital Always
135 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
136 F 1 S S U 1 ˂₦500 0 1 Amatem No Pharmacy store Always
137 F 1 S S U 1 ˂₦500 0 2 Chloroquine I don’t know Pharmacy store I stop when I feel better
138 M 4 M T E 3 ˂₦500 2 1 Other Yes Drug vendors Most times
139 F 1 S P E 2 ˂₦500 1 1 Chloroquine No Hospital Always
140 M 1 S S E 1 ˂₦500 1 1 Amatem I don’t know Hospital Always
141 F 2 S T E 2 ˂₦500 2 1 Amatem No Hospital I stop when I feel better
142 M 1 S T U 1 ˂₦500 0 1 Chloroquine I don’t know Pharmacy store Always
143 M 1 S S U 1 ˂₦500 0 1 Coartem I don’t know Pharmacy store Always
144 M 1 S P U 1 ˂₦500 0 1 Chloroquine No Hospital I stop when I feel better
154 F 4 M T E 2 ˂₦500 0 1 Coartem I don’t know Pharmacy store I stop when I feel better
146 F 4 M S U 2 ˃₦500 0 1 Coartem No Hospital Always
147 M 1 S S E 1 ˂₦500 0 1 Chloroquine Yes Hospital I stop when I feel better
148 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
149 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
150 M 2 S T U 2 ˂₦500 2 1 combiart Yes Hospital I stop when I feel better
151 M 1 S S E 2 ˂₦500 2 2 combiart No Hospital I stop when I feel better
152 M 3 M N U 1 ˂₦500 1 3 Chloroquine Yes Drug vendors Most times
153 F 4 M P E 3 ˃₦500 1 2 Fansidar Yes No treatment Most times
154 F 2 M S U 1 ˂₦500 2 3 Lonart Yes Drug vendors Always
155 F 2 S S U 1 ˂₦500 0 1 Amatem Yes Hospital Always
156 F 3 S T S 1 ˂₦500 0 1 Chloroquine Yes Hospital I stop when I feel better
157 F 2 S T U 1 ˂₦500 0 1 Chloroquine No Drug vendors Most times
158 F 4 S S S 1 ˃₦500 0 1 Chloroquine No Pharmacy store I stop when I feel better
159 F 4 M P S 2 ˂₦500 1 1 Amatem I don’t know Drug vendors I stop when I feel better
160 M 4 M N U 1 ˃₦500 1 1 Amatem No Pharmacy store Always
161 F 4 M N S 2 ˃₦500 0 2 Fansidar No Pharmacy store Always
162 M 4 M S S 1 ˃₦500 2 1 Chloroquine I don’t know Pharmacy store Always
163 M 4 M T E 1 ˂₦500 0 1 Lonart No Drug vendors Always
164 M 3 M S E 2 ˂₦500 0 2 Coartem Yes Hospital I stop when I feel better
165 M 4 M S U 2 ˃₦500 1 2 Herbal No No treatment Always
166 M 3 M S S 2 ˃₦500 0 2 Chloroquine Yes Hospital Always
167 F 2 S T U 2 ˃₦500 1 3 Chloroquine No Hospital Most times
168 M 2 S P U 1 ˂₦500 0 1 Chloroquine No Hospital Most times
169 F 2 S S U 1 ˂₦500 1 2 Herbal No Pharmacy store Always
170 M 3 S S U 3 ˃₦500 2 1 Chloroquine Yes Drug vendors Always
171 F 4 M S S 1 ˃₦500 2 2 Amatem I don’t know Drug vendors I stop when I feel better
172 M 3 S T U 1 ˂₦500 2 1 Lonart I don’t know Drug vendors I stop when I feel better
173 F 4 D P E 1 ˂₦500 0 3 Chloroquine I don’t know Pharmacy store Most times
174 F 2 S P E 1 ˂₦500 0 1 Lonart Yes Drug vendors Most times
175 F 1 S P U 2 ˂₦500 1 1 Amatem I don’t know No treatment Most times
176 F 1 S S E 1 ˂₦500 0 1 Chloroquine I don’t know Drug vendors I stop when I feel better
177 F 1 S S U 1 ˂₦500 0 1 Coartem No Drug vendors I stop when I feel better
178 F 2 S S S 1 ˂₦500 0 1 Chloroquine No Drug vendors Most times
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Community result Lagos rural 
 
ParticipantSex M/F Age groupM.status Education Employement statusSalary properties ownedWTP (₦) History cases/yearTreatment Diagnosed? Place where treated completion of dosage?
1 F 3 M P U 1 ˂₦500 1 2 CHLOROQUINE No Pharmacy store I stop when I feel better
2 F 2 M P U 1 ˃₦500 1 1 CHLOROQUINE No Drug vendors I stop when I feel better
4 F 3 M T U 1 ˂₦500 2 2 FANSIDAR Yes Hospital Always
5 M 2 S P U 1 ˂₦500 0 1 FANSIDAR No Drug vendors Most times
6 M 3 S S U 1 ˂₦500 2 2 CHLOROQUINE No Hospital Always
7 F 4 M P U 1 ˂₦500 2 1 LONART No Hospital Most times
8 M 4 S P U 1 ˂₦500 0 1 CHLOROQUINE No Drug vendors Always
9 M 4 M P E 1 <₦500 1 2 NONE No Pharmacy store I stop when I feel better
10 F 4 S S E 2 ˂₦500 2 1 LONART Yes Hospital Always
11 F 4 M T U 2 ₦500 0 1 CHLOROQUINE I don’t know Pharmacy store I stop when I feel better
12 F 3 S S E 2 ˂₦500 0 1 FANSIDAR No Hospital Always
13 F 3 M P E 1 ˃₦500 1 1 NONE I don’t know Drug vendors Always
14 F 2 M S U 1 ˂₦500 0 1 NONE Yes Hospital Most times
15 M 3 S P E 1 ˂₦500 0 2 FANSIDAR Yes Drug vendors Always
16 F 2 M P S 1 ˂₦500 2 1 FANSIDAR No Pharmacy store I stop when I feel better
17 M 1 S S S 1 ˂₦500 2 1 COARTEM I don’t know Others Most times
18 F 2 M S U 1 ˂₦500 1 2 AMATEM] Yes Hospital I stop when I feel better
19 F 1 S T U 1 ˂₦500 1 2 FANSIDAR No Drug vendors Most times
20 F 2 M T U 1 ˃₦500 0 1 CHLOROQUINE No Pharmacy store Always
21 F 1 M N S 1 ˃₦500 1 1 CHLOROQUINE I don’t know Drug vendors I stop when I feel better
22 M 2 S N U 1 ˂₦500 2 2 COARTEM I don’t know Hospital I stop when I feel better
23 M 3 S N E 1 ˃₦500 0 2 CHLOROQUINE No Hospital Always
24 M 3 M N E 2 ˂₦500 0 1 CHLOROQUINE I don’t know Drug vendors Always
25 M 3 M N U 1 ˂₦500 0 1 AMATEM Yes Hospital Always
26 F 2 M N U 1 ˂₦500 1 2 CHLOROQUINE No Drug vendors I stop when I feel better
27 F 4 D T U 1 ˂₦500 2 1 CHLOROQUINE I don’t know no treatment I stop when I feel better
28 M 4 M P E 1 ˂₦500 1 1 FANSIDAR No Pharmacy store I stop when I feel better
29 F 4 M N U 1 ˂₦500 0 2 FANSIDAR I don’t know Hospital Always
30 M 4 S T U 1 ˂₦500 1 2 FANSIDAR No Pharmacy store I stop when I feel better
31 F 3 M P S 1 ˂₦500 2 1 FANSIDAR I don’t know Drug vendors Always
32 F 3 M N S 2 ˃₦500 0 1 HERBAL No Others I stop when I feel better
33 F 3 T U 1 ˂₦500 2 2 NONE No Hospital Always
34 M 3 M P U 1 ˂₦500 2 1 NONE No Pharmacy store Always
35 M 2 S P S 1 ˂₦500 1 2 HERBAL No Drug vendors I stop when I feel better
36 M 3 M N U 1 ˂₦500 0 1 FANSIDAR I don’t know Hospital I stop when I feel better
37 M 2 M N U 1 ˂₦500 0 1 COARTEM Yes Hospital Always
38 F 2 S P U 1 ˂₦500 1 2 FANSIDAR No Drug vendors I stop when I feel better
39 F 2 S N N 2 ˃₦500 1 1 CHLOROQUINE I don’t know Pharmacy store I stop when I feel better
40 F 2 T E 2 ˃₦500 0 2 CHLOROQUINE I don’t know Drug vendors Always
41 M 2 M P N 1 ˂₦500 2 1 CHLOROQUINE No Drug vendors I stop when I feel better
42 M 2 S N U 1 ˂₦500 1 2 FANSIDAR No Drug vendors I stop when I feel better
43 M 3 M N U 1 ˂₦500 0 1 LONART I don’t know Hospital Always
44 F 1 S N E 2 ˂₦500 0 1 COARTEM Yes Hospital I stop when I feel better
45 F 2 S N U 1 ˂₦500 1 2 AMATEM No Drug vendors Most times
46 M 4 S N U 1 ˂₦500 0 1 FANSIDAR I don’t know Hospital Most times
47 F 1 M S U 1 ˂₦500 0 1 FANSIDAR No Drug vendors Always
48 M 2 S P S 2 ˂₦500 1 2 CHLOROQUINE No Drug vendors Most times
49 F 2 M P E 1 ˃₦500 0 1 NONE Yes Hospital Always
50 F 2 S P U 1 ˂₦500 1 1 NONE No Hospital Always
51 M 3 M P S 1 ˂₦500 2 1 HERBAL Yes Hospital I stop when I feel better
52 F 2 S T S 2 ˂₦500 0 1 CHLOROQUINE No Hospital Most times
53 M 2 M P U 1 ˃₦500 1 1 CHLOROQUINE I don’t know Drug vendors Always
54 F 4 S N U 1 ˂₦500 2 1 HERBAL Yes Drug vendors Always
55 M 1 M S S 1 ˂₦500 0 2 HERBAL No Drug vendors Most times
56 F 1 M N U 1 ˂₦500 2 1 HERBAL I don’t know Hospital Most times
57 M 3 M S U 1 ˂₦500 0 1 FANSIDAR I don’t know Hospital Always
57 F 4 D P S 2 ˂₦500 0 1 NONE No Hospital Most times
57 F 1 S S U 1 ˃₦500 2 1 NONE Yes Hospital Always
57 F 4 S N E 1 ˃₦500 0 2 NONE Yes Hospital Always
61 M 3 M N E 2 ˂₦500 1 2 FANSIDAR No Drug vendors I stop when I feel better
62 F 2 S T U 1 ˂₦500 2 1 FANSIDAR No Drug vendors Most times
63 M 1 S N U 1 ˃₦500 2 1 CHLOROQUINE No Pharmacy store Most times
64 F 1 S S U 1 ˂₦500 1 1 COARTEM No Drug vendors I stop when I feel better
65 M 4 D/W N U 1 ˂₦500 0 1 FANSIDAR No Drug vendors I stop when I feel better
66 M 4 D/W P U 1 <₦500 0 1 AMATEM No Drug vendors I stop when I feel better
67 F 3 M P S 1 ˂₦500 2 1 NONE No others Always
68 F 2 M S U 2 ˃₦500 1 1 LONART Yes Hospital Always
69 M 4 M T E 3 ˂₦500 2 1 AMATEM Yes Hospital Always
70 M 2 S N U 1 ˂₦500 1 1 CHLOROQUINE No Pharmacy store I stop when I feel better
71 M 2 S N U 1 ˂₦500 2 1 CHLOROQUINE No Drug vendors I stop when I feel better
72 F 1 S N E 1 <₦500 1 2 COMBIART No Drug vendors Most times
73 F 2 S S U 2 ˃₦500 2 1 CHLOROQUINE No Drug vendors Always
74 F 4 M N S 2 ˃₦500 0 2 Fansidar No Pharmacy store Always
75 M 4 M S S 1 ˃₦500 2 1 Chloroquine I don’t know Pharmacy store Always
76 M 4 M T E 1 ˂₦500 0 1 Lonart No Drug vendors Always
77 M 3 M S E 2 ˂₦500 0 2 Coartem Yes Hospital I stop when I feel better
78 M 4 M S U 2 ˃₦500 1 2 Herbal No No treatment Always
79 M 3 M S S 2 ˃₦500 0 2 Chloroquine Yes Hospital Always
80 F 2 S T U 2 ˃₦500 1 3 Chloroquine No Hospital Most times
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81 M 2 S P U 1 ˂₦500 0 1 Chloroquine No Hospital Most times
82 F 2 S S U 1 ˂₦500 1 2 Herbal No Pharmacy store Always
83 M 3 S S U 3 ˃₦500 2 1 Chloroquine Yes Drug vendors Always
84 F 4 M S S 1 ˃₦500 2 2 Amatem I don’t know Drug vendors I stop when I feel better
85 M 3 S T U 1 ˂₦500 2 1 Lonart I don’t know Drug vendors I stop when I feel better
86 F 4 D P E 1 ˂₦500 0 3 Chloroquine I don’t know Pharmacy store Most times
87 F 2 S P E 1 ˂₦500 0 1 Lonart Yes Drug vendors Most times
88 F 1 S P U 2 ˂₦500 1 1 Amatem I don’t know No treatment Most times
89 F 1 S S E 1 ˂₦500 0 1 Chloroquine I don’t know Drug vendors I stop when I feel better
90 F 1 S S U 1 ˂₦500 0 1 Coartem No Drug vendors I stop when I feel better
91 F 2 S S S 1 ˂₦500 0 1 Chloroquine No Drug vendors Most times
92 M 4 M T E 2 ˂₦500 1 1 Herbal No Pharmacy store Always
93 F 4 M T E 2 ˃₦500 0 1 Chloroquine Yes Hospital Always
94 M 3 S T E 3 ˃₦500 1 1 Coartem No Drug vendors Always
95 F 3 M T E 2 ˂₦500 1 1 Chloroquine Yes Drug vendors Always
96 F 4 S T U 1 ˂₦500 1 2 Chloroquine No No treatment
97 M 2 S T U 1 ˂₦500 0 3 Lonart I don’t know Pharmacy store I stop when I feel better
98 M 1 S S U 1 ˂₦500 0 3 Chloroquine Yes Hospital I stop when I feel better
99 F 1 S S U 1 ˃₦500 0 1 Herbal I don’t know Hospital Always
100 M 1 S S U 1 ˂₦500 0 1 Coartem I don’t know Others I stop when I feel better
101 F 2 S S U 1 ˂₦500 1 1 Amatem Yes Hospital I stop when I feel better
102 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
103 F 3 S S U 1 ˂₦500 0 1 Fansidar I don’t know Pharmacy store I stop when I feel better
104 F 2 S S U 1 ˃₦500 2 1 Herbal Yes Drug vendors Always
105 F 3 S N U 2 ˃₦500 1 2 Lonart Yes Pharmacy store Most times
106 F 4 S T E 1 ˂₦500 0 1 Chloroquine Yes Hospital I stop when I feel better
107 M 1 S S U 1 ˂₦500 2 1 Coartem Yes Drug vendors I stop when I feel better
108 M 1 S S U 1 ˂₦500 0 1 Chloroquine Yes Hospital Always
109 F 2 M N U 1 ˂₦500 1 2 Chloroquine No Drug vendors I stop when I feel better
110 M 4 S T U 1 ˂₦500 2 1 Herbal I don’t know Drug vendors I stop when I feel better
111 M 2 S T E 1 ˂₦500 0 1 Lonart I don’t know Hospital I stop when I feel better
112 F 3 M T E 2 ˃₦500 1 1 combiart I don’t know Drug vendors I stop when I feel better
113 F 2 S P U 1 ˂₦500 1 2 Fansidar No Pharmacy store I stop when I feel better
114 F 1 S S E 2 ˂₦500 1 1 Chloroquine Yes Drug vendors Most times
115 F 4 S T E 2 ˃₦500 1 2 Herbal No Pharmacy store Always
116 F 1 S S E 2 ˃₦500 1 2 Lonart I don’t know Hospital I stop when I feel better
117 M 3 M T E 2 ˂₦500 1 2 Chloroquine Yes Drug vendors Most times
118 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
119 M 4 M S S 2 ˃₦500 0 1 combiart I don’t know Hospital I stop when I feel better
120 F 3 M T E 2 ˃₦500 2 2 Chloroquine I don’t know Hospital I stop when I feel better
121 F 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
122 F 2 S T U 2 ˃₦500 0 1 Herbal I don’t know Hospital I stop when I feel better
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ParticipantSex M/F Age groupM.status Education Employement statusSalary properties ownedWTP (₦) History cases/yearTreatmentDiagnosed?Place where treated completion of dosage?
1 F 3 M T U 1 ₦500 0 1 Fansidar No Others I stop when I feel better
2 M 4 M T U 2 ˃₦500 2 2 Fansidar Yes Hospital Most times
4 F 4 M S E 2 ₦500 2 1 Lonart No Pharmacy store Always
5 F 3 S T S 1 ˂₦500 1 1 Coartem Yes Hospital Most times
6 F 2 S S S 1 ₦500 2 1 Amatem I don’t knowHospital I stop when I feel better
7 F 2 S T S 1 ˂₦500 0 1 Coartem No Drug vendors I stop when I feel better
8 F 2 S T U 1 ₦500 1 2 Herbal No Pharmacy store Always
9 M 4 M T E 2 ˂₦500 1 1 Coartem No Pharmacy store Always
10 F 4 M T E 2 ˃₦500 0 1 Amatem Yes Hospital Always
11 M 3 S T E 3 ˃₦500 1 1 Coartem No Hospital Always
12 M 3 M T E 2 ˂₦500 1 1 ChloroquineYes Drug vendors Always
13 M 4 S T U 1 ˂₦500 1 2 Herbal No No treatment
14 F 2 S T E 1 ₦500 0 3 Lonart I don’t knowPharmacy store I stop when I feel better
15 M 1 S S U 1 ˂₦500 0 3 Fansidar Yes Hospital I stop when I feel better
16 F 1 S S U 1 ˃₦500 0 1 Coartem I don’t knowHospital Always
17 M 1 S S U 1 ₦500 0 1 Coartem I don’t knowOthers I stop when I feel better
18 F 2 S S E 1 ₦500 1 1 Amatem Yes Hospital I stop when I feel better
19 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
20 F 3 S S U 1 ˂₦500 0 1 Fansidar I don’t knowPharmacy store I stop when I feel better
21 M 2 S S U 1 ˃₦500 2 1 Amatem Yes Pharmacy store Always
22 F 3 S N E 2 ˃₦500 1 2 Lonart Yes Pharmacy store Most times
23 F 4 M T E 1 ₦500 0 1 ChloroquineYes Hospital I stop when I feel better
24 F 1 S S U 1 ˂₦500 2 1 Coartem Yes Hospital I stop when I feel better
25 M 1 S S U 1 ₦500 0 1 Amatem Yes Hospital Always
26 F 2 M N U 1 ˂₦500 1 2 ChloroquineNo Drug vendors I stop when I feel better
27 M 4 M T U 1 ₦500 2 1 combiart I don’t knowDrug vendors I stop when I feel better
28 M 2 S T E 1 ₦500 0 1 Lonart I don’t knowHospital I stop when I feel better
29 M 3 M T E 2 ˃₦500 1 1 combiart I don’t knowHospital I stop when I feel better
30 M 2 S P U 1 ˂₦500 1 2 Fansidar No Pharmacy store I stop when I feel better
31 F 1 S S E 2 ₦500 1 1 ChloroquineYes Hospital Most times
32 F 4 M T E 2 ˃₦500 1 2 Coartem No Pharmacy store Always
33 F 1 S S E 2 ˃₦500 1 2 Lonart I don’t knowHospital I stop when I feel better
34 F 3 M T E 2 ₦500 1 2 Lonart Yes Hospital Most times
35 M 2 S P U 1 ˂₦500 1 2 Herbal No Drug vendors I stop when I feel better
36 M 4 M S S 2 ˃₦500 0 1 combiart I don’t knowHospital I stop when I feel better
37 M 3 M T E 2 ˃₦500 2 2 combiart I don’t knowHospital I stop when I feel better
38 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
39 M 2 S T U 2 ˃₦500 0 1 Coartem I don’t knowHospital I stop when I feel better
40 M 2 S T E 2 ˃₦500 1 2 Fansidar Yes Pharmacy store Most times
41 M 2 S T E 1 ˂₦500 0 1 ChloroquineNo Pharmacy store Most times
42 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
43 M 2 S T U 1 ₦500 0 1 ChloroquineYes Pharmacy store Always
44 M 3 M T E 2 ˃₦500 2 2 Coartem Yes Hospital I stop when I feel better
45 M 2 M S U 1 ˂₦500 1 2 Fansidar No Drug vendors Most times
46 M 3 S T E 1 ˂₦500 0 1 Fansidar No Drug vendors I stop when I feel better
47 F 4 M T E 2 ₦500 1 1 ChloroquineYes Hospital Always
48 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
49 M 1 S S U 1 ₦500 0 1 Amatem No Pharmacy store Always
50 F 1 S S U 1 ˂₦500 0 2 ChloroquineI don’t knowPharmacy store I stop when I feel better
51 F 4 M T E 3 ₦500 2 1 Other Yes Hospital Most times
52 F 1 S P E 2 ˂₦500 1 1 Amatem No Hospital Always
53 M 1 S S E 1 ₦500 1 1 Amatem I don’t knowHospital Always
54 F 2 S T E 2 ₦500 2 1 Amatem No Hospital I stop when I feel better
55 M 1 S T U 1 ˂₦500 0 1 Amatem I don’t knowPharmacy store Always
56 F 1 S S U 1 ˂₦500 0 1 Herbal I don’t knowPharmacy store Always
57 F 1 S P U 1 ₦500 0 1 Herbal No Hospital I stop when I feel better
58 F 4 M T E 2 ˂₦500 0 1 Coartem I don’t knowPharmacy store I stop when I feel better
57 F 4 M S U 2 ˃₦500 0 1 Coartem No Hospital Always
60 F 1 S S E 1 ₦500 0 1 ChloroquineYes Hospital I stop when I feel better
61 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
62 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
63 M 2 S T U 2 ₦500 2 1 combiart Yes Hospital I stop when I feel better
64 M 1 S S E 2 ₦500 2 2 combiart No Hospital I stop when I feel better
65 M 3 M T E 2 ₦500 1 1 combiart No Hospital I stop when I feel better
66 M 3 M T E 2 ˃₦500 2 1 combiart I don’t knowHospital Most times
67 F 1 S S U 2 ₦500 1 1 combiart I don’t knowHospital I stop when I feel better
68 M 1 S N S 1 ˂₦500 1 2 ChloroquineNo Pharmacy store I stop when I feel better
69 F 1 S S U 1 ˂₦500 1 1 Fansidar Yes Hospital I stop when I feel better
70 M 4 M T E 3 ˃₦500 2 1 Lonart Yes Hospital Most times
71 F 4 S T U 1 ˃₦500 2 1 Amatem Yes Hospital Always
72 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
73 M 4 M T E 2 ˃₦500 0 1 Lonart Yes Pharmacy store Most times
74 M 2 S S E 2 ˂₦500 0 1 Amatem No Drug vendors Most times
75 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
76 M 4 M T E 3 ˂₦500 2 1 Fansidar Yes Drug vendors I stop when I feel better
77 M 3 S T E 3 ˃₦500 0 2 Lonart Yes Pharmacy store Most times
78 M 2 S P U 1 ˂₦500 1 2 Fansidar No Drug vendors I stop when I feel better
79 M 4 M T E 3 ˃₦500 2 1 Lonart Yes Hospital Most times
80 F 4 M T E 2 ˃₦500 2 1 Lonart Yes Hospital I stop when I feel better
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81 M 4 M T E 3 ₦500 1 1 Coartem No Pharmacy store Always
82 M 2 S N U 1 ˂₦500 1 2 ChloroquineNo Drug vendors I stop when I feel better
83 M 4 M T E 2 ˃₦500 1 2 Coartem Yes Pharmacy store Always
84 M 4 M T E 2 ˂₦500 0 1 Coartem No Hospital Always
85 M 4 M T U 1 ˂₦500 1 1 Fansidar No Pharmacy store Most times
86 F 4 M T S 1 ˂₦500 1 2 Fansidar Yes Hospital Always
87 F 2 S S U 2 ˂₦500 0 1 Fansidar Yes Hospital I stop when I feel better
88 M 4 M T E 1 ˂₦500 1 1 Coartem No Pharmacy store Most times
89 M 2 S T E 1 ˂₦500 1 1 Amatem I don’t knowPharmacy store I stop when I feel better
90 M 4 M N U 1 ˂₦500 0 2 ChloroquineNo Drug vendors I stop when I feel better
91 F 4 M T E 1 ˂₦500 1 2 combiart No Pharmacy store Always
92 M 4 D T E 2 ₦500 0 2 Herbal Yes Pharmacy store I stop when I feel better
93 M 3 M T S 2 ˂₦500 0 2 combiart No Hospital Most times
94 F 2 S S E 1 ˂₦500 2 1 Amatem I don’t knowPharmacy store Always
95 M 3 M S S 1 ˃₦500 0 1 Lonart Yes Hospital I stop when I feel better
96 F 4 M S S 1 ˃₦500 2 2 Fansidar No Drug vendors I stop when I feel better
97 M 1 S T E 1 ˃₦500 0 2 Lonart Yes Pharmacy store Always
98 M 1 S T E 1 ˂₦500 1 1 Amatem Yes Hospital I stop when I feel better
99 F 2 S S S 1 ˃₦500 0 1 Lonart No Drug vendors I stop when I feel better
100 M 2 S S E 1 ˃₦500 0 3 Herbal No Pharmacy store Always
101 F 2 S T S 1 ˂₦500 0 3 Lonart Yes Pharmacy store I stop when I feel better
102 F 3 M S S 1 ˂₦500 1 2 Amatem Yes Hospital Most times
103 M 4 D P S 2 ˃₦500 0 1 ChloroquineYes Pharmacy store I stop when I feel better
104 F 3 S T S 1 ˃₦500 0 3 Fansidar Yes Pharmacy store I stop when I feel better
105 M 3 M T S 1 ˂₦500 1 2 Lonart Yes Hospital Most times
106 M 3 M S E 2 ˃₦500 0 3 Lonart No Hospital I stop when I feel better
107 F 4 M S E 2 ˂₦500 1 2 Coartem Yes Pharmacy store I stop when I feel better
108 F 4 D S S 2 ˂₦500 1 2 Lonart No Pharmacy store Always
109 M 2 S T S 2 ˂₦500 1 3 Amatem Yes Pharmacy store I stop when I feel better
110 F 3 M T S 2 ˃₦500 0 1 Fansidar Yes Drug vendors I stop when I feel better
111 M 3 M T U 1 ˂₦500 0 2 Fansidar Yes Hospital I stop when I feel better
112 F 4 M S U 2 ˃₦500 0 1 Lonart No Hospital I stop when I feel better
113 M 3 S T S 1 ˂₦500 2 2 Lonart No Drug vendors Most times
114 M 4 M P S 1 ˂₦500 2 1 Amatem Yes Hospital I stop when I feel better
115 F 2 S T E 2 ˃₦500 1 2 ChloroquineYes Hospital I stop when I feel better
116 M 4 M T S 2 ˃₦500 0 2 Fansidar Yes Pharmacy store Most times
117 M 3 S T U 1 ˂₦500 2 2 Coartem No Drug vendors I stop when I feel better
118 M 4 M T E 2 ˂₦500 0 1 Herbal No Hospital Always
119 F 3 S S E 2 ˃₦500 1 2 Lonart Yes Pharmacy store I stop when I feel better
120 F 3 M T E 2 ˃₦500 0 2 ChloroquineYes Hospital I stop when I feel better
121 F 3 S T S 1 ˃₦500 0 2 Lonart Yes Pharmacy store Most times
122 M 4 M T S 2 ˂₦500 0 1 Amatem No Hospital I stop when I feel better
123 F 4 M T S 1 ˂₦500 1 2 Fansidar Yes Pharmacy store Most times
124 F 4 M T S 2 ˂₦500 2 2 Lonart Yes Hospital I stop when I feel better
125 M 4 M T U 2 ˃₦500 0 3 combiart No Pharmacy store I stop when I feel better
126 F 2 M T U 2 ˂₦500 0 3 Coartem Yes Drug vendors Most times
127 F 3 M P S 1 ˂₦500 2 1 ChloroquineYes Hospital I stop when I feel better
128 F 4 M T U 2 ˂₦500 0 1 Lonart Yes Drug vendors Always
129 M 4 M T S 2 ˃₦500 1 2 Fansidar No Hospital I stop when I feel better
130 F 4 M T E 1 ˂₦500 2 2 Amatem No Pharmacy store I stop when I feel better
131 F 3 M T E 1 ˂₦500 2 3 ChloroquineYes Hospital Most times
132 M 4 M S S 1 ˃₦500 1 2 Lonart Yes Drug vendors I stop when I feel better
133 F 4 M S S 1 ˂₦500 0 2 ChloroquineYes Hospital Most times
134 M 2 S T S 2 ˂₦500 0 1 Coartem No Pharmacy store I stop when I feel better
135 F 2 M T S 1 ˂₦500 0 1 Lonart Yes Hospital Always
136 M 4 M T E 1 ˂₦500 2 1 Amatem Yes Hospital I stop when I feel better
137 M 4 M T E 2 ˃₦500 0 2 Coartem No Pharmacy store Always
138 M 4 M T S 2 ˃₦500 1 2 ChloroquineNo Hospital I stop when I feel better
139 F 3 S S U 2 ˂₦500 0 2 Herbal Yes Drug vendors I stop when I feel better
140 F 3 M T S 2 ˂₦500 2 2 Herbal Yes Pharmacy store Most times
141 F 3 M T E 1 ˂₦500 1 3 Coartem Yes Hospital I stop when I feel better
142 F 3 S T E 1 ˃₦500 0 1 Lonart No Drug vendors Most times
143 M 4 M T E 2 ˂₦500 1 3 Coartem No Hospital Most times
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ParticipantSex 0/1 Age groupMarital StatusEducation Employment StatSalary properties ownedWTP (₦) History cases/yearTreatment Diag0sed? Place where treated completion of dosage?
1 1 1 0 1 0 0 0 0 0 Amatem 1 0 0
2 1 2 1 0 0 0 0 0 0 Chloroquine 0 2 2
4 1 2 1 0 0 0 0 2 0 Chloroquine 1 0 0
5 0 3 1 0 1 1 0 0 0 Fansidar 1 0 0
6 0 2 0 1 1 1 0 2 0 Chloroquine 1 0 0
7 1 2 1 0 0 0 0 2 0 Coartem 1 0 0
8 0 0 0 1 0 0 0 0 0 combiart 0 0 0
9 0 2 1 1 1 0 0 2 0 Amatem 0 2 2
10 0 3 1 1 1 1 0 2 0 Lonart 1 0 0
11 0 3 1 3 0 0 0 0 0 Chloroquine 2 2 2
12 1 2 1 1 1 1 0 0 0 Fansidar 1 0 0
13 1 2 1 0 0 0 0 1 0 Chloroquine 2 0 0
14 1 1 1 1 0 0 0 0 0 Amatem 1 0 0
15 0 0 0 1 1 0 0 0 0 Lonart 1 0 0
16 1 1 1 0 2 0 0 2 0 Fansidar 0 2 2
17 0 0 0 1 0 0 0 0 0 Coartem 2 4 2
18 1 1 0 1 0 0 0 1 0 Amatem 1 0 2
19 0 1 0 0 0 0 0 1 1 Fansidar 0 1 2
20 1 1 1 0 0 0 0 0 0 Coartem 0 2 2
21 1 2 1 3 2 0 0 0 0 Chloroquine 2 2 2
22 1 1 1 0 0 0 0 2 0 Coartem 2 0 2
23 1 1 1 0 0 0 0 0 0 Fansidar 1 0 0
24 1 2 1 0 1 0 0 0 0 Coartem 2 0 0
25 1 2 1 1 0 0 0 0 0 Amatem 1 0 0
26 1 1 1 3 0 0 0 1 1 Chloroquine 0 1 2
27 1 1 1 1 0 0 0 2 0 Coartem 2 3 2
28 0 2 1 0 1 0 0 0 0 Chloroquine 0 2 2
29 1 2 1 3 0 0 0 0 0 Chloroquine 2 0 0
30 0 1 0 0 0 0 0 1 1 Fansidar 0 2 2
31 1 2 1 0 1 0 0 2 0 Fansidar 2 0 0
32 0 2 1 3 0 1 1 0 0 herbal 2 4 2
33 1 0 1 0 0 0 0 2 0 Chloroquine 0 0 0
34 0 2 1 1 0 0 0 2 0 Chloroquine 0 2 0
35 0 1 0 0 1 0 0 1 1 Fansidar 0 1 2
36 1 2 1 1 0 0 0 0 0 Fansidar 2 0 2
37 0 2 1 0 0 0 0 0 0 Coartem 1 0 0
38 0 1 0 0 0 0 0 1 1 Fansidar 0 1 2
39 1 0 0 0 1 0 1 0 0 Chloroquine 2 2 2
40 1 1 1 2 2 1 1 0 0 Fansidar 2 0 0
41 1 1 1 0 0 0 0 2 0 Coartem 2 2 2
42 0 1 0 0 0 0 0 1 1 Fansidar 0 1 2
43 0 2 1 0 0 0 0 0 0 Coartem 2 0 0
44 1 1 0 2 1 0 0 0 0 Coartem 1 0 0
45 0 1 1 1 0 0 0 1 1 Fansidar 0 1 1
46 0 3 1 0 0 0 0 0 0 Amatem 2 0 2
47 0 3 1 1 0 0 0 0 0 Coartem 2 0 0
48 0 1 0 0 2 0 0 1 1 Fansidar 0 1 2
49 1 1 1 1 0 0 0 1 0 Coartem 1 0 0
50 1 0 0 1 0 0 0 0 0 Amatem 1 0 0
51 1 2 1 1 2 3 0 2 0 Coartem 1 0 0
52 1 1 1 1 2 0 0 0 0 Amatem 1 0 0
53 1 1 1 1 0 0 0 0 0 Chloroquine 2 0 0
54 1 0 0 1 1 0 0 0 0 Coartem 1 0 0
55 0 0 0 1 2 0 0 1 0 Fansidar 0 2 2
56 1 0 0 1 0 0 0 2 0 Coartem 2 0 0
57 0 2 1 1 0 0 0 0 0 Coartem 2 0 0
58 1 2 1 0 2 0 0 0 0 Fansidar 1 0 2
57 1 0 0 1 0 0 0 2 0 Amatem 1 0 0
60 0 1 0 1 1 0 0 0 0 Amatem 1 0 0
61 0 1 0 2 0 0 0 1 1 Fansidar 0 1 2
62 1 3 1 2 1 1 1 2 0 Fansidar 1 1 1
63 0 0 0 1 1 0 0 0 0 Coartem 0 2 2
64 0 2 1 1 0 0 1 1 1 Chloroquine 0 2 1
65 1 0 0 0 0 0 0 2 2 Coartem 1 1 2
66 0 3 1 0 1 0 0 2 0 Fansidar 0 0 1
67 1 3 1 2 0 0 0 2 0 Chloroquine 0 1 2
68 0 3 1 1 0 0 0 0 0 Chloroquine 1 0 1
69 1 2 1 1 2 1 1 1 0 Chloroquine 0 2 2
70 1 3 1 0 0 0 0 0 1 Lonart 0 0 0
71 1 3 0 1 1 0 0 0 0 Coartem 1 0 2
72 0 2 0 2 1 1 0 0 0 Chloroquine 0 1 2
73 0 2 1 1 0 0 0 1 2 Amatem 1 2 1
74 1 2 1 0 2 1 1 0 1 Chloroquine 0 2 1
75 1 3 0 1 0 0 0 0 0 Chloroquine 1 0 2
76 0 1 1 0 1 0 0 0 0 Lonart 1 0 0
77 0 3 1 1 0 0 0 1 0 Lonart 0 2 1
78 1 3 1 1 2 0 1 2 1 Fansidar 1 2 2
79 0 2 0 1 1 0 0 0 0 Chloroquine 0 0 2
80 1 3 1 1 0 1 0 1 2 Amatem 1 2 1
81 1 3 1 0 0 0 0 0 0 Chloroquine 0 0 2
82 1 3 1 1 2 0 0 0 0 Chloroquine 0 2 0
83 0 3 1 2 1 1 1 1 1 Coartem 1 1 1
84 0 3 1 1 1 1 0 0 0 Chloroquine 0 2 2
85 1 1 0 0 2 0 0 2 0 Chloroquine 1 0 1
86 1 2 0 1 0 0 1 2 0 Chloroquine 0 2 2
87 1 3 1 2 0 0 0 1 0 Fansidar 0 0 0
88 0 1 0 1 2 1 0 1 2 Chloroquine 0 2 1
89 0 3 0 0 0 0 0 0 0 Chloroquine 1 0 2
90 1 3 0 1 2 0 1 1 1 Lonart 1 0 1
91 0 2 1 1 0 0 0 1 1 Fansidar 0 0 2
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Pharmacy data Lagos 
 
Education of pharmacist Urban/Rural Antimalarial mostly prescribed sex of client proof of diagnosis self-medicating? Antimalarial purchasedACT? influence of pharmacist?price
Client 1 Tertiary Urban Lonart F Y Y Chloroquine N N ₦80
Client 2 Tertiary Urban Lonart F N Y Fansidar N Y ₦160
Client 3 Tertiary Urban Lonart F Y N lonart Y Y ₦850
Client 4 Tertiary Urban Lonart F Y N Amatem Y Y ₦600
Client 5 Tertiary Urban Lonart F Y N Chloroquine N N ₦80
Client 6 Tertiary Urban Lonart M Y N lonart Y Y ₦850
Client 7 Tertiary Urban Lonart F N N lonart Y N ₦850
Client 8 Tertiary Urban Lonart F N N Amatem Y Y ₦600
Client 9 Tertiary Urban Lonart F N N Amatem Y Y ₦600
Client 10 Tertiary Urban Lonart F N Y lonart Y Y ₦850
Client 11 Tertiary Urban Lonart M Y N Chloroquine N N ₦80
Client 12 Tertiary Urban Lonart M Y N Coartem Y Y ₦850
Client 13 Tertiary Urban Lonart F N N lonart Y Y ₦850
Client 14 Tertiary Urban Lonart M N N Fansidar N Y ₦170
Client 15 Tertiary Urban Lonart F Y Y Fansidar N N ₦170
Client 16 Tertiary Urban Lonart F N Y Coartem Y Y ₦600
Client 17 Tertiary Urban Lonart F N Y Chloroquine N N ₦80
Client 18 Tertiary Urban Lonart F Y N lonart Y Y ₦850
Client 19 Tertiary Urban Lonart F Y N lonart Y Y ₦850
Client 20 Tertiary Urban Lonart F Y N Fansidar N N ₦170
Client 21 Tertiary Urban Lonart M Y N Chloroquine N Y ₦80
Client 22 Tertiary Urban Lonart F Y N Chloroquine N N ₦80
Client 23 Tertiary Urban Lonart M N Y lonart Y N ₦850
Client 24 Tertiary Urban Lonart F N Y lonart Y Y ₦850
Client 25 Tertiary Urban Lonart F Y N lonart Y Y ₦850
Client 26 Tertiary Urban Coartem/Amatem M N Y Coartem Y Y ₦250
Client 27 Tertiary Urban Coartem/Amatem M N Y Coartem Y N ₦250
Client 28 Tertiary Urban Coartem/Amatem F N Y Amatem Y Y ₦500
Client 29 Tertiary Urban Coartem/Amatem M N Y Coartem Y N ₦250
Client 30 Tertiary Urban Coartem/Amatem F Y N Coartem Y Y ₦250
Client 31 Tertiary Urban Coartem/Amatem F N Y Coartem Y N ₦250
Client 32 Tertiary Urban Coartem/Amatem M N Y Coartem Y Y ₦250
Client 33 Tertiary Urban Coartem/Amatem M N Y Amatem Y Y ₦500
Client 34 Tertiary Urban Coartem/Amatem M N Y Amatem Y Y ₦500
Client 35 Tertiary Urban Coartem/Amatem M N Y Amatem Y Y ₦500
Client 36 Tertiary Urban Coartem/Amatem F N Y Coartem Y N ₦250
Client 37 Tertiary Urban Coartem/Amatem M N Y Coartem Y N ₦250
Client 38 Tertiary Urban Coartem/Amatem M N Y Coartem Y N ₦250
Client 39 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 40 Tertiary Urban Coartem/Amatem F N Y Amatem Y Y ₦500
Client 41 Tertiary Urban Coartem/Amatem F Y N Amatem Y Y ₦500
Client 42 Tertiary Urban Coartem/Amatem M N Y Coartem Y Y ₦250
Client 43 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 44 Tertiary Urban Coartem/Amatem F N Y Amatem Y Y ₦500
Client 45 Tertiary Urban Coartem/Amatem F N Y Coartem Y N ₦250
Client 46 Tertiary Urban Coartem/Amatem F N Y Coartem Y N ₦250
Client 47 Tertiary Urban Coartem/Amatem F N Y Coartem Y N ₦250
Client 48 Tertiary Urban Coartem/Amatem M N Y Coartem Y N ₦250
Client 49 Tertiary Urban Coartem/Amatem F N Y Amatem Y Y ₦500
Client 50 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 51 Tertiary Urban Coartem/Amatem F N Y Lonart Y Y ₦700
Client 52 Tertiary Urban Coartem/Amatem F N Y Coartem Y N ₦250
Client 53 Tertiary Urban Coartem/Amatem M Y N Lonart Y N ₦700
Client 54 Tertiary Urban Coartem/Amatem M N Y Coartem Y Y ₦250
Client 55 Tertiary Urban Coartem/Amatem M N Y Amatem Y Y ₦500
Client 56 Tertiary Urban Coartem/Amatem M N Y Amatem Y Y ₦500
Client 57 Tertiary Urban Coartem/Amatem M N Y Amatem Y Y ₦500
Client 58 Tertiary Urban Coartem/Amatem M N Y Amatem Y Y ₦500
Client 59 Tertiary Urban Coartem/Amatem M N Y Coartem Y Y ₦250
Client 60 Tertiary Urban Coartem/Amatem F N Y Coartem Y N ₦250
Client 61 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 62 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 63 Tertiary Urban Coartem/Amatem M Y N Coartem Y N ₦250
Client 64 Tertiary Urban Coartem/Amatem F Y Y Coartem Y Y ₦250
Client 65 Tertiary Urban Coartem/Amatem M N Y Amatem Y Y ₦500
Client 66 Tertiary Urban Coartem/Amatem F N Y Lonart Y Y ₦700
Client 67 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 68 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 69 Tertiary Urban Coartem/Amatem M N Y Coartem Y Y ₦250
Client 70 Tertiary Urban Coartem/Amatem M N Y Coartem Y Y ₦250
Client 71 Tertiary Urban Coartem/Amatem F N Y Amatem Y Y ₦500
Client 72 Tertiary Urban Coartem/Amatem M N Y Coartem Y Y ₦250
Client 73 Tertiary Urban Coartem/Amatem F Y N Coartem Y Y ₦250
Client 74 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 75 Tertiary Urban Coartem/Amatem M N Y Coartem Y Y ₦250
Client 76 Tertiary Urban Coartem/Amatem M N Y Amatem Y N ₦500
Client 77 Tertiary Urban Coartem/Amatem M N Y Amatem Y N ₦500
Client 78 Tertiary Urban Coartem/Amatem M N Y Amatem Y Y ₦500
Client 79 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 80 Tertiary Urban Coartem/Amatem M N Y Coartem Y Y ₦250
Client 81 Tertiary Urban Coartem/Amatem M N Y Coartem Y Y ₦250
Client 82 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 83 Tertiary Urban Coartem/Amatem F N Y Amatem Y Y ₦500
Client 84 Tertiary Urban Coartem/Amatem F Y N Amatem Y Y ₦500
Client 85 Tertiary Urban Coartem/Amatem M N Y Coartem Y Y ₦250
Client 86 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 87 Tertiary Urban Coartem/Amatem F N Y Amatem Y Y ₦500
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Client 88 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 89 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 90 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 91 Tertiary Urban Coartem/Amatem M N Y Coartem Y Y ₦250
Client 92 Tertiary Urban Coartem/Amatem F N Y Amatem Y N ₦500
Client 93 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 94 Tertiary Urban Coartem/Amatem F N Y Lonart Y N ₦700
Client 95 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 96 Tertiary Urban Coartem/Amatem M Y N Lonart Y Y ₦700
Client 97 Tertiary Urban Coartem/Amatem M N Y Coartem Y Y ₦250
Client 98 Tertiary Urban Coartem/Amatem M N Y Amatem Y Y ₦500
Client 99 Tertiary Urban Coartem/Amatem M N Y Amatem Y Y ₦500
Client 100 Tertiary Urban Coartem/Amatem M N Y Amatem Y Y ₦500
Client 101 Tertiary Urban Coartem/Amatem M N Y Amatem Y Y ₦500
Client 102 Tertiary Urban Coartem/Amatem M N Y Coartem Y Y ₦250
Client 103 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 104 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 105 Tertiary Urban Coartem/Amatem F N Y Coartem Y N ₦250
Client 106 Tertiary Urban Coartem/Amatem M Y N Coartem Y N ₦250
Client 107 Tertiary Urban Coartem/Amatem F Y Y Coartem Y Y ₦250
Client 108 Tertiary Urban Coartem/Amatem M N Y Amatem Y Y ₦500
Client 109 Tertiary Urban Coartem/Amatem F N Y Lonart Y Y ₦700
Client 110 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 111 Tertiary Urban Coartem/Amatem F N Y Coartem Y Y ₦250
Client 112 Tertiary Rural Amatem/Coartem/Lonart M N Y Chloroquine N N ₦80
Client 113 Tertiary Rural Amatem/Coartem/Lonart F N Y Coartem Y Y ₦250
Client 114 Tertiary Rural Amatem/Coartem/Lonart M N Y Coartem Y Y ₦250
Client 115 Tertiary Rural Amatem/Coartem/Lonart F N Y Amatem Y Y ₦450
Client 116 Tertiary Rural Amatem/Coartem/Lonart F N Y Amatem Y Y ₦450
Client 117 Tertiary Rural Amatem/Coartem/Lonart F N Y Chloroquine N N ₦80
Client 118 Tertiary Rural Amatem/Coartem/Lonart F N Y Chloroquine N N ₦80
Client 119 Tertiary Rural Amatem/Coartem/Lonart M N Y Amatem Y Y ₦450
Client 120 Tertiary Rural Amatem/Coartem/Lonart F N Y Amatem Y Y ₦450
Client 121 Tertiary Rural Amatem/Coartem/Lonart F N Y Coartem Y Y ₦250
Client 122 Tertiary Rural Amatem/Coartem/Lonart M N Y Chloroquine N Y ₦80
Client 123 Secondary Rural Amatem/Coartem/Lonart F N Y Fansidar N Y ₦180
Client 124 Secondary Rural Amatem/Coartem/Lonart F N Y Coartem Y Y ₦250
Client 125 Secondary Rural Amatem/Coartem/Lonart F N Y Chloroquine N Y ₦80
Client 126 Secondary Rural Amatem/Coartem/Lonart F N Y Fansidar N Y ₦180
Client 127 Secondary Rural Amatem/Coartem/Lonart F N Y Coartem Y Y ₦250
Client 128 Secondary Rural Amatem/Coartem/Lonart F N Y Fansidar N Y ₦180
Client 129 Secondary Rural Amatem/Coartem/Lonart M N Y Fansidar N N ₦180
Client 130 Secondary Rural Amatem/Coartem/Lonart M N Y Coartem Y N ₦250
Client 131 Secondary Rural Amatem/Coartem/Lonart F N Y Coartem Y Y ₦250
Client 132 Tertiary Rural Amatem/Coartem/Lonart F N Y Chloroquine N Y ₦80
Client 133 Tertiary Rural Amatem/Coartem/Lonart F N Y Lonart Y Y ₦700
Client 134 Tertiary Rural Amatem/Coartem/Lonart F N Y Amatem Y Y ₦450
Client 135 Secondary Rural Amatem/Coartem/Lonart M N Y Lonart Y Y ₦700
Client 136 Secondary Rural Amatem/Coartem/Lonart M N Y Fansidar N Y ₦180
Client 137 Secondary Rural Amatem/Coartem/Lonart F N Y Chloroquine N N ₦80
Client 138 Secondary Rural Amatem/Coartem/Lonart F N Y Coartem Y Y ₦450
Client 139 Secondary Rural Amatem/Coartem/Lonart F N Y Amatem Y Y ₦450
Client 140 Secondary Rural Amatem/Coartem/Lonart M N Y Chloroquine N Y ₦80
Client 141 Secondary Rural Amatem/Coartem/Lonart F N Y Chloroquine N N ₦80
Client 142 Secondary Rural Amatem/Coartem/Lonart F N Y Chloroquine N Y ₦80
Client 143 Secondary Rural Amatem/Coartem/Lonart F N Y Chloroquine N N ₦80
Client 144 Secondary Rural Amatem/Coartem/Lonart F N Y Amatem Y Y ₦250
Client 145 Secondary Rural Amatem/Coartem/Lonart F N Y Lonart Y N ₦700
Client 1 Tertiary Urban Coartem/Amatem M N Y Coartem Yes Y ₦250
Client 2 Tertiary Urban Coartem/Amatem M N Y Lonart Yes Y ₦250
client 3 Tertiary Urban Coartem/Amatem F N Y Amatem Yes Y ₦500
Client 4 Tertiary Urban Coartem/Amatem M N Y Coartem Yes Y ₦250
Client 5 Tertiary Urban Coartem/Amatem F Y N Coartem Yes Y ₦250
Client 6 Tertiary Urban Coartem/Amatem F N Y Lonart Yes Y ₦250
Client 7 Tertiary Urban Coartem/Amatem M N Y Coartem Yes Y ₦250
Client 8 Tertiary Urban Coartem/Amatem M N Y Amatem Yes Y ₦500
Client 9 Tertiary Urban Coartem/Amatem M N Y Amatem Yes Y ₦500
Client 10 Tertiary Urban Coartem/Amatem M N Y Chloroquine No Y ₦500
Client 11 Tertiary Urban Coartem/Amatem F N Y Coartem Yes Y ₦1850
Client 12 Tertiary Urban Coartem/Amatem M N Y Coartem Yes Y ₦1850
Client 13 Tertiary Urban Coartem/Amatem M N Y Lonart Yes Y ₦250
Client 14 Tertiary Urban Coartem/Amatem F N Y Coartem Yes Y ₦1850
Client 15 Tertiary Urban Coartem/Amatem F N Y Amatem Yes Y ₦500
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Client 16 Tertiary Urban Coartem/Amatem F Y N Amatem Yes Y ₦500
Client 17 Tertiary Urban Coartem/Amatem M N Y Coartem Yes Y ₦1850
Client 18 Tertiary Urban Coartem/Amatem F N Y Coartem Yes Y ₦250
Client 19 Tertiary Urban Coartem/Amatem F N Y Amatem Yes Y ₦500
Client 20 Tertiary Urban Coartem/Amatem F N Y Coartem Yes Y ₦1850
Client 21 Tertiary Urban Coartem/Amatem F N Y Coartem Yes Y ₦1850
Client 22 Tertiary Urban Coartem/Amatem F N Y Lonart Yes Y ₦250
Client 23 Tertiary Urban Coartem/Amatem M N Y Coartem Yes Y ₦1850
Client 24 Tertiary Urban Coartem/Amatem F N Y Chloroquine No Y ₦500
Client 25 Tertiary Urban Coartem/Amatem F N Y Fansidar No Y ₦250
Client 26 Tertiary Urban Coartem/Amatem F N Y Lonart Yes Y ₦700
Client 27 Tertiary Urban Coartem/Amatem F N Y Chloroquine No Y ₦250
Client 28 Tertiary Urban Coartem/Amatem M Y N Lonart Yes Y ₦700
Client 29 Tertiary Urban Coartem/Amatem M N Y Coartem Yes Y ₦1850
Client 30 Tertiary Urban Coartem/Amatem M N Y Amatem Yes Y ₦500
Client 31 Tertiary Urban Coartem/Amatem M N Y Amatem Yes Y ₦500
Client 32 Tertiary Urban Coartem/Amatem M N Y Amatem Yes Y ₦500
Client 33 Tertiary Urban Coartem/Amatem M N Y Amatem Yes Y ₦500
Client 34 Tertiary Urban Coartem/Amatem M N Y Lonart Yes Y ₦250
Client 35 Tertiary Urban Coartem/Amatem F N Y Coartem Yes Y ₦1850
Client 36 Tertiary Urban Coartem/Amatem F N Y Coartem Yes Y ₦1850
Client 37 Tertiary Urban Coartem/Amatem F N Y Lonart Yes Y ₦250
Client 38 Tertiary Urban Coartem/Amatem M Y N Coartem Yes Y ₦1850
Client 39 Tertiary Urban Coartem/Amatem F Y Y Coartem Yes Y ₦1850
Client 40 Tertiary Urban Coartem/Amatem M N Y Amatem Yes Y ₦500
Client 41 Tertiary Urban Coartem/Amatem F N Y Lonart Yes Y ₦700
Client 42 Tertiary Urban Coartem/Amatem F N Y Coartem Yes Y ₦1850
Client 43 Tertiary Urban Coartem/Amatem F N Y Coartem Yes Y ₦1850
Client 1 Secondary Rural Amatem/Coartem/Lonart M N Y Chloroquine No Y ₦80
Client 2 Secondary Rural Amatem/Coartem/Lonart F N Y Coartem Yes Y ₦250
client 3 Secondary Rural Amatem/Coartem/Lonart M N Y Coartem Yes Y ₦250
Client 4 Secondary Rural Amatem/Coartem/Lonart F N Y Amatem Yes Y ₦450
Client 5 Secondary Rural Amatem/Coartem/Lonart F N Y Amatem Yes Y ₦450
Client 6 Secondary Rural Amatem/Coartem/Lonart F N Y Chloroquine No Y ₦80
Client 7 Secondary Rural Amatem/Coartem/Lonart F N Y Chloroquine No Y ₦80
Client 8 Secondary Rural Amatem/Coartem/Lonart M N Y Amatem Yes Y ₦450
Client 9 Secondary Rural Amatem/Coartem/Lonart F N Y Amatem Yes Y ₦450
Client 10 Secondary Rural Amatem/Coartem/Lonart F N Y Coartem Yes Y ₦250
Client 11 Secondary Rural Amatem/Coartem/Lonart M N Y Chloroquine No Y ₦80
Client 12 Secondary Rural Amatem/Coartem/Lonart F N Y Fansidar No Y ₦180
Client 13 Secondary Rural Amatem/Coartem/Lonart F N Y Coartem Yes Y ₦250
Client 14 Secondary Rural Amatem/Coartem/Lonart F N Y Chloroquine No Y ₦80
Client 15 Secondary Rural Amatem/Coartem/Lonart F N Y Fansidar No Y ₦180
Client 16 Secondary Rural Amatem/Coartem/Lonart F N Y Coartem Yes Y ₦250
Client 17 Secondary Rural Amatem/Coartem/Lonart F N Y Fansidar No Y ₦180
Client 18 Secondary Rural Amatem/Coartem/Lonart M N Y Fansidar No Y ₦180
Client 19 Secondary Rural Amatem/Coartem/Lonart M N Y Coartem Yes Y ₦250
Client 20 Secondary Rural Amatem/Coartem/Lonart F N Y Coartem Yes Y ₦250
Client 21 Secondary Rural Amatem/Coartem/Lonart F N Y Chloroquine No Y ₦80
Client 22 Secondary Rural Amatem/Coartem/Lonart F N Y Lonart Yes Y ₦700
Client 23 Secondary Rural Amatem/Coartem/Lonart F N Y Amatem Yes Y ₦450
Client 24 Secondary Rural Amatem/Coartem/Lonart M N Y Lonart Yes Y ₦700
Client 25 Secondary Rural Amatem/Coartem/Lonart M N Y Fansidar No Y ₦180
Client 26 Secondary Rural Amatem/Coartem/Lonart F N Y Chloroquine No Y ₦80
Client 27 Secondary Rural Amatem/Coartem/Lonart F N Y Coartem Yes Y ₦250
Client 28 Secondary Rural Amatem/Coartem/Lonart F N Y Amatem Yes Y ₦450
Client 29 Secondary Rural Amatem/Coartem/Lonart M N Y Chloroquine No Y ₦80
Client 30 Secondary Rural Amatem/Coartem/Lonart F N Y Chloroquine No Y ₦80
Client 31 Secondary Rural Amatem/Coartem/Lonart F N Y Chloroquine No Y ₦80
Client 32 Secondary Rural Amatem/Coartem/Lonart F N Y Chloroquine No Y ₦80
Client 33 Secondary Rural Amatem/Coartem/Lonart F N Y Amatem Yes Y ₦250
Client 34 Secondary Rural Amatem/Coartem/Lonart F N Y Lonart No Y ₦700
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Pharmacy data Osun 
 
Education of pharmacist Urban/Rural Antimalarial mostly prescribed sex of clientproof of diagnosis self-medicating? Antimalarial purchased ACT? influence of pharmacist? price
Client 1 Tertiary Urban Lonart/Combiart M Y N Lonart Y Y ₦950
Client 2 Tertiary Urban Lonart/Combiart F N Y Fansidar N Y ₦250
Client 3 Tertiary Urban Lonart/Combiart F N Y Fansidar N N ₦250
Client 4 Tertiary Urban Lonart/Combiart M Y N Lonart Y Y ₦950
Client 5 Tertiary Urban Lonart/Combiart F Y N Lonart Y Y ₦950
Client 6 Tertiary Urban Lonart/Combiart F N Y Lonart Y N ₦950
Client 7 Tertiary Urban Lonart/Combiart M Y N Chloroquine N N ₦80
Client 8 Tertiary Urban Lonart/Combiart F Y N Other Y ₦1400
Client 9 Tertiary Urban Lonart/Combiart M N Y Fansidar N N ₦250
Client 10 Tertiary Urban Lonart/Combiart F N Y Lonart Y N ₦950
Client 11 Tertiary Urban Lonart/Combiart M N Y Fansidar N N ₦250
Client 12 Tertiary Urban Lonart/Combiart F Y N Lonart Y N ₦950
Client 13 Tertiary Urban Lonart/Combiart M N Y Coartem Y Y ₦1200
Client 14 Tertiary Urban Lonart/Combiart F N Y P-Alaxin N Y ₦600
Client 15 Tertiary Urban Lonart/Combiart F N Y Fansidar N N ₦250
Client 16 Tertiary Urban Lonart/Combiart F N Y Coartem Y Y ₦1200
Client 17 Tertiary Urban Lonart/Combiart M N Y Chloroquine N N ₦80
Client 18 Tertiary Urban Lonart/Combiart F Y N Lonart Y Y ₦950
Client 19 Tertiary Urban Lonart/Combiart M N Y Fansidar N N ₦250
Client 20 Tertiary Urban Lonart/Combiart F N Y Fansidar N N ₦250
Client 21 Tertiary Urban Lonart/Combiart F N Y Lonart Y Y ₦950
Client 22 Tertiary Urban Lonart/Combiart F N Y Lonart Y N ₦950
Client 23 Tertiary Urban Lonart/Combiart M Y N Lonart Y N ₦950
Client 24 Tertiary Urban Lonart/Combiart M Y N Chloroquine N N ₦80
Client 25 Tertiary Urban Lonart/Combiart F N Y Chloroquine N N ₦80
Client 26 Tertiary Urban Lonart/Combiart M N Y Coartem Y Y ₦1200
Client 27 Tertiary Urban Lonart/Combiart F N Y Fansidar N N ₦250
Client 28 Tertiary Urban Lonart/Combiart F N Y Chloroquine N N ₦80
Client 29 Tertiary Urban Lonart/Combiart F N Y Lonart Y N ₦950
Client 30 Tertiary Urban Lonart/Combiart M Y N Lonart Y N ₦950
Client 31 Tertiary Urban Lonart/Combiart M N Y Chloroquine N N ₦80
Client 32 Secondary Rural Amatem/Coartem F N Y Fansidar Y Y ₦1250
Client 33 Secondary Rural Amatem/Coartem F Y N Chloroquine N Y ₦1250
Client 34 Secondary Rural Amatem/Coartem F N Y Amatem Y Y ₦550
Client 35 Secondary Rural Amatem/Coartem F N Y Coartem Y Y ₦1250
Client 36 Secondary Rural Amatem/Coartem M N Y Chloroquine N Y ₦1250
Client 37 Secondary Rural Amatem/Coartem F Y N Coartem Y Y ₦1250
Client 38 Secondary Rural Amatem/Coartem M N Y Amatem Y Y ₦550
Client 39 Secondary Rural Amatem/Coartem F N Y Coartem Y Y ₦1250
Client 40 Secondary Rural Amatem/Coartem F N Y Chloroquine N Y ₦50
Client 41 Secondary Rural Amatem/Coartem F N Y Fansidar Y Y ₦1250
Client 42 Secondary Rural Amatem/Coartem F N Y Amatem Y Y ₦550
Client 43 Secondary Rural Amatem/Coartem F N Y Coartem Y Y ₦1250
Client 44 Secondary Rural Amatem/Coartem F N Y Chloroquine N Y ₦50
Client 45 Secondary Rural Amatem/Coartem M N Y Lonart Y Y ₦600
Client 46 Secondary Rural Amatem/Coartem F N Y Chloroquine N Y ₦950
Client 47 Secondary Rural Amatem/Coartem F N Y Coartem Y Y ₦1250
Client 48 Secondary Rural Amatem/Coartem M N Y Amatem Y Y ₦550
Client 49 Secondary Rural Amatem/Coartem F N Y Coartem Y Y ₦1250
Client 50 Secondary Rural Amatem/Coartem F N Y Coartem Y Y ₦1250
Client 51 Secondary Rural Amatem/Coartem M N Y Chloroquine N Y ₦1250
Client 52 Secondary Rural Amatem/Coartem M N Y Amatem Y Y ₦550
Client 53 Secondary Rural Amatem/Coartem F N Y Coartem Y Y ₦1250
Client 54 Secondary Rural Amatem/Coartem M Y N Lonart Y Y ₦950
Client 55 Secondary Rural Amatem/Coartem F N Y Fansidar N Y ₦550
Client 56 Secondary Rural Amatem/Coartem F N Y Fansidar N Y ₦1250
Client 57 Secondary Rural Amatem/Coartem M N Y Coartem Y Y ₦1250
Client 58 Tertiary Urban Combisunate/Coartem M Y N Lonart Y Y ₦950
Client 59 Tertiary Urban Combisunate/Coartem F N Y Fansidar N Y ₦250
Client 60 Tertiary Urban Combisunate/Coartem F N Y Fansidar N N ₦250
Client 61 Tertiary Urban Combisunate/Coartem M Y N Lonart Y Y ₦950
Client 62 Tertiary Urban Combisunate/Coartem F Y N Lonart Y Y ₦950
Client 63 Tertiary Urban Combisunate/Coartem F N Y Lonart Y N ₦950
Client 64 Tertiary Urban Combisunate/Coartem M Y N Chloroquine N N ₦80
Client 65 Tertiary Urban Combisunate/Coartem F Y N Other N Y ₦1400
Client 66 Tertiary Urban Combisunate/Coartem M N Y Fansidar N N ₦250
Client 67 Tertiary Urban Combisunate/Coartem F N Y Lonart Y N ₦950
Client 68 Tertiary Urban Combisunate/Coartem M N Y Fansidar N N ₦250
Client 69 Tertiary Urban Combisunate/Coartem F Y N Lonart Y N ₦950
Client 70 Tertiary Urban Combisunate/Coartem M N Y Coartem Y Y ₦1200
Client 71 Tertiary Urban Combisunate/Coartem F N Y P-Alaxin Y Y ₦600
Client 72 Tertiary Urban Combisunate/Coartem F N Y Fansidar N N ₦250
Client 73 Tertiary Urban Combisunate/Coartem F N Y Coartem Y N ₦1200
Client 74 Tertiary Urban Combisunate/Coartem M N Y Chloroquine N N ₦80
Client 75 Tertiary Urban Lonart/Combiart F Y N Lonart Y Y ₦950
Client 76 Tertiary Urban Lonart/Combiart M N Y Fansidar N N ₦250
Client 77 Tertiary Rural Lonart/Combiart F N Y Fansidar N N ₦250
Client 78 Tertiary Rural Lonart/Combiart F N Y Lonart Y Y ₦950
Client 79 Tertiary Rural Lonart/Combiart F N Y Lonart Y N ₦950
Client 80 Tertiary Rural Lonart/Combiart M Y N Lonart Y N ₦950
Client 81 Tertiary Rural Lonart/Combiart M Y N Chloroquine N N ₦80
Client 82 Tertiary Rural Lonart/Combiart F N Y Chloroquine N N ₦80
Client 83 Tertiary Rural Lonart/Combiart M N Y Coartem Y Y ₦1200
Client 84 Tertiary Rural Lonart/Combiart F N Y Fansidar N N ₦250
Client 85 Tertiary Rural Lonart/Combiart F N Y Chloroquine N Y ₦80
Client 86 Tertiary Urban Lonart/Amatem F N Y Lonart Y Y ₦950
Client 87 Tertiary Urban Lonart/Amatem M Y N Lonart Y Y ₦950
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Client 88 Tertiary Urban Lonart/Amatem M Y N Lonart Y Y ₦950
Client 89 Tertiary Urban Lonart/Amatem M Y N Coartem Y N ₦1200
Client 90 Tertiary Urban Lonart/Amatem M Y N Amatem Y N ₦550
Client 91 Tertiary Urban Lonart/Amatem M Y N Chloroquine N N ₦80
Client 92 Tertiary Urban Lonart/Amatem M Y N Chloroquine N N ₦80
Client 93 Tertiary Urban Lonart/Amatem M Y N Amatem Y N ₦550
Client 94 Tertiary Urban Lonart/Amatem M N Y Lonart Y N ₦950
Client 95 Tertiary Urban Lonart/Amatem M N Y Lonart Y N ₦950
Client 96 Tertiary Urban Lonart/Amatem M Y N Chloroquine N Y ₦80
Client 97 Tertiary Urban Lonart/Amatem M Y N Fansidar N Y ₦250
Client 98 Tertiary Urban Lonart/Amatem M Y N Lonart Y Y ₦950
Client 99 Tertiary Urban Lonart/Amatem M Y N Lonart Y N ₦950
Client 100 Tertiary Urban Lonart/Amatem M Y N Amatem Y N ₦550
Client 101 Tertiary Urban Lonart/Amatem M N Y Lonart Y N ₦950
Client 102 Tertiary Rural Lonart/Combiart M Y N Chloroquine N N ₦80
Client 103 Tertiary Rural Lonart/Combiart M Y N Lonart Y N ₦950
Client 104 Tertiary Rural Lonart/Combiart M N Y Chloroquine N N ₦80
Client 105 Tertiary Rural Lonart/Combiart M Y N Amatem Y N ₦550
Client 106 Tertiary Rural Lonart/Combiart M Y N Fansidar N N ₦250
Client 107 Tertiary Rural Lonart/Combiart M N Y Fansidar N N ₦250
Client 108 Tertiary Rural Lonart/Combiart M N Y Fansidar N N ₦250
Client 109 Tertiary Rural Lonart/Combiart M Y N Chloroquine N N ₦80
Client 110 Tertiary Rural Lonart/Combiart M N Y Other N N ₦973
Client 111 Tertiary Rural Lonart/Combiart M N Y Coartem Y N ₦1200
Client 112 Tertiary Rural Lonart/Combiart M N Y Amatem Y N ₦550
Client 113 Tertiary Rural Lonart/Combiart M Y N Amatem Y N ₦550
Client 114 Tertiary Rural Lonart/Combiart M Y N Chloroquine N N ₦80
Client 115 Tertiary Urban Lonart/Amatem M Y N Chloroquine N N ₦80
Client 116 Tertiary Urban Lonart/Amatem M Y N Lonart Y Y ₦950
Client 117 Tertiary Urban Lonart/Amatem M Y N Amatem Y N ₦550
Client 118 Tertiary Urban Lonart/Amatem M Y N Amatem Y N ₦550
Client 119 Tertiary Urban Lonart/Amatem M Y N Amatem Y N ₦550
Client 120 Tertiary Urban Lonart/Amatem M Y N Lonart Y N ₦950
Client 121 Tertiary Urban Lonart/Amatem M Y N Amatem Y N ₦550
Client 122 Tertiary Urban Lonart/Amatem M Y N Chloroquine N N ₦80
Client 123 Tertiary Urban Lonart/Amatem M Y N Amatem Y Y ₦550
Client 124 Tertiary Urban Lonart/Amatem M N Y Chloroquine N N ₦80
Client 125 Tertiary Urban Lonart/Amatem M N Y Fansidar N N ₦250
Client 126 Tertiary Urban Lonart/Amatem M N Y Lonart Y N ₦950
Client 127 Tertiary Urban Lonart/Amatem M Y N Lonart Y N ₦950
Client 128 Tertiary Urban Lonart/Amatem M N Y Amatem Y N ₦550
Client 129 Tertiary Urban Lonart/Amatem M Y N Amatem Y N ₦550
Client 130 Tertiary Urban Lonart/Amatem M Y N Amatem Y N ₦550
Client 131 Tertiary Urban Lonart/Amatem M Y N Amatem Y N ₦550
Client 132 Tertiary Urban Lonart/Amatem M Y N Chloroquine N N ₦80
Client 133 Tertiary Urban Lonart/Amatem M N Y Amatem Y Y ₦550
Client 134 Tertiary Urban Lonart/Amatem M Y N Amatem Y Y ₦550
Client 135 Tertiary Urban Lonart/Amatem M N Y Lonart Y Y ₦950
Client 136 Tertiary Urban Lonart/Amatem M Y N Chloroquine N Y ₦80
Client 137 Tertiary Rural Combisunate/Amatem M N Y Lonart Y N ₦950
Client 138 Tertiary Rural Combisunate/Amatem M N Y Combisunate Y N ₦950
Client 139 Tertiary Rural Combisunate/Amatem M N Y Combisunate Y N ₦950
Client 140 Tertiary Rural Combisunate/Amatem M N Y Lonart Y N ₦950
Client 141 Tertiary Rural Combisunate/Amatem M N Y Chloroquine N Y ₦80
Client 142 Tertiary Rural Combisunate/Amatem M N Y Lonart Y Y ₦950
Client 143 Tertiary Rural Combisunate/Amatem M N Y Combisunate Y Y ₦950
Client 144 Tertiary Rural Combisunate/Amatem M N Y Amatem Y N ₦550
Client 145 Tertiary Rural Combisunate/Amatem M N Y Fansidar N N ₦250
Client 146 Tertiary Rural Combisunate/Amatem M N Y Lonart Y N ₦950
Client 147 Tertiary Rural Combisunate/Amatem M N Y Combisunate Y Y ₦950
Client 148 Tertiary Rural Combisunate/Amatem M N Y Chloroquine Y N ₦80
Client 149 Tertiary Rural Combisunate/Amatem M N Y Chloroquine N N ₦80
Client 150 Tertiary Rural Combisunate/Amatem M N Y Chloroquine N N ₦80
Client 151 Tertiary Rural Combisunate/Amatem M Y N Chloroquine N Y ₦80
Client 152 Tertiary Rural Combisunate/Amatem M N Y Fansidar N N ₦250
Client 153 Tertiary Rural Combisunate/Amatem M N Y Lonart Y N ₦950
Client 154 Tertiary Rural Combisunate/Amatem M N Y Amatem Y Y ₦550
Client 155 Tertiary Rural Combisunate/Amatem M Y N Amatem Y Y ₦550
Client 156 Tertiary Rural Combisunate/Amatem M N Y Amatem Y Y ₦550
Client 157 Tertiary Rural Combisunate/Amatem M N Y Amatem Y Y ₦550
Client 158 Tertiary Rural Combisunate/Amatem M N Y Combisunate Y N ₦950
Client 159 Tertiary Rural Combisunate/Amatem M N Y Combisunate Y N ₦950
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Client 160 Tertiary Urban Lonart/Amatem M N Y Chloroquine N Y ₦80
Client 161 Tertiary Urban Lonart/Amatem M Y N Lonart Y N ₦950
Client 162 Tertiary Urban Lonart/Amatem M Y N Lonart Y N ₦950
Client 163 Tertiary Urban Lonart/Amatem M Y N Lonart Y Y ₦950
Client 164 Tertiary Urban Lonart/Amatem M N Y Lonart Y N ₦950
Client 165 Tertiary Urban Lonart/Amatem M N Y Amatem Y N ₦550
Client 166 Tertiary Urban Lonart/Amatem M N Y Amatem Y Y ₦550
Client 167 Tertiary Urban Lonart/Amatem M Y N Amatem Y N ₦550
Client 168 Tertiary Urban Lonart/Amatem M Y N Coartem Y N ₦1200
Client 169 Tertiary Urban Lonart/Amatem M Y N Coartem Y N ₦1200
Client 170 Tertiary Rural Lonart/Coartem M Y N Lonart Y N ₦950
Client 171 Tertiary Rural Lonart/Coartem M N Y Lonart Y N ₦950
Client 172 Tertiary Rural Lonart/Coartem M N Y Lonart Y N ₦950
Client 173 Tertiary Rural Lonart/Coartem M Y N Fansidar N Y ₦250
Client 174 Tertiary Rural Lonart/Coartem M Y N Fansidar N Y ₦250
Client 175 Tertiary Rural Lonart/Coartem M N Y Lonart Y Y ₦950
Client 176 Tertiary Rural Lonart/Coartem M N Y Lonart Y Y ₦950
Client 177 Tertiary Rural Lonart/Coartem M N Y Amatem Y Y ₦550
Client 178 Tertiary Rural Lonart/Coartem M N Y Lonart Y Y ₦950
Client 179 Tertiary Rural Lonart/Coartem M N Y Coartem Y Y ₦1200
Client 180 Tertiary Rural Lonart/Coartem M Y N Lonart Y Y ₦950
Client 1 Secondary Rural Amatem/Coartem F N Y CHLOROQUINE No Y ₦50
Client 2 Secondary Rural Amatem/Coartem F Y N CHLOROQUINE No Y ₦50
client 3 Secondary Rural Amatem/Coartem F N Y Amatem Yes Y ₦550
Client 4 Secondary Rural Amatem/Coartem F N Y FANSIDAR No Y ₦250
Client 5 Secondary Rural Amatem/Coartem M N Y FANSIDAR No Y ₦250
Client 6 Secondary Rural Amatem/Coartem F Y N AMATEM Yes Y ₦550
Client 7 Secondary Rural Amatem/Coartem M N Y CHLOROQUINE No Y ₦50
Client 8 Secondary Rural Amatem/Coartem F N Y Coartem Yes Y ₦1250
Client 9 Secondary Rural Amatem/Coartem F N Y CHLOROQUINE No Y ₦50
Client 10 Secondary Rural Amatem/Coartem F N Y CHLOROQUINE No Y ₦50
Client 11 Secondary Rural Amatem/Coartem F N Y AMATEM Yes Y ₦550
Client 12 Secondary Rural Amatem/Coartem F N Y CHLOROQUINE No Y ₦50
Client 13 Secondary Rural Amatem/Coartem F N Y CHLOROQUINE No Y ₦50
Client 14 Secondary Rural Amatem/Coartem M N Y LONART Yes Y ₦600
Client 15 Secondary Rural Amatem/Coartem F N Y COARTEM Yes Y ₦1250
Client 16 Secondary Rural Amatem/Coartem F N Y COARTEM Yes Y ₦1250
Client 17 Secondary Rural Amatem/Coartem M N Y CHLOROQUINE No Y ₦80
Client 18 Secondary Rural Amatem/Coartem F N Y CHLOROQUINE No Y ₦1250
Client 19 Secondary Rural Amatem/Coartem F N Y COARTEM Yes Y ₦1250
Client 20 Secondary Rural Amatem/Coartem M N Y FANSIDAR No Y ₦250
Client 21 Secondary Rural Amatem/Coartem M N Y FANSIDAR No Y ₦250
Client 22 Secondary Rural Amatem/Coartem F N Y CHLOROQUINE No Y ₦80
Client 23 Secondary Rural Amatem/Coartem M Y N CHLOROQUINE No Y ₦80
Client 24 Secondary Rural Amatem/Coartem F N Y FANSIDAR No Y ₦250
Client 25 Secondary Rural Amatem/Coartem F N Y FANSIDAR No Y ₦250
Client 26 Secondary Rural Amatem/Coartem M N Y CHLOROQUINE No Y ₦80
Client 1 Tertiary Urban Lonart/Combiart M Y N Lonart Yes Y ₦950
Client 2 Tertiary Urban Lonart/Combiart F N Y Fansidar No Y ₦250
client 3 Tertiary Urban Lonart/Combiart F N Y Fansidar No N ₦250
Client 4 Tertiary Urban Lonart/Combiart M Y N Lonart Yes Y ₦950
Client 5 Tertiary Urban Lonart/Combiart F Y N Lonart Yes Y ₦950
Client 6 Tertiary Urban Lonart/Combiart F N Y Lonart Yes N ₦950
Client 7 Tertiary Urban Lonart/Combiart M Y N Chloroquine No N ₦80
Client 8 Tertiary Urban Lonart/Combiart F Y N Other Y ₦1400
Client 9 Tertiary Urban Lonart/Combiart M N Y Fansidar No N ₦250
Client 10 Tertiary Urban Lonart/Combiart F N Y Lonart Yes N ₦950
Client 11 Tertiary Urban Lonart/Combiart M N Y Fansidar No N ₦250
Client 12 Tertiary Urban Lonart/Combiart F Y N Lonart Yes N ₦950
Client 13 Tertiary Urban Lonart/Combiart M N Y Coartem Yes Y ₦1200
Client 14 Tertiary Urban Lonart/Combiart F N Y P-Alaxin Yes Y ₦600
Client 15 Tertiary Urban Lonart/Combiart F N Y Fansidar No N ₦250
Client 16 Tertiary Urban Lonart/Combiart F N Y Coartem Yes N ₦1200
Client 17 Tertiary Urban Lonart/Combiart M N Y Chloroquine No N ₦80
Client 18 Tertiary Urban Lonart/Combiart F Y N Lonart Yes Y ₦950
Client 19 Tertiary Urban Lonart/Combiart M N Y Fansidar No N ₦250
Client 20 Tertiary Urban Lonart/Combiart F N Y Fansidar No N ₦250
Client 21 Tertiary Urban Lonart/Combiart F N Y Lonart Yes Y ₦950
Client 22 Tertiary Urban Lonart/Combiart F N Y Lonart Yes N ₦950
Client 23 Tertiary Urban Lonart/Combiart M Y N Lonart Yes N ₦950
Client 24 Tertiary Urban Lonart/Combiart M Y N Chloroquine No N ₦80
Client 25 Tertiary Urban Lonart/Combiart F N Y Chloroquine No N ₦80
Client 26 Tertiary Urban Lonart/Combiart M N Y Coartem Yes Y ₦1200
Client 27 Tertiary Urban Lonart/Combiart F N Y Fansidar No N ₦250
Client 28 Tertiary Urban Lonart/Combiart F N Y Chloroquine No N ₦80
Client 29 Tertiary Urban Lonart/Combiart F N Y Lonart Yes N ₦950
Client 30 Tertiary Urban Lonart/Combiart M Y N Lonart Yes N ₦950
Client 31 Tertiary Urban Lonart/Combiart M N Y Chloroquine No N ₦80
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Appendix IV: List of drugs 
 
 
 
ANTIMALARIAL ACT? STATE URBAN/RURAL STORE CONTENT RATIO MANUFACTURER EXPIRY DATE SOLUBILITY DOSAGE WEIGHT PER TABLET
Combisunate ACT Osun Rural Pharmacy Artemether/Lumefantrine 20/120 Ajanta pharma ltd Jul-18 Chloroform
4tablet 1st dose
4 tablet 8 hours after 1st dose
4 tablet 24 hours after 1st dose
4 tablet 36hours after 1st dose
4 tablet 48 hours after 1st dose
4 tablet 60 hours after 1st dose 0.25g
Chloroquine Quinine Osun urban Pharmacy quinine Alben Healthcare Ltd Jun-18 freely soluble in water
4 tablets per day for the 1st two days
2 per day for the next two weeks 0.33g
Fansidar SP Osun Rural vendor sulfadoxine/pyrimethamine 500/20mg swiss pharma ltd Oct-19 3 tablets (one dose) 0.70g
Lonart ACT Osun Rural vendor Artemether/Lumefantrine 80/480 Bliss GVS Chloroform
1 tablet 1st dose
1 tablet 8 hours after 1st dose
1 tablet 24 hours after 1st dose
1 tablet 36hours after 1st dose
1 tablet 48 hours after 1st dose
1 tablet 60 hours after 1st dose 0.70g
Lumartem ACT Osun urban Pharmacy Artemether/Lumefantrine 20/120 Cipla ltd Feb-17 Chloroform
4tablet 1st dose
4 tablet 8 hours after 1st dose
4 tablet 24 hours after 1st dose
4 tablet 36hours after 1st dose
4 tablet 48 hours after 1st dose
4 tablet 60 hours after 1st dose 0.37g
Chloroquine Quinine Osun Rural vendor quinine jopan pharmaceutical Jun-19 freely soluble in water
4 tablets per day for the 1st two days
2 per day for the next two weeks 0.33g
Lonart ACT lagos urban Pharmacy Artemether/Lumefantrine 80/480 Bliss GVS Sep-17 Chloroform
1 tablet 1st dose
1 tablet 8 hours after 1st dose
1 tablet 24 hours after 1st dose
1 tablet 36hours after 1st dose
1 tablet 48 hours after 1st dose
1 tablet 60 hours after 1st dose 0.70g
Combisunate ACT lagos urban Pharmacy Artemether/Lumefantrine 20/120 Ajanta pharma ltd Sep-17 Chloroform
4tablet 1st dose
4 tablet 8 hours after 1st dose
4 tablet 24 hours after 1st dose
4 tablet 36hours after 1st dose
4 tablet 48 hours after 1st dose
4 tablet 60 hours after 1st dose 0.25g
Fansidar SP lagos rural Pharmacy sulfadoxine/pyrimethamine swiss pharma ltd Dec-19 3 tablets (one dose) 0.70g
Chloroquine Quinine lagos Rural Pharmacy quinine freely soluble in water
4 tablets per day for the 1st two days
2 per day for the next two weeks 0.33g
Chloroquine Quinine lagos urban Pharmacy quinine dana pharmaceuticals Dec-17 freely soluble in water
4 tablets per day for the 1st two days
2 per day for the next two weeks 0.33g
Fansidar sp lagos urban Pharmacy sulfadoxine/pyrimethamine Swiss pharma ltd Jan-20 3 tablets (one dose) 0.70g
Lonart ACT Osun urban Pharmacy Artemether/Lumefantrine 80/480 Bliss GVS Nov-18 Chloroform
1 tablet 1st dose
1 tablet 8 hours after 1st dose
1 tablet 24 hours after 1st dose
1 tablet 36hours after 1st dose
1 tablet 48 hours after 1st dose
1 tablet 60 hours after 1st dose 0.70g
Lonart ACT lagos urban vendor Artemether/Lumefantrine 80/480 Bliss GVS Nov-17 Chloroform
1 tablet 1st dose
1 tablet 8 hours after 1st dose
1 tablet 24 hours after 1st dose
1 tablet 36hours after 1st dose
1 tablet 48 hours after 1st dose
1 tablet 60 hours after 1st dose 0.70g
Chloroquine Quinine lagos Rural vendor quinine Alben Healthcare Ltd Sep-17 freely soluble in water
4 tablets per day for the 1st two days
2 per day for the next two weeks 0.33g
Combisunate ACT Osun urban vendor Artemether/Lumefantrine 20/120 Ajanta pharma ltd Jul-17 Chloroform
4tablet 1st dose
4 tablet 8 hours after 1st dose
4 tablet 24 hours after 1st dose
4 tablet 36hours after 1st dose
4 tablet 48 hours after 1st dose
4 tablet 60 hours after 1st dose 0.25g
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Lonart ACT Osun Rural Artemether/Lumefantrine 80/480 Nov-17 Chloroform
1 tablet 1st dose
1 tablet 8 hours after 1st dose
1 tablet 24 hours after 1st dose
1 tablet 36hours after 1st dose
1 tablet 48 hours after 1st dose
1 tablet 60 hours after 1st dose 0.70g
Amatem ACT Osun urban Artemether/Lumefantrine 80/480 elbe pharma Feb-18 Cloroform
1 tablet 1st dose
1 tablet 8 hours after 1st dose
1 tablet 24 hours after 1st dose
1 tablet 36hours after 1st dose
1 tablet 48 hours after 1st dose
1 tablet 60 hours after 1st dose 0.70g
Coartem ACT lagos urban Pharmacy Artemether/Lumefantrine 20/120 Oct-18 Cloroform
4 tablets 1st dose
4 tablets 8 hours after 1st dose
4 tablets 24 hours after 1st dose
4 tablets 36hours after 1st dose
4 tablets 48 hours after 1st dose
4 tablets 60 hours after 1st dose 0.25g
Coartem ACT lagos urban Pharmacy Artemether/Lumefantrine 80/480 Oct-17 Cloroform
1 tablet 1st dose
1 tablet 8 hours after 1st dose
1 tablet 24 hours after 1st dose
1 tablet 36hours after 1st dose
1 tablet 48 hours after 1st dose
1 tablet 60 hours after 1st dose 0.99g
Coartem ACT lagos urban Pharmacy Artemether/Lumefantrine 20/120 Oct-18 Chloroform
4 tablets 1st dose
4 tablets 8 hours after 1st dose
4 tablets 24 hours after 1st dose
4 tablets 36hours after 1st dose
4 tablets 48 hours after 1st dose
4 tablets 60 hours after 1st dose 0.25g
Coartem 2 ACT lagos urban Pharmacy Artemether/Lumefantrine 80/480 Oct-17 Chloroform
1 tablet 1st dose
1 tablet 8 hours after 1st dose
1 tablet 24 hours after 1st dose
1 tablet 36hours after 1st dose
1 tablet 48 hours after 1st dose
1 tablet 60 hours after 1st dose 0.99g
Fansidar SP lagos urban Pharmacy sulfadoxine/pyrimethamine 500/25mg May-21 3 tablets (one dose)
Lonart ACT lagos urban Pharmacy Artemether/Lumefantrine 80/480 Aug-17 Chloroform
1 tablet 1st dose
1 tablet 8 hours after 1st dose
1 tablet 24 hours after 1st dose
1 tablet 36hours after 1st dose
1 tablet 48 hours after 1st dose
1 tablet 60 hours after 1st dose 0.70g
Amatem ACT lagos urban Pharmacy Artemether/Lumefantrine 80/480 Nov-17 Chloroform
1 tablet 1st dose
1 tablet 8 hours after 1st dose
1 tablet 24 hours after 1st dose
1 tablet 36hours after 1st dose
1 tablet 48 hours after 1st dose
1 tablet 60 hours after 1st dose 0.70g
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Chloroquine Quinine lagos urban Pharmacy quinine 250mg Apr-19 freely soluble in water
4 tablets per day for the 1st two days
2 per day for the next two weeks
Amatem ACT lagos urban Pharmacy Artemether/Lumefantrine 80/480 Nov-17 Chloroform
1 tablet 1st dose
1 tablet 8 hours after 1st dose
1 tablet 24 hours after 1st dose
1 tablet 36hours after 1st dose
1 tablet 48 hours after 1st dose
1 tablet 60 hours after 1st dose
Lonart ACT lagos urban Pharmacy Artemether/Lumefantrine 80/480 Aug-17 Chloroform
1 tablet 1st dose
1 tablet 8 hours after 1st dose
1 tablet 24 hours after 1st dose
1 tablet 36hours after 1st dose
1 tablet 48 hours after 1st dose
1 tablet 60 hours after 1st dose 0.70g
Fansidar ACT lagos urban Pharmacy sulfadoxine/pyrimethamine 500/25MG May-21 3 tablets (one dose)
Lonart ACT lagos urban Pharmacy Artemether/Lumefantrine 80/480 Mar-17 Chloroform
1 tablet 1st dose
1 tablet 8 hours after 1st dose
1 tablet 24 hours after 1st dose
1 tablet 36hours after 1st dose
1 tablet 48 hours after 1st dose
1 tablet 60 hours after 1st dose 0.70g
Combisunate ACT lagos urban Pharmacy Artemether/Lumefantrine 80/480 Nov-17 Chloroform
4tablet 1st dose
4 tablet 8 hours after 1st dose
4 tablet 24 hours after 1st dose
4 tablet 36hours after 1st dose
4 tablet 48 hours after 1st dose
4 tablet 60 hours after 1st dose 0.25g
Chloroquine Quinine lagos urban Pharmacy quinine 250mg Apr-19 freely soluble in water
4 tablets per day for the 1st two days
2 per day for the next two weeks 0.33g
Maladar
Combiart ACT Osun Rural Pharmacy Artemether/Lumefantrine 80/480
1 tablet 1st dose
1 tablet 8 hours after 1st dose
1 tablet 24 hours after 1st dose
1 tablet 36hours after 1st dose
1 tablet 48 hours after 1st dose
1 tablet 60 hours after 1st dose 0.70g
Artesunate ACT lagos urban Pharmacy
Methanol
Water
4 tablets 1st day
4 tablet 8 hours after first dose
4 tablets daily afterwards 0.25g
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Appendix V: Drug calculation 
 
Region Drug name 
(Code) 
Drug weight Artemether/lumefantrine 
ratio 
Quantity 
needed in 1 ml 
for 5 nM 
solution 
Lagos rural A 230 mg (0.23g) 20/120 mg 17.1565 mg 
 B 730 mg (0.73g) 80/480 mg 13.6133 mg 
 C 250 mg (0.25g) 20/120 mg 18.6483 mg 
 D 680 mg (0.68g) 80/480 mg 12.6809 mg 
 E 680 mg (0.68g) 80/480 mg 12.6809 mg 
 F 230 mg (0.23g) 20/120 mg 17.1565 mg 
 1F 250 mg (0.25g) 20/120 mg 18.6483 mg 
 1D 230 mg (0.23g) 20/120 mg 17.1565 mg 
Lagos urban G 950 mg (0.95g) 80/480 mg 17.7160 mg 
 H 250 mg (0.25g) 20/120 mg 18.6483 mg 
 I 250 mg (0.25g) 20/120 mg 18.6483 mg 
 J 680 mg (0.68g) 80/480 mg 12.6809 mg 
 K 680 mg (0.68g) 80/480 mg 12.6809 mg 
Osun rural L 230 mg (0.23g) 20/120 mg 17.1565 mg 
 M 960 mg (0.96g) 80/480 mg 17.9024 mg 
 N 730 mg (0.73g) 80/480 mg 13.6133 mg 
 O 680 mg (0.68g) 80/480 mg 12.6809 mg 
 1K 250 mg (0.25g) 20/120 mg 18.6483 mg 
Osun urban P 230 mg (0.23g 20/120 mg 17.1565 mg 
 Q 680 mg (0.68g) 80/480 mg 12.6809 mg 
 R 730 mg (0.73g) 80/480 mg 13.6133 mg 
 S 250 mg (0.25g) 20/120 mg 18.6483 mg 
 T 730 mg (0.73g) 80/480 mg 13.6133 mg 
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